Accumulation of drugs in tubular cells of the kidney by Masereeuw, R.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/18645
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
ACCUMULATION OF DRUGS IN TUBULAR CELLS
OF THE KIDNEY
ACCUMULATION OF DRUGS IN TUBULAR CELLS 
OF THE KIDNEY
Een wetenschappelijke proeve op het gebied van de 
Medische Wetenschappen
Proefschrift
ter verkrijging van de graad van doctor 
aan de Katholieke Universiteit Nijmegen, 
volgens besluit van het College van Decanen in het 
openbaar te verdedigen op woensdag 22 januari 1997 
des namiddags om 3.30 uur precies
door
Rosalinde Masereeuw
geboren op 3 mei 1967 te Wognum
Promotor: Prof. dr. P. Smits
Copromotor: Dr. F.G.M. Russel
Manuscriptcommissie: Prof. dr. L.A. Ginsel
Prof. dr. L. Monnens
Prof. dr. D.D. Breimer (Rijksuniversiteit te Leiden)
The investigations described in this thesis were carried out in the Department of 
Pharmacology, University of Nijmegen, Nijmegen, The Netherlands, and were 
supported by a grant from the Dutch Kidney Foundation (Nierstichting Nederland; grant 
no. C.90.1047).
Paranimfen: Dr. E.M. van der Aa
Mw. drs. I. van der Woude
Printing o f this thesis was financially supported by: 
Nierstichting Nederland (Dutch Kidney Foundation) 
Dr. Saal van Zwanenbergstichting 
Nycomed B.V.
Organon Nederland B.V.
Molecular Probes Europe B.V.
Cover illustration: Confocal fluorescence microscopical image of freshly isolated 
proximal tubular cells incubated with 2 |iM CFDA (Chapter 9 for details).
Cover design: Frank Schmidt and Rosalinde Masereeuw
© 1997 R. Masereeuw, Lunteren 
ISBN: 90-9010000-8
Druk: Uitgeverij KU Nijmegen, 1996
ACCUMULATION OF DRUGS IN TUBULAR CELLS 
OF THE KIDNEY
Contents
Section I: 
Chapter 1.
Section II: 
Chapter 2.
Chapter 3.
Chapter 4.
Chapter 5.
Chapter 6. 
Chapter 7. 
Section III: 
Chapter 8.
General introduction
Mechanisms involved in renal accumulation of drugs 11
Studies in the isolated perfused rat kidney 
Renal excretion and accumulation kinetics of
2-methylbenzoylglycine 53
Renal excretion and accumulation kinetics of
4-methylbenzoylglycine 69
Saturable accumulation kinetics and diuretic activity of 
hydrochlorothiazide 85
Active secretion and extensive accumulation of 
rhodamine 123 101
Glomerular filtration and saturable absorption of iohexol 121
Renal excretion and accumulation of diatrizoate 139
Studies in isolated rat proximal tubular cells 
and killifish proximal tubules
Characterization of fluorescein transport in isolated 
proximal tubular cells of the rat: evidence for 
mitochondrial accumulation 153
7
Chapter 9.
Interaction of fluorescein with the dicarboxylate carrier 
in rat kidney cortex mitochondria 171
Chapter 10. Active secretion and intracellular accumulation of
Lucifer Yellow in renal proximal tubules 191
Chapter 11. Multiple pathways of organic anion secretion in renal
proximal tubule revealed by confocal microscopy 207
Summary, conclusions and final perspectives 229
Samenvatting en conclusies 239
Dankwoord 249
Curriculum Vitae 251
List of publications 252
Abbreviations 254
Section I
General introduction
Chapter 1 
MECHANISMS INVOLVED IN RENAL ACCUMULATION OF 
DRUGS
Rosalinde Masereeuw and Frans G.M. Russel
Department of Pharmacology, Faculty of Medical Sciences, University of Nijmegen,
The Netherlands
1. Introduction
2. The kidney: morphology and physiology
3. Renal clearance and metabolism
3.1 Renal clearance
3.2 Drug metabolism
4. Accumulation of drugs in proximal tubules
4.1 Accumulation of anionic drugs
4.1.1 Basolateral uptake
4.1.2 Intracellular incidents
4.1.3 Luminal secretion
4.1.4 Tubular reabsorption
4.2 Accumulation of cationic drugs
4.2.1 Basolateral uptake
4.2.2 Intracellular incidents
4.2.3 Luminal secretion
4.2.4 Tubular reabsorption
5. Accumulation of drugs in other transporting epithelia
6. Clinical implications of proximal tubular drug accumulation
7. Scope of this thesis
8. References
11
Chapter 1
1. Introduction
The kidney is especially vulnerable to toxic effects of drugs on renal tubules. This is a 
result of the high renal blood flow and concentration function of the kidney. 
Furthermore, the proximal tubule of the kidney possesses various transport systems for 
the secretion of endogenous and exogenous compounds from blood into tubular lumen. 
In this regard, these compounds can be divided into two major classes: organic anions 
and cations.
Marshall and Vickers were the first (in 1923) to demonstrate active secretion (109). 
They showed that the organic anion, phenolsulfonphthalein (PSP, phenol red), 
accumulated in renal proximal tubular cells to much higher levels than in other tissues. 
In addition, the amount of PSP excreted into urine was more than could be accounted 
for by glomerular filtration and they concluded that PSP must be secreted into the urine 
by the proximal tubular cells. After this discovery by Marshall and Vickers, it took more 
than twenty years before evidence was obtained for the existence of a secretory system 
for organic cations (161). The transport mechanisms for both organic anions and cations 
are believed to have a primary function in the elimination of endogenous waste products 
and xenobiotics in order to reduce the incidence of accumulation. As a consequence of 
active secretory transport, anionic and cationic drugs may achieve high concentrations 
within the proximal tubular cells, often accompanied by the development of tubular 
injury. The majority of examples of drug-induced nephrotoxicity concern organic 
anions, e.g. cephalosporins, anti-inflammatory agents, radio-contrast agents, the 
chemotherapeutic agent methotrexate and the mycotoxin ochratoxin A, although some 
cationic drugs have shown to possess a nephrotoxic potential as well, e.g. cisplatin and 
para-aminophenol (metabolite of acetaminophen) (57,61,81,235). The extent of 
accumulation will depend on the physicochemical properties of the compound and is 
determined by the efficiency of uptake, association with intracellular components, 
intracellular trafficking and secretion into the luminal compartment. In this chapter the 
present knowledge on the mechanisms dealing with the renal handling of drugs and 
accumulation in proximal tubular cells is summarized.
2. The kidney: morphology and physiology
The major function of the kidney is to maintain the homeostasis of the internal 
environment. To this end, the kidney excretes waste products and regulates electrolyte 
content, and volume of the internal environment. Furthermore, the kidney is involved in
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the production and processing of several hormones (95,218).
The functional unit of the kidney is the nephron, of which the human kidneys contain 
about 1.2 million in each kidney. Most nephrons lie largely or entirely in the cortex, 
which is the outer region of the kidney. Figure 1-1 shows a schematic diagram of the 
organization in the kidney. The essential segments of a nephron are the glomerulus, 
proximal convoluted tubule, loop of Henle, distal tubule and collecting duct. Each 
kidney is supplied with blood from a renal artery arising from the aorta.
Figure 1-1. The anatomy of the nephron. Left: A juxtamedullary (right) and cortical nephron 
(left) are shown. The nephron components are glomerulus; proximal convoluted tubule (S1 and 
S2); proximal straight tubule (S3); thin limb (TL); thick ascending limb (TAL); distal 
convoluted tubule (DCT); connecting tubule (CNT); cortical collecting duct (CD). Adapted 
from (146) with permission, which is a modified scheme of(100). Right: Cortical nephron with 
assigned blood vessels, adapted from (215).
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The details of the blood supply to nephrons are complex, but there are two main patterns 
of vascular supply (104). For the cortical nephrons the afferent arterioles branch to form 
the capillaries of the glomerulus, and empty into the efferent arterioles which in turn 
form a second capillary network around the tubule apparatus before emptying into the 
veins (Figure 1-1). The juxtamedullary nephrons have a different pattern in that the 
proximal tubules are not fully supplied by the afferent arterioles. The glomeruli receive 
nearly a quarter of the cardiac output and approximately 10% of the incoming renal 
plasma flow is filtered to produce an ultrafiltrate. The major portion of the filtered 
solutes and 99% of the water volume are reabsorbed into blood along the tubular 
apparatus. The rate and extent by which solutes and drugs appear in urine is determined 
by the relative contribution of renal mechanisms involved in excretion, and include 
glomerular filtration, passive reabsorption, active tubular reabsorption and active tubular 
secretion. In these processes, each of the nephron components has special functions.
Glomerulus and filtration
The filtration barrier between blood and tubular lumen is composed of the capillary 
endothelium, glomerular basement membrane and the epithelial cell layer of Bowman's 
capsule. The fluid is driven from the capillaries into the capsule by hydrodynamic force. 
The process of filtration separates the plasma water and blood components with a 
molecular weight up to 50 kD or 75 to 100 Â in diameter, from the blood cells and 
protein macromolecules (colloids) that normally remain in the vascular compartment 
(229). Besides this separation on molecular weight and size, ionic charge is an important 
determinant. Larger negatively charged molecules, such as albumin, are highly retained 
from the filtrate (217). Most drugs, however, are small enough to be filtered and only 
binding to plasma proteins restricts them from filtration.
Tubular apparatus and urine composition
After filtration, the fluid passes through the tubular apparatus, where several 
mechanisms are involved in volume and solute reabsorption, and drug and metabolite 
excretion. The proximal tubules reabsorb the major part of the filtered solutes and 70% 
of the volume of the ultrafiltrate. To perform this task the tubular cells contain a large 
variety of absorptive mechanisms. Examples of simple diffusion (urea), facilitated 
transport (glucose), channel transport (water, K), anion-cation cotransport (Na-K-Cl-, 
Na-dicarboxylate-, Na-amino acid-, and H-dipeptide-cotransport), anion-anion 
countertransport (Cl-HCO3 exchange), cation-cation countertransport (Na-H antiport), 
and active transport (Na-K-ATPase, H-ATPase, Ca-ATPase) are known (226). In the 
loop of Henle a countercurrent exchange system is responsible for the initiation of the
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process of urinary concentration, which is generated further along the distal tubule and 
collecting duct. In these latter nephron segments, the final adjustments in urine 
composition are made.
Water is almost completely reabsorbed and, as a consequence, drugs concentrate in 
the filtrate which favors their passive reabsorption. Passive reabsorption occurs to a high 
proportion for lipophilic, non-ionized drugs. For organic acids (anions) or bases 
(cations), the extent of passive back-diffusion is dependent on the pKa value of the drug 
and the urine pH, which determine the degree of ionization. Another determinant in 
passive drug reabsorption is the urine flow rate.
Accumulation may take place as a result of secretory transport activity, which is 
predominantly confined to the proximal convoluted tubules. Separate mechanisms exist 
for secreting acidic (anionic) and basic (cationic) drugs from plasma into tubular lumen 
(14,62,138,156,227). Active transport processes, such as organic anion and cation 
transport, may raise the intracellular concentration of drugs by driving concentrative 
movement of these compounds into tubular cells (52,160). A remarkable heterogeneity 
in drug transport has been found. Morphologically, the proximal tubule can be divided 
in three distinct segments, S1, S2 and S3, from the convoluted tubule to the proximal 
straight tubule, respectively (Figure 1-1) (116). Organic cations are secreted mainly in 
S1 and S2 segments (118,179,180), whereas maximal secretion rates of organic anions 
are achieved in S2 segments (191,243), although species differences in anion secretion 
have been reported (178,183).
The composition of the urine is a reflection of renal function. For example, the 
appearance of large molecular weight proteins is indicative for glomerular damage and 
abnormal excretion of glucose may reflect a diminished proximal tubular reabsorptive 
function. A quantitative method to assess the functionality of the kidney is to determine 
the renal clearance (197,198).
3. Renal clearance and drug metabolism
3.1 Renal clearance
Although originally used by renal physiologists, renal clearance is now an important 
parameter for pharmacologists and toxicologists to determine drug elimination and drug 
effects on kidney function (6,20,53,169,220,232). The renal clearance value reflects the 
proportion of the renal plasma flow which is completely cleared of a compound per 
minute. In pharmacokinetic terms:
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r r
CLR ~ C  (1-1)
CP
where CLR is the renal clearance (ml/min); R  Ris the renal excretion rate (g/min) and C P 
the plasma concentration of the compound concerned (g/l) (169).
Separate pharmacokinetic analysis of plasma and renal excretion data provide an overall 
impression of the renal clearance. For a compound which is filtered freely into the 
tubule, not influenced by protein binding, and neither secreted nor reabsorbed, the renal 
clearance is identical with the glomerular filtration rate (GFR). Such a compound is 
inulin, and therefore:
CLR,inulin GFR (1-2)
A plot of CLr versus Clnu]ln results in a straight line (Figure 1-2).
Active secretion
When the rate of excretion exceeds that of filtration, active secretion must be involved 
in the elimination of a drug. Active secretion is characterized as a carrier-mediated 
process, which is sensitive to competition by structural analogs, dependent on drug 
concentration and temperature, and utilizes energy (14,62,138,156,227). The secretory 
systems are located predominantly along the proximal tubule. Para-aminohippuric acid 
(PAH) is the most extensively studied organic anion with an extremely high excretion 
rate (Figure 1-2). Approximately 92% of the amount of PAH is extracted from the blood 
plasma in a single passage through the kidneys. When plasma concentrations are high, 
however, the secretory system becomes saturated and a maximum transport capacity for 
PAH (Tmpah) can be calculated. This parameter has been used as a measure of tubular 
function (29,152,198).
Protein binding may be an important determinant in drug secretion. If dissociation of 
the drug-protein complex is very rapid, tubular secretion will not be limited by protein 
binding, as is seen for PAH. However, for some drugs the contact time between blood 
and the proximal secretory site is insufficient to transport high amounts of drug into the 
tubular lumen (23,65,105). On the other hand, in some cases the blood protein albumin 
seems to facilitate drug secretion (11,212).
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Reabsorption
Reabsorption must occur if the renal clearance of a compound is less than the calculated 
clearance by filtration. Many endogenous compounds (e.g. glucose, electrolytes and 
amino acids) and some drugs are subject to active reabsorption, which takes 
predominantly place in the proximal tubule (10,138). Glucose transport by the proximal 
tubules occurs via two transport proteins, the glucose-sodium cotransporter present in 
the luminal membrane, and the glucose transporter in the basolateral membrane. The 
activities of both transporters provide a complete reabsorption of glucose from the 
glomerular filtrate. However, when plasma concentrations are elevated, glucose will 
appear in urine because the filtered load exceeds the capacity of the transport system, as 
is seen in diabetes mellitus (10,69) (Figure 1-2).
Figure 1-2. The renal excretion profiles of PAH, inulin and glucose as a function of their 
plasma concentrations. Left: renal excretion rates, and right: corresponding clearances 
(from (184) with permission).
For the vast majority of organic anions and cations reabsorption involves a passive 
back-diffusion. The rate of reabsorption is proportional to the concentration gradient of
17
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diffusible drug across the luminal membrane, and may be affected by the urine flow rate 
and urine pH if  the drug is a weak acid or base (169). The endogenous organic anion, 
urate, is an exception. Besides active tubular secretion via the organic anion system, 
urate can be reabsorbed along the proximal tubule with the highest reabsorption rate in 
the S1 segments. Species differences in the relative contribution o f the secretory and 
reabsorptive mechanisms in renal urate handling exist, and a distinction between urate 
reabsorbers (humans, dogs, rats) and urate secreters (pigs, rabbits, guinea pigs) can be 
made. The bidirectional active transport o f urate is largely influenced by coadministered 
drugs, like probenecid, salicylate, pyrazinamide or benzbromarone (62,136,138,165).
Endocytosis is another important reabsorptive mechanism in kidney proximal tubules. 
Vesicles are formed from the brush-border membrane, and fluid and compounds are 
incorporated. Subsequently, the vesicles fuse with primary lysosomes, which are 
transferred to secondary lysosomes where the incorporated substances can be 
metabolized or released in cytoplasm. In proximal tubular cells, endocytosis is involved 
in the uptake o f low molecular weight proteins like peptide hormones (e.g. insulin, 
glucagon, growth hormone), enzymes (e.g. lysozyme, ribonuclease), immunoprotein 
fragments and membrane antigens. These compounds may enter the tubular fluid 
through filtration and bind to specific sites at the brush-border membrane (32). The 
early segments o f the proximal tubules are the major sites o f endocytosis (35). 
Additionally, endocytosis has been reported to be involved also in aminoglycoside 
uptake, however, the mechanism differs from that for proteins. It is assumed that the 
cationic aminoglycosides bind to anionic phospholipids in the brush-border membrane 
and are internalized subsequently (88).
3.2 Drug metabolism
Although drug biotransformation takes predominantly place in the liver, the kidney may 
play an important role in the metabolism o f a drug during its renal transport. Especially 
for drugs for which the kidney is the major route o f elimination. The biotransformation 
pathways reported involve oxidative, reductive and hydrolytic reactions (phase I 
reactions), and conjugation into glucuronides, sulfate esters or glutathiones (phase II 
reactions) (2,59,134).
Microsomal oxidation o f drugs through cytochrome-P450-dependent mechanisms 
take place in the kidney proximal tubules. Acute toxicity o f acetaminophen is dependent 
on the metabolic activation to p-aminophenol through cytochrome-P450, and cell 
damage is detected first in S3 segments where the highest concentration o f the enzyme
18
is found (64,122,142). Other phase I biotransformation reactions that may occur in the 
kidney are oxidations o f alcohols and aldehydes, and reduction reactions dependent on 
cytochrome P450, NADPH or glutathione (2).
Glucuronides are formed through the enzymatic activity o f UDP- 
glucuronyltransferase, an enzyme that is susceptible to induction by salicylic acid. The 
enzyme and its cofactor (UDP) are not uniformly distributed in the kidney. Data on 
morphine conjugation showed the highest activity in the S1 segment (179). Sulfate 
conjugation by the kidney is quantitatively less than glucuronide conjugation. Both 
conjugation products are highly soluble in water and readily excreted in urine (70). 
Glutathione conjugation is catalyzed by the enzyme glutathione transferase, and the 
conjugates may subsequently be transformed into cysteine conjugates and mercapturic 
acid. The different enzymes involved in these latter biotransformation reactions (y- 
glutamyltranspeptidase and N-acetyltransferase) express a high activity in renal tissue 
and are predominantly localized in S3 segments (80). Glutathione S-transferase shows 
uniform distributions over the three segments o f the proximal tubule (64).
Although biotransformation reactions are primarily detoxication mechanisms, the 
kidney may produce toxic metabolites too. This has been reported for acetaminophen 
(45,132,142), cephalosporin antibiotics (132,224), cisplatin (41), cyclosporin A (241), 
and the mycotoxins citrinin and ochratoxin A (8,46). Also bioactivation through 
glutathione S-transferase to nephrotoxic haloalkenes and by ß-lyase o f cysteine S- 
conjugates have been demostrated (33). Furthermore, metabolites formed in other 
organs may accumulate in proximal tubular cells by active uptake mechanisms and be 
involved in the development o f nephrotoxicity (45).
4. A ccum ulation of d rugs in proxim al tubules
If  all processes involved in renal clearance are taken into account, the incidence and 
degree o f accumulation can be predicted. Several methods have been developed to study 
renal drug handling. Renal drug excretion in vivo is described best by a physiologically 
based pharmacokinetic model, which includes all functional characteristics o f the 
kidney that determine the excretion o f drugs, i.e. renal plasma flow, urine flow, 
nonlinear protein binding, glomerular filtration, tubular secretion, and tubular 
accumulation (173-175). An advantage o f such a model is that proximal tubular cell 
concentrations o f organic anions in the course o f their excretion can be simulated. These 
model-predicted concentrations were confirmed in vitro at the organ level in the isolated 
perfused kidney (36,111). An advantage o f this technique is that it allows accurate 
determination o f renal drug clearance under controlled conditions and in the absence of 
nonrenal effects.
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M oreover, by using a single-pass perfusion system, the different membrane transport 
rates involved in excretion can be described by a noncompartmental data analytical 
method (66,90). Studies with isolated vesicles from both basolateral and brush-border 
membranes have revealed more insight in the molecular mechanisms o f the carrier 
systems which control the transtubular transport o f anionic and cationic drugs (9,93,94). 
M ajor advantages o f this method are that metabolism is eliminated and that the 
composition o f solutions on both sides o f the membrane can be controlled. To elucidate 
the molecular structures and characteristics o f transporters, expression cloning in 
oocytes o f Xenopus laevis have shown to be a promising method (25,27,63,101,242). It 
is obvious that membrane vesicles and oocytes may provide detailed information on the 
transport mechanisms that influence proximal tubular drug accumulation, however, the 
intracellular events are beyond their scope. Subcellular fractionation o f proximal tubules 
have revealed incorporation o f drugs in various organelles (55,56), but failed to provide 
insight into the regulation o f compartmentation. Isolated proximal tubular cells are 
useful in studying overall cellular uptake and accumulation (17,19,39,115), but uptake is 
a hybrid parameter determined by both influx and efflux rates. Yet, overall transport 
characteristics o f proximal tubular cells in suspension seem to resemble basolateral to 
luminal flux as compared to cells on filters (17,115). Cells grown as monolayers on 
filters have several technically important advantages, however, a major disadvantage is 
dedifferentiation resulting in a selective loss o f transporter system in the cell cultures, as 
is shown for the organic anion system (131). Clearly, the methods described may each 
contribute to dissolve the puzzle concerning proximal tubular drug accumulation. W ith 
the aid o f sensitive fluorescence microscopic techniques, it is now possible to 
investigate the intracellular disposition and compartmentation characteristics within the 
tubular cells in more detail, in real-time (114,115,129,130).
Table 1-1 presents a list o f drugs that accumulate within tubular cells in the course o f 
excretion, and what is known about their intracellular disposition. Three major classes 
o f compounds can be distinguished: drugs that are secreted by the organic anion and 
organic cation carrier system, and drugs for which renal accumulation is a consequence 
o f other mechanisms. Table 1-1 is far from complete, but gives examples o f the most 
frequently studied drugs. The various processes that contribute to organic anion and 
cation accumulation within the proximal tubule will be discussed in the next paragraph.
Table 1-1: Organic anions and cations known to accumulate in proximal tubular cells during 
renal excretion
Compounds Intracellular disposition Reference
Organic anions
p-Aminohippurate intracellular binding, probably to ligandina (97)
Cephalosporins binding to intracellular- and mitochondrial (55,56,221,222,235)
Diatrizoate binding, probably to ligandin (60,139)
Fluorescein accumulation in mitochondria and vesicles (115,127,129)
Hydrochlorothiazide unknown (47,112)
Indomethacin unknown (28,37,158)
Methotrexate unknown; intraluminal precipitation (79,84,143)
Penicillins binding, probably to ligandin (97,143)
Phenolsulfonphthalein extensive binding, probably to ligandin (97,188)
Phlorizinb binding, probably to ligandin (97)
Probenecid binding, probably to ligandin (5,97,189)
Quinolones unknown (141)
Salicylates unknown (28,102)
Salicyluric acid unknown (36)
Sulphonamides unknown; intraluminal precipitation (81)
Zidovudine unknown (44)
Organic cations
Acridine orange accumulation in acidic vesicles and (157,236)
Amiloride possible accumulation in acidic vesicles (236)
Cimetidine unknown (19,21,120)
Cisplatin binding to proteins (163)
Daunomycin binding to nuclei; accumulation in acidic (126,186)
N-Methylnicotinamide binding to cytosolic proteins; accumulation (7,12,200)
Morphine unknown (179)
Procainamide unknown (121)
Quinine possible accumulation in endosomes (157 )
Tetraethylammonium accumulation in acidic vesicles and (7,156,157)
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Table 1-1: continued
Compounds Intracellular disposition Reference
Miscellaneous compounds
Aminoglycosides sequestration in (secondary) lysosomes (55,56,88)
Amphotericin B binding to sterols (50,72)
Cyclosporins binding to polypeptides; accumulation in 
lysosomes, and vesicles from endoplasmic 
reticulum and Golgi apparatus
(182,247)
Iohexol unknown (113,145)
Ricin accumulation in vesicles from Golgi 
apparatus
(123)
Tetracycline accumulation in mitochondria (42,55,56)
a Ligandin is also known as gluthatione-S-transferase B.
b There is no direct evidence that phlorizin is a substrate for the organic anion carrier, but the 
compound inhibits PAH secretion in tubular lumen and has affinity for ligandin (97,138).
4.1 Accumulation o f  anionic drugs
In general much less is known about the mechanisms that govern the intracellular 
disposition o f anionic drugs than that o f cationic drugs. Anionic drugs accumulate in 
proximal tubules as a result o f secretory transport, possibly in combination with 
reabsorption. The degree o f accumulation is determined by the extent at which anionic 
drugs are actively transported across the basolateral membrane, their intracellular 
disposition and ease at which they can be transported across the brush-border membrane 
into the tubular lumen. Detailed knowledge o f each o f these steps will provide more 
insight in the incidence o f anionic drug accumulation.
4.1.1 Basolateral uptake
The mechanisms o f basolateral uptake o f anionic drugs are well documented. The 
secretory transport o f organic anionic compounds occurs against a negatively membrane 
potential across the basolateral membrane (-60 to -80 mV), and is likely to be driven by 
an active transport mechanism. Cellular uptake o f organic anions appears to be tertiary 
active, in which a sodium gradient is the driving force. The sodium gradient is 
maintained by Na,K-ATPase and creates a dicarboxylate gradient by Na-dicarboxylate 
cotransport. Subsequently, the organic anion can enter the proximal tubular cell in 
exchange for a dicarboxylate ion (Figure 1-3) (154,190). Three different transport
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mechanisms for organic anions have been identified, with overlapping specificities: the 
sulphate system, the dicarboxylate carrier and the PAH-transporter. Primary 
requirements for a substrate o f the PAH-carrier are a hydrophobic domain longer than 4 
Â (optimally 8-10 Â), and a negative charge. A second negative charge may be present, 
but must be 6-7 Â distant from the first (54). Probenecid has been used as an inhibitor of 
the organic anion system ever since this compound was found to reduce the rapid renal 
secretion o f penicillin (15), although the drug is also a substrate for the carrier system 
(189). Competition for secretion with PAH and inhibition o f transport by probenecid are 
usually accepted as good evidence for a drug to be a substrate for the organic anion 
system (14,62,119,138,156,227,237).
a-Ketoglutarate is by far the m ost abundant potential dicarboxylate counterion within 
the proximal tubular cell, and it has been shown that PAH uptake in renal cortical slices 
increases with increasing internal a-ketoglutarate concentration (30,108,155). This 
increase in PAH uptake occurs at intracellular a-ketoglutarate concentrations that 
should have been saturating, indicating that much intracellular a-ketoglutarate must be 
sequestered (155). Mitochondrial metabolism is responsible for the generation o f the 
intracellular a-ketoglutarate and from liver studies it is known that the mitochondrial a- 
ketoglutarate concentration exceeds that in cytoplasm 3-6 times (193,199). These 
findings imply that alterations in cellular metabolism may have a direct effect on the 
secretory function o f the proximal tubular cells.
Recent investigations showed that fluorescein can act as a useful model substrate for 
the PAH-transport system. W ith the aid o f sensitive fluorescence microscopic 
techniques, cellular uptake, intracellular compartmentation, and luminal secretion were 
visualized for this highly fluorescent anionic compound. Fluorescein showed 
concentration-dependent, saturable and probenecid-sensitive transport with a higher 
affinity to the PAH-transport system than PAH itself (115,128,130,144,209,210).
4.1.2 Intracellular incidents
In vitro studies in isolated proximal tubular cells revealed that, at low medium 
concentrations, PAH and fluorescein accumulated w ithin the cells. Intracellular 
concentrations o f 3-5 times the medium concentration were determined. Confocal 
microscopic images o f rat proximal tubular cells showed that fluorescein was 
compartmentalized within subcellular organelles, the major one being mitochondria 
(115). Simultaneously, a paper on fluorescein accumulation in crab urinary bladder 
showed nocodazole-sensitive vesicular compartmentation and luminal secretion 
(127,129). Nocodazole disrupts the Golgi apparatus and subsequently microtubules, 
which are involved in the movement o f transporting vesicles thorough the cells (22).
23
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Luminal m em brane Basolateral m embrane
Figure 1-3. Mechanisms mediating renal organic anion (OA) accumulation. Active 
uptake o f organic anions into the proximal tubule cell is indirectly coupled to a Na+- 
gradient at the basolateral membrane through Na+-dicarboxylate cotransport and 
dicarboxylate-organic anion exchange. Intracellularly the anions may be sequestered in 
mitochondria and, not yet further identified, vesicular structures, or bind to ligandin (L). 
Efflux into the lumen may be via a potential-driven pathway and via inorganic- and 
organic-anion exchange mechanisms, for which X- is the counterion. Scheme is modified 
from (156).
Although the species used in these studies differ, the findings suggest that at least two 
different compartments are involved in the intracellular accumulation of this anion 
(Figure 1-3).
Uptake o f anionic compounds in mitochondria is energetically uphill (inside negative 
membrane potential o f -220 mV) and must therefore be driven by active transport. 
Recent studies have shown that fluorescein competitively interacts with the
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dicarboxylate, succinate, for uptake into rat renal cortical mitochondria (114). 
Moreover, confocal images revealed that mitochondrial uptake o f fluorescein could be 
inhibited by phenyl succinate, an agent known to block mitochondrial dicarboxylate 
transport irreversibly. These findings suggest that fluorescein may be a substrate for the 
mitochondrial dicarboxylate carrier. Interaction with mitochondrial transporters has 
been reported for other anionic drugs, like valproate and cephalosporins (171,221,222).
In the hepatocyte, it was shown that intracellular compartmentation o f organic anions 
and bile salts may involve vesicular accumulation (148). This is comparable to the 
vesicular accumulation found for fluorescein, however, the nature and function o f this 
compartment has, as yet, not been elucidated. The involvement o f microtubules in 
vesicular compartmentation suggest a role in transcellular transport and/or secretion. 
Another possibility is that endosomal membranes contain carrier proteins for the 
regulation o f transport activity on plasma membranes, which are accidently involved in 
the accumulation of organic anions into these vesicles.
Hardly any research is done on transcellular transport o f organic anions in the renal 
proximal tubule. Two decades ago, the presence o f anion binding proteins were shown, 
the major one being ligandin (26,106) or glutathione S-transferase B (187). Anionic 
drugs, like PAH, penicillin, probenecid, phlorizin and diatrizoate, were found to interact 
with ligandin suggesting that this protein may play a role in the reduction o f free 
cytoplasmic drug concentrations and in transcellular drug trafficking (60,97,106), 
although binding to glutathione S-transferase is not a determinant for the rate o f luminal 
secretion (151). Unfortunately, more recent data on the role o f binding proteins is not 
available.
4.1.3 Luminal transport
The passive permeability o f the brush-border membrane for organic anions is 
considerably greater than the permeability o f the basolateral membrane, and efflux 
across the brush-border membrane is therefore the principal route o f exit (223). 
Although efflux o f organic anions out o f proximal tubular cells is energetically 
downhill, facilitated efflux driven by the membrane potential has been reported (93) 
(Figure 1-3). Furthermore, in brush-border membrane vesicles o f the dog and rat a PAH- 
anion exchanger is present (93,147,172), where Cl-, OH- and HCO3- appeared to be the 
endogenous counterions (16,87,147,205). In human and bovine brush-border 
membranes an additional PAH-dicarboxylate exchanger is involved in luminal organic 
anion efflux (164,181), whereas no exchange mechanism has been found in pigs and 
rabbits (110,240). In these species, organic anions are transported by a voltage-sensitive 
pathway, which may be also present in rats (147).
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Studies in isolated dog kidney brush-border membrane vesicles showed that PAH 
transport across the luminal membrane is concentration-dependent, probenecid-sensitive 
and susceptible to competition by other anionic drugs (e.g. salicylate, hippurate, 
hydrochlorothiazide) (172). Although the affinity o f PAH for this transport system is 10 
times lower than that for the basolateral organic anion carrier, the maximum capacity of 
the system is considerably greater (93,172). These kinetic parameters are consistent with 
the existence o f a simple transport mechanism for organic anions across the dog kidney 
brush-border membrane.
4.1.4 Tubular reabsorption
The renal excretion and tubular accumulation o f organic anions will be influenced by 
passive and active reabsorption. Passive tubular reabsorption may be driven by the large 
concentration gradients between tubular fluid and interstitial fluid, the transcellular 
electrical potential difference (which is slightly negative in the proximal tubular fluid), 
and the negative pH difference between tubular and interstitial fluid. The transcellular 
route is the major pathway for back-diffusion o f organic anions such as PAH, however, 
for certain organic anions (e.g. probenecid and salicylate) the tight-junctions possesses a 
higher permeability (138). As a consequence, reabsorption o f these drugs will not 
contribute to their cellular accumulation (38). Active reabsorption may, o f course, 
account for intracellular drug accumulation. Carrier-mediated tubular reabsorption has 
been reported for the anionic drugs, m-hydroxybenzoate (117), pyrazinoate (13,238) and 
nicotinate (34). It is not clear how active reabsorption o f organic anions is regulated, but 
the urate transporter may be involved. This carrier system is supposed to be the 
bidirectional PAH-anion exchanger localized in the brush-border membrane
(87,110,164), however in pigs a sodium cotransporter was found (13). Additionally, 
only in the Necturus kidney active reabsorption o f PAH and diodrast has been described 
(96).
Some cephalosporin antibiotics are substrates for a peptide carrier localized at the 
brush-border membrane (140,162). This transport is H+-dependent and exhibits similar 
properties to the peptide-H+-cotransporter identified in the intestine (98,207,208,239). 
Since most compounds transported by this latter system are zwitterions, the carrier is not 
depicted in Figure 1-3 as an anion transporter.
4.2 Accumulation o f cationic drugs
The group o f drugs actively secreted by the cation system is structurally heterogeneous, 
and include primary, secondary and tertiary amines, and quaternary ammonium salts 
(62,119,156,227). Alike organic anions, cationic drug accumulation in proximal tubules
26
is a result o f secretory transport. However, in contrast with anionic drugs, transport over 
the brush-border membrane into the tubular lumen is in favor o f basolateral uptake, 
implying that the degree o f accumulation is determined by other factors than transport 
solely. The electrochemical potential difference and intracellular compartmentation are 
important elements in the extent o f accumulation of cationic drugs. The different steps 
in renal organic cation handling will be discussed below.
4.2.1 Basolateral uptake
Similar to the model function that PAH plays for the organic anion system, 
tetraethylammonium (TEA) and N^m ethylnicotinamide (NMN) have been used as 
model compounds for studying organic cation transport (49,160,161,168). Quinine, 
cimetidine and mepiperphenidol are potent inhibitors o f the transport system (202,219). 
Although the widely prescribed histamine H2-receptor antagonist, cimetidine, has been 
proposed to be useful as a marker for organic cation transport as well, because o f its 
high affinity for the transport system (120). Organic cations enter proximal tubular cells 
by facilitated diffusion for which the potential difference o f -60 to -80 mV across the 
basolateral membrane is the driving force (62,93,119,156,227) (Figure 1-4). Similar to 
what was found for basolateral organic anion transport, there are special requirements 
for organic cations to be a substrate for the basolateral carrier system. The interaction 
depends largely on hydrophobicity, charge strength and hydrogen bond formation (228), 
whereas ionization o f the organic compound is not required (19). Nevertheless, 
ionization does count in the intracellular concentration that can be achieved, because it 
prevents the compound from diffusing passively into the proximal tubular cell (228).
The basolateral uptake o f cationic drugs is still not completely understood. Tissue-to- 
medium concentration ratios up to 10 would support the existence o f a facilitated 
diffusion mechanism for TEA. However, TEA reached cellular concentrations much 
higher than 10, suggesting that another active system is located at the basolateral 
membrane (14,180). In isolated basolateral membrane vesicles o f the rabbit kidney, 
the existence o f a countertransport mechanism for organic cations against protons has 
been reported, which seems to be absent in other species (135,201). Furthermore, the 
link between organic cation uptake to Na+-K+-ATPase activity is still unknown 
(14,120,121,213).
4.2.2 Intracellular incidents
As discussed in 4.2.1, during secretion the intracellular concentration o f TEA exceeds 
electrochemical equilibrium. In the perfused rabbit proximal tubule, the cation reached
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intracellular concentrations o f 40 and in nonperfused tubules even up to 100 times the 
medium concentration (180). Because no additional active uptake mechanism has been 
identified, it was suggested that cations may be sequestered intracellularly 
(135,160,245). Intracellular binding may be involved in the accumulation o f TEA and 
N M N in rat and rabbit renal cortex, where these cations bind to cytosolic proteins 
(7,160) (Figure 1-4).
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Luminal membrane Basolateral membrane
Figure 1-4. Mechanisms mediating renal organic cation (OC) accumulation. Facilitated 
diffusion into the proximal tubular cell is driven by the potential difference of -60 to -80 mV 
across the basolateral membrane. Intracellularly, the cations may be sequestered in 
mitochondria, endosomes and/or bind to cytosolic proteins (P). Efflux into the lumen is 
regulated via exchange with protons, for which the energy is provided by the Na+/H+-antiport 
system. In addition, some cations are excreted by the P-glycoprotein-associated MDR 
transporter (Pgp), which is involved also in the efilux o f neutral compounds, such as digoxin. 
Scheme is modified from (156).
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Another mode o f intracellular sequestration is accumulation within intracellular 
organelles. Uptake in mitochondria is driven by the inside negative membrane potential, 
which is -220 mV (86,167). Several other organelles, e.g. endosomes, lysosomes and 
Golgi vesicles, are more acidic than the surrounding cytoplasm and this inside negative 
pH gradient could drive organic cation uptake. Cations may become trapped after 
nonionic diffusion into these organelles because they will be ionized in the acidic 
interior (124). Recent investigations showed that TEA could accumulate within 
endosomal membrane vesicles o f the renal cortex, however, the mechanism of 
accumulation seems to be more specific than by "pH-trapping" alone. Pritchard et al. 
(157) showed that endosomal accumulation is mediated by a proton/TEA exchange 
mechanism, which is driven by the pH gradient, maintained by H+-ATPase (Figure 1-4). 
ATP-dependent TEA uptake was sensitive to various organic cations like quinine, 
verapamil and quinacrine, and to a lower extent to NMN. This poor inhibition by NM N 
is consistent with its lower tendency to accumulate within renal tubules as compared to 
TEA (7,12). The results o f Pritchard et al. (157) suggest that an identical mechanism of 
accumulation could be expected for other accumulating cations. The authors 
hypothesized that endosomes might cycle between cell interior and brush-border 
membrane and play a role in luminal organic cation secretion. This phenomenon of 
subcellular endosomal transport and secretion has been described for intracellularly 
synthesized proteins and (receptor-mediated) endocytosed substances in renal epithelial 
cells (22,123,195).
4.2.3 Luminal transport
Various investigations with isolated brush-border membrane vesicles showed that 
transport across this membrane is mediated by an electroneutral organic cation-proton 
antiporter. The energy for this exchange mechanism is provided by a proton gradient, 
which is generated by a Na+-H+-exchanger (74,75,200,236). To maintain the 
intracellular sodium gradient, the influx o f sodium is eliminated by Na+-K+-ATPase. So 
efflux o f cations is regulated by a tertiary active transport mechanism. Strikingly, the 
secretion o f organic cations appeared to be sensitive to PAH, probenecid and phlorizin, 
suggesting an interaction between anionic and cationic drugs (17,78,120).
A second transport system involved in luminal organic cation transport is the P- 
glycoprotein (Pgp) associated multidrug resistance (MDR) transporter. This transport 
protein is an ATP-dependent integral membrane protein which is predominantly present 
in chemotherapeutic drug resistant tumor cells, but also present in normal tissues such 
as liver, intestine, adrenal glands, placenta and kidney (51,216) (Figure 1-4). Pgp 
transports a broad spectrum of cationic and nonionic drugs, viz. anthracyclines, vinca 
alkaloids, epipodophyllotoxins, taxol, actinomycin D (51), and the cardiac glycoside,
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digoxin (43,77). The ability o f cells to exclude these drugs can be reduced by 
chemosensitizers, including hydrophobic amines known to interact with the organic 
cation transport system. For this reason it was suggested that the M DR transporter was 
an unidentified component o f the organic cation carrier, however, photoaffinity labeling 
studies revealed that separate carrier systems exist in the brush-border membrane (76). 
A recent study with the anthracycline and organic cation, daunomycin, showed that 
active luminal secretion is driven by the M DR transporter. But at lower medium pH the 
cation carrier was found to contribute also in daunomycin secretion, suggesting that 
both systems may provide parallel excretory pathways for organic cations (126) (Figure
1-4).
4.2.4 Tubular reabsorption
Passive tubular reabsorption o f organic cations may be driven by the large concentration 
gradients between tubular and interstitial fluid and a urinary pH change from acidic to 
relatively alkaline, however, this mechanism will not contribute to cellular accumulation 
above electochemical equilibrium (14,18,169). An active reabsorptive mechanism has 
been reported for the endogenous cation choline, for which a high affinity transporter is 
present on renal cortical brush-border membranes (246). Several compounds known to 
interact with the organic cation-proton exchanger had little or no effect on choline 
reabsorption, indicating that this mechanism o f reabsorption is not likely to play a role 
in renal cationic drug handling.
5. A ccum ulation of d rugs in o ther tran sp o rtin g  epithelia
Other epithelial organs able to transport drugs are the liver, intestine, choroid plexus, 
placenta and ciliary body o f the eye. Alike the kidney, the intestine and liver have a 
function in the excretion o f drugs. The intestine is the major route o f entry o f drugs into 
the organism. Its main function is the absorption o f ingested nutrients and, therefore, 
intestinal transport is predominantly organized from brush-border (mucosal) side to 
basolateral (serosal) side.
A primary requirement for drugs to enter the intestinal epithelial cells is to diffuse 
through the mucosal barrier. To this end, the xenobiotic must be solubilized or may be 
metabolized. Subsequently, the drug molecules are transcytosed mainly by simple 
diffusion (40,71,125,185). A tertiary active transport system has been reported for small 
peptides, which co-transports also several ß-lactam antibiotics and penicillins together 
with protons (153,207,208,239). A sodium-dependent cotransporter mediates luminal 
uptake o f bile acids and may be sensitive to various drugs (73).
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In addition to the absorptive mechanisms, intestinal secretion has been reported 
for cardiac glycosides, cationic and anionic drugs. For cationic drugs, a P-glycoprotein- 
mediated efflux system at the brush-border membrane has been reported. It is suggested 
that this efflux system plays a dominant role in the low oral bioavailability o f some 
hydrophobic drugs (82,177). A similar organic cation transport system found in renal 
proximal tubular cells seems not to be present in the enterocyte, although a guanidine- 
proton antiporter with a sensitivity to some cationic drugs (but not TEA) has been 
reported (133). To date, no information is available on the intracellular disposition of 
drugs in the intestine. The transport function o f the enterocytes, as well as the high 
exposure to xenobiotics and the structural similarity to other polarized epithelia (kidney 
and liver), suggest that drug accumulation may take place.
Much more is known about the accumulation o f drugs in the liver. After intestinal 
absorption drugs are carried with the portal blood to the liver. The specific architecture 
o f the hepatic sinusoids brings the drugs in close contact with the hepatocytes. A broad 
spectrum of transporters are involved in sinusoidal (basolateral) uptake, intracellular 
compartmentation and canalicular secretion (reviewed in ref. (149)). In the category of 
organic anions, a distinction between bile salts and non-bile salt organic anions can be 
made. The uptake o f bile salts involves a Na+-dependent and a N a +-independent 
mechanism and is sensitive to cyclosporin A and bromosulfonphthalein. Hepatic uptake 
o f non-bile salt organic anions is Na+-independent and electrogenic.
Intracellularly, organic anions may bind to cytosolic proteins, including glutathione-S- 
transferases (106,187), Y'-binding protein and fatty acid binding proteins (206). Such 
binding proteins are suggested to be responsible for transcellular transport o f organic 
anions and reduce free cytoplasmic concentrations and organellar accumulation. 
Moreover, transcellular vesicular movement has been reported, which may involve 
microtubules (3). These vesicles probably originate from the Golgi network and 
endoplasmic reticulum (194). Furthermore, it was shown that the canalicular 
multispecific organic anion transporter (cMOAT) may be localized on intracellular 
vesicles and probably involved in the accumulation o f organic anions in vesicles (148). 
A comparable endosomal compartmentation mechanism has been proposed for the bile 
salt taurocholate (48,91). It is still unclear whether these vesicles have a function in the 
transport o f organic anions or bile salts, or a regulatory function in transporter activity 
on the canalicular membrane (48,166).
Canalicular transport o f bile salts and non-bile salt organic anions is regulated via 
distinct ATP-dependent transporters. The canalicular multispecific organic anion 
transporter, cMOAT, was found to be absent in a certain rat strain (TR- rats), whereas 
bile salt secretion was unaffected. In the same species, impaired canalicular secretion of 
anionic antibiotics, like cephalosporins and penicillins, was found, indicating that their
31
Chapter 1
secretion is regulated by cMOAT (149,234).
Organic cations accumulate in hepatocytes to a high extent, via several uptake and 
sequestration mechanisms. Hepatocyte uptake systems include two types o f cation 
carriers, with overlapping specificities, endocytosis and passive diffusion. Cell 
fractionation studies o f livers revealed that cations accumulate w ithin lysosomes, 
endosomes and mitochondria. Sequestration in acidic organelles, like lysosomes and 
endosomes, is suggested to be a result o f organic cation-proton exchange, driven by H -  
ATPase, and a possible supplementary mechanism o f pH-trapping after nonionic 
diffusion (137,231). Uptake in mitochondria is driven by the inside negative membrane 
potential o f the organelle (-220 mV). Furthermore, the substantial intramitochondrial 
volume, as well as binding to mitochondrial DNA may contribute to its organic cation 
accumulation (204,244). Canalicular excretion o f organic cations occurs via 
electroneutral exchange with organic or inorganic cations, or by formation o f ion-pairs 
with lipophilic anions (170). In similarity with renal proximal tubular cells, the 
hepatocyte canalicular membrane possesses a P-glycoprotein-mediated, ATP-dependent 
transport system, which may play an important role in organic cation secretion (214).
In summary, drug accumulation as a consequence o f vectorial transport and 
intracellular binding or compartmentation in hepatocytes is comparable with that in 
kidney proximal tubules.
6. C linical im plications of proxim al tu b u la r  d ru g  accum ulation
A great number o f drugs are eliminated from the body mainly by urinary excretion, and 
renal proximal tubular accumulation in the course o f excretion may therefore be the 
basis o f a variety o f clinical implications. For example, applications o f PAH or 
radiocontrast agents to measure renal blood flow or maximal secretory transport 
capacity can lead to erroneous conclusions concerning the function o f the kidney, when 
intracellular drug concentrations are not taken into account (53,62,113). Furthermore, 
for drugs with a mechanism o f action dependent upon their transport, e.g. diuretics and 
certain antibacterial agents, an indirect relationship between plasma concentration and 
effect may result (31,112). The clinical use o f aminoglycoside antibiotics is frequently 
limited by a dose-related nephrotoxicity as a result o f proximal tubular accumulation 
(88,103). A similar effect can be ascribed to amphotericin B, which accumulates 
extensively in the distal tubule and collecting duct (50,72,176).
Active transport processes, such as organic anion and cation transport, may raise the 
intracellular concentration and appear to be directly related to the development of 
tubular injury. Clinically important examples are cephaloridine, cisplatin, methotrexate 
and ochratoxin A (57,81,235). A change in urinary pH may affect drug retention within
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the proximal tubular cells as a consequence o f a change in transport rate across the 
brush-border membrane (18,89), hereby affecting the pharmacologic activity o f the 
cationic drug (225).
Drug interactions at the level of secretion may modify drug accumulation in tubular 
cells (143,230), and is especially important when one o f the drugs has a narrow 
therapeutic index. Moreover, fatal interactions have been reported between methotrexate 
and non-steroidal anti-inflammatory drugs (92,99,107,196). The interaction between 
drugs and endogenous compounds has been demonstrated evidently for urate
(87,110,164), and may have clinical consequences (203,238). The cationic drugs 
cimetidine and trimethoprim compete with the zwitterion creatinine for secretion, 
leading to an increase in plasma creatinine concentration, thus influencing the suitability 
o f creatinine as a renal function marker (24,192). Furthermore, coadministration of 
cationic and anionic or zwitterionic drugs may affect the renal elimination o f the cation 
(58,83), anion (1) or zwitterion (85).
In patients with reduced renal function the clinical implications for urinary excreted 
drugs are much more abundant. The exposure time to drugs is lengthened as a result o f a 
prolonged half-life, and an increased intensity o f drug effect will result and drug 
accumulation may be more extensive (159). Renal insufficiency is an important risk 
factor in the development o f contrast-associated nephropathy (4,211). In addition, 
concomitant use o f cisplatin and contrast media may intensify the nephrotoxicity o f the 
contrast agent (150). In rats and rabbits in vivo, the combination o f indomethacin and 
radiocontrast agents produces acute renal failure, and this combination o f drugs is used 
to provide an adequate model o f clinical radiocontrast nephropathy (67,68,233).
For the reasons mentioned earlier, detailed knowledge o f the mechanisms that govern 
renal drug handling is necessary for safe and well-considered drug therapy
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7. Scope of this thesis
The intent o f the present study was to elucidate by which mechanisms drugs accumulate 
within proximal tubular cells during renal excretion. The experimental approach o f the 
accumulation process included transport studies in the isolated perfused rat kidney 
(IPK), uptake experiments in isolated proximal tubular cells (PTC) and mitochondria of 
the rat kidney, and proximal tubules o f the killifish kidney.
In section II, the tubular accumulation characteristics o f various compounds in the 
IPK, determined from their excretion profiles, are described. The influence o f drug- 
protein binding on the secretory transport o f two methyl-substituted hippurates, for 
which extensive accumulation is a direct result o f efficient tubular uptake, is discussed 
(chapter 2 and 3). Also, the relationship between renal accumulation and diuretic 
activity o f hydrochlorothiazide is described (chapter 4). The mitochondrial dye 
rhodamine 123, possesses affinity for the P-glycoprotein associated multidrug resistance 
transporter in various tumor cell lines. In chapter 5, the transport and accumulation 
characteristics in the isolated perfused rat kidney are presented, showing organic cation­
carrier mediated transport o f the dye. The renal handling o f two radiocontrast agents, 
iohexol and diatrizoate, are discussed in chapters 6 and 7. For iohexol there are 
indications that this compound is endocytosed in the proximal tubular cell, which is in 
contradiction with other reports that iohexol may be useful as a glomerular filtration 
marker. The presence and role o f an endocytotic mechanism in the overall renal 
clearance o f iohexol was investigated in the IPK (chapter 6). The renal handling of 
diatrizoate involved a secretory as well as a reabsorptive mechanism through which the 
drug accumulated in the IPK (chapter 7).
In section III, the intracellular events o f fluorescent anionic compounds, investigated 
in PTC and killifish proximal tubules, are discussed. The uptake o f fluorescein was 
found to be regulated by the PAH transport system, and compartmentation o f this 
fluorescent organic anion within mitochondria was visualized by means o f confocal 
microscopy (chapter 8). Accumulation in mitochondria is probably a result o f uptake 
mediated by the mitochondrial dicarboxylate carrier (chapter 9). The uptake, excretion 
and compartmentation characteristics o f another fluorescent organic anion, Lucifer 
Yellow, was studied in the IPK and in PTC, and the suitability o f this compound as a 
marker for studying organic anion accumulation is discussed (chapter 10). The last 
chapter (chapter 11) deals with the cellular uptake and luminal secretion o f fluorescein- 
methotrexate in killifish proximal tubules. Finally, the results described in this thesis are 
reviewed briefly and perspectives in future research are discussed.
34
8. References
1. AIBA, T., Y. SAKURAI, S. TSUKADA, AND T. KOIZUMI. Effects of probenecid and 
cimetidine on the renal excretion of 3'-azido-3'-deoxythymidine in rats. J. Pharmacol. 
Exp. Ther. 272: 94-99, 1995.
2. ANDERS, M. W. Metabolism of drugs by the kidney. Kidney Int. 18: 636-647, 1980.
3. AOYAMA, N., H. TOKUMO, T. OHYA, K. CHANDLER, AND R. T. HOLZBACH. A 
novel transcellular transport pathway for non-bile salt cholephilic organic anions. Am. J. 
Physiol. 261: G305-G311, 1991.
4. BARRETT, B. J., P. S. PARFEY, H. M. VAVASOUR, J. MCDONALD, G. KENT, D. 
HEFFERTON, F. O'DEA, E. STONE, R. REDDY, AND P. J. MCMANAMON. Contrast 
nephropathy in patients with impaired renal function: high versus low osmolar media. 
Kidney Int. 41: 1274-1279, 1992.
5. BERNDT, W. O. Probenecid binding by renal cortical slices and homogenates. Proc. 
Soc. Exp. Biol. Med. 126: 123-126, 1967.
6. BERNDT, W. O. Use of renal function tests in the evaluation of nephrotoxic effects. In: 
Toxicology of the kidney, edited by J. B. Hook. New York: Raven Press, Ltd., 1981, p.
1-29.
7. BERNDT, W. O. Organic base transport: a comparative study. Pharmacol. 22: 251-262, 
1981.
8. BERNDT, W. O. Effects of selected fungal toxins on renal function. In: Toxicology of 
the kidney, edited by J. B. Hook and R. S. Goldstein. New York: Raven Press, 1993, p. 
459-475.
9. BERNER, W. AND R. KINNE. Transport of p-aminohippuric acid by plasma membrane 
vesicles isolated from rat kidney cortex. Pflügers Arch. 361: 269-277, 1976.
10. BERRY, C. A. AND F. C. JR. RECTOR. Renal transport of glucose, amino acids, 
sodium, chloride, and water. In: The kidney, edited by B. M. Brenner and F. C. Rector 
jr.. Philadelphia: W.B. Saunders Company, 1991, p. 245-282.
11. BESSEGHIR, K., D. MOSIG, AND F. ROCH-RAMEL. Facilitation by serum albumin of 
renal tubular secretion of organic anions. Am. J. Physiol. 256: F475-F484, 1989.
12. BESSEGHIR, K., D. MOSIG, AND F. ROCH-RAMEL. Transport of the organic cation 
N-methylnicotinamide by the rabbit proximal tubule. I. Accumulation in the isolated 
nonperfused tubule. J. Pharmacol. Exp. Ther. 253: 444-460, 1990.
13. BESSEGHIR, K. AND F. ROCH-RAMEL. Pyrazinoate transport in the isolated perfused 
rabbit proximal tubule. Pflügers Arch. 407: 643-648, 1986.
14. BESSEGHIR, K. AND F. ROCH-RAMEL. Renal excretion of drugs and other 
xenobiotics. Renal Physiol. 10: 221-241, 1987.
15. BEYER, K. H., H. F. RUSSO, E. K. TILLSON, A. K. MILLER, W. F. VERWEY, AND
S. R. GASS. 'Benemid' p-(di-n-propylsulfamyl)-benzoic acid: its renal affinity and its 
elimination. Am. J. Physiol. 166: 625-640, 1951.
16. BLOMSTEDT, J. W. AND P. S. ARONSON. pH gradient-stimulated transport of urate 
and p-aminohippurate in dog renal microvillus membrane vesicles. J. Clin. Invest. 65: 
931-934, 1980.
35
17. BOOM, S. P. A., F. W. J. GRIBNAU, AND F. G. M. RUSSEL. Organic cation transport 
and cationic drug interactions in freshly isolated proximal tubular cells of the rat. J. 
Pharmacol. Exp. Ther. 263: 445-450, 1992.
18. BOOM, S. P. A., M. M. MOONS, AND F. G. M. RUSSEL. Renal tubular transport of 
cimetidine in the isolated perfused kidney of the rat. Drug Metab. Dispos. 22: 148-153,
1994.
19. BOOM, S. P. A. AND F. G. M. RUSSEL. Cimetidine uptake and interactions with 
cationic drugs in freshly isolated proximal tubular cells of the rat. J. Pharmacol. Exp. 
Ther. 267: 1039-1044, 1993.
20. BRATER, D. C., P. P. SOKOL, S. D. HALL, AND T. D. MCKINNEY. Renal 
elimination of drugs: methods and determinants. In: The kidney: physiology and 
pathophysiology, edited by D. W. Seldin and G. Giebisch. New York: Raven Press, Ltd.,
1992, p. 3597-3628.
21. BRÄNDLE, E. AND J. GREVEN. Transport of cimetidine across the basolateral 
membrane of rabbit kidney proximal tubules: characterization of transport mechanisms. 
J. Pharmacol. Exp. Ther. 258: 1038-1045, 1991.
22. BROWN, D. Epithelial cell polarity: molecular mechanisms. In: Molecular nephrology, 
kidney fucntion in health and disease, edited by D. Schlöndorff and J. V. Bonventre. 
New York: Marcel Dekker, Inc., 1995, p. 21-32.
23. BRYAN, C. W. AND J. F. MAHER. Factors influencing the renal excretion of 
o-iodohippurate. Am. J. Physiol. 225: 1220-1225, 1973.
24. BURGESS, E., A. BLAIR, K. KRICHMAN, AND R. E. CUTLER. Inhibition of renal 
creatinine secretion in humans. Renal Physiol. 5: 27-30, 1982.
25. BUSCH, A. E., S. WALDEGGER, H. MURER, AND F. LANG. The molecules of 
proximal tubular transport: insights from electrophysiology. Nephron 72: 1-8, 1996.
26. CAMPBELL, J. A. H., N. M. BASS, AND R. E. KIRSCH. Immunohistological 
localization of ligandin in human tissues. Cancer 45: 503-510, 1980.
27. CASTILLO, G., J. C. VERA, C-P. HUANG YANG, S. BAND HORWITZ, AND O. M. 
ROSEN. Functional expression of murine multidrug resistance in Xenopus laevis 
oocytes. Proc. Natl. Acad. Sci. USA 87: 4737-4741, 1990.
28. CATERSON, R. J. AND G. G. DUGGIN. Intrarenal distribution of salicylate. Proc. Aus. 
Soc. Med. Res. 11: 1-57, 1978.
29. CHASIS, H., J. REDISH, W. GOLDRING, H. A. RANGES, AND H. W. SMITH. The 
use of sodium p-aminohippurate for the functional evaluation of the human kidney. J. 
Clin. Invest. 24: 583-588, 1945.
30. CHATSUDTHIPONG, V. AND W. H. DANTZLER. PAH/a-KG countertransport 
stimulates PAH uptake and net secretion in isolated rabbit renal tubules. Am. J. Physiol. 
2631: F384-F391, 1992.
31. CHENNA VASIN, P., R. SEIWELL, D. C. BRATER, AND W. M. M. LIANG. 
Pharmacodynamic analysis of the furosemide-probenecid interaction in man. Kidney Int. 
16: 187-195, 1979.
Chapter 1_______________________________________________________________________
36
32. CHRISTENSEN, E. I. AND S. NIELSEN. Structural and functional features of protein 
handling in the kidney proximal tubule. Semin. Nephrol. 11: 414-439, 1991.
33. COMMANDEUR, J. N. M., G. J. STIJNTJES, AND N. P. E. VERMEULEN. Enzymes 
and transport systems involved in the formation and disposition of glutathione 
S-conjugates. Physiol. Rev. 47: 271-330, 1995.
34. CORR, P. B. AND D. G. MAY. Renal mechanisms for the excretion of nicotinic acid. J. 
Pharmacol. Exp. Ther. 192: 195-200, 1975.
35. CORTNEY, M. A., L. L. SAWIN, AND D. D. WEISS. Renal tubular protein absorption 
in the rat. J. Clin. Invest. 49: 1-4, 1970.
36. COX, P. G. F., M. M. MOONS, F. G. M. RUSSEL, AND C. A. M. VAN GINNEKEN. 
Renal handling of salicyluric acid in the isolated perfused rat kidney: evidence for 
accumulation in tubular cells. J. Pharmacol. Exp. Ther. 251: 750-755, 1989.
37. COX, P. G. F., M. M. MOONS, F. G. M. RUSSEL, AND C. A. M. VAN GINNEKEN. 
Indomethacin: renal handling and effects in the isolated perfused rat kidney. Pharmacol. 
42: 287-296, 1991.
38. COX, P. G. F., M. M. MOONS, F. G. M. RUSSEL, AND C. A. M. VAN GINNEKEN. 
Renal handling of and effects of salicylic acid in the isolated perfused rat kidney. 
Pharmacol. Toxicol. 68: 322-328, 1991.
39. COX, P. G. F., C. H. VAN OS, AND F. G. M. RUSSEL. Accumulation of salicylic acid 
and indomethacin in isolated proximal tubular cells of the rat kidney. Pharmacol. Res. 
27: 241-252, 1993.
40. CSAKY, T. Z. Intestinal absorption of xenobiotics. Handb. Exp. Pharmacol. 70: 1-30, 
1984.
41. DALEY-YATES, P. T. AND D. C. H. MCBRIEN. Cisplatin metabolites: a method for 
their separation and for measurement of their renal clearances in vivo. Biochem. 
Pharmacol. 33: 3063-3070, 1984.
42. DE BUY, H. G. AND J. L. SHOWACRE. Selective localization of tetracycline in 
mitochondria of living cells. Science 133: 196-197, 1961.
43. DE LANNOY, I. A. M., G. KOREN, J. KLEIN, J. CHARUK, AND M. SILVERMAN. 
Cyclosporin and quinidine inhibition of renal digoxin excretion: evidence for luminal 
secretion of digoxin. Am. J. Physiol. 263: F613-F622, 1992.
44. DE MIRANDA, P., T. C. BURNETTE, AND S. S. GOOD. Tissue distribution and 
metabolic disposition of zidovudine in rats. Drug Metab. Dispos. 18: 315-320, 1990.
45. DEKANT, W. AND S. VAMVAKAS. Biotransformation and membrane transport in 
nephrotoxicity. Crit. Rev. Toxicol. 26: 309-334, 1996.
46. DELACRUZ, L. AND P. H. BACH. The role of ochratoxin A metabolism and 
biochemistry in animal and human nephrotoxicity. J. Biopharm. Sci. 1: 277-304, 1990.
47. DUGGAN, D. E. The accumulation of chlorothiazide and related saluretic agents by 
isolated renal tubules. J. Pharmacol. Exp. Ther. 152: 122-129, 1966.
48. ERLINGER, S. Do intracellular organelles have any role in transport of bile acids by 
hepatocytes? J. Hepatology 24: 88-93, 1996.
49. FARAH, A. AND M. FRAZER. Studies on the renal tubular secretion of 
N1-methylnicotinamide. J. Pharmacol. Exp. Ther. 134: 245, 1961.
37
50. FINN, J. T., L. H. COHEN, AND P. R. STEINMETZ. Acidifying defect induced by 
amphotericin B: comparison of bicarbonate and hydrogen ion permeabilities. Kidney 
Int. 11: 261-266, 1977.
51. FORD, J. M. AND W. N. HAIT. Pharmacology of drugs that alter multidrug resistance in 
cancer. Pharmacol. Rev. 42: 155-199, 1990.
52. FORSTER, R. P. AND J. H. COPENHAVER JR.. Intracellular accumulation as an active 
process in a mammalian renal transport system in vitro. Energy dependence and 
competitive phenomena. Am. J. Physiol. 186: 167-171, 1956.
53. FOULKES, E. C. Functional assessment of the kidney. In: Toxicology of the kidney, 
edited by J. B. Hook and R. S. Goldstein. New York: Raven Press, Ltd., 1993, p. 37-60.
54. FRITZSCH, G., G. RUMRICH, AND K. J. ULLRICH. Anion transport through the 
contraluminal cell membrane of renal proximal tubule. The influence of hydrophobicity 
and molecular charge distribution on the inhibitory activity of organic anions. Biochim. 
Biophys. Acta 978: 249-256, 1989.
55. FUJITA, K. AND H. M. FUJITA. Reversibility of antibiotic incorporation in large 
organelles of kidney cell. Int. J. Clin. Pharmacol. Ther. Toxicol. 23: 291-294, 1985.
56. FUJITA, K. AND H. M. FUJITA. The localization of antibiotics by continuous sucrose 
gradient density. Int. J. Clin. Pharmacol. Ther. Toxicol. 23: 288-290, 1985.
57. GEKLE, M. AND S. SILBERNAGL. The role of the proximal tubule in ochrotoxin A 
nephrotoxicity in vivo: Toxodynamic and toxokinetic aspects. Renal Physiol. Biochem. 
17: 40-49, 1994.
58. GISCLON, L. G., R. A. BOYD, R. L. WILLIAMS, AND K. M. GIACOMINI. The effect 
of probenecid on the renal elimination of cimetidine. Clin. Pharmacol. Ther. 45: 
444-452, 1989.
59. GOLDBERG, J. P. AND R. J. ANDERSON. Renal metabolism and excretion of drugs. 
In: The kidney: physiology and pathophysiology, edited by D. W. Seldin and G. 
Giebisch. New York: Raven Press, Ltd., 1985, p. 2097-2110.
60. GOLDSTEIN, E. J. AND I. M. ARIAS. Interaction of ligandin with radiographic contrast 
media. Invest. Radiol. 11: 594-597, 1976.
61. GOLDSTEIN, R. S. Biochemical heterogeneity and site-specific tubular injury. In: 
Toxicology of the kidney, edited by J. B. Hook and R. S. Goldstein. New York: Raven 
Press, Ltd., 1993, p. 201-247.
62. GRANTHAM, J. J. AND A. M. CHONKO. Renal handling of organic anions and 
cations; excretion of uric acid. In: The kidney, edited by B. M. Brenner and F. C. Rector 
jr.. Philadelphia: W.B. Saunders Company, 1991, p. 483-509.
63. GRÜNDEMANN, D., V. GORBOULEV, S. GAMBARYAN, M. VEYHL, AND H. 
KOEPSELL. Drug excretion mediated by a new prototype of polyspecific transporter. 
Nature 372: 549-552, 1994.
64. GUDER, W. G. AND B. D. ROSS. Enzyme distribution along the nephron. Kidney Int. 
26: 101-111, 1984.
Chapter 1_______________________________________________________________________
38
65. HALL, S. AND M. ROWLAND. Influence of fraction unbound upon the renal clearance 
of furosemide in the isolated perfused rat kidney. J. Pharmacol. Exp. Ther. 232: 
263-268, 1985.
66. HE, Y-L., Y. TANIGAWARA, A. KAMIYA, AND R. HORI. Moment analysis of drug 
disposition in kidney. VI: Assessment of In Vivo transmembrane transport of 
p-Aminohippurate in tubular epithelium. J. Pharmacokin. Biopharm. 19: 667-690, 
1991.
67. HEYMAN, S. N., M. BREZIS, F. H. EPSTEIN, K. SPOKES, P. SILVA, AND S. 
ROSEN. Early renal medullary hypoxic injury from radiocontrast and indomethacin. 
Kidney Int. 40: 632-642, 1991.
68. HEYMAN, S. N., M. BREZIS, C. A. REUBINOFF, Z. GREENFELD, C. LECHENE, F.
H. EPSTEIN, AND S. ROSEN. Acute renal failure with selective medullary injury in the 
rat. J. Clin. Invest. 82: 401-412, 1988.
69. HIGGINS JR., J. T. AND P. J. MULROW. Fluid and electrolyte disorders of endocrine 
diseases. In: Clinical disorders of fluid and electrolyte metabolism, edited by M. H. 
Maxwell and C. R. Kleeman. New York: McGraw-Hill, 1980,
70. HJELLE, J. T., G. A. HAZELTON, C. D. KLAASSEN, AND J. J. HJELLE. 
Glucuronidation and sulphation in rabbit kidney. J. Pharmacol. Exp. Ther. 236: 
150-156, 1986.
71. HOENSCH, H. P. AND M. SCHWENK. Intestinal absorption and metabolism of 
xenobiotics in humans. In: Intestinal toxicology, edited by C. M. Schiller. New Uork: 
Raven Press, 1984, p. 169.
72. HOEPRICH, P. D. Chemotherapy of systemic fungal diseases. Ann. Rev. Pharmacol. 
Toxicol. 18: 205-231, 1978.
73. HOFMAN, A. F., C. D. SCHTEINGART, AND J. LILLIENAU. Biological and medical 
aspects of active ileal transport of bile acids. Ann. Med. 23: 169-175, 1991.
74. HOLOHAN, P. D. AND C. R. ROSS. Mechanisms of organic cation transport in kidney 
plasma membrane vesicles: 1. Countertransport studies. J. Pharmacol. Exp. Ther. 215: 
191-197, 1980.
75. HOLOHAN, P. D. AND C. R. ROSS. Mechanisms of organic cation transport in kidney 
plasma membrane vesicles: 2. ôpH studies. J. Pharmacol. Exp. Ther. 216: 294-298, 
1981.
76. HOLOHAN, P. D., K. E. WHITE, P. P. SOKOL, AND J. REBBEOR. Photoaffinity 
labeling of the organic cation/H+ exchanger in renal brush border membrane vesicles. J. 
Biol. Chem. 267: 13513-13519, 1992.
77. HORI, R., N. OKAMURA, T. AIBA, AND Y. TANIGAWARA. Role of P-glycoprotein 
in renal tubular secretion of digoxin in the isolated perfused rat kidney. J. Pharmacol. 
Exp. Ther. 266: 1620-1625, 1993.
78. HSYU, P-H., L. G. GISCLON, A. C. HUI, AND K. M. GIACOMINI. Interaction of 
organic anions with the organic cation transporter in renal BBMV. Am. J. Physiol. 254: 
F56-F61, 1988.
79. HUANG, K. C., B. A. WENCZAK, AND Y. K. LIU. Renal tubular transport of 
mehotrexate in the rhesus monkey and dog. Cancer Res. 39: 4843, 1979.
39
80. HUGHEY, R. P., B. B. RANKIN, J. S. ELCE, AND N. P. CURTHOYS. Specificity of a 
particulate rat renal peptidase and its localization along with other enzymes of 
mercapturic acid synthesis. Arch. Biochem. Biophys. 186: 211-217, 1978.
81. HUMES, H. D. AND J. M. WEINBERG. Toxic nephropathies. In: The kidney, edited by 
B. M. Brenner and F. C. Rector jr.. Philadelphia: W.B. Saunders Company, 1986, p. 
1491-1532.
82. HUNTER, J., B. H. HIRST, AND N. L. SIMMONS. Drug absorption limited by 
P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 
cell layers. Pharm. Res 10: 743-749, 1993.
83. INOTSUME, N., M. NISHIMURA, M. NAKANO, S. FUJIYAMA, AND T. SATO. The 
inhibitory effect of probenecid on renal excretion of famotidine in young, healthy 
volunteers. J. Clin. Pharmacol. 30: 50-56, 1990.
84. JACOBS, S. A. AND ET AL.. Hydroxymethotrexate as a urinary metabolite in human 
subjects and rhesus monkeys receiving high-dose methotrexate. J. Clin. Invest. 57: 
534--, 1976.
85. JAEHDE, U., F. SORGEL, A. REITER, G. SIGL, K. G. NABER, AND W. 
SCHUNACK. Effect of probenecid on the distribution and elimination of ciprofloxacin 
in humans. Clin. Pharmacol. Ther. 58: 532-541, 1995.
86. JOHNSON, L. V., M. L. WALSH, B. J. BOCKUS, AND L. B. CHEN. Monitoring of 
relative mitochondrial membrane potential in living cells by fluorescence microscopy. J. 
Cell Biol. 88: 526-535, 1981.
87. KAHN, A. M. AND P. S. ARONSON. Urate transport via anion exchange in dog renal 
microvillus membrane vesicles. Am. J. Physiol. 244: F56-F63, 1983.
88. KALOYANIDES, G. J. Drug-phospholipid interactions: role in aminoglycoside 
nephrotoxicity. Ren. Fail. 14: 351-357, 1992.
89. KAMIYA, A., Y. TANIGAWARA, Y. SAITO, Y. HAYASHI, T. AIBA, K-I. INUI, 
AND R. HORI. Moment analysis of drug disposition in kidney. II: Urine pH-dependent 
tubular secretion of tetraethylammonium in the isolated perfused rat kidney. J. Pharm. 
Sci. 79: 692-697, 1990.
90. KAMIYA, A., Y. TANIGAWARA, Y. SAITO, Y. HAYASHI, T. AIBA, K-I. INUI, 
AND R. HORI. Moment analysis of drug disposition in kidney. II: Urine pH-dependent 
tubular secretion of tetraethylammonium in the isolated perfused rat kidney. J. Pharm. 
Sci. 79: 692-697, 1990.
91. KAST, C., B. STIEGER, K. H. WINTERHALTER, AND P. J. MEIER. Hepatocellular 
transport of bile acids. J. Biol. Chem. 269: 5179-5186, 1994.
92. KING, H. W., A. W. MACFARLANE, R. M. GRAHAM, AND J. L. VERBOV. Near 
fatal drug interactions with methotrexate given for psoriasis. Br. Med. J. 295: 752-753,
1987.
93. KINSELLA, J. L., P. D. HOLOHAN, N. I. PESSAH, AND C. R. ROSS. Transport of 
organic ions in renal cortical luminal and antiluminal membrane vesicles. J. Pharmacol. 
Exp. Ther. 209: 443-450, 1979.
Chapter 1_______________________________________________________________________
40
94. KINSELLA, J. L., P. D. HOLOHAN, N. I. PESSAH, AND C. R. ROSS. Isolation of 
luminal and antiluminal membranes from dog kidney cortex. Biochim. Biophys. Acta 
552: 468-477, 1979.
95. KINTER, L. B. AND B. G. SHORT. Anatomy and physiology of the kidney. In: 
Toxicology of the kidney, edited by J. B. Hook and R. S. Goldstein. New York: Raven 
Press, Ltd., 1993, p. 1-36.
96. KINTER, W. B. Renal tubular transport of diodrast-I131 and PAH in necturus: Evidence 
for simultaneous reabsorption and secretion. Am. J. Physiol. 196: 1141-1149, 1959.
97. KIRSCH, R., G. FLEISCHNER, K. KAMISAKA, AND I. M. ARIAS. Structural and 
functional studies of ligandin, a major renal organic anion-binding protein. J. Clin. 
Invest. 55: 1009-1019, 1975.
98. KRAMER, W., I. LEIPE, E. PETZOLDT, AND F. GIBING. Characterization of the 
transport system for ß-lactam antibiotics and dipeptides in rat renal brush-border 
membrane vesicles by photoaffinity labeling. Biochim. Biophys. Acta 939: 167-172,
1988.
99. KREMER, J. M. AND R. A. HAMILTON. The effects of nonsteroidal antiinflammatory 
drugs on methotrexate (MTX) pharmacokinetics: impairment of renal clearance of MTX 
at weekly maintenance doses but not at 7.5 mg. J. Rheumatol. 22: 2072-2077, 1995.
100. KRIZ, W. AND L. BANKIR. A standard nomenclature for structures of the kidney. Am. 
J. Physiol. 254: F1-F8, 1988.
101. KWON, O., H. M. KWON, S. K. HONG, AND J. M. GOLDINGER. Size selected 
mRNA induces expression of p-aminohippurate transport in Xenopus oocytes. Proc. Soc. 
Exp. Biol. Med. 192: 205-208, 1989.
102. LAZNICEK, M. AND A. LAZNICKOVA. Kidney and liver contributions to salicylate 
metabolism in rats. Eur. J. Drug Metab. Pharmacokin. 1: 21-26, 1994.
103. LEITMAN, P. S. AND C. R. SMITH. Aminoglycoside nephrotoxicity in humans. J. 
Infect. Dis. 5(Suppl.2): S284-S293, 1983.
104. LEMLY, K. V. AND W. KRIZ. Structure and function of the renal vasculature. In: Renal 
pathology with clinical and functional correlations, edited by C. C. Tisher and B. M. 
Brenner. Philadelphia: J.B. Lippincott, 1989, p. 926-964.
105. LEVY, G. Effect of plasma protein binding on renal clearance of drugs. J. Pharm. Sci. 
69: 482-483, 1980.
106. LITWACK, G., B. KETTERER, AND I. M. ARIAS. Ligandin: a hepatic protein which 
binds steroids, bilirubin, carcinogens and a number of exogenous organic anions. Nature 
234: 466-467, 1971.
107. MAICHE, A. G. Acute renal failure due to concommitant action of methotrexate and 
indomethacin. Lancet jun.14: 1390, 1986.
108. MAKHULI, M. J., C. A. POLKOWSKI, AND S. M. GRASSL. Organic anion transport 
in rabbit renal basolateral membrane vesicles. J. Pharmacol. Exp. Ther. 273: 146-153, 
1995.
109. MARSHALL, E. K. AND J. L. VICKERS. The mechanism of the elimination of 
phenolsulphonphtalein by the kidney-A proof of secretion by the convoluted tubules. 
Bull. Johns Hopkins Hosp. 34: 1-6, 1923.
41
110. MARTINEZ, F., M. MANGANEL, C. MONTROSE-RAFIZADEH, D. WERNER, AND 
F. ROCH-RAMEL. Transport of urate and p-aminohippurate in rabbit renal brush-border 
membranes. Am. J. Physiol. 258: F1145-F1153, 1990.
111. MASEREEUW, R., M. M. MOONS, AND F. G. M. RUSSEL. Renal excretion and 
accumulation kinetics of 2-methylbenzoylgycine in the isolated perfused rat kidney. J. 
Pharm. Pharmacol. 48: 560-565, 1996.
112. MASEREEUW, R., M. M. MOONS, AND F. G. M. RUSSEL. Saturable accumulation 
and diuretic activity of hydrochlorothiazide in the isolated perfused rat kidney. 
Pharmacol. 1996
113. MASEREEUW, R., M. M. MOONS, P. SMITS, AND F. G. M. RUSSEL. Glomerular 
filtration and saturable absorption of iohexol in the isolated perfused rat kidney. Br. J. 
Pharmacol. 119: 57-64, 1996.
114. MASEREEUW, R., W. C. SALEMING, D. S. MILLER, AND F. G. M. RUSSEL. 
Interaction of fluorescein with the dicarboxylate carrier in rat kidney cortex 
mitochondria. J. Pharmacol. Exp. Ther. 1996
115. MASEREEUW, R., E. J. VAN DEN BERGH, R. J. M. BINDELS, AND F. G. M. 
RUSSEL. Characterization of fluorescein transport in isolated proximal tubular cells of 
the rat: evidence for mitochondrial accumulation. J. Pharmacol. Exp. Ther. 269: 
1261-1267, 1994.
116. MAUNSBACH, A. B. Observations on the segmentation of the proximal tubule in the rat 
kidney. Comparison of results from phase contrast fluorescence and electron microscopy. 
J. Ultrastruct. Res. 16: 239-258, 1966.
117. MAY, D. G. AND I. M. WEINER. The renal mechanisms for the excretion of 
m-hydroxybenzoic acid in cebus monkeys: Relationship to urate transport. J. 
Pharmacol. Exp. Ther. 176: 407-417, 1971.
118. MCKINNEY, T. D. Heterogeneity of organic base secretion by proximal tubules. Am. J. 
Physiol. 243: F404-F407, 1982.
119. MCKINNEY, T. D. Renal transport of organic anions and cations. In: Diseases of the 
kidney, edited by R. W. Schrier and C. W. Gottschalk. Boston: Little, Brown and 
Company, 1988, p. 285-307.
120. MCKINNEY, T. D., P. MYERS, AND K. V. SPEEG,JR.. Cimetidine secretion by rabbit 
renal tubules in vitro. Am. J. Physiol. 241: F69-F76, 1981.
121. MCKINNEY, T. D. AND K. V. SPEEG,JR.. Cimetidine and procainamide secretion by 
proximal tubules in vitro. Am. J. Physiol. 242: F672-F680, 1982.
122. MCMURTRY, R. J., W. R. SNODGRASS, AND J. R. MITCHELL. Renal necrosis, 
glutathione depletion, and covalent binding after acetaminophen. Toxicol. Appl. 
Pharmacol. 46: 87-100, 1978.
123. MELBY, E. L., K. PRYDZ, S. OLSNES, AND K. SANDVEG. Effect of monensin on 
ricin and fluid phase transport in polarized MDCK cells. J. Cell. Biochem. 47: 251-260,
1991.
124. MELLMAN, I., R. FUCHS, AND A. HELENIUS. Acidification of the endocytic and 
exocytic pathways. Annu. Rev. Biochem. 55: 663-700, 1986.
125. MEUNIER, V., M. BOURRIÉ, Y. BERGER, AND G. FABRE. The human intestinal 
epithelial cell line Caco-2; pharmacological and pharmacokinetic applications. Cell Biol. 
Toxicol. 11: 187-194, 1995.
Chapter 1_______________________________________________________________________
42
126. MILLER, D. S. Daunomycin secretion by killifish renal proximal tubules. Am. J. 
Physiol. 269: R370-R379, 1995.
127. MILLER, D. S., D. M. BARNES, AND J. B. PRITCHARD. Confocal microscopic 
analysis of fluorescein compartmentation within crab urinary bladder cells. Am. J. 
Physiol. 267: R695-R704, 1994.
128. MILLER, D. S. AND J. B. PRITCHARD. Indirect coupling of organic anion secretion to 
sodium teleost (Paralichtlys lethostigma) renal tubules. Am. J. Physiol. 261: 
R1470-R1477, 1991.
129. MILLER, D. S. AND J. B. PRITCHARD. Nocodazole inhibition of organic anion 
secretion in teleost renal proximal tubules. Am. J. Physiol. 267: R695-R704, 1994.
130. MILLER, D. S., D. E. STEWART, AND J. B. PRITCHARD. Intracellular 
compartmentation of organic anions within renal cells. Am. J. Physiol. 264: R882-R890,
1993.
131. MILLER, J. H. Sodium-sensitive, probenecid-insensitive p-aminohippuric acid uptake in 
cultured renal proximal tubule cells of the rabbit. Proc. Soc. Exp. Biol. Med. 199: 
298-304, 1992.
132. MITCHELL, J. R., R. J. MCMURTRY, C. N. STRATHAM, AND S. D. NELSON. 
Molecular basis for several drug-induced nephropathies. Am. J. Med. 62: 518, 1977.
133. MIYAMOTO, Y., V. GANAPATHY, AND F. H. LEIBACH. Transport of guanidine in 
rabbit intestinal brush-border membrane vesicles. Am. J. Physiol. 255: G85-G92, 1988.
134. MONKS, T. J. AND S. S. LAU. Commentary: Renal transport processes and glutathione 
conjugated-mediated nephrotoxicity. Drug Metab. Dispos. 15: 437-441, 1987.
135. MONTROSE-RAFIZADEH, C., F. MINGARD, H. MURER, AND F. ROCH-RAMEL. 
Carrier-mediated transport of tetraethylammonium across rabbit renal basolateral 
membrane. Am. J. Physiol. 257: F243-F251, 1987.
136. MORIWAKI, Y., T. YAMAMOTO, S. TAKAHASHI, T. HADA, AND K. 
HIGASHINO. Analysis of uric acid transport in renal tubules using benzbromarone and 
pyrazinamide. Int. J. Clin. Pharmacol. Ther. Toxicol. 28: 84-88, 1990.
137. MOSELEY, R. H. AND R. W. VAN DYKE. Organic cation transport by rat liver 
lysosomes. Am. J. Physiol. 268: G480-G486, 1995.
138. M0LLER, J. V. AND M. I. SHEIKH. Renal organic anion transport system: 
pharmacological, physiological, and biochemical aspects. Pharmacol. Rev. 34: 315-358,
1983.
139. MUDGE, G. H., W. O. BERNDT, A. SAUNDERS, AND B. BEATTIE. Renal transport 
of diatrizoate in the rabbit, dog and rat. Nephron 8: 156-172, 1971.
140. NAASANI, I., M. SUGAWARA, M. KOBAYASHI, K. ISEKI, AND K. MIYAZAKI. 
Transport mechanism of ceftibuten, a dianionic cephem, in rat renal brush-border 
membrane. Pharm. Res 12: 605-608, 1995.
141. NEUMAN, M. Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin. 
Pharmacokin. 14: 96-121, 1988.
43
Chapter 1
142. NEWTON, J. F., D. A. PASINO, AND J. B. HOOK. Acetaminophen nephrotoxicity in 
the rat: quantitation of renal metabolic activation in vivo. Toxicol. Appl. Pharmacol. 78: 
39-46, 1985.
143. NIERENBERG, D. W. Drug inhibition of penicillin tubular secretion: concordance 
between in vitro and clinical findings. J. Pharmacol. Exp. Ther. 240: 712-240, 1987.
144. NIKIFOROV, A. A. Stimulation by aminooxyacetate of fluorescein uptake in rat renal 
tubules in vitro: Role of intracellular a-ketoglutarate. J. Pharmacol. Exp. Ther. 274: 
1204-1208, 1995.
145. NORDBY, A., K. E. TVEDT, J. HALGUNSET, AND O. A. HAUGEN. Intracellular 
penetration and accumulation of radiographic contrast media in the rat kidney. Scanning 
Micros. 4: 651-666, 1990.
146. NOUWEN, E. J. AND M. E. DE BROE. Human intestinal versus tissue-nonspecific 
alkaline phosphatase as complementary urinary markers for the proximal tubule. Kidney 
Int. 46: S43-S51, 1994.
147. OHOKA, K., M. TAKANO, T. OKANO, S. MAEDA, K-I. INUI, AND R. HORI. 
p-Aminohippurate transport in rat renal brush-border membranes: a potential-sensitive 
transport system and an anion exchanger. Biol. Pharm. Bull. 16: 395-401, 1993.
148. OUDE ELFERINK, R. P. J., C. T. M. BAKKER, H. ROELOFSEN, E. MIDDELKOOP, 
R. OTTENHOFF, M. HEIJN, AND P. L. M. JANSEN. Accumulation of organic anion in 
intracellular vesicles of cultured rat hepatocytes is mediated by the canalicular 
multispecific organic anion transporter. Hepatology 17: 434-444, 1993.
149. OUDE ELFERINK, R. P. J., D. K. F. MEIJER, F. KUIPERS, P. L. M. JANSEN, A. K. 
GROEN, AND G. M. M. GROOTHUIS. Hepatobiliary secretion of organic compounds; 
molecular mechanisms of membrane transport. Biochim. Biophys. Acta 1241: 215-268, 
1995.
150. OYMAK, O. Contrast media induced irreversible acute renal failure in a patient treated 
with intraperitoneal cisplatin. Clin. Nephrol. 44: 135-136, 1995.
151. PEGG, D. G. AND J. B. HOOK. Glutathione S-transferases: an evaluation of their role in 
renal organic anion transport. J. Pharmacol. Exp. Ther. 200: 65-74, 1977.
152. PITTS, R. F. Tubular secretion. In: , edited by R. F. Pitts. Chicago: Year Book Med. 
Publ., 1974, p. 140-157.
153. POSCHET, J. F., S. M. HAMMOND, AND P. D. FAIRCLOUGH. Characterisation of 
penicillin-G uptake in rabbit small-intestinal brush-border membrane vesicles. Biochim. 
Biophys. Acta 1278: 233-240, 1996.
154. PRITCHARD, J. B. Luminal and peritubular steps in renal transport of 
p-aminohippurate. Biochim. Biophys. Acta 906: 295-308, 1987.
155. PRITCHARD, J. B. Intracellular a-ketoglutarate controls the efficacy of renal organic 
anion transport. J. Pharmacol. Exp. Ther. 274: 1278-1284, 1995.
156. PRITCHARD, J. B. AND D. S. MILLER. Mechanisms mediating renal secretion of 
organic anions and cations. Physiol. Rev. 73: 765-769, 1993.
44
157. PRITCHARD, J. B., D. B. SYKES, R. WALDEN, AND D. S. MILLER. ATP-dependent 
transport of tetraethylammonium by endosomes isolated from rat renal cortex. Am. J. 
Physiol. 266: F966-F976, 1994.
158. RAINSFORD, K. D., A. SCHWEITZER, AND K. BRUNE. Autoradiographic and 
biochemical observations on the distribution of non-steroid anti-inflammatory drugs. 
Arch. Int. Pharmacodyn. 250: 180-194, 1981.
159. REIDENBERG, M. M. AND D. E. DRAYER. Drug therapy in renal failure. Ann. Rev. 
Pharmacol. Toxicol. 20: 45-54, 1980.
160. RENNICK, B. R. Renal tubule transport of organic cations. Am. J. Physiol. 240: 
F83-F89, 1981.
161. RENNICK, B. R., G. K. MOE, R. H. LYONS, S. W. HOOBLER, AND R. NELIGH. 
Absorption and renal excretion of the tetraethylammonium ion. J. Pharmacol. Exp. 
Ther. 91: 210-217, 1947.
162. RIES, M., U. WENZEL, AND H. DANIEL. Transport of cefadroxil in rat kidney 
brush-border membranes is mediated by two electrogenic H+-coupled systems. J. 
Pharmacol. Exp. Ther. 271: 1327-1333, 1994.
163. ROBINS, A. B. The binding of platinum ethylenediamine dichloride to proteins, in vitro 
and in vivo. Chem. Biol. Interact. 38: 349-356, 1982.
164. ROCH-RAMEL, F., B. GUISAN, AND L. SCHILD. Indirect coupling of urate and 
p-aminohippurate transport to sodium in human brush-border membrane vesicles. Am. J. 
Physiol. 270: F61-F68, 1996.
165. ROCH-RAMEL, F. AND I. M. WEINER. Renal excretion of urate: Factors determining 
the actions of drugs. Kidney Int. 18: 665-676, 1980.
166. ROELOFSEN, H., C. T. M. BAKKER, B. SCHOEMAKER, M. HEIJN, P. L. M. 
JANSEN, AND R. P. J. OUDE ELFERINK. Redistribution of canalicular organic anion 
transport activity in isolated and cultured rat hepatocytes. Hepatology 21: 1649-1657, 
1995.
167. ROGERS, K. S. AND E. S. HIGGINS. Lipophilic interactions of organic cations with 
mitochondrial inner membranes during respiratory control. J. Biol. Chem. 248: 
7142-7148, 1973.
168. ROSS, C. R., F. DIEZI-CHOMÉTY, AND F. ROCH-RAMEL. Renal excretion of 
N1-methylnicotinamde in the rat. Am. J. Physiol. 228: 1641-1645, 1975.
169. ROWLAND, M. AND T. N. TOZER. Clinical pharmacokinetics, concepts and 
applications. Philadelphia: Lea & Febiger, 1989.
170. RUIFROK, P. G. Uptake of quarternary ammonium compounds into rat liver plasma 
membrane vesicles. Biochem. Pharmacol. 31: 1431-1435, 1982.
171. RUMBACH, L., G. CREMEL, C. MARESCAUX, J. M. WARTER, AND A. 
WAKSMAN. Succinate transport inhibition by valproate in rat renal mitochondria. Eur. 
J. Pharmacol. 164: 577-581, 1989.
172. RUSSEL, F. G. M., P. E. M. VAN DER LINDEN, W. G. VERMEULEN, M. HEIJN, C.
H. VAN OS, AND C. A. M. VAN GINNEKEN. Na+ and H+ gradient-dependent transport 
of p-aminohippurate in membrane vesicles from dog kidney cortex. Biochem. 
Pharmacol. 37: 2639-2649, 1988.
45
173. RUSSEL, F. G. M., A. C. WOUTERSE, AND C. A. M. VAN GINNEKEN. 
Physiologically based kidney model for the renal clearance of phenolsulfonphthalein and 
the interaction with probenecid and salicyluric acid in the dog. J. Pharmacokin. 
Biopharm. 15: 349-368, 1987.
174. RUSSEL, F. G. M., A. C. WOUTERSE, AND C. A. M. VAN GINNEKEN. 
Physiologically based kidney model for the renal clearance of salicyluric acid and the 
interaction with phenolsulfonphthalein in the dog. Drug Metab. Dispos. 15: 695-701, 
1987.
175. RUSSEL, F. G. M., A. C. WOUTERSE, AND C. A. M. VAN GINNEKEN. 
Physiologically based kidney model for the renal clearance of iodopyracet and the 
interaction with probenecid in the dog. Biopharm. Drug Dispos. 10: 137-152, 1989.
176. SABRA, R. AND R. A. BRANCH. Amphotericin B nephrotoxicity. Drug Safety 5: 
94-108, 1990.
177. SAITOH, H. AND B. J. AUNGST. Possible involvement of multiple 
P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic 
cations across rat intestine. Pharm. Res 12: 1304-1310, 1995.
178. SCHÄLI, C. AND F. ROCH-RAMEL. Uptake of [3H]PAH and [14C]urate into isolated 
proximal segments of the pig kidney. Am. J. Physiol. 241: F591-F596, 1981.
179. SCHÄLI, C. AND F. ROCH-RAMEL. Transport and metabolism of [3H]morphine in 
isolated nonperfused proximal tubule segments of the rabbit kidney. J. Pharmacol. Exp. 
Ther. 223: 811-815, 1982.
180. SCHÄLI, C., L. SCHILD, J. OVERNEY, AND F. ROCH-RAMEL. Secretion of 
tetraethylammonium by proximal tubules of rabbit kidneys. Am. J. Physiol. 245: 
F238-F246, 1983.
181. SCHMITT, C. AND G. BURCKHARDT. p-Aminohippurate/a-ketoglutarate exchange in 
bovine renal brush-border and basolateral membrane vesicles. Pflügers Arch. 423: 
280-290, 1993.
182. SCHRAMM, U., G. FRICKER, R. WENGER, AND D. S. MILLER. 
P-glycoprotein-mediated secretion of a fluorescent cyclosporin analogue by teleost renal 
proximal tubules. Am. J. Physiol. 268: F46-F52, 1995.
183. SCHUSTER, V. L. Organic anion transporters. In: Molecular nephrology, kidney 
function in health and disease, edited by D. Schlöndorff and J.V. Bonventre. New York: 
Marcel Dekker Inc., 1995, p. 309-318.
184. SCHUSTER, V. L. AND D. W. SELDIN. Renal clearance. In: The kidney: Physiology 
and Pathophysiology, edited by D. W. Seldin and G. Giebisch. New York: Raven Press,
1992, p. 943-978.
185. SCHWENK, M. Drug transport in intestine, liver and kidney. Arch. Toxicol. 60: 37-42, 
1987.
186. SEIDEL, A., M. HASMANN, R. LOSER, A. BUNGE, B. SCHAEFER, I. HERZIG, K. 
STEIDTMANN, AND M. DIETEL. Intracellular localization, vesicular accumulation 
and kinetics of daunorubicin in sensitive and multidrug-resistant gastric carcinoma 
EPG85-257 cells. Virchows Archiv. 426: 249-256, 1995.
187. SHEEHAN, D. AND T. J. MANTLE. Evidence for two forms of ligandin (YaYa dimers 
of glutathione S-transferase) in rat liver and kidney. Biochem. J. 218: 893-897, 1984.
Chapter 1_______________________________________________________________________
46
188. SHEIKH, M. I. Renal handling of phenol red. I. A comparative study on the 
accumulation of phenol red and p-aminohippurate om rabbit kidney tubules in vitro. J. 
Physiol. Lond. 227: 565-590, 1972.
189. SHEIKH, M. I. AND M. STAHL. Characteristics of accumulation of probenecid by 
rabbit cortical slices. Am. J. Physiol. 232: F513-F523, 1977.
190. SHIMADA, H., B. MOEWES, AND G. BURCKHARDT. Indirect coupling to Na of 
p-aminohippuric acid uptake into rat renal basolateral membrane vesicles. Am. J. 
Physiol. 253: F795-F801, 1987.
191. SHIMOMURA, A., A. M. CHONKO, AND J. J. GRANTHAM. Basis for heterogeneity 
of para-aminohippurate secretion in rabbit proximal tubules. Am. J. Physiol. 240: 
F430-F436, 1981.
192. SHOUVAL, D., M. LIGUMSKY, AND D. BEN-ISHAY. Effect of co-trimoxazole on 
normal creatinine clearance. Lancet 1: 244-245, 1978.
193. SIESS, E. A., D. G. BROCKS, AND O. WIELAND. Subcellular distribution of key 
metabolites in isolated liver cells from fasted rats. F. E. B. S. Lett. 69: 265-271, 1976.
194. SIMION, F. A., B. FLEISCHER, AND S. FLEISCHER. Subcellular distribution of bile 
acids, bile salts, and taurocholate binding sites in rat liver. Biochemistry 23: 6459-6466,
1984.
195. SIMONS, K. AND A. WANDINGER-NESS. Polarized sorting in epithelia. Cell 62: 
207-210, 1990.
196. SINGH, R. R., A. N. MALAVIYA, J. N. PANDLEY, AND J. S. GULERIA. Fatal 
interaction between methotrexate and naproxen. Lancet jun.14: 1390, 1986.
197. SMITH, H. W. The kidney: Structure and function in health and disease. New York: 
Oxford University Press, 1951.
198. SMITH, H. W., W. GOLDRING, AND H. CHASIS. The measurement of the tubular 
excretory mass, effective blood flow and filtration rate in the normal kidney. J. Clin. 
Invest. 17: 263-278, 1938.
199. SOBOLL, S., R. SCHOLZ, M. FRIESL, R. ELBERS, AND H. W. HELDT. Distribution 
of metabolites between mitochondria and cytosol of perfused liver. In: Use of isolated 
liver cells and kidney tubules in metabolic studies, edited by J. M. Tager, H. D. Söling, 
and J. R. Williamson. Amsterdam: North-Holland Publishing Company, 1975, p. 29-40.
200. SOKOL, P. P., P. D. HOLOHAN, S. M. GRASS, AND C. R. ROSS. Proton-coupled 
organic cation transport in renal brush-border membrane vesicles. Biochim. Biophys. 
Acta 940: 209-218, 1988.
201. SOKOL, P. P. AND T. D. MCKINNEY. Mechanism of organic cation transport in rabbit 
renal basolateral membrane vesicles. Am. J. Physiol. 258: F1599-F1607, 1990.
202. SOMOGOYI, A. New insights into the renal secretion of drugs. Trends Pharmacol. Sci. 
8: 354-357, 1987.
203. STEELE, T. H. Urate secretion in man: the pyrazinamide suppression test. Ann. Intern. 
Med. 79: 734-737, 1973.
47
204. STEEN, H., J. G. MARING, AND D. K. F. MEIJER. Differential effects of metabolic 
inhibitors on cellular and mitochondrial uptake of organic cations in rat liver. Biochem. 
Pharmacol. 45: 809-818, 1993.
205. STEFFENS, T. G., P. D. HOLOHAN, AND C. R. ROSS. Operational modes of the 
organic anion exchanger in canine renal brush-border membrane vesicles. Am. J. 
Physiol. 256: F596-F609, 1989.
206. STOLZ, A. H., H. TAKIKAWA, M. OOKHTENS, AND N. KAPLOWITZ. The role of 
cytoplasmic proteins in hepatic bile acid transport. Annu. Rev. Physiol. 51: 161-176,
1989.
207. SUGAWARA, M., T. TODA, K. ISEKI, K. MIYAZAKI, H. SHIROTO, Y. KONDO, 
AND J-I. UCHINO. Transport characteristics of cephalosporin antibiotics across 
intestinal brush-border membrane in man, rat and rabbit. J. Pharm. Pharmacol. 44: 
968-972, 1992.
208. SUGAWARA, M., T. TODA, M. KOBAYASHI, K. ISEKI, K. MIYAZAKI, H. 
SHIROTO, J-I. UCHINO, AND Y. KONDO. The inhibitory effects of cephalosporin and 
dipeptide on ceftibuten uptake by human and rat intestinal brush-border membrane 
vesicles. J. Pharm. Pharmacol. 46: 680-684, 1994.
209. SULLIVAN, L. P., J. A. GRANTHAM, L. ROME, D. WALLACE, AND J. J. 
GRANTHAM. Fluorescein transport in isolated proximal tubules in vitro: 
epifluorometric analysis. Am. J. Physiol. 258: F46-F51, 1990.
210. SULLIVAN, L. P. AND J. J. GRANTHAM. Specificity of basolateral organic anion 
exchanger in proximal tubule for cellular and extracellular solutes. J. Am. Soc. Nephrol. 
2: 1192-1200, 1992.
211. SWARTZ, R. D., J. E. RUBIN, B. W. LEEMING, AND P. SILVA. Renal failure 
following major angiography. Am. J. Med. 65: 31-37, 1978.
212. TAFT, D. R. AND K. R. SWEENEY. The influence of protein binding on the 
elimination of acetazolamide by the isolated perfused rat kidney: evidence of 
albumin-mediated tubular secretion. J. Pharmacol. Exp. Ther. 274: 752-760, 1995.
213. TARLOFF, J. B. AND P. H. BRAND. Active tetraethylammonium uptake across the 
basolateral membrane of the proximal tubule. Am. J. Physiol. 251: F141-F149, 1986.
214. THALHAMMER, T., V. STAPF, L. GAJDZIK, AND J. GRAF. Bile canalicular cationic 
dye secretion as a model for P-glycoprotein mediated transport. Eur. J. Pharmacol. 
(Environ. Toxicol. Pharmacol. ) 270: 213-220, 1994.
215. THEWS, G., E. MUTSCHLER, AND P. VAUPEL. Kidneys and urinary tract. In: 
Human anatomy, physiology and pathophysiology, edited by G. Thews, E. Mutschler, 
and P. Vaupel. Amsterdam: Elsevier, 1985, p. 413-449.
216. THIBAUT, F., T. TSURUO, H. HAMADA, M. M. GOTTESMAN, I. PASTAN, AND 
M. C. WILLINGHAM. Cellular localization of the multidrug resistance gene product 
P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA 84: 7735-7738, 
1987.
217. TISHER, C. C. AND B. M. BRENNER. Structure and function of the glomerulus. In: 
Renal pathology with clinical and functional correlations, edited by C. C. Tisher and B. 
M. Brenner. Philadelphia: J.B. Lippincott, 1989, p. 92-110.
218. TISHER, C. C. AND K. M. MADSEN. Anatomy of the kidney. In: The kidney, edited by 
B. M. Brenner and F. C. Rector jr.. Piladelphia: W.B. Saunders Company, 1986, p. 3-60.
Chapter 1_______________________________________________________________________
48
219. TORRETTI, J., I. M. WEINER, AND G. H. MUDGE. Renal tubular secretion and 
reabsorption of organic bases in the dog. J. Clin. Invest. 41: 793-804, 1962.
220. TUCKER, G. T. Measurement of the renal clearance of drugs. Br. J. Clin. Pharmac. 12: 
761-770, 1981.
221. TUNE, B. The nephrotoxicity of ß-lactam antibiotics. In: Toxicology of the kidney, 
edited by J. B. Hook and R. S. Goldstein. New York: Raven Press, 1993, p. 257-281.
222. TUNE, B. M. The nephrotoxicity of cephalosporin antibiotics. Structure-activity 
relationships. Commun. Toxicol. 1: 145-170, 1986.
223. TUNE, B. M., M. B. BURG, AND C. S. PATLAK. Charateristics of p-aminohippurate 
transport in proximal renal tubules. Am. J. Physiol. 217: 1057-1063, 1969.
224. TUNE, B. M. AND D. FRAVERT. Mechanisms of cephalosporin in nephrotoxicity: A 
comparison of cephaloridine and cephaloglycin. Kidney Int. 18: 591-600, 1980.
225. UJHELYI, M. R., M. B. BOTTORFF, M. SCHUR, K. ROLL, H. ZHANG, J. 
STEWART, AND M. L. MARKEL. Urine acidification affects the activity of the organic 
base transporter in a nonstereoselective manner. J. Pharmacol. Exp. Ther. 276: 
683-689, 1996.
226. ULLRICH, K. J. Epithelial transport: an introduction. In: Methods in Enzymology, Vol.
191, Biomembranes, part V, edited by S. Fleischer and B. Fleischer. San Diego: 
Academic Press, 1990, p. 1-4.
227. ULLRICH, K. J. Specificity of transporters for 'organic anions' and 'organic cations' in 
the kidney. Biochim. Biophys. Acta 1197: 45-62, 1994.
228. ULLRICH, K. J., G. RUMRICH, C. DAVID, AND G. FRITSCHZ. Bisubstrates: 
substances that interact with both, renal contraluminal organic anion and organic cation 
transport systems. I. Amines, piperidines, piperazines, azepines, pyridines, quinolines, 
imidazoles, guanidines, and hydrazines. Pflügers Arch. 425: 280-299, 1993.
229. VALTIN, H. Renal function: mechanisms preserving fluid and solute balance in health. 
Boston: Little, Brown and Company, 1983
230. VAN CRUGTEN, J., F. BOCHNER, J. KEAL, AND A. SOMOGOYI. Selectivity of the 
cimetidine-induced alterations in the renal handling of organic substrates in humans. 
Studies with anionic, cationic and zwitterionic drugs. J. Pharmacol. Exp. Ther. 236: 
481-487, 1986.
231. VAN DYKE, R. W., E. D. FABER, AND D. K. F. MEIJER. Sequestration of organic 
cations by acidified hepatic endocytic vesicles and implications for biliary excretion. J. 
Pharmacol. Exp. Ther. 261: 1-11, 1992.
232. VAN GINNEKEN, C. A. M. AND F. G. M. RUSSEL. Saturable pharmacokinetics in the 
renal excretion of drugs. Clin. Pharmacokin. 16: 38-54, 1989.
233. VARI, R. C., L. A. NATARAJIAN, S. A. WHITESCARVER, B. A. JACKSON, AND C. 
M. OTT. Induction prevention and mechanisms of contrast media induced acute renal 
failure. Kidney Int. 33: 699-707, 1988.
234. VERKADE, H. J., M. J. WOLBERS, R. HAVINGA, D. R. UGES, R. J. VONK, AND F. 
KUIPERS. The uncoupling of biliary lipid from bile acid secretion by organic anions in 
the rat. Gastroenterology 99: 1485-1492, 1990.
49
235. WALKER, R. J. AND G. G. DUGGIN. Cellular mechanisms of drug nephrotoxicity. In: 
The kidney: physiology and pathophysiology, edited by D. W. Seldin and G. Giebisch. 
New York: Raven Press, Ltd., 1992, p. 3571-3595.
236. WARNOCK, D. G., W. W. REENSTRA, AND V. J. YEE. Na+/H+ antiporter of brush 
border vesicles: studies with acridine orange. Am. J. Physiol. 242: F733-F739, 1982.
237. WEINER, I. M. Transport of weak acids and bases. In: Handbook of physiology, section 
8: Renal physiology, edited by J. Orloff and R. W. Berliner. Washington, D.C.: American 
Physiology Society, 1973, p. 521-554.
238. WEINER, I. M. AND J. P. TINKER. Pharmacology of pyrazinamide: Metabolic and 
renal function related to the mechanism of drug induced urate retention. J. Pharmacol. 
Exp. Ther. 180: 411-434, 1972.
239. WENZEL, U., D. T. THWAITES, AND H. DANIEL. Stereoselective uptake of ß-lactam 
antibiotics by the intestinal peptide transporter. Br. J. Pharmacol. 116: 3021-3027,
1995.
240. WERNER, D., F. MARTINEZ, AND F. ROCH-RAMEL. Urate and p-aminohippurate 
transport in the brush-border membrane of the pig kidney. J. Pharmacol. Exp. Ther. 
252: 792-799, 1990.
241. WHITING, P. H., A. W. THOMSON, J. T. BLAIR, AND ET AL.. Experimental 
cyclosporin A nephrotoxicity. Br. J. Exp. Path. 63: 88, 1982.
242. WOLFF, N. A., R. M. PHILPOT, D. S. MILLER, AND J. B. PRITCHARD. Functional 
expression of renal organic anion transport in Xenopus laevis oocytes. Mol. Cell. 
Biochem. 114: 35-41, 1992.
243. WOODHALL, P. B., C. C. TISHER, C. A. SIMONTON, AND R. K. ROBINSON. 
Relationship between para-aminohippurate secretion and cellular morphology in rabbit 
proximal tubules. J. Clin. Invest. 61: 1320-1329, 1978.
244. WOOLLEY, G. A., M. K. KAPRAL, AND C. M. DEBER. Potential-sensitive membrane 
association of a fluorescent dye. F. E. B. S. Lett. 224: 337-342, 1987.
245. WRIGHT, S. H. AND T. M. WUNZ. Transport of tetraethylammonium by rabbit renal 
burh-border and basolateral vesicles. Am. J. Physiol. 253: F1040-F1050, 1987.
246. WRIGHT, S. H., T. M. WUNZ, AND T. P. WUNZ. A choline transporter in renal 
brush-border membrane vesicles: energetics and structural specificity. J. Membr. Biol. 
126: 51-65, 1992.
247. ZIEGLER, K., M. FRIMMER, G. FRITSCHZ, AND H. KOEPSELL. Cyclosporin 
binding to a protein component of the renal Na+-D-glucose cotransporter. J. Biol. Chem. 
1023: 12-18, 1990.
Chapter 1_______________________________________________________________________
50
Section II
Studies in the isolated perfused rat kidney
Chapter 2
RENAL EXCRETION AND ACCUMULATION KINETICS 
OF 2-METHYLBENZOYLGLYCINE
Rosalinde Masereeuw, Miek M. Moons, and Frans G.M. Russel
Department o f Pharmacology, Faculty o f Medical Sciences, University o f Nijmegen,
The Netherlands
Journal o f  Pharmacy and Pharmacology, 48: 560-565, 1996
Sum m ary
Renal accumulation and secretion o f the hippurate analogue 2-methylbenzoylglycine 
was investigated in the isolated perfused rat kidney IPK in the absence and presence of 
bovine serum albumin (BSA). Experiments were performed with either 2.5% pluronic 
or a combination o f 2.2% pluronic and 2% BSA as oncotic agents, and a wide 
concentration range o f 2-methylbenzoylglycine (1-190 |ig/ml) was studied. Tubular 
secretion appeared to be a function o f unbound drug in perfusate and was best described 
by a model consisting o f a high and low affinity M ichaelis-M enten term. Parameters 
obtained after the analysis o f renal excretion data were TMM = 3.0 ± 2.8 |ig/min, K  TH =
0.5 ± 0.8 ng/ml, TML= 250 ± 36 |ig/min, and K  TL= 62 ± 17 |ig/ml. The compound 
accumulated extensively in kidney tissue, ratios up to 175 times the perfusate 
concentration were reached. Accumulation data were analysed best by a two-site model 
similar to the model used to describe renal excretion. Calculated parameters were RMH= 
26 ± 23 |ig/g, KAH= 0.2 ± 0.4 ng/ml, R ML= 1640 ± 1100 |ig/g, and K  AL = 60 ± 58 
Hg/ml. In conclusion, the very high accumulation in kidney tissue could be explained by 
active tubular uptake, mediated by the secretory mechanisms involved, and dependent 
on free drug in perfusate. This study shows that anionic drugs, subject to active 
secretion, may reach high concentrations in tubular cells even at low plasma 
concentration.
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In troduction
The kidney is an important organ in the elimination o f exogenous compounds from the 
body. Drugs may be secreted efficiently by various transport systems for organic anions 
and cations in the proximal tubules. During the process o f secretion, the drug has to be 
transported across the proximal tubular cells. For organic anions, cellular uptake can be 
mediated actively by at least three different carrier systems with overlapping 
specificities at the basolateral membrane: the p-aminohippurate transporter and the 
related dicarboxylate and sulphate systems. Once inside the cell, the drug will enter the 
tubular lumen down its electrochemical gradient via an anion exchanger or a potential- 
driven pathway (3,10,18,23). As a result o f the sequence o f these events, drugs can 
achieve high intracellular concentrations. In addition to a difference in basolateral and 
brush-border membrane transport, accumulation can be also caused by extensive 
intracellular binding or sequestration in certain cell organelles. The intracellular 
disposition o f drugs may affect proximal tubular function or lead to tubular toxicity 
(9,12).
If  the extent o f drug accumulation in proximal tubular cells depends on the efficiency 
of the secretory mechanism involved, factors influencing tubular secretion will also 
have an effect on the intracellular concentration. In this regard, the degree o f plasma 
protein binding could be an important determinant in tubular accumulation (5).
Hippurates (benzoylglycines) are known to be cleared very rapidly by the kidney, 
mainly via tubular secretion. p-Aminohippurate is commonly used as a model 
compound for testing kidney function and for the investigation o f the anionic secretory 
system in the proximal tubule. Due to the efficiency o f the secretory process, the renal 
extraction ratio practically equals 1, indicating that renal clearance and accumulation are 
insensitive to changes in protein binding and only influenced by changes in renal blood 
flow (10,15). On the other hand, the presence o f serum protein may even facilitate p- 
aminohippurate secretion (2). However, plasma protein binding o f this compound is low 
(21). For this study we have chosen a hippurate analogue with a relatively high plasma 
protein binding. In vivo experiments in the dog showed that the high protein binding of
2-methylbenzoylglycine possibly limits tubular secretion, in spite o f its high intrinsic 
clearance (20). It is, therefore, supposed that changes in protein binding o f this 
compound will result in an altered accumulation, although nothing is known about the 
extent o f renal accumulation.
The present investigation was designed to examine the renal secretion and 
accumulation kinetics o f 2-methylbenzoylglycine in the absence and presence of 
protein, by using the isolated perfused rat kidney (IPK). Previously, we showed that the 
IPK is a useful method for the investigation o f renal secretion and accumulation of
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drugs (4,7,8). An advantage o f this technique is that it allows accurate determination of 
renal drug clearance over a wide concentration range, under controlled protein-binding 
conditions and in absence o f nonrenal effects.
M ateria ls  and  M ethods
Materials
Pluronic F-108 was obtained from BASF (Arnhem, The Netherlands), bovine serum 
albumin (BSA) was purchased from Boehringer (Mannheim, Germany), inulin was 
from Sigma (St.Louis, Mo.), and salicyluric acid from M erck AG (Darmstadt, 
Germany). 2-Methylbenzoylglycine was prepared as described previously (20). All other 
chemicals were o f analytical grade and obtained either from Sigma (St.Louis, Mo.) or 
M erck AG (Darmstadt, Germany).
Experimental procedure
The isolation and perfusion o f the rat kidney were described in detail previously (8). 
Studies were performed with perfusate containing either 2.5% pluronic or a combination 
o f 2% BSA and 2.2% pluronic. In presence o f 2% BSA, the addition o f 2.2% pluronic 
was necessary to obtain an oncotic pressure comparable with protein free perfusate 
containing only 2.5 % pluronic. To maintain a perfusate pressure o f approximately 90 
mm Hg, a low glomerular filtration rate (GFR) resulted (between 230 and 350). For the 
determination o f GFR, cyanocobalamin (20 |ig/ml) was added to the perfusion fluid. 
GFR was monitored on line using a micro flow-through cuvette in which the 
cyanocobalamin concentration was m easured colorim etrically (6). Because 
cyanocobalamin binds to BSA, inulin (100 |ig/ml in perfusion fluid) was used to 
determine the GFR in the experiments with 2.2% pluronic and 2% BSA, as described 
under analysis. The perfusion fluid was filtered before the experiment using a 0.22 |im 
pore-size membrane filter composed o f cellulose acetate and cellulose nitrate (Millipore, 
Bedford, MA). W ith BSA in the perfusion fluid, a similar membrane filter was used 
with 3.0 |im  pore-size (Schleicher & Schuell, Dassel, Germany).
Experimental design
The experimental period was 120 min and was started after 30 min o f control. During 
the control period, the volume o f the circulating perfusate was 500 ml, from which a 
sample o f 5 ml was drawn. After the control period, the kidney was connected to 
perfusion fluid with a total volume o f 250 ml, in which 2-methylbenzoylglycine was 
already dissolved. Doses added to the perfused kidneys were: 0.625, 1.875, 6.25, 18.75,
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37.5, and 62.5 mg o f 2-methylbenzoylglycine. Urine samples were collected during 
control and experimental periods over 10 min intervals. Perfusate samples (300 ^l) were 
drawn at the midpoint o f the urine collection intervals. Two additional perfusate 
samples were taken, one at the beginning o f the experiment and one at the end. At the 
end o f the experiment the kidney was removed from the system, blotted and weighed. 
Urine, perfusate and kidney samples were stored at -20 °C until analysis.
Analysis
Urine and perfusate samples were analysed for glucose and various electrolytes as 
described previously (8). In the presence o f 2% BSA, perfusate and urine samples were 
analysed also for inulin and protein content. The Bio-Rad Protein Assay from Bio-Rad 
(München, Germany) was used for the determination o f protein. Inulin was determined 
according to a previously published method (11).
The concentration o f 2-methylbenzoylglycine in perfusate, urine and kidney samples 
was determined by means o f reversed-phase high-performance liquid chromatography 
(HPLC), as described below.
HPLC assay
A 1084B Liquid Chromatograph o f Hewlett Packard (Böblingen, Germany) was used 
equipped with an auto-injector (HP 79841A), terminal (HP 79850B LC) and an UV 
absorbance detector (Spectroflow 773, Kratos analytical instruments, Ramsey, N.J., 
USA) at an operating wavelength o f 228 nm. Chromatography was performed on a 
stainless steel column (10 cm x 4.6 mm ID) packed with LiChrosorb RP-18 (particle 
size 5 |im). The mobile phase consisted o f 15% methanol and 85% 0.01 M  phosphate 
buffer pH 2.6. The flow rate was 1 ml/min. To 100 |il o f all samples 10 |il o f a 
salicyluric acid solution (0.1 mg/ml) was added as internal standard. After addition of
1.2 ml di-ethyl ether, the samples were vortexed for 10 sec and centrifuged for 10 min at 
2000g. W hen BSA was present in the perfusion fluid, the samples were first treated with 
50 |il 6N HCL, vortexed for 10 sec and centrifuged at 2000g. Subsequently, 100 |il 
supernatant was removed to which 1.2 ml di-ethyl ether was added. Again, the samples 
were vortexed and centrifuged. In all cases the di-ethyl layer was added to glass tubes on 
ice and evaporated with air until dryness. The residue was dissolved in 200 |il mobile 
phase, and 10 or 20 |il was injected into the HPLC system. Concentrations were 
determined by comparing the peak area ratios o f 2-methylbenzoylglycine and internal 
standard with the ratios o f a calibration curve, prepared by adding various amounts o f 2- 
methylbenzoylglycine to blank perfusate. The concentration o f 2-methylbenzoylglycine 
in kidney tissue was determined in a similar way. The kidney was homogenized in 5 or
56
Renal accumulation of2-methylbenzoylglycine
10 ml distilled water with a Polytron homogenizer (Braun Melsungen, Germany) on 
setting 10 for 2 times 60 sec. To 450 |il o f this homogenate 40 |il internal standard (0.1 
mg/ml), and 100 |il 6N HCl were added. After protein precipitation and centrifugation 
at 2000g, 200 |il o f supernatant was extracted twice with 1.2 ml di-ethyl ether, vortexed 
for 10 sec and centrifuged for 10 min at 2000g. The di-ethyl ether layer was added to 
ice-cold glass tubes and evaporated until dryness. The residue was dissolved in 500 |il 
mobile phase and 10 or 20 |il was injected into the HPLC system. Concentrations were 
calculated by comparing peak area ratios o f 2-methylbenzoylglycine and internal 
standard with a calibration curve o f spiked samples o f blank kidney homogenates with 
internal standard and various amounts o f 2-methylbenzoylglycine. Linear correlations 
were obtained in all cases (R2>0.98).
Protein binding
Protein binding was determined by ultrafiltration as described previously (19). The 
ultrafiltrates were treated and analysed in the same way as the urine samples were. 
Perfusate protein binding was calculated according to the following set o f equations, 
assuming one class o f binding site:
in which C = total perfusate concentration (^g/ml); Cu = unbound drug concentration 
(^g/ml); fu  = fraction o f unbound drug in perfusate; P  = total concentration o f protein 
binding sites (^g/ml); Kd = dissociation constant o f the drug-protein complex (^g/ml).
Renal excretion model
For an adequate description o f the renal clearance of 2-methylbenzoylglycine by the 
IPK, a model was necessary in which tubular secretion was expressed by two M ichaelis­
M enten terms. Assuming that renal excretion o f 2-methylbenzoylglycine is dependent 
upon unbound perfusate concentrations, the renal clearance o f this compound can be 
expressed as:
C = Cu + P ' Cu 
(Kd + Cu) (2-1)
Cu = fu • C (2-2)
ClR = ( QGF #fu + (2-3)
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The renal excretion rate (Rr) is:
RR ClR ' C (2-4)
where ClR = renal clearance (ml/min); R  R= renal excretion rate (^g/min); Q GF= 
glomerular filtration rate (ml/min); C = total drug concentration in perfusate (^g/ml); Cu 
= unbound drug concentration in perfusate (^g/ml); fu  = fraction o f unbound drug; TM = 
maximum transport velocity (^g/min) and KT = Michaelis-M enten constant for tubular 
transport (^g/ml), for the high (H) and low (L) affinity site; F  = fraction o f excreted 
drug reabsorbed.
Renal accumulation
The concentration o f 2-methylbenzoylglycine in the kidney ( CT) was expressed as the 
amount o f drug per weight o f tissue. The concentration in kidney tissue divided by the 
concentration in perfusate at the end o f the experiment (Cu,z), resulted in an 
accumulation ratio (kidney/perfusate ratio). If  accumulation in kidney tissue is 
considered to be a result o f both active and passive transport processes, the renal 
accumulation ratio can be described as follows:
In which Rm = theoretical maximum capacity (^g/g) and K  A = affinity constant for renal 
accumulation (^g/ml), for the high (H) and low (L) affinity site; a = ratio CT/Cu,z due to 
passive transport.
Data analysis
Renal excretion rate and accumulation data were analysed according to equations 4 and 
5 by the nonlinear least square regression program PCNonlin (17). The goodness o f fit 
was evaluated through the deviation between the observed and model predicted values 
as R2 = 1-£(D ev)2 / E(Obs)2, where E(Obs) 2 is the observed sum of squared 
observations and E(Dev)2 the sum of squared deviations. The weighted residual sums of 
squares o f the renal excretion and accumulation models with two Michaelis-Menten 
terms were compared with the residual sums o f squares o f the corresponding models 
with only one term, and significance was determined with an F-test (P<0.05). All data 
are expressed as mean ± SD. Statistical differences between means were determined 
with Student's t-test, in which the level o f significance was set to P<0.05.
(2-5)Cu,z Kah  + Cu,z Kal + Cu,z
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Effects on kidney function
The renal functional parameters obtained from 12 control IPK experiments in the 
absence and presence o f BSA, and after administration o f the highest dose o f 2- 
methylbenzoylglycine, are presented in Table 2-1. The control IPK experiments with 
2% BSA in perfusate showed a significantly lower GFR and fractional excretion of 
potassium, glucose and magnesium, and a significant increase in urinary pH, in 
comparison with the control experiments without BSA. Furthermore, to maintain a 
perfusate pressure o f 90 mm Hg, the perfusate flow had to be raised significantly. No 
negative effects on kidney function were observed with 2-methylbenzoylglycine. Only 
the highest dose altered renal function, as is shown in Table 2-1.
Table 2-1. Functional parameters o f the IPK in control experiments and after administration of 62.5 mg 
2-methylbenzoylglycine (2-MBG).
2.5% pluronic 2.2% pluronic/ 2% BSA
Parameter controla 2-MBGb controla 2-MBGb
FE sodium (%) 2.9 ± 0.6 2.2 ± 0.9 3.1 ± 1.7 4.0 ± 1.8
FE potassium (%) 38 ± 14 73 ± 11* 14 ± 6* 51 ± 5*
FE glucose (%) 7.3 ± 2.1 7.3 ± 1.2 4.1 ± 2.0* 7.0 ± 2.1
FE magnesium (%) 42 ± 10 47 ± 6 17 ± 12* 37 ± 5*
FE calcium (%) 3.5 ± 1.3 4.0 ± 0.7 2.4 ± 1.3 4.5 ± 1.1*
H2O reabsorption (%) 94 ± 1 93 ± 1 93 ± 1 92 ± 1
urine flow (^l/min) 18 ± 3 23 ± 2* 16 ± 3 24 ± 2*
GFR (^l/min) 277 ± 35 327 ± 24* 232 ± 53* 298 ± 25*
urinary pH 5.8 ± 0.3 6.0 ± 0.1 6.2 ± 0.2* 6.3 ± 0.1
perfusate flow (ml/min) 15 ± 2 14.3 ± 0.3 23 ± 2* 23 ± 3
perfusate pressure (mm Hg) 89 ± 8 81 ± 4 93 ± 8 102 ± 7
Mean values ± SD over the period 30-120 min are given. FE: fractional excretion; *:P<0.05 as 
compared with control experiments; *:P<0.05 as compared with corresponding experiments without 
BSA;a: n=12;b: n=4.
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In both experimental conditions, a significant increase in GFR, urine flow and 
fractional excretion o f potassium were found for this compound, as compared to the 
controls. In the experiments with BSA, the fractional excretions o f magnesium and 
calcium were also significantly enhanced.
Protein binding
Protein binding was determined for each dose o f 2-methylbenzoylglycine administered, 
and all data were pooled and analysed according to equation 2-2. Parameters obtained 
were a dissociation constant, Kd, o f 58 ± 16 |ig/ml and a total concentration o f BSA 
binding sites, P, o f 70 ± 16 |ig/ml (n=36). The binding o f 2-methylbenzoylglycine 
decreased gradually, with fractions unbound between 0.4 and 0.7 over a concentration 
range o f 0.5 to 250 ng/ml. The experiments with 6.25 and 37.5 mg o f 2- 
methylbenzoylglycine were carried out with an other BSA batch. This resulted in a 
different binding in these experiments, with fractions unbound o f 0.38 and 0.35, 
respectively.
Renal excretion and accumulation
2-Methylbenzoylglycine was slowly eliminated from perfusate. Fig. 2-1 shows the mean 
unbound perfusate concentration and corresponding excretion rate data, as a function of 
time under both experimental conditions. All doses gave log-linear concentration time 
curves. The urinary excretion rate increased rapidly after addition o f 2- 
methylbenzoylglycine, followed by a gradual decrease. The presence o f protein in 
perfusate resulted in a lower renal excretion rate. Renal handling data for 2- 
methylbenzoylglycine are presented in Table 2-2. The renal clearance was higher than 
the clearance by glomerular filtration corrected for the fraction unbound (ClR/GF>1), 
indicating active tubular secretion. A decrease in ClR/GF at higher perfusate 
concentrations was in accordance with saturable tubular secretion. The ClR/GF values in 
the presence o f BSA surpass those obtained from the experiments with 2.5% pluronic, 
supporting the view that the renal excretion of 2-methylbenzoylglycine is dependent on 
unbound drug concentrations.
A linear plot o f the renal excretion rate against unbound perfusate concentration, a so 
called tubular titration curve, is presented (Fig. 2-2). A two-site model dependent on 
unbound drug concentration in perfusate fitted the data best (F-test, P<0.05). The line 
through the data points was obtained after analyzing renal excretion data over the period 
30 to 90 min, according to equation 2-4. The results show that renal excretion was 
composed o f glomerular filtration and active tubular secretion. At high perfusate 
concentration the titration curves paralleled the glomerular filtration line, indicating that 
tubular secretion was saturated and reabsorption was negligible (F=0 in equation 2-3).
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Table 2-2. Renal handling of2-methylbenzoylglycine in the isolated perfused rat kidney.
Dose BSA Perfusate fu Excretion rate ClR/GF Amount in
(Mg) concentration (^g/min) kidney (Mg/g)
(Mg/ml)
625 - 1.2 ± .20. - .35. ± 1.3 12.2 ± 1.2 24 ± 2
+ 1.1 ± 0.1 0.42 3.1 ± 0.5 22.9 ± 1.5 26 ± 5
1875 - 2.5 ± 0.8 - 19 ± 6 17.5 ± 0.5 44 ± 10
+ 2.1 ± 0.3 0.42 15 ± 3 44.2 ± 2.7 77 ± 32
6250 - 10 ± 3 - 44 ± 8 11.6 ± 0.8 220 ± 50
+A 19 ± 1 0.38 27 ± 3 10.5 ± 0.5 200 ± 10
18750 - 44 ± 8 - 119 ± 15 7.0 ± 0.3 650 ± 130
+ 50 ± 8 0.52 115 ± 16 14.8 ± 0.6 590 ± 80
37500 - 85 ± 16 - 203 ± 12 7.3 ± 0.6 910 ± 240
+A 120 ± 6 0.35 116 ± 8 9.0 ± 0.5 710 ± 140
62500 - 189 ± 20 - 282 ± 22 4.3 ± 0.3 1410 ± 180
+ 176 ± 16 0.73 194 ± 22 4.4 ± 0.3 1120 ± 140
Mean data over the period 30-90 min are given for both experimental conditions (n=4); fu: 
fraction unbound; CLR/GF: renal clearance of 2-methylbenzoylglycine corrected for 
glomerular filtration rate and fraction unbound in perfusate; A: An other BSA batch was used.
Because renal excretion was dependent on unbound drug concentration in perfusate, 
clearance data from both experimental conditions could be pooled and analysed 
simultaneously. The kinetic parameters o f the two transport systems involved in tubular 
secretion o f 2-methylbenzoylglycine are presented in Table 2-3.
The 2-methylbenzoylglycine concentration in kidney tissue was determined at the end 
of each experiment (Table 2-2). A plot o f kidney/perfusate ratio vs unbound perfusate 
concentration is illustrated (Fig. 2-3). At low perfusate concentration very high 
accumulation ratios were observed, which decreased at increasing perfusate 
concentrations, indicating that a saturable component is involved in cellular uptake. 
Kinetic parameters for renal accumulation were obtained after fitting equation 2-5 to the 
accumulation data of 2-methylbenzoylglycine (Table 2-3).
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Figure 2-2. Tubular titration curve of 2-methylbenzoylglycine. Renal excretion rate and 
rate o f filtration as a function of concentration unbound in perfusate. Data obtained over 
the period 30-90 min of both experimental conditions were pooled and analysed 
simultaneously. The solid line represents the fit according to equation 2-4, the dashed 
line corresponds to the clearance by glomerular filtration only (GF). The closed symbols 
represent data from experiments without BSA, and the open symbols data from 
experiments with 2% BSA in perfusion medium. All data points are means of 4 
experiments.
Table 2-3. Kinetic parameters of renal 2-methylbenzoylglycine handling.
Parameter High affinity site Low affinity site
Tm (^g/min) 3.0 ± 2.8 250 ± 36
Kt (^g/ml) 0.5 ± 0.8 62 ± 17
RM (^g/g) 26 ± 23 1640 ± 1100
Ka (^g/ml) 0.2 ± 0.4 60 ± 58
Parameters were obtained after fitting equations 4 and 5 to the data. Ratio of 
concentration in kidney tissue over unbound perfusate concentration (CT/CU) due to passive 
transport (a in equation 2-5) was determined to be 2.4 ±  2.2.
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K i d n e y / p e r f u s a t e  rat io
2 - m e t h y l b e n z o y l g l y c i n e
U n b o u n d  c o n c e n t r a t i o n  (| jg/ml)
Figure 2-3. Accumulation of 2-methylbenzoylglycine in kidney tissue. The 
kidney/perfusate ratio is plotted against the unbound perfusate concentration. Closed 
symbols express data from experiments in the absence of BSA in perfusate, open symbols 
data from the experiments in the presence o f BSA.. All data points are individual kidneys, 
n=24 for both experimental conditions.
Discussion
The kidneys used in this study showed a good renal functioning, and were stable for 
at least 2 hours. Changes in kidney function due to the addition o f BSA to the 
perfusion fluid are in accordance with those reported by M aack (16) and Bekersky
(1). The fractional excretion (%) o f potassium, glucose and magnesium decreased, 
indicating that kidney viability was increased in the presence o f 2% BSA in control 
IPK experiments. Although the colloid osmotic pressure was comparable in both 
experimental perfusion fluids, a higher perfusate flow was necessary with albumin in 
the perfusion fluid, to maintain the perfusate pressure at approximately 90 mm Hg. 
GFR decreased in presence o f 2% BSA, due to an enhanced oncotic pressure within 
the glomerulus and peritubular capillaries, which is in agreement with the concept of 
Starling (16,22).
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The ClR/GF o f 2-methylbenzoylglycine was many times higher than 1 (Table 2-2), 
indicating that clearance proceeded via glom erular filtration and pronounced active 
secretion. As a result o f the large perfusate volum e (250 ml) in proportion to the 
renal clearance (1-7 ml/min), the decline in perfusate concentration was slow. 
Tubular secretion followed Michaelis-Menten kinetics, and interestingly, a model 
with two affinity sites was necessary to describe the renal excretion rate. A low and 
high affinity site o f the basolateral p-aminohippurate transporter seems very unlikely, 
as numerous membrane studies have never provided evidence indicating more than 
one site.
A two-site model is consistent with high affinity, low capacity uptake across the 
basolateral membrane and subsequent low affinity, high capacity transport across the 
brush-border membrane into the tubular lumen, as was proposed previously for the 
renal excretion o f furosemide in the IPK (13). However, the similarity o f the kinetic 
parameters for secretion and accumulation strongly suggest that uptake takes place at 
the basolateral membrane o f the proximal tubule, and that both saturable steps are 
connected with transport across this membrane. An explanation that could fit in this 
view may be that 2-methylbenzoylglycine is transported with high affinity via the p- 
aminohippurate carrier and that it has also a low affinity for one o f the other 
basolateral organic anion transporters, i.e. dicarboxylate or sulphate system.
The results o f the IPK experiments in the presence o f BSA show that the renal 
excretion and accumulation o f 2-methylbenzoylglycine was dependent on unbound 
drug concentration, however, in contrast with in vivo studies in the dog (20), the 
compound is not efficiently cleared by the kidney. This is most probably a 
consequence o f the high perfusion flow, resulting from a lack o f red blood cells and 
maximum dilation o f the vessels o f the perfused kidney. In presence o f 2% BSA, 
even a higher flow (23 vs 15 ml/min) was necessary to sustain a normal perfusate 
pressure, due to lower perfusate viscosity. Similar to the in vivo situation, the 
intrinsic secretion clearance o f 2-methylbenzoylglycine in the IPK (Clint = T MH / K TH 
+ Tml / K TL) was high: 10 ml/min. However, as a result o f the high perfusion flow 
the renal extraction ratio, calculated as Clint divided by the sum of Cl int and 
perfusate flow, is low. Dependent on the experimental condition the extraction ratio 
varied between 0.3 and 0.4, and as a result, 2-methylbenzoylglycine behaves as a low 
clearance drug. Lee et al (14) have reported similar findings for the diuretic 
chlorothiazide which also shows a high renal extraction in vivo. In the IPK, however, 
this diuretic is cleared as a low clearance drug as a result of the high perfusate flow.
Contrary to what was found in rabbit renal proximal tubules for p-aminohippurate
(2), BSA did not enhance tubular secretion o f this hippurate analogue. Our results
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show that kidney/perfusate ratios did increase in presence o f BSA at low perfusate 
concentration, however, this could be explained by a strongly reduced free 
concentration o f 2-methylbenzoylglycine in perfusate rather than a stimulatory effect 
o f BSA. At low perfusate concentrations, accumulation ratios up to 175 times the 
perfusate concentration were observed. Such high accumulation ratios have as yet 
never been reported for an in vitro renal perfusion system. It is obvious that anionic 
drugs, pharmacologically less inert than hippurates, that are subject to tubular 
secretion, may have harmful effects on kidney functioning even at low plasma 
concentrations.
In conclusion, 2-methylbenzoylglycine is handled as a low-clearance drug in the 
IPK and, as a consequence, renal clearance appeared to be a function o f the unbound 
drug concentration in perfusion medium. Renal tubular excretion data were described 
best by a model in which tubular secretion is composed o f a high and a low affinity 
M ichaelis-M enten term. The very high accumulation in kidney tissue could be 
explained by active tubular uptake, mediated by the secretory mechanisms involved. 
This study shows that anionic drugs, subject to active secretion, may reach high 
concentrations in tubular cells even at low plasma concentration.
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Chapter 3
Sum m ary
Renal secretion and accumulation o f the hippurate analogue 4-methylbenzoylglycine 
was investigated in the IPK in the absence and presence o f BSA. Experiments were 
performed w ith either 2.5% pluronic or a combination o f 2.2% pluronic and 2% BSA as 
oncotic agents, and a wide concentration range o f 4-methylbenzoylglycine was studied 
(1-200 ^g/ml). Tubular secretion appeared to be a function o f unbound drug in 
perfusate. Renal excretion data were best fitted by a model in which a M ichaelis­
M enten term was used to describe active secretion. Parameters obtained were TM = 55 ± 
2 |ig/min and KT = 4.2 ± 0.8 |ig/ml. The compound accumulated extensively in kidney 
tissue, ratios up to 600 times the perfusate concentration were reached. Accumulation 
could be explained by active tubular uptake and data were analysed best by a model 
similar to the model used to describe renal excretion. Calculated parameters were RM = 
300 ± 210 |ig/g and KA = 5.0 ± 4.4 |ig/ml. The high intracellular concentrations were 
without harmful effects on kidney functional parameters as well as on mitochondrial 
oxygen consum ption. A change in substitution from  4-m ethyl- to  4- 
aminobenzoylglycine (p-aminohippurate), however, resulted in a significant inhibition 
o f succinate-stimulated respiration, probably due to reduced mitochondrial succinate 
uptake.
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In troduction
Hippurates (benzoylglycines) are known to be cleared very rapidly by the kidney 
through active secretion mediated by the organic anion transport system in proximal 
tubules, for which p-aminohippurate has been considered as the model compound. The 
drug undergoes extensive secretion and is only minimally bound to plasma proteins (7). 
Therefore, renal p-aminohippurate clearance is a suitable measure of renal tubular 
function (2).
In a series o f two papers Russel et al. (16,17) studied the renal clearance o f a series of 
ortho-, meta- and para-substituted benzoylglycines in vivo in the dog, in order to 
determine the influence o f ring substitution on the excretion o f hippurate. A large 
diversity in excretory characteristics were observed but in general it was concluded that 
introduction o f a substituent in the ring o f benzoylglycine results in a compound to 
which the kidney has a higher clearance capacity. Two compounds o f special interest 
emerged from these studies: 2-methylbenzoylglycine because o f its tight protein binding 
and exceptional clearance profile, and 4-methylbenzoylglycine because it had the 
highest intrinsic clearance, almost four times that o f p-aminohippurate.
In a previous study we examined the renal secretion and accumulation kinetics o f 2- 
methylbenzoylglycine in the isolated perfused rat kidney (IPK) (10). W e observed that, 
despite a high intrinsic clearance, active tubular secretion appeared to be a function of 
unbound drug in perfusate and was described best by two M ichaelis-Menten terms. 
Furthermore, extensive accumulation o f the drug in kidney tissue was directly related to 
active tubular uptake. This was in good agreement with several findings that hippurates 
accumulate in proximal tubular cells during transepithelial secretion, as a consequence 
o f active cellular uptake (4,6,12,18,19).
Relatively minor attention has been paid to the intracellular disposition o f hippurates. 
Two decades ago, p-aminohippurate was found to interact with the anion binding 
protein ligandin and it was suggested that this protein plays a role in the reduction o f the 
free cytoplasmic concentration (9). More recently it was shown that compartmentation 
within cellular organelles may also occur for organic anions during secretion: for 
fluorescein, a fluorescent model compound o f p-aminohippurate transport, 
mitochondrial accumulation was observed (12). At present it is not clear whether 
mitochondrial accumulation occurs with other organic anions during secretion.
In the present study we examined the renal secretion and accumulation characteristics 
o f 4-methylbenzoylglycine in the IPK. The purpose was to determine as to whether a 
higher intrinsic clearance leads to a higher accumulation in kidney tissue. An advantage 
o f using the IPK is that the technique enables accurate determination o f renal drug 
clearance in the absence o f nonrenal effect. In the dog in vivo, 4-methylbenzoylglycine
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was partially deconjugated to its corresponding benzoate (16). Nevertheless, 4- 
methylbenzoate was only found in plasma and not in urine, indicating that the 
compound was cleared extrarenally or completely metabolized during transepithelial 
secretion in the kidney. Importantly, the presence o f 4-methylbenzoate might have 
influenced the renal clearance o f 4-methylbenzoylglycine, and consequently resulted in 
an inadequate determination o f renal excretory kinetic parameters.
M ateria ls  and  m ethods
Materials
Pluronic F-108 was obtained from BASF (Arnhem, The Netherlands), bovine serum 
albumin (BSA) was purchased from Boehringer (Mannheim, Germany) and inulin was 
from Sigma (St.Louis, Mo.). 4-Methylbenzoylglycine was synthesized as described 
previously (16). All other chemicals were o f analytical grade and obtained either from 
Sigma or M erck AG (Darmstadt, Germany).
Experimental procedure
The isolation and perfusion procedure o f the rat kidney were described in detail 
previously (10). Studies were performed with perfusate containing either 2.5% pluronic 
or a combination o f 2% BSA and 2.2% pluronic. For the determination o f GFR, 
cyanocobalamin (20 |ig/ml) was added to the perfusion fluid and GFR was monitored 
on line using a micro flow-through cuvette. In presence o f BSA, inulin (100 |ig/ml) was 
used to determine GFR. Doses added to the perfused kidneys were: 0.625, 1.875, 6.25, 
18.75, 37.5, and 62.5 mg o f 4-methylbenzoylglycine in 250 ml o f perfusion fluid.
Mitochondrial respiration measurements
The effect o f 4- and 2-methylbenzoylglycine and p-aminohippurate on mitochondrial 
respiration were determined in the absence o f ADP (state 2), in the presence o f ADP 
(state 3), after ADP consumption (state 4), and after the addition o f dinitrophenol 
(DNP). To this end, rat kidney cortex mitochondria were isolated as described by Cain 
and Skilleter (1), with some modifications. All steps were carried out at 4 °C. Briefly, 
kidneys were isolated after perfusion with ice-cold solution containing 140 mM NaCl 
and 10 mM KCl. The capsula was removed, medulla was dissected and cortex was 
collected in a Potter-Elvehjem homogenizer with Teflon pestle (clearance 0.5 mm) in 
three times the tissue weight o f homogenization buffer (300 mM  mannitol, 10 mM 
HEPES, 1 mM EGTA, 1 mg/ml BSA at pH 7.4). Tissue was homogenized gently six 
times by hand, and the resulting suspension was centrifuged for 10 min at 500g. The
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supernatant was collected and centrifuged for 7 min at 11,000g. The pellet was washed 
with homogenization buffer and again centrifuged (7 min, 11,000g). The final pellet was 
diluted to a concentration o f 5 mg/ml protein in respiration medium (210 mM mannitol, 
10 mM KCl, 10 mM KH 2PO4, 0.5 mM  EGTA, 60 mM Tris-HCl, at pH 7.4). Oxygen 
consumption was measured at 30 °C with a Clarke-type platinum electrode, using 1 mg 
of mitochondrial protein in 2.0 ml o f respiration medium. Succinate (10 mM) was used 
as the metabolic substrate, and rotenone (1 |iM) was added to block electron transport 
proximal to succinate entry into the respiratory chain. ADP stimulated respiration (state 
3) was measured in the presence o f 0.3 mM  ADP. DNP (44 |iM) was used as 
uncoupling agent. Respiratory rates were calculated and expressed as nanogram atoms 
of oxygen per minute per milligram o f mitochondrial protein (ng atom O/min-mg prot.). 
Analysis
Urine and perfusate samples were analysed for glucose and various electrolytes as 
described previously (5). In the presence o f 2% BSA, perfusate and urine samples were 
analysed also for inulin and protein content. The Bio-Rad Protein Assay from Bio-Rad 
(München, Germany) was used for the determination o f protein. Inulin was determined 
according to a previously published method (8). The concentration o f 4- 
methylbenzoylglycine in perfusate, urine and kidney samples was determined by means 
o f reversed-phase high-performance liquid chromatography (HPLC) essentially based 
on a previously described method for 2-methylbenzoylglycine (10). The only 
modification was an operating UV absorbance wavelength o f 238 nm.
Protein binding
Protein binding was determined by ultrafiltration as described by (15). The ultrafiltrates 
were treated and analysed in the same way as the urine samples were. Perfusate protein 
binding was calculated according to the following set o f equations, assuming one class 
o f binding site:
in which C = total perfusate concentration (^g/ml); Cu = unbound drug concentration 
(^g/ml); fu  = fraction o f unbound drug in perfusate; P  = total concentration o f protein 
binding sites (^g/ml); Kd = dissociation constant o f the drug-protein complex (^g/ml).
r  r  P  • Cu C = Cu -  -------------
( K  -  Cu) (3-1)
Cu = fu • C (3-2)
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Renal excretion model
The renal clearance o f 4-methylbenzoylglycine by the IPK could be described by a 
model comprised o f glomerular filtration and tubular secretion according to M ichaelis­
M enten kinetics. Assuming that renal excretion o f 4-methylbenzoylglycine is dependent 
upon unbound perfusate concentrations, the renal clearance o f this compound can be 
expressed as:
T • fu
Cl„ = ( Q,„- fu +-------------) • (1 -  F )  (3 -3 )
(K+ + Cu) ( 33 )
The renal excretion rate (RR) is:
R  = Ch - C (3-4)
where ClR = renal clearance (ml/min); R  R = renal excretion rate (^g/min); Q GF= 
glomerular filtration rate (ml/min); C = total drug concentration in perfusate (^g/ml); Cu 
= unbound drug concentration in perfusate (^g/ml); fu = fraction o f unbound drug; TM = 
maximum transport velocity (^g/min) and KT = Michaelis-M enten constant for tubular 
transport (^g/ml); F  = fraction o f excreted drug reabsorbed.
Renal accumulation
The concentration o f 4-methylbenzoylglycine in the kidney (C T) was expressed as the 
amount o f drug per weight o f tissue. The concentration in kidney tissue divided by the 
concentration in perfusate at the end o f the experiment (Cu,z), resulted in an 
accumulation ratio (kidney/perfusate ratio). If  accumulation in kidney tissue is 
considered to be a result o f both active and passive transport processes, the renal 
accumulation ratio can be described as follows:
C R
------ = ------------- + a (4-5)
Cu,z K, + Cu,z ( )
In which Rm = theoretical maximum capacity (^g/g) and K  A = affinity constant for renal 
accumulation (^g/ml); a = ratio CT /Cu,z due to passive transport.
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Data analysis
Renal excretion rate and accumulation data were analysed according to equations 3-4 
and 3-5 by the nonlinear least square regression program PCNonlin (13). The goodness 
o f fit was evaluated through the coefficients o f determination: R2 = 1 -((D ev)2 / ((O b s)2, 
where ((O b s)2 is the observed sum of squared observations and ((D ev ) 2 the sum of 
squared deviations. All data are expressed as mean ± SD. Statistical differences between 
means were determined with Student's t-test. In respiration measurements, the multiple 
means were compared by using one-way analysis o f variance followed by the least 
significant differences test. Differences were considered significant if  P<0.05.
Results
Kidney function
The renal functional parameters obtained from 12 control IPK experiments in the 
absence and presence o f BSA, and after administration o f the highest dose o f 4- 
methylbenzoylglycine, are presented in Table 3-1. In presence o f 2% BSA a lower GFR 
was observed, due to an enhanced oncotic pressure within the glomerulus and 
peritubular capillaries. Furthermore, due to lower perfusate viscosity, a higher perfusate 
flow was necessary to sustain a normal perfusate pressure. The fractional excretion (%) 
o f most electrolytes and glucose was decreased in the presence o f BSA, indicating that 
the kidney viability was enhanced. Administration o f the highest dose o f 4- 
methylbenzoylglycine did not affect the function o f the kidney negatively.
Protein binding
Protein binding was determined for each dose o f 4-methylbenzoylglycine administered, 
and was found to be concentration-dependent. The fraction unbound varied between 0.1 
and 0.7 over a concentration range o f 0.5 to 150 |ig/ml. Protein binding data o f each 
dose were pooled and analysed according to equation 3-2. The parameters obtained after 
analysis were a dissociation constant, Kd, o f 9 ± 2 |ig/ml and a total concentration of 
BSA binding sites, P, o f 35 ± 4 |ig/ml (n= 18; R2=0.984).
Renal excretion and accumulation
4-Methylbenzoylglycine was slowly eliminated from perfusate. Fig. 3-1 shows the mean 
unbound perfusate concentration and corresponding excretion rate data, as a function of 
tim e under both experimental conditions. All doses gave log-linear concentration time 
curves. The urinary excretion rate increased rapidly after addition o f 4- 
methylbenzoylglycine, followed by a gradual decrease. The presence o f protein in
74
Renal accumulation of 4-methylbenzoylglycine
perfusate resulted in lower renal excretion rates for all doses. Plasma and urine samples 
were checked for the presence o f 4-methylbenzoate, but the deconjugation product 
could not be detected. Renal handling data are presented in Table 3-2. At low dose, the 
renal clearance was many times higher than the clearance by glomerular filtration 
corrected for the fraction unbound (ClR>GF), indicating active tubular secretion. A 
decrease in ClR/GF at higher perfusate concentration is an indication o f saturation of 
tubular secretion. The ClR/GF values in the presence o f BSA were higher than those 
obtained from the corresponding experiments with 2.5% pluronic, supporting the view 
that the renal excretion o f 4-methylbenzoylglycine is dependent on unbound drug 
concentrations. Therefore, clearance data from the experiments with BSA in perfusion 
fluid were pooled with those from the experiments in absence o f BSA and analysed 
simultaneously.
Table 3-1. Functional parameters ofthe IPK in control experiments and after administration of 
62.5 mg 4-methylbenzoylglycine (4-MBG).
2.5% pluronic 2.2% pluronic/ 2% BSA
Parameter controla 4-MBGb controla 4-MBGb
FE sodium (%) 2.9 ± 0.6 2.8 ± 1.0 3.1 ± 1.7 2.9 ± 0.8
FE potassium (%) 38 ± 14 40 ± 14 14 ± 6 22 ± 7
FE glucose (%) 7.3 ± 2.1 8.9 ± 1.8 4.1 ± 2.0 6.0 ± 0.6
FE magnesium (%) 42 ± 10 22 ± 4* 17 ± 12 18 ± 5
FE calcium (%) 3.5 ± 1.3 4.0 ± 1.4 2.4 ± 1.3 2.6 ± 0.6
H2O reabsorption (%) 94 ± 1 93 ± 1 93 ± 1 93 ± 1
urine flow (^l/min) 18 ± 3 19 ± 3 16 ± 3 15 ± 1
GFR (^l/min) 277 ± 35 284 ± 15 232 ± 53 234 ± 44
urinary pH 5.8 ± 0.3 6.0 ± 0.1 6.2 ± 0.2 6.3 ± 0.03
perfusate flow (ml/min) 15 ± 2 14 ± 2 23 ± 2 23 ± 3
perfusate pressure (mm Hg) 89 ± 8 80 ± 3 93 ± 8 97 ± 4
Mean values ±  SD over the period 30-120 min are given. FE: fractional excretion; *:P<0.05 
as compared with control experiments; t :P<0.05 as compared with corresponding experiments 
without BSA;a: n=12;b: n=4.
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Figure 3-1. 4-Methylbenzoylglycine perfusate concentration (upper panels) and urinary 
excretion rate (lower panels) as a function of time. Closed symbols represent the experiments 
without BSA in perfusate, open symbols represent the experiments in the presence of BSA in 
perfusate. Doses added are indicated next to lines (in mg). All data points are means of 4 
experiments. For the sake of clarity standard deviations were omitted from this figure, but 
varied for low perfusate concentrations (0-25 ¡Jg/ml) between 20 and 51% and for high 
concentrations (25-250 Jg/ml) between 1 and 30%. For renal excretion rate standard 
deviations varied between 6 and 39%.
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Table 3-2. Renal handling of4-methylbenzoylglycine in the isolated perfused rat kidney
Dose
(Mg)
BSA Perfusate
concentration
(Mg/ml)
fu Excretion rate 
(Mg/min)
ClR/GF Amount in 
kidney (Mg/g)
625 - 1.2 ± 0.2 - 5.8 ± 1.1 11 ± 1 20 ± 7
+ 1.7 ± 0.2 0.17 2.6 ± 0.4 25 ± 3 90 ± 38
1875 - 1.6 ± 0.8 - 24 ± 8 26 ± 3 46 ± 13
+ 4.5 ± 0.5 0.18 10 ± 2 40 ± 2 72 ± 20
6250 - 11 ± 3 - 41 ± 6 9.2 ± 0.9 235 ± 102
+ 17 ± 1 0.23 19 ± 2 13.6 ± 0.4 112 ± 40
18750 - 45 ± 5 - 59 ± 8 4.0 ± 0.4 487 ± 76
+ 46 ± 4 0.42 49 ± 3 7.9 ± 0.7 391 ± 55
37500 - 117 ± 7 - 94 ± 7 2.3 ± 0.1 793 ± 118
+ 123 ± 7 0.72 87 ± 3 3.1 ± 0.2 540 ± 51
62500 - 201 ± 4 - 106 ± 6 1.29 ± 0.03 1027 ± 149
+ 193 ± 6 0.81 104 ± 10 2.4 ± 0.2 882 ± 90
Mean data1 over the period 30-90 min are given for both experimental conditions (n=4); fu:
fraction unbound; CLR/GF: renal clearance of 4-methylbenzoylglycine corrected for 
glomerular filtration rate and fraction unbound in perfusate.
The tubular titration curve in Fig. 3-2 represents the relationship between renal 
excretion rate and unbound perfusate concentration at the midpoint o f a urine collection 
interval. The plot gives a clear impression o f the processes involved in renal 4- 
methylbenzoylglycine clearance. The compound undergoes net tubular secretion which 
becomes saturated at higher perfusate concentration. At these concentrations, the 
titration curve parallels the glomerular filtration (GF) line, indicating that passive 
reabsorption o f 4-methylbenzoylglycine was negligible (F=0 in equation 3-3). The 
kinetic parameters determined after fitting equation 3-4 to the data were a TM o f 55 ± 2 
Mg/min and a KT o f 4.2 ± 0.8 Mg/ml.
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At the end o f each experiment the concentration o f drug in kidney tissue was 
determined (Table 3-2). Concentrations up to 600 times the perfusate concentration 
were observed at low perfusate concentration (Fig. 3-3). Values o f individual kidneys 
are presented because o f the high variation at low medium concentrations. After fitting 
equation 3-5 to the accumulation data, the kinetic parameters for renal accumulation 
were RM = 300 ± 210 |ig/g, KA = 5.0 ± 4.4 |ig/ml and a = 4.1 ± 3.1.
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Figure 3-2. Tubular titration curve of4-methylbenzoylglycine. Renal excretion rate and rate of 
filtration as a function of concentration unbound in perfusate. The solid line represents the fit 
according to equation 3-4, the dashed line corresponds to the clearance by glomerular 
filtration only (GF). Data obtained over the period 30-90 min of both experimental conditions 
were pooled and analyzed simultaneously The closed symbols represent data from experiments 
without BSA, and the open symbols data from experiments with 2% BSA in perfusion medium. 
All data points are mean values o f 4 experiments.
78
Renal accumulation of4-methylbenzoylglycine
kidney/perfusate ratio
800 -|Q
0  4-m ethylbenzoylg lycine
200 • - BSA
unbound concentration (æg/ml)
Figure 3-3. Accumulation of 4-methylbenzoylglycine in kidney tissue. The 
kidney/perfusate ratio is plotted against the unbound perfusate concentration after fitting 
data according to equation 5. Symbols as described in the legend of Figure 2. All data 
points are individual kidneys, n=24 for both experimental conditions.
Mitochondrial respiration
The effect o f 4-methylbenzoylglycine on mitochondrial oxygen consumption was 
determined and compared with the effects o f 2-methylbenzoylglycine and p- 
aminohippurate. The respiratory control ratio (RCR) in Table 3-3 demonstrates that our 
mitochondrial preparation was o f good quality and tightly coupled. A concentration of 
100 |iM 4-methylbenzoylglycine was used, which is similar to a free cytoplasmic 
concentration o f 518 |ig/ml (Mw=193) and in agreement with kidney tissue 
concentrations determined at an intermediate dose (Table 3-2). At this concentration, the
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drug did not alter the succinate-stimulated respiration, neither at basal respiration nor 
after ADP addition. No effect on uncoupled respiratory rate was observed. At the same 
concentration 2-methylbenzoylglycine decreased ADP stimulated respiration (state 3) 
slightly, but not significantly, and, as a consequence, RCR was diminished. p- 
Aminohippurate showed a significant reduction in basal respiration, state 3 respiration 
and RCR at 100 |iM, suggesting that the availability of succinate for oxidation was 
reduced.
Table 3-3. Effect o f substituted hippurates on succinate-stimulated respiration in rat 
kidney cortex mitochondria.
Drugb
Respiratory rate (ng atom O/min-mg prot.)a
RCRdN state 2 state 3 state 4 DNPc
Control 9 29 ± 6 93 ± 22 28 ± 7 81 ± 20 3.4 ± 0.5
4-MBGe 5 32 ± 3 94 ± 13 30 ± 7 76 ± 30 3.3 ± 0.7
2-MBGe 6 31 ± 4 74 ± 23 28 ± 8 71 ± 28 3.0 ± 0.5
PAHe 4 19 ± 5* 68 ± 8* 27 ± 8 75 ± 26 2.6 ± 0.4*
a Oxygen consumption was measured prior to ADP addition (state 2), after addition of 0.3 mM 
ADP (state 3) and after ADP consumption (state 4). Mean values ±  SD are presented. 
b Mitochondria were preincubated for 3 min in respiration buffer in presence of100 ¡jM  of the
drug tested to affect succinate-dependent respiration. 
c Uncoupled respiratory rate was measured in presence of 44 j M  dinitrophenol (DNP). 
d Respiratory control ratio (RCR) is the ratio of state 3 respiration over state 4 respiration. e 
MBG means methylbenzoylglycine, PAH is p-aminohippurate.
* P<0.05 as compared to control values (paired Student’s t test).
Discussion
The renal excretion of 4-methylbenzoylglycine in the IPK is determined by glomerular 
filtration and active, saturable secretion. The compound was not deconjugated and did 
not affect kidney functioning. 4-Methylbenzoylglycine showed concentration-dependent 
plasma protein binding, which affected its renal clearance. The maximum clearance 
capacity of the secretory system, as described by the intrinsic clearance (CLint= Tm/Kt), 
was high: a value of 13 ml/min could be calculated from the renal excretion rate fit. In 
agreement with intrinsic clearance values determined in the dog in vivo (16,17), this is
80
Renal accumulation of4-methylbenzoylglycine
the highest clearance capacity value reported for hippurates in the IPK. For 2- 
methylbenzoylglycine we determined an intrinsic clearance value of 10 ml/min (10), 
whereas for 2-hydroxybenzoylglycine (salicyluric acid) this value was only 4 (3).
The Michaelis-Menten constant for secretion in the IPK, 4 |ig/ml, is in close 
agreement with the value reported for the dog (16). According to Cox et al. (4), the 
maximum transport velocities of hippurates in rat and dog kidney can be compared 
assuming that TM is a linear function of the tubular cell volume. For the rat kidney a 
ratio of Tm over cell volume (i.e. 340 |il) of 162 is obtained, and for the dog kidney this 
ratio is 267 (total cell volume is approximately 30 ml) (16).
In contrast with earlier findings in the dog (16), tubular secretion of 4- 
methylbenzoylglycine was a function of unbound drug concentration in perfusion fluid. 
This is predominantly a result of the high perfusion flow in our perfused kidney 
preparations, i.e. 14 ml/min in absence of BSA and 23 ml/min in presence of 2% BSA. 
As a consequence the renal extraction ratio, calculated as CLint divided by the sum of 
CLint and perfusate flow, is low despite the efficient secretion of 4- 
methylbenzoylglycine. Dependent on the experimental condition the renal extraction 
ratio varied between 0.4 and 0.5, indicating that in the IPK 4-methylbenzoylglycine is 
handled as an intermediate clearance drug.
The Michaelis-Menten constant for renal accumulation is in good agreement with the 
value for renal excretion, suggesting that the same active mechanism is involved. Most 
likely the basolateral organic anion system in proximal tubules mediates cellular uptake 
of 4-methylbenzoylglycine (7,14). For a compound subject to efficient secretion 
mediated by the basolateral system, a high accumulation in proximal tubular cells can 
be expected. For 4-methylbenzoylglycine we found indeed a high accumulation: 
intracellular concentrations up to 600 times the medium concentration were determined. 
Other hippurate analogs never achieved such high accumulation ratios. In the IPK we 
determined a maximum accumulation ratio of 175 for 2-methylbenzoylglycine (10), 
whereas 2-hydroxybenzoylglycine reached 20 times the medium concentration (3).
The high intracellular concentrations of 4-methylbenzoylglycine were without 
harmful effects on kidney functional parameters. Moreover, mitochondrial oxygen 
consumption was not affected, which is a good indication that the compound does not 
interfere with mitochondrial metabolism. Surprisingly, a change in ring substitution 
may affect kidney functioning and mitochondrial respiration. 2-Methylbenzoylglycine 
affected mitochondrial oxygen consumption slightly, but not significantly, which is in 
agreement with its moderate effect on perfused kidney function (10). p-Aminohippurate, 
however, inhibited both state 2 and state 3 of the succinate-stimulated respiration 
significantly. A similar effect has been observed for fluorescein (a diagnostic agent and
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transported by the p-aminohippurate carrier) which interacted competitively with 
succinate for mitochondrial uptake (11). Whether p-aminohippurate interacts 
competitively with mitochondrial dicarboxylate uptake, or accumulates within 
mitochondria through specific uptake by one of the metabolite anion carriers remains to 
be elucidated.
Hippurates are end-products of metabolism and (basically) pharmacologically inert 
compounds. Therefore, it is remarkable that they affected mitochondrial metabolism. A 
consequence of reduced mitochondrial oxygen consumption is a diminished ATP 
production, and a long-term exposure of the drug may result in the development of 
tubular toxicity. The reason that tubular cell injury has never been reported for p- 
aminohippurate is probably due to the lower concentrations used clinically as compared 
to the high concentration used in the present study. It is unclear whether the influence of 
the hippurates on mitochondrial metabolite uptake is related to certain physicochemical 
properties. If such a relationship exists, possible toxic effects on cellular metabolism 
could be predicted for other anionic drugs.
In conclusion, 4-methylbenzoylglycine is handled as an intermediate clearance drug in 
the IPK and, in contrast with in vivo results, renal clearance appeared to be a function of 
unbound drug concentration in perfusion medium. The compound accumulated 
extensively in kidney tissue as a result of active tubular uptake, mediated by the 
secretory mechanism. The results revealed that anionic drugs with a high intrinsic 
clearance reach high intracellular concentrations. Intracellularly accumulated 4- 
methylbenzoylglycine had no effect on kidney function and mitochondrial oxygen 
consumption, however, its structure analogue p-aminohippurate affected mitochondrial 
metabolism significantly.
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Summ ary
The role of tubular accumulation in renal disposition and diuretic efficacy of 
hydrochlorothiazide was studied in the IPK. Hydrochlorothiazide gave a dose- 
dependent increase in the fractional excretion of sodium, chloride and potassium, and in 
urinary flow and pH. Renal clearance of the drug was low as a result of a low extraction 
ratio and extensive non-ionic back diffusion. Hydrochlorothiazide was subject to 
saturable tubular secretion, following Michaelis-Menten kinetics. Parameters obtained 
after nonlinear regression analysis were a TM of 42 ± 6 |ig/min, a K  T of 38 ± 11 |ig/ml 
and a FPR of 0.49 ± 0.03. The thiazide diuretic accumulated extensively in kidney tissue 
due to active cellular uptake (RM of 500 ± 270 ^g/g, K  A of 28 ± 16 |ig/ml) and passive 
diffusion. Plots were constructed of sodium excretion rate vs hydrochlorothiazide 
perfusate concentration or renal excretion rate. The perfusate plot could be described by 
the sigmoid Emax model, while a simplification of the model had to be used for the 
response curve in urine because a maximum effect was not observed. The apparent 
maximum effect resulting from the perfusate concentration-response curve and the 
discrepancy with the renal excretion rate-response curve indicated that the diuretic 
effect of hydrochlorothiazide is restricted by saturable accumulation and secretion.
85
Chapter 4
Introduction
The renal excretion of an anionic drug is determined by the relative contribution of 
glomerular filtration, active tubular secretion and reabsorption, and the physicochemical 
properties of the compound. A transport system located at the basolateral membrane of 
the proximal tubule is known to mediate the secretion of anionic drugs. For weak acids 
partially ionized in urine, passive reabsorption may also play an important role, finally 
resulting in a net secretion or net reabsorption relative to the clearance by glomerular 
filtration. As a result of active secretion, the anion might accumulate in the proximal 
tubular cell and lumen (4,15). Cellular accumulation and high urinary concentrations of 
drugs can cause tubular injury, resulting in acute renal failure (3). For drugs with a 
mechanism of action dependent upon their transport, e.g. certain antibacterial agents and 
diuretics, an indirect relationship between plasma concentration and effect may exist 
(6).
The isolated perfused rat kidney (IPK) is a useful method for the investigation of 
proximal tubular accumulation of drugs. This in vitro technique has several advantages 
in studying renal handling and disposition of drugs and their effects on kidney function. 
During perfusion it is possible to determine several important functional parameters on 
line, viz. renal perfusion flow, perfusion pressure, glomerular filtration rate (GFR), 
urinary flow and urinary pH. Extrarenal drug elimination and effects influencing kidney 
function, i.e. neural and hormonal factors, are absent (5,7).
In the present study we wanted to investigate how tubular accumulation affects the 
renal activity of a drug that exerts its action from the luminal side of the nephron. For 
this purpose the thiazide diuretic hydrochlorothiazide, a dibasic acid which is secreted 
via the organic anion transport system, was chosen as a model compound. 
Hydrochlorothiazide inhibits p-aminohippurate transport in rat and rabbit proximal 
tubules (1,18) and in dog kidney cortex membrane vesicles (16). In isolated tubules 
concentrations up to 55 times the medium concentration were found (8).
In humans, hydrochlorothiazide is eliminated efficiently and more than 95% of a dose 
is secreted unchanged into urine. Approximately 40% of the drug is bound to plasma 
proteins (21). Although the mechanism of action of hydrochlorothiazide is still not 
completely elucidated, it is well established that the primary mode of action is inhibition 
of the sodium-chloride co-transport mechanism at the luminal membrane of distal 
convoluted tubular cells. A second mode of action is proximally induced and probably 
involves inhibition of carbonic anhydrase (17,20).
Aim of this investigation was to study how, and to what extent, hydrochlorothiazide 
accumulates in the IPK and how this influences the relationship between diuretic
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response and plasma drug concentration.
M aterials and methods
Materials
Sodium pentobarbital was purchased from Apharmo (Arnhem, The Netherlands). 
Heparin, insulin and aldosterone were obtained from Organon (Oss, The Netherlands). 
Pluronic F-108 was from BASF (Arnhem, The Netherlands), lysine-vasopressin from 
Sandoz (Basel, Switzerland), angiotensin II from Beckman (Palo Alto, Ca.), synthamin 
14 from Travenol (Thetford, Norfolk, UK), hydrochlorothiazide and hydroflumethiazide 
were purchased from Sigma (St.Louis, Mo.).
Experimental procedure
The isolation and perfusion of the rat kidney is described in detail previously (7). The 
experimental period was 120 min and started after a 30 min control period. During the 
control period the perfusate volume was 500 ml from which a sample of 5 ml was 
drawn. After the control period, the experimental perfusion fluid was connected to the 
kidney, with a total volume of 250 ml in which hydrochlorothiazide was already 
dissolved. Perfusion medium was albumin-free and pluronic F108 was used as oncotic 
agent (7). Doses added to the perfused kidneys were: 1.25, 2.5, 12.5, 25, 50 and 75 mg 
of hydrochlorothiazide, resulting in initial perfusate concentrations of 16.8, 33.6, 168, 
336 and 1008 |iM (between 5 and 300 |ig/ml). Urine samples were collected during 
control and experimental periods over 10 min intervals. Perfusate samples (300 |il) were 
drawn at the midpoint of each urine collection interval. Two additional perfusate 
samples were taken, one at the beginning of the experimental period (t=0), and one at 
the end of the experiment. At the end of the experiment the kidney was removed from 
the system, blotted, weighed, and frozen until analysis. Urine and perfusate samples 
were stored at -20 °C until analysis.
Analysis
Urine and perfusate samples were analyzed for sodium, potassium, chloride, glucose, 
magnesium, and calcium, as described previously (7). The concentration of 
hydrochlorothiazide in kidney tissue, perfusate and urine samples were determined 
using reversed-phase high-performance liquid chromatography (HPLC), essentially 
based on a previously described method for naproxen (7). Modifications were an 
operating UV absorbance wavelength of 272 nm and a mobile phase of 10% methanol 
and 90% 0.01 M phosphate buffer with pH 2.6. Hydroflumethiazide (0.25-1 |ig) was 
added as internal standard.
87
Chapter 4
Renal excretion model
The renal excretion of hydrochlorothiazide is determined by active tubular secretion and 
passive reabsorption. Active tubular secretion can be described according to Michaelis­
Menten kinetics. Since binding proteins were absent in perfusate and 
hydrochlorothiazide did not bind to any of the perfusate constituents, drug 
concentrations can be considered as unbound. Renal clearance is expressed as:
ClR = ( Qgf+K  + c   ^ ^  _ FPR) ( ^ )
The renal excretion rate is:
Rr = ClR ' Cp (4"2)
where ClR=renal clearance (ml/min); R  R=renal excretion rate (^g/min); Q GF= glomerular 
filtration rate (ml/min); CP=drug concentration in perfusate (^g/ml); T M=maximum 
tubular transport velocity (^g/min); KT=Michaelis-Menten constant of secretion 
(^g/ml); FPR=fraction of excreted drug reabsorbed passively.
Accumulation in kidney tissue
The concentration of hydrochlorothiazide in the kidney (CT) was expressed as the 
amount of drug per weight of tissue. The concentration in kidney tissue divided by the 
concentration in perfusate at the end of the experiment, resulted in an accumulation ratio 
(kidney/perfusate ratio). If accumulation in kidney tissue is considered to be a 
combination of active and passive transport, this ratio can be described as follows:
CT RM
C K  + C aP A  P
where RM=maximum capacity of renal accumulation (^g/g); KA=affinity constant of 
renal accumulation (^g/ml); a=ratio C /C P due to passive transport.
Diuretic response
The diuretic effect of hydrochlorothiazide was quantified by the urinary sodium 
excretion rate. The concentration-effect curves for hydrochlorothiazide were analyzed
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according to the sigmoid Emax model, defined as:
E = K  +
E ■ X Smax
EX5s0 + X s
(4-4)
in which E=sodium excretion rate (^eq/min); E0=basal sodium excretion rate; E mix: 
=maximum sodium excretion rate; X=either perfusate concentration or renal excretion 
rate of hydrochlorothiazide (^g/ml and |ig/min, respectively); EX50=either perfusate 
concentration (EC50) or renal excretion rate (ER 50) at half maximum effect; S=slope 
factor of the response curve.
Data analysis
Renal excretion rate, accumulation in kidney tissue and diuretic responses were 
analyzed using the nonlinear least square regression program PCNonlin (12). The 
goodness of fit was evaluated through the coefficients of determination: R2=1- 
((D ev)2/((O bs)2, where ((O bs)2 is the observed sum of squared observations and 
((D ev) 2 the sum of squared deviations. All data are expressed as means ± SD. 
Statistical differences between means were analyzed by using a one-way analysis of 
variance followed by the least significant difference post test. Values were considered 
statistically different when P<0.05.
Results
Kidney function
A wide concentration range of hydrochlorothiazide was examined, with initial perfusate 
concentrations ranging from 5 to 300 |ig/ml. A concentration-dependent effect on renal 
function was found. This was determined from an increase in the fractional excretion of 
sodium, chloride, potassium and magnesium, an increase in urinary pH and diuresis, 
resulting in a decrease in water reabsorption. Fig. 4-1 shows the normalized values of 
the renal functional parameters during the experimental period for 20 min intervals. The 
mean values for the functional parameters of the control period are presented in Table 4­
1, to which renal functional parameters during the experimental period (Fig. 4-1) were 
normalized. The experimental period of 30 to 90 min was used for parameter 
comparison. Kidney function declines after 90 min, which was also observed in control 
IPK experiments (Fig. 4-1). There was no significant change in glucose excretion during
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the experimental period of 30 to 90 min, therefore proximal tubular function remained 
fairly constant.
Table 4-1. Renal functional parameters o f the isolated perfused rat kidney experiments 
during the control period.
Parameter value
FE(%) sodium 2.1 ± 0.6
FE(%) potassium 21 ± 8
FE(%) chloride 1.4 ± 0.6
FE(%) calcium 2.8 ± 1.0
FE(%) glucose 2.9 ± 0.6
FE(%) magnesium 29 ± 9
GFR (^l/min) 320 ± 33
urine flow (^l/min) 17 ± 2
urine pH 5.7 ± 0.2
water reabsorption (%) 94.7 ± 0.3
perfusion pressure (mm Hg) 86 ± 6
perfusion flow (ml/min) 15 ± 2
Each value is the mean ± SD of 33 different IPK experiments. FE, fractional excretion; GFR, 
glomerular filtration rate.
Figure 4-1. Fractional excretion (FE %) of sodium, chloride, potassium, calcium, 
glucose and magnesium, as well as urinary flow and urinary pH are shown. Renal 
functional values are normalized for the mean values of the control period, as presented 
in Table 4-1. Hydrochlorothiazide was administered at time t=0 min, and samples were 
collected and analyzed as described in Materials and methods. The effects after six 
different perfusate concentrations are presented. Concentrations studied were: none 
(control, +, N=12); 5 /Jg/ml (*, N=6); 10 /Jg/ml (0, N=4); 50 /Jg/ml (v , N=6); 100 
/jg/ml (*, N=6); 200 jg/ml (o , N=5) and 300 jg/ml 0 ,  N=6). *P<0.05: significant 
difference from control IPK experiments.
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Renal excretion of hydrochlorothiazide
Hydrochlorothiazide was eliminated slowly from the perfusate. In Fig. 4-2, a typical 
tubular titration curve is given in which the renal excretion rate is plotted linearly 
against the plasma concentration at the midpoint of a urine collection interval. Table 4-2 
presents the renal handling data. The total renal clearance of hydrochlorothiazide 
exceeded the clearance by glomerular filtration slightly, but significantly, at low 
perfusate concentration, indicating active tubular secretion. At higher perfusate 
concentrations passive tubular reabsorption dominated. Data were analyzed according to 
equation 4-2, and this resulted in a TM of 42 ± 6 |ig/min and a KT of 38 ± 11 |ig/ml, with 
a Fpr of 0.49 ± 0.03 (R2=0.92).
Renal excretion rate (æ g/m in)
Perfusate concentration (æ g/m l)
Figure 4-2. Tubular titration curve of hydrochlorothiazide. Renal excretion rate and rate of 
filtration are plotted against the perfusate concentration. The solid line represents the fit 
according to equation 1, the dashed line corresponds to the clearance by glomerular filtration 
only (GF). Data obtained over the period 30-90 min were used and presented as means of 4 to 
6 experiments. For the sake of clarity standard deviations were omitted from this figure, but 
varied between 15 and 40%.
92
Renal accumulation and effect of hydrochlorothiazide
Table 4-2. Renal handling o f hydrochlorothiazide in the isolated perfused rat kidney
Dose
(mg)
Perfusate
concentration
(Mg/ml)
Excretion rate 
(Mg/min)
ClR/GF Amount in 
kidney 
(Mg/g)
Kidney/ 
perfusate ratio
1.25 4.9 ± 0.2 2.0 ± 0.2 1.37 ± 0.13* 73 ± 18 18 ± 9
2.5 9.2 ± 0.4 3.7 ± 0.4 1.35 ± 0.13* 150 ± 40 18 ± 3
12.5 42 ± 2 18 ± 1 1.41 ± 0.10* 370 ± 60 10 ± 2
25 83 ± 2 29 ± 1 1.18 ± 0.06* 630 ± 130 8 ± 2
50 190 ± 5 65 ± 6 0.9 ± 0.07 880 ± 90 5 ± 1
75 270 ± 1 60 ± 2 0.7 ± 0.02 1060 ± 190 4 ± 1
Each value is the mean ± SD of 4-6 experiments over the period of 30-90 min after 
hydrochlorthiazide administration; except for the amount in kidney which was determined at 
the end of the experiment. ClR /GF means ratio of renal clearance over clearance by 
glomerular filtration. * P<0.05: significant difference from 1.
Accumulation in kidney tissue
Hydrochlorothiazide accumulated extensively in kidney tissue, as was determined by 
the kidney/perfusate ratio. The accumulation ratios, measured for each kidney 
individually, are plotted against the perfusate concentration in Fig. 4-3. The average 
weight of the kidneys was 1.48 ± 0.12 g (N=33). Table 4-2 presents the mean 
kidney/perfusate ratio values for each dose administered to the IPK. The 
hydrochlorothiazide concentration determined in kidney tissue exceeds the perfusate 
concentration 18 times at low perfusate concentrations (5 and 10 Mg/ml), clearly 
indicating that an active and saturable mechanism is involved in cellular uptake. 
Individual data were analyzed according to equation 4-3, and this resulted in a RM of
500 ± 270 Mg/g, a K A of 28 ± 16 Mg/ml and a passive uptake component of 2.5 ± 1.6 
(R2=0.70).
Diuretic response
The urinary sodium excretion rate was used to quantify the diuretic effect of 
hydrochlorothiazide in the IPK. The sodium excretion rate is plotted against the 
perfusate concentration and presented in Fig. 4-4 (upper panel). The observed curve 
could be described by the sigmoid Emax model, expressed by equation 4-4. This resulted 
in an apparent Emax of 6.3 ± 1.0 Mg/min, an EC 50 of 72 ± 5 Mg/ml and a slope factor of 
1.6 ± 0.8 (R2=0.90). A plot of urinary sodium excretion rate vs renal excretion rate of 
hydrochlorothiazide did not fit the sigmoid Emax model because a maximum effect was
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not achieved (Fig. 4-4, lower panel). In this situation, where the renal excretion rate of 
hydrochlorothiazide is negligible with respect to its ER00 value (X«ER50), equation 4-4 
simplifies to:
E
1 7 - 1 7  . max n S
E  -  E 0 + — S RR (4-5)
E R 50
The parameters obtained by fitting this equation to the data were a slope factor of 2.8 ±
0.2 with a Emax/ER50 ratio of 0.82 ± 0.09 (R2=0.97). We have tried to increase the 
hydrochlorothiazide dose to reach a maximum effect in urine, however, the kidney did 
not tolerate perfusate concentrations above 300 |ig/ml (data not shown).
Kidney/perfusate ratio
Perfusate concentration (æg/ml)
Figure 4-3. Accumulation of hydrochlorothiazide in kidney tissue. The kidney/perfusate ratio is 
plotted against the perfusate concentration. The solid line represents the fit according to 
equation 4-3. All data points represent individual kidneys; N=33.
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Sodium excretion rate (peq/min)
Perfusate  con centra t ion  (pg/ml)
S od iu m  excret ion  rate (peq/min)
Renal excret ion rate (jjg/min)
F igure 4-4. Upper panel: Response curve o f  hydrochlorothiazide perfusate 
concentration  v s  sodium excretion rate. Line through closed squares represents the f i t  
o f  the data according to the sigmoid model. Lower panel: Response curve o f  renal 
excretion rate o f  hydrochlorothiazide vs sodium excretion rate. Line through open 
squares represents the f i t  o f  equation 4-5 to the data. A ll data points are means o f  4 to 
6 experiments. For the sake o f  clarity standard deviations were om itted from  this figure, 
but varied between 2 and 14%  fo r  perfusate concentration, and between 15 and 40%  
fo r  renal excretion rate.
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Discussion
Although the kinetics and dynamics of hydrochlorothiazide have been studied widely, 
this is the first report on renal disposition and effects in the IPK. The IPK is the most 
appropriate technique for studying drug accumulation and effects at the organ level, 
without any disturbing extrarenal factors. Lee et al. (10) have investigated the renal 
transport kinetics of chlorothiazide in the IPK, but they did not evaluate the diuretic 
activity and accumulation behaviour. Our study focusses on the excretion and 
accumulation kinetics of hydrochlorothiazide and the relationship with the induced 
diuretic effect.
After administering hydrochlorothiazide to the IPK, renal excretion of sodium, 
chloride and potassium increased dose-dependently. Furthermore, an increased urine 
flow rate and urine pH were observed. The dose-dependent alterations in the fractional 
excretion of the electrolytes are in good agreement with a distally induced diuretic 
response (15,17). An apparent maximum diuretic activity was reached after the addition 
of 50 mg of hydrochlorothiazide to the IPK. With a higher dose (75 mg), only a slight 
increase in sodium and chloride excretion was found.
Thiazide diuretics have been shown to enhance calcium reabsorption after chronic 
administration, due to an increase in calcium uptake in the distal tubule (9). The 
fractional excretion of calcium was increased in our IPK experiments, however, we 
found a decrease in the calcium to sodium excretion ratio. Manitius et al. (11) have 
reported similar findings in the IPK, in which they compared the calciuretic effect of 
hydrochlorothiazide with furosemide. They found a retarded calcium excretion relative 
to that of sodium after hydrochlorothiazide administration, which was not observed after 
furosemide administration. This is in good agreement with the in vivo effects of these 
diuretics.
In humans, the renal clearance of hydrochlorothiazide is high (approximately 300 
ml/min) and involves glomerular filtration and proximal tubular secretion, whereas 
reabsorption was not found (18). In our IPK, the renal clearance of hydrochlorothiazide 
exceeded clearance by glomerular filtration only at low perfusate concentrations. At 
higher concentrations (>100 |ig/ml) the renal excretion changed from net secretion into 
net reabsorption, due to saturation of the secretory system and substantial passive 
tubular reabsorption. In perfusion medium with pH 7.4, only 4% of the dibasic acid is 
ionized (pKa values are 7.9 and 9.2), which is reduced to less than 1% at an urinary pH 
of 5.7. In consequence of this low grade of ionization, hydrochlorothiazide exhibits high
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non-ionic back diffusion.
Another cause of the low clearance observed is the low renal extraction ratio. The 
perfusate flow is high, resulting from maximum dilation of the vessels and a lack of red 
blood cells. Accordingly, a low filtration fraction (only 2.3%) and a low extraction ratio 
(0.12) are observed. The extraction ratio is determined by the intrinsic tubular clearance 
(Clint=TM/Kt) divided by the sum of perfusion flow and Clint. These findings are similar 
to the low renal extraction reported for chlorothiazide in the IPK (10), however, 
chlorothiazide exhibited a higher renal clearance as a result of a more efficient excretion 
and the absence of tubular reabsorption.
Hydrochlorothiazide accumulated extensively in kidney tissue, in accordance with a 
basolateral active uptake system. Accumulation showed saturable kinetics and 
kidney/perfusate ratios of up to 18 times the perfusate concentration were observed. 
Duggan (8) reported similar findings in isolated rabbit renal tubules, in which both an 
active and passive component were involved in tubular accumulation of 
hydrochlorothiazide. Our data confirm these findings and it is apparent that, when the 
carrier system reaches saturation, the accumulation diminishes and will only be 
determined by the passive component. The equivalence of the affinity constants for 
secretion and accumulation and the results of Duggan (8) suggest that accumulation due 
to saturable tissue protein binding is unlikely, although this cannot be fully excluded by 
our experiments.
The diuretic response by a drug generally results in an enhanced sodium excretion 
rate. Plots can be constructed of the sodium excretion rate vs either perfusate 
concentration or urinary excretion rate of the diuretic. With hydrochlorothiazide, 
however, a difference was observed between those two plots, which indicates that the 
concentration of drug at the effector site is not keeping up with the perfusate 
concentration. As the amount of drug reaching the effector site is limited by saturable 
tubular accumulation and secretion, an apparent maximum effect is observed in the 
perfusate concentration-effect curve.
In humans, a diuretic effect with hydrochlorothiazide is achieved at much lower 
concentrations. Therapeutic plasma concentrations between 100 and 500 ng/ml have 
been reported (2), concentrations at which no effect was observed in our IPK. It seems 
likely that in vivo the drug is transported more efficiently to the distal lumen due to 
efficient secretion and minor passive reabsorption. In the IPK, the main part of 
hydrochlorothiazide reabsorption probably takes place before the drug reaches its 
effector site. The role of intracellularly accumulated hydrochlorothiazide in the overall 
diuretic response is still unknown. However, this study clearly shows that during the 
process of tubular secretion high cellular concentrations can be reached.
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Hydrochlorothiazide is a potent inhibitor of carbonic anhydrase located in the 
proximal tubule, but this effect seems to be smaller than its inhibitory activity on distal 
sodium chloride co-transport. The increase in urinary pH suggests a proximally induced 
effect, however, the natriuretic response was not affected. This can be explained by the 
fact that the increased natriuresis in the proximal tubule will be mainly abolished by 
transport mechanisms in the loop of Henle (17).
In summary, hydrochlorothiazide excretion in the IPK is low as a result of a low 
extraction ratio and substantial passive reabsorption. A considerable accumulation was 
found at low perfusate concentration. Accumulation kinetics were concentration- 
dependent and saturable in parallel with saturation of the active tubular secretory 
mechanism. Saturable accumulation and secretion limited the dose-dependent diuretic 
response of hydrochlorothiazide. These findings confirm that the diuretic effect of 
hydrochlorothiazide is more closely related to the renal excretion rate of the drug rather 
than to its plasma concentration.
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Summ ary
Rhodamine 123 has been shown to be a substrate for P-glycoprotein (Pgp) in multidrug 
resistant cells. In the present investigation the disposition of rhodamine 123 was studied 
in the isolated perfused rat kidney (IPK). After exposing the kidneys to perfusate 
concentrations ranging from 10-1000 ng/ml, the renal clearance was 4-1 times the 
clearance by glomerular filtration, respectively, indicating active, and saturable 
secretion of rhodamine 123. The rate-limiting step in secretion was found to be 
membrane passage from cell to tubular lumen. Surprisingly, renal clearance was not 
influenced by the Pgp inhibitors cyclosporin A or digoxin. However, pretreatment of the 
kidneys with verapamil, quinidine or cimetidine resulted in a significantly reduced 
rhodamine 123 clearance, indicating that the renal organic cation carrier may be 
involved in active secretion. Rhodamine 123 accumulated extensively in the IPK; tissue 
concentrations of 270-360 times the perfusate concentration were determined. Similar 
accumulation ratios at different perfusate concentrations were found, suggesting that the 
compound enters the tubular cells by (facilitated) diffusion. In conclusion, rhodamine 
123 accumulated extensively in the IPK and active renal secretion appears to be 
mediated by the organic cation carrier and not by Pgp.
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Introduction
Resistance to various chemotherapeutic drugs is a phenomenon often observed in 
patients and cell cultures. Drug resistance associated with the overexpression of the 
mdr1 gene, which encodes the P-glycoprotein (Pgp) or multidrug (MDR-1) transport 
protein, is characterized by a reduced intracellular drug accumulation and increased 
cellular drug efflux. Pgp is an ATP-dependent integral membrane protein, which is not 
only expressed in resistant tumor cells, but also in normal tissues such as liver, intestine, 
adrenal gland, placenta and kidney. The physiological function of Pgp is not clear, but 
its apical distribution in secretory epithelia and role in drug efflux suggest that Pgp may 
function in the excretion of endogenous compounds and naturally occurring toxins 
(1,11,12,20,33). Physiological substrates for Pgp are cortisol, dexamethasone and 
aldosterone, whereas progesterone is a potent inhibitor of Pgp-mediated transport 
(17,34). Other substrates for Pgp are anthracyclines, vinca alkaloids, 
epipodophyllotoxins, taxol, actinomycin D (11). Furthermore, the widely used cardiac 
glycoside, digoxin, is actively secreted into urine by Pgp in the kidney (8,15).
The ability to excrete these substrates can be reduced by treatment with 
chemosensitizers, compounds that reverse or antagonize multidrug resistance. The 
group of inhibitors consists of a wide variety of structurally unrelated drugs, including 
calcium channel blockers, hormones and steroids, hydrophobic peptides, cyclosporins, 
calmodulin antagonists, and miscellaneous hydrophobic cationic drugs. It is suggested 
that the interaction between substrates and inhibitors is related to a common binding site 
on Pgp. Resistance reversal by cyclosporin A may in part also be due to competition for 
transport. ATP binding is not blocked by any of the reversal agents, indicating separate 
ATP and drug binding sites on Pgp (11,12,20).
The proximal tubule of the kidney is the most important site in active renal drug 
elimination, and proximal tubular cells contain separate systems for organic anions and 
cations. The active step in the secretion of organic anions is located at the basolateral 
membrane, and that of organic cations at the luminal membrane (28). In addition, Pgp is 
also present at the luminal membrane (21). Several hydrophobic amines known to 
interact with the classical organic cation transport system, for example verapamil, 
quinine, quinidine, and quinacrine, inhibit Pgp-mediated transport. For this reason Pgp 
was suggested to be an unidentified component of the renal organic cation carrier, 
however, photoaffinity labeling studies implied that separate carrier systems exist (14). 
More recently, it was shown in a functional expression system in Xenopus laevis 
oocytes, that Pgp and the organic cation carrier are indeed different transport proteins 
(24).
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In the present investigation the transport mechanisms of rhodamine 123 and the 
interaction with various cationic drugs were studied in the isolated perfused rat kidney 
(IPK). This in vitro technique has been shown useful for the investigation of renal 
organic anionic and cationic drug excretion (4,7). Previous investigations in various 
carcinoma cells showed that the mitochondrial dye with anticarcinoma activity, 
rhodamine 123 (2), is effectively pumped out of these cells via Pgp (9,19,25). More 
recently, rhodamine 123 resistance was found to be related to the expression of the mdr1 
gene in a monkey kidney epithelial cell line, although direct evidence that rhodamine 
123 is transported by Pgp in this cell line was not obtained (5). Rhodamine 123 is not in 
use as a drug, but because of its excellent fluorescent properties and transport 
characteristics it is a potential model compound for studying P-glycoprotein-mediated 
transport in the kidney and other organs. Aim of our study was to investigate the role of 
P-glycoprotein as a drug transport system in the isolated perfused rat kidney.
M aterials and M ethods
Materials
Sodium pentobarbital was obtained from Apharmo (Arnhem, The Netherlands). 
Heparin, aldosterone and inulin were from Organon (Oss, The Netherlands). Rhodamine 
123 was purchased from ICN (Costa Mesa, Ca., USA), lysine-vasopressin from Sandoz 
Pharma Ltd. (Basel, Switzerland), angiotensin II from Beckman (Palo Alto, USA) and 
Synthamin 14 was from Travenol (Thetford, Norfolk, UK). Cyclosporin A was kindly 
provided by Sandoz Pharma Ltd. (Basel, Switzerland) and Pluronic F-108 was obtained 
from BASF (Arnhem, The Netherlands). All other chemicals were of analytical grade 
and obtained either from Sigma (St.Louis, Mo., USA) or Merck AG (Darmstadt, 
Germany). A stock solution of cyclosporin A was prepared in DMSO (20 mg/ml).
Kidney isolation and perfusion
The isolation and perfusion of the rat kidney and stability of the perfused kidney system 
were described in detail previously (7). Briefly, male Wistar-Hannover rats (225-275 g) 
were anesthetized intraperitoneally with pentobarbital (6 mg/100 g) and furosemide was 
injected intraperitoneally (1 mg/100 g) to prevent deterioration of the distal nephron. 
Heparin (125 I.U./100 g) was injected via the femoral vein. The ureter of the right 
kidney was cannulated and the renal artery via the mesenteric artery without 
interruption of the blood flow. The kidney was then excised and placed in a fluid bath 
with a constant temperature of 37.5 °C. The perfusion fluid had the following
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composition (mM, except indicated otherwise): NaCl 114.0, KCl 5.2, CaCl2 1.8, MgCl 
21.0, NaHCO 322.5, Na2HPO4 0.84, KH2PO4 0.28, glucose 5.0, urea 4.0, pluronic F108 
25.0 g/l, glutathione 0.33, inositol 0.083, cysteine 0.50, glycine 2.3, Na-pyruvate 2.0, 
Na-acetate 1.22, Na-propionate 0.21, inosine 1.0, alanine 5.0, glutamine 0.11, L- 
glutamine acid 2.0, a-ketoglutarate 1.15, ascorbic acid 0.01, Na-lactate 1.0, choline 
chloride 1.0 mg/l, insulin 4 I.U./l, aldosterone 2.0 |ig/l, lysine-vasopressin 0.01 I.U./l, 
and angiotensin II 15.0 ng/l. To this solution 1.0 % Synthamin 14, a mixture of 15 
amino acids, was added. Pluronic F-108 was used as oncotic agent in the albumin-free 
perfusion fluid. For the determination of glomerular filtration rate, inulin was added to 
the perfusion fluid (100 |ig/ml).
Clearance experiments
In our perfused kidney preparation, perfusion medium was recirculated at a constant 
flow rate with a perfusate pressure of approximately 90 mmHg. During the first 5 
minutes of perfusion, the venous effluent was discarded and after this period the 
perfusion fluid was recirculated and the kidney allowed to stabilize for 30 min. Then the 
experiment was started with a 30 min baseline period, after which rhodamine 123 was 
administered. During the baseline period the perfusate volume was 500 ml from which a 
sample of 5 ml was drawn. After the baseline period, the experimental fluid was 
connected to the kidney, with a total volume of 150 ml in which rhodamine 123 was 
already dissolved. The experimental period was 120 min. Doses added to the perfused 
kidneys were 0 (time controls), 1.5, 15, 52,5 and 150 |ig of rhodamine 123, resulting in 
initial perfusate concentrations of 0, 10, 100, 350 and 1000 ng/ml. The influence on 
rhodamine 123 clearance of the following compounds were studied: cyclosporin A and 
digoxin (Pgp-inhibitors), verapamil and quinidine (organic cation transport and Pgp 
inhibitors), and cimetidine (organic cation transport inhibitor). All inhibitory agents 
were added to the IPK at the start of the baseline period, and remained in perfusion fluid 
during the experimental period. Urine samples were collected during control and 
experimental periods over 10 min intervals. Perfusate samples (500 |il) were drawn at 
the midpoint of each urine collection interval. Two additional perfusate samples were 
taken, one at the beginning of the experimental period (t=0), and one at the end of the 
experiment. At the end of the experiment the kidney was removed from the system, 
blotted, weighed, and frozen until analysis. Urine and perfusate samples were stored at 
-20 °C until analysis. Perfusion fluid during experimental period, and perfusion and 
urine samples were protected from light.
Preload experiments
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Kidneys were isolated and perfused in a similar way as described above for the 
clearance experiments, except for the experimental period. The 30 min baseline period 
was followed by a 60 min preload period, in which 150 |ig rhodamine 123 was added to 
perfusion medium (150 ml). Subsequently an efflux period was studied for 90 min, at 
which kidneys were perfused with clean perfusion fluid (1000 ml) without recirculation. 
In this period a urinary flow change from 60 to 16 |il/min was induced by changing the 
perfusate flow rate from 16 to 11 ml/min. Whenever verapamil was used to inhibit 
rhodamine 123 transport, this agent was added to perfusion fluid at the start of the 
baseline period and remained in perfusion fluid during the preload and efflux period. 
Urine samples were collected during all periods over 10 min intervals. Perfusate 
samples (400 |il) were drawn at the beginning and after 5, 15, 35, 55 and 60 min of the 
preload period. During the single-pass efflux period, samples of 600 |il were drawn from 
the perfusion fluid every 5 min, and one at the end of the efflux period. Perfusate and 
urine samples, and kidneys were handled as described for the clearance experiments.
Analysis
Urine and perfusate samples were analyzed for glucose and various electrolytes as 
described previously (7). Inulin was determined according to a previously published 
method (13). The concentration of rhodamine 123 in perfusate, urine and kidney 
samples was determined by means of fluorescence spectrophotometry. To this end, an 
aliquot of 2-200 |il of the perfusate sample or 0.5-20 |il of the urine samples was taken 
and adjusted to 600 |il with analysis buffer (0.01 M KH2PO4, pH 2.6), and fluorescence 
was measured using a Perkin Elmer LS50 luminescence spectrophotometer (Perkin 
Elmer Ltd., Beaconsfield, Buckinghamshire, UK). The excitation wavelength was set to
501 nm, the emission wavelength to 531 nm and for both wavelengths a slit width of 5 
nm was used. Concentrations were calculated by comparing fluorescence intensity (in 
photomultiplier units) with a calibration curve of spiked samples of blank perfusion 
fluid with different concentrations of rhodamine 123. The concentration of rhodamine 
123 in kidney tissue was determined similarly. The kidneys were homogenized in 5 ml 
distilled water with a Polytron homogenizer (Braun Melsungen, Germany) on setting 10 
for 2 times 60 sec. Subsequently, to 50 |il of the kidney homogenate 250 |il acetonitrile 
was added, vortexed and centrifuged for 10 min at 2000g. Of the supernatant, an aliquot 
of 200 |il was added to ice-cold glass tubes and evaporated until dryness. The residue 
was dissolved in 600 |il analysis buffer, either undiluted or 10 to 50 times diluted 
(dependend on the expected concentration), and fluorescence intensities of triplicate 
samples was measured and averaged. Concentrations were calculated by comparing 
fluorescence intensity with a calibration curve of spiked samples of blank kidney
105
Chapter 5
homogenates with various concentrations of rhodamine 123. Linear calibration curves 
were obtained in all cases (r2 > 0.998). Rhodamine 123 did not bind to pluronic F-108. 
This was checked by means of ultrafiltration using YM-10 membranes with a molecular 
weight cut-off of 10,000 in the MPS-1 micropartition system (Amicon, Grace B.V., 
Dronten, The Netherlands).
Data analysis
All data are expressed as mean ± SD. Statistical differences between means were 
determined with one-way analysis of variance followed by the least significant 
difference test for comparison of multiple means. Differences were considered 
significant if  P<0.05. The concentration of rhodamine 123 in kidney tissue (CT) was 
expressed as the amount of drug per weight of tissue.
Results
Effect on kidney function
The mean values for the functional parameters of baseline period (-30-0 min) of all IPK 
experiments are presented in Table 5-1. The control values (first data column) represent 
mean values of all experiments in which rhodamine 123 was added solely to the 
perfused kidney system. The other columns show data of the functional parameters after 
pretreatment of the kidneys with verapamil, cimetidine, cyclosporin A, quinidine or 
digoxin. Although some parameters were slightly changed after pretreatment with one 
of the inhibitory agents, no severe effects on kidney functioning could be determined. In 
agreement with previous investigations (7), the system remained stable and viable 
during the whole experimental period. Addition of rhodamine 123 slightly increased 
renal functioning as compared to control experiments, which could be concluded from a 
slightly decreased fractional excretion of sodium, calcium and glucose throughout the 
whole experimental period (P<0.05).
Renal handling
Rhodamine 123 was cleared very rapidly from perfusate. Fig. 5-1 shows the perfusate 
concentration and corresponding excretion rate data as a function of time. Biphasic 
perfusate concentration-time curves were obtained, with initially a rapid decline (50% 
of the amount rhodamine 123 was cleared after 35 min of perfusion), and subsequently a 
virtual infinite terminal phase. The urinary excretion rate increased slowly after addition 
of rhodamine 123, a maximum rate was achieved after 40-50 min followed by a gradual 
decrease.
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Table 5-1. Experimental conditions of the isolated perfused rat kidney in baseline period, without or with pretreatment with 
verapamila________________________________________________________________________________________________
Functional
parameter
Control Verapamil Verapamil Cimetidine Cyclosporin A Quinidine Digoxine
(10 ^M) (50 ^M) (10 ^M) (5 ^g/ml) (6 ^M) (10 ^M)
FEglucose (%) 0.84 ± 0.31 0.46 ± 0.13b 0.87 ± 0.74 1.5 ± 0.8 1.3±0.6 1.4 ± 0.2b 1.5 ± 1.0
FEsodium (%) 1.8 ± 0.4 1.8 ± 0.8 2.6 ± 1.9 2.2 ± 0.7 2.5±0.1b 2.1 ± 0.8 2.5 ± 0.9
GFR (^l/min) 530 ± 80 540 ± 100 520 ± 70 468 ± 34 422±44 445 ± 53 458 ± 12 
8
Urinary flow 
(^l/min)
25 ± 4 25 ± 2 25 ± 4 26 ± 1 24±3 23 ± 2 24 ± 3
Urinary pH 5.5 ± 0.2 5.6 ± 0.3 5.5 ± 0.2 5.8 ± 0.4 5.5±0.1 5.5 ± 0.1 5.8 ± 0.2b
RPP (mm Hg) 94 ± 11 95 ± 7 90 ± 10 105 ± 10 105±7 89 ± 2 100 ± 10
FRwater (%) 95 ± 1 95 ± 1 95 ± 2 94 ± 1 94.2±0.1 95 ± 1 95 ± 1
Perfusate flow 
(ml/min)
13 ± 3 14 ± 2 12 ± 2 12 ± 2 16±5 13 ± 2 13 ± 2
N 16 8 8 6 3 3 4
a Mean ± SD. FE = fractional excretion, FR = fractional reabsorption, RPP = renal perfusion pressure. 
b P<0.05: significantly different from control value.
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Perfusate concentration Renal excretion rate
(ng/ml) (ng/min)
Time (min)
Figuure 5-1. Rhodamine 123 perfusate concentration (left panel) and urinary excretion rate 
(right panel), as a function of time. Doses added to the perfused kidneys were 1.5 (*); 15 0 ) ;
52.5 (*) and 150 jjg(0). All data points are means ±  SD of 4 experiments.
Within the perfusate concentration range, the renal clearance was 1-4 times higher 
than the clearance by glomerular filtration (renal fractional clearance or ClR/GF>1), 
indicating active secretion of rhodamine 123 (Fig. 5-2A). Surprisingly, the renal 
clearance of rhodamine 123 (at a dose of 1.5 |ig) was not affected by the Pgp inhibitors, 
cyclosporin A (5 |ig/ml) and digoxin (10 |iM) (Fig. 5-2B). However, pretreatment of the 
kidneys with cimetidine (10 |iM) and quinidine (6 |iM) resulted in a significant 
reduction in renal rhodamine 123 clearance. Treatment with 10 or 50 |iM verapamil also 
resulted in a significantly decreased renal clearance of rhodamine 123 (Fig. 5-2C).
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Figure 5-2. Renal fractional clearance (Cl¡/GF) as a function of time. Panel A: 4 different 
doses of rhodamine 123 were studied (N=4 for each dose). Doses added to the perfused kidneys 
were 1.5 (*); 15 0 ) ;  52.5 (*) and 150 pg 0 ) .  Panel B: a dose of1.5 pg was studied (*, N=4), 
and after preincubation with 10 pM cimetidine, CM (+, N=6), 5 pg/ml cyclosporin A, CSA (o, 
N=3), 10 pM digoxin, DGX (O, N=4) and 5 pg/ml quinidine, QD (a, N=3). Panel C: a dose of
1.5 pg rhodamine 123 was used alone (*, N=4), and after preincubation with 10 (v, N=4) or 50 
pM verapamil, VP (D, N=4). Mean values are presented. For the sake of clarity standard 
deviations were omitted from this figure, but varied between 8 and 40% for the different doses 
rhodamine. For the pretreated kidneys standard deviations varied between 14 and 38% for 
cimetidine and quinidine, between 38 and 67% for cyclosporin A and digoxin, and between 4 
and 26% for verapamil.
None of the inhibitors had an effect on the perfusate concentration-time profiles of 
rhodamine 123, suggesting that transport from perfusion fluid into the tubular cells was 
unaffected. Treatment with 50 mM verapamil resulted in a ClR/GF<1, suggesting that a 
reabsorptive mechanism is also involved in the overall renal clearance of rhodamine 
123.
To further investigate renal excretion and reabsorption of rhodamine 123, preload 
experiments were performed. In these experiments, the perfused kidneys were exposed 
to 150 Mg rhodamine 123 for 60 min, after which the kidneys were connected to clean 
perfusion fluid. Functional parameters of the perfused kidneys in preload experiments 
were not different from the parameters in normal clearance experiments (data not 
shown). In order to determine the mechanism of reabsorption for rhodamine 123 found 
after pretreatment with 50 mM  verapamil, urine flow was changed after preloading the 
kidneys. Fig. 5-3 presents the curves of the perfusate rate and renal excretion rate of 
rhodamine 123 as a function of time, with and without pretreatment of the kidneys with 
50 mM  verapamil. Evidently, a certain amount of rhodamine 123 is transported back 
from tubular cells to the perfusion fluid (upper panel), and a urinary flow change from 
60 to 16 Ml/min hardly affected this transport (A versus B). Verapamil (50 mM) 
significantly reduced rhodamine 123 transport back into the perfusion medium. The 
renal excretion rate after preloading the kidneys with rhodamine 123 decreased with the 
urine flow, indicating that passive back-diffusion probably accounts for the reabsorptive 
mechanism found earlier. At a urinary flow of 16 Ml/min, a renal excretion rate of 118 ± 
18 ng/min was found (Fig. 5-3, lower panel, B), which is very similar to the renal 
excretion rate of rhodamine 123 after addition of 150 Mg in the normal clearance 
experiments (103 ± 12 ng/min, Fig. 5-1). This suggests that in the overall renal 
clearance of rhodamine 123 membrane passage from cell to tubular lumen is the rate- 
limiting step in secretion.
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F igure 5-3. Rate o f  transport back into the perfusate (perfusate excretion rate) and  
renal excretion rate after preloading the kidneys with 150 p g  rhodamine 123. Preload  
experim ents were done as described in detail in m aterials a n d  m ethods. C losed circles 
represent data with rhodamine 123 alone, open circles are data a fter pretreatm ent with 
50  p M  verapamil. During the f ir s t  40 min o f  the efflux period, the urinary flo w  was 60  
pl/m in  (A), whereafter the flo w  was reduced to 16 p l/m in  (B). A ll data points are means 
± SD o f  3 experiments.
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Pretreatment of the perfused kidneys with verapamil resulted in significantly 
lower excretion rates, which were also similar to the rates obtained in the normal 
clearance experiments. In presence of 50 mM verapamil rhodamine 123 excretion rates 
were 41 ± 6 and 27 ± 6 for preload and normal clearance experiments, respectively, 
which corresponded with a reduction in renal clearance of approximately 70%.
A m ount in kidney tissue 
(æ g /g  kidney)
Time (min)
Figure 5-4. Calculated amount of rhodamine 123 per weight of kidney as a function of time. 
Four different doses were added to the IPK: 1.5 pg (*); 15 pg 0 ) ;  52.5 pg (*) and 150 pg 0 ) .  
All data points are means ±  S.D. of4 experiments.
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Renal accumulation
The rapid disappearance from perfusion fluid and the delayed appearance in urine of 
rhodamine 123, indicate that the compound is retained by the tubular cells. In Fig. 5-4, 
the concentration of rhodamine 123 in the kidney, expressed as the amount of drug per 
weight of tissue, is plotted as a function of time. For every time point, the concentration 
was estimated by subtracting the amount in perfusate and the amount excreted in urine 
at time t from the total amount added to perfusate at time 0. Actual kidney tissue 
concentrations were determined at the end of the experiments and presented in tables 5­
2 and 5-3. For every rhodamine 123 dose, the tissue concentration is 30 to 40% lower 
than the estimated concentration after 120 min of perfusion. Probably because of an 
extensive intracellular binding we were not able to recover 100% of the theoretically 
calculated concentration in kidney tissue (Fig. 5-4). Furthermore, the accumulation 
ratios are given, which were obtained by dividing the concentration in kidney tissue by 
the concentration at the end of the experiment (Tables 5-2 and 5-3). Between the doses, 
similar accumulation ratios were found. Treatment with cimetidine and quinidine 
significantly enhanced the cellular rhodamine 123 uptake.
Table 5-2. Effect o f various drugs on the accumulation o f rhodamine 123 in the isolated 
perfused rat kidney1
treatment amount in kidney 
(Mg/g)
kidney/perfusate
ratio
N
control (dose = 1.5 ^g) 0.53 ± 0.06 350 ± 50 4
+ VP10b 0.57 ± 0.05 340 ± 50 4
+ VP50c 0.60 ± 0.03 390 ± 80 4
+ CM10d 0.85 ± 0.13* 470 ± 160 6
+ DGX10e 0.56 ± 0.05 490 ± 270 4
+ CSA6f 0.41 ± 0.30 330 ± 170 3
+ QD6g 0.67 ± 0.07 750 ± 70* 3
a Mean data ±  SD are presented. Measurements as described in materials and methods. b in 
presence of 10 pM verapamil, c50 pM verapamil, d10 pM cimetidine, e10 pM digoxin, f 6 pM 
cyclosporin A and g6 pM quinidine; * P<0.05: significantly different from same dose without 
treatment; N represents number of perfused kidneys used.
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Table 5-3. Dose-dependent accumulation o f rhodamine 123 in the
isolated perfused rat kidney3
dose (^g) amount in kidney 
(Hg/g)
kidney/perfusate
ratio
N
15 5.0 ± 1.2 350 ± 140 4
52.5 17 ± 1 270 ± 60 4
150 52 ± 8 360 ± 100 4
150 + VP10b 64 ± 28 350 ± 180 4
150 + VP50c 57 ± 5 350 ± 50 4
a Mean data ±  SD are presented. Measurements as described in materials and methods. b in 
presence of 10 ¡jM verapamil and c50 ¡jM verapamil; N represents number of perfused kidneys 
used.
Discussion
The kidneys used in this study showed a good renal functioning, and were stable for at 
least 2 hours. Surprisingly, the fractional excretion (%) of sodium, calcium and glucose 
decreased after addition of rhodamine 123, indicating that kidney viability increased as 
compared to control experiments. This is in contrast with several in vitro investigations 
which showed that rhodamine 123 possesses a cytotoxic potential, including uncoupling 
of oxidative phosphorylation and mitochondrial swelling (2,10,18). The reason that we 
did not found a decrease in renal function is most likely a result of the low 
concentrations we used; perfusate concentrations were between 25 nM and 2.5 |iM. At 
these concentrations other investigators also found little or no toxic effects for 
rhodamine 123 (10). However, we have no explanation for the slight increase in 
proximal tubular function observed in the present study. Kidney functional parameters 
were hardly changed due to the presence of verapamil, cimetidine, cyclosporin A, 
quinidine or digoxin in perfusion fluid. In contrast with the known renal effects of 
verapamil (6), the fractional excretion of calcium and glomerular filtration rate were not 
enhanced in the IPK, which can be explained by the fact that vessels are maximally 
dilated in this preparation.
Our clearance experiments demonstrate that the cationic drug, rhodamine 123, is 
efficiently secreted by the perfused kidney in a dose-dependent manner. Fig. 5-2A 
shows that the ClR/GF of the lowest dose is significantly higher than that for the highest 
dose (3.1 ± 0.5 vs 1.6 ± 0.2; P<0.01), indicating active, saturable secretion. However, it 
is unlikely that Pgp is involved. Cyclosporin A, a potent Pgp inhibitor, which has been
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shown to inhibit rhodamine 123 efflux in multidrug resistant cells (19) and in the 
isolated perfused rat liver (32), failed to reduce the renal excretion of the compound in 
the IPK. Further, digoxin, a substrate for Pgp, was not able to affect rhodamine 123 
transport either. Two other Pgp inhibitors, verapamil and quinidine, significantly 
reduced renal rhodamine 123 clearance, however, this effect is probably related to the 
organic cation carrier of which both compounds are also known to be good inhibitors 
(28). Supporting evidence is given by cimetidine, an effective inhibitor of the organic 
cation carrier (3,31), which reduced the renal rhodamine 123 clearance by as much as 
70%. It was recently speculated that cimetidine might also be a substrate for Pgp, 
because in a distal tubule-derived epithelial cell line (MDCK) transfected with human 
Pgp an increased capacity for cimetidine transport from basolateral to luminal 
membrane was observed (26). However, in the same model it was also shown that the 
H2-receptor antagonist was not able to inhibit transport of Pgp substrates. Additionally, 
cimetidine had no effect on the Pgp-mediated biliary excretion and disposition of 
cyclosporin A (16), an inhibitor as well as a substrate for Pgp (30). Therefore, we 
believe that the inhibitory potency of cimetidine is related to inhibition of the organic 
cation system, although the involvement of Pgp-mediated transport in overall renal 
rhodamine 123 excretion can not be ruled out completely, because both transport 
systems exhibit overlapping substrate specificities (11). In a recent study with 
daunomycin in renal proximal tubules of killifish, Miller (23) revealed that Pgp and the 
organic cation system may provide parallel excretory pathways for drugs in the kidney.
Organic cation transport in renal proximal tubules involves entry into the tubular cell 
by (facilitated) diffusion, for which the potential difference over the basolateral 
membrane of -60 to -80 mV is the driving force (28). Although the contribution of a 
nonsaturable active uptake mechanism for rhodamine 123 into proximal tubular cells 
can not be ruled out completely, the similar accumulation ratios at different perfusate 
concentrations and the lack of an effect of any of the inhibitory agents on the perfusate 
concentration-time curves suggest that the compound enters the cells by (facilitated) 
diffusion. After preloading the kidneys with a high dose of rhodamine 123, a substantial 
amount of the drug was transported back into the perfusion fluid, suggesting that the 
basolateral organic cation carrier is bidirectional and driven by the concentration 
gradient. Verapamil significantly reduced rhodamine 123 back-flux by about 50%, 
indicating that this transport is specific. These two properties are in agreement with the 
characteristics found for facilitated diffusion, as has been described for the basolateral 
organic cation system.
The next step in proximal tubular secretion is transport into the luminal compartment. 
For organic cations this step is active and in exchange for protons (28). Since neither
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one of the inhibitors affected the plasma concentration-time curves, active secretion 
may be considered to take place at the luminal membrane. An important finding in the 
characterization of the overall excretion of rhodamine 123 is that the rate-limiting step 
in secretion is transport from tubular cells into the luminal compartment. Pietruck and 
Ullrich (27) showed previously that rhodamine 123 exhibits affinity for the renal 
organic cation system, but to a higher extent for the luminal carrier in comparison to the 
basolateral carrier. Furthermore, they also observed a net reabsorption in their in situ 
perfused rat kidney preparation, but in contrast to our results they suggested that 
reabsorption is an active mechanism. The preload experiments in our study revealed that 
reabsorption is a passive process.
Because perfusate clearance was initially very rapid and urinary excretion delayed, a 
substantial amount of rhodamine 123 must be retained by the tubular cells. We were 
able to estimate the amount accumulated in kidney tissue accurately in the course of the 
experiment. The extensive accumulation found for rhodamine 123 in the IPK, with 
tissue-to-medium concentrations up to 360, can not be simply explained by uptake 
driven by the electrochemical gradient, which is the mechanism for basolateral entry of 
organic cations. The similar accumulation ratios at different perfusate concentrations 
may signify that uptake of rhodamine 123 is not mediated by an active mechanism, 
which is able to transport the organic cation to levels above its electrochemical gradient. 
Therefore, the drug is most likely subject to intracellular sequestration. In addition, the 
biphasic profile of the perfusate concentration-time curves suggests the existence of an 
intracellular compartment in the renal handling of rhodamine 123. Earlier reports 
showed that rhodamine 123 accumulates specifically in mitochondria (2,10), probably 
driven by the inside negative membrane potential (-220 mV). Preliminary uptake 
experiments in isolated proximal tubular cells of the rat kidney using confocal 
microscopy, demonstrated that intracellular accumulation may include more than just 
mitochondrial compartmentation (Masereeuw et al., unpublished findings). Additional 
organellar compartments that sequester this cationic dye may be endosomes, lysosomes 
and Golgi vesicles. These organelles are more acidic than the surrounding cytoplasm, 
and the inside negative pH gradient may drive organic cation uptake (22). A recent 
study on tetra-ethylammonium accumulation in rat kidney cortex endosomal vesicles 
showed that uptake is specific, ATP-dependent, and driven by a pH-gradient (29). 
Whether or not such a specific sequestration mechanism is involved in rhodamine 123 
accumulation remains to be determined.
Significant enhancement of rhodamine 123 accumulation in the perfused kidney was 
found for cimetidine and quinidine, probably due to inhibition of the cation system at 
the luminal membrane. For cimetidine it has been reported that this cationic drug
115
Chapter 5
exhibits a higher affinity for the luminal transporter than for the basolateral system (27), 
and possesses also a higher inhibitory potency against the luminal system (3). Less clear 
is the fact that verapamil did not reduce the renal accumulation of rhodamine 123. An 
explanation may be that verapamil reduced both influx and efflux of the organic cation. 
Supporting evidence is given by the preload experiments in which verapamil was able 
to affect the back-flux of rhodamine 123 into perfusion medium by inhibition of the 
basolateral system.
In summary, rhodamine 123 is actively secreted in the IPK. Transport across the 
luminal membrane into the tubular urine was found to be the rate-limiting step in overall 
excretion. Renal clearance was susceptible to inhibition by cimetidine, quinidine and 
verapamil, but not to cyclosporin A and digoxin. These observations suggest that 
rhodamine 123 is secreted by the organic cation transport system in the IPK, and that 
Pgp probably is not involved
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Summ ary
The renal handling of iohexol was examined in the isolated perfused rat kidney (IPK) 
over a perfusate concentration range of 5-20 Mg/ml. At a concentration of 5 Mg/ml, a 
ratio of renal clearance over clearance by glomerular filtration (ClR/GF) of 0.63 ± 0.06 
could be determined. This ratio increased till 1.02 ± 0.06 at 20 Mg/ml, indicating that a 
saturable mechanism was involved in the luminal disappearance of the drug. 
Pretreatment of the kidneys with polylysine, probenecid or diatrizoate resulted in a 
significantly enhanced clearance of iohexol, probably due to inhibition of membrane 
binding. Renal clearance data were fitted to a kinetic model including filtration into the 
primary urine followed by saturable absorption at the luminal membrane. An absorption 
constant, Ka, of 7.3 ± 1.3 Mg/ml, and a maximum rate of absorption, Vam^ax, of 1.4 ± 0.1 
Mg/min were determined. Iohexol accumulated in kidney tissue, reaching a 
concentration of 2 to 7.5 times the perfusate concentration. In freshly isolated proximal 
tubular cells and kidney cortex mitochondria, iohexol reduced the uncoupled respiratory 
rate at a concentration comparable to the highest tissue concentration found in the IPK. 
In conclusion, iohexol is not only filtered by the kidney but also reabsorbed via a 
saturable mechanism, which results in tubular accumulation. Intracellularly sequestered 
iohexol may affect mitochondrial oxidative metabolism. Our results indicate that 
iohexol is not a true filtration marker.
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Introduction
Iodinated contrast media are widely used for the imaging of organs and blood vessels. 
The currently used intravascular contrast media are derivatives of triiodinated benzoic 
acids, and most compounds are excreted primarily by the kidney. While being cleared 
the contrast agent is concentrated by the kidney and provides good visualization of the 
entire renal system. All triiodinated contrast media are hyperosmolar, metabolically 
stable, and can be divided roughly into two major groups: the ionic, high osmolar 
(1,200-2,000 mOsm/l), and nonionic and relatively low osmolar agents (300-650 
mOsm/l) (1,21,25).
A drawback in the use of radiocontrast media is the risk of acute renal failure. Factors 
involved in nephropathy are renal hemodynamic alterations, direct tubular cell injury 
and tubular obstruction (1,24). Although nephrotoxicity has been reported to be more 
severe with the use of high-osmolar contrast agents (27), in patients with pre-existing 
renal failure the incidence of contrast nephropathy was not significantly different 
comparing high and low osmolar media (2). Nonionic contrast media have even shown 
to induce more morphologic changes in proximal tubules of the kidney. For iohexol, 
vacuolization was observed in proximal convoluted tubular cells (4,26). Heyman et al. 
(13) suggested that the vacuoles are developed by invagination of membranes of lateral 
cellular interdigitations. However, it is speculated also that the vacuoles might be 
secondary lysosomes, in which the contrast medium is sequestered, and formed after the 
drug enters tubular cells from the tubular lumen via endocytosis (23). If the renal 
handling of contrast agents comprises endocytosis and, subsequently, accumulation 
within proximal tubular cells, high intracellular concentrations may directly affect 
tubular cell integrity and be the basis of the nephropathy induced. However, the 
mechanism of direct tubular cell injury remains to be elucidated (1). Among a variety of 
suggested mechanisms, some reports showed that a reduction in renal oxidative 
metabolism can occur, which may be caused by a diminished oxygen supply or a direct 
interaction with mitochondrial respiration (1,13,15).
The existence of an endocytotic mechanism is in contradiction with other reports that 
iohexol may be useful as a marker for the determination of GFR. In these studies the 
contrast agent was supposed to be handled by the kidney in a fashion similar to inulin, 
implying that neither secretion nor reabsorption occurred (11,18).
In this report we examined the renal handling of iohexol in the isolated perfused rat 
kidney (IPK). Previously, we showed that the IPK is a useful technique for studying the 
renal clearance and accumulation of drugs, and their effects on kidney function (5,10). 
The purpose of this study was to investigate the presence and role of a reabsorptive
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mechanism in the overall clearance of iohexol in the IPK, and the effect of 
intracellularly sequestered drug on mitochondrial oxidative metabolism. The results 
reveal that iohexol clearance is determined by filtration and saturable absorption, 
resulting in tubular accumulation. Moreover, the intracellular sequestration of iohexol 
appears to affect mitochondrial oxidative metabolism.
Methods
Materials
Pluronic F-108 was from BASF (Arnhem, The Netherlands) and cyanocobalamin was 
obtained from Sigma (St.Louis, Mo.). Iohexol was purchased from Nycomed (Oslo, 
Norway), diatrizoate, probenecid and poly-l-lysine (Mw 1,000-4,000) were from Sigma 
(St.Louis, Mo.), iodopyracet was obtained from Dagra (Diemen, The Netherlands). 
Bovine serum albumin (BSA) and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) were from Boehringer Mannheim (Mannheim, Germany). All other chemicals 
were of analytical grade and purchased from either Sigma (St.Louis, Mo.) or Merck 
(Darmstadt, Germany).
Experimental procedure
The isolation and perfusion of the rat kidney is described in detail previously (9). 
Pluronic F-108 was used as oncotic agent in the albumin-free perfusion fluid. For the 
determination of glomerular filtration rate (GFR), cyanocobalamin was added to the 
perfusion fluid. GFR was monitored on line using a micro flow-through cuvette in 
which the cyanocobalamin concentration was measured colorimetrically (6). The 
experimental period was 120 min and started after a 30 min baseline period. During the 
baseline period the perfusate volume was 500 ml from which a sample of 5 ml was 
drawn. After the baseline period, the experimental perfusion fluid was connected to the 
kidney, with a total volume of 250 ml in which iohexol was already dissolved. Doses 
added to the perfused kidneys were 0 (time controls), 1.25, 1.88, 2.5 and 5.0 mg of 
iohexol, resulting in initial perfusate concentrations of 5, 7.5, 10, and 20 |ig/ml. 
Compounds used to affect iohexol clearance were a contrast analog, diatrizoate, an 
inhibitor of organic anion transport, probenecid, and an inhibitor of aminoglycoside 
brush-border membrane binding, polylysine. These agents were added to the IPK at the 
start of the baseline period, and remained in perfusion fluid during the experimental 
period. Urine samples were collected during control and experimental periods over 10 
min intervals. Perfusate samples (300 |il) were drawn at the midpoint of each urine
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collection interval. Two additional perfusate samples were taken, one at the beginning 
of the experimental period (t=0), and one at the end of the experiment. At the end of the 
experiment the kidney was removed from the system, blotted, weighed, and frozen until 
analysis. Urine and perfusate samples were stored at -20 °C until analysis.
Respiration measurements
The effect of iohexol on cellular and mitochondrial respiration was determined in 
isolated rat kidney proximal tubular cells and kidney cortex mitochondria. Proximal 
tubular cells were isolated as described previously (19) and suspended to 10-15 mg 
protein/ml in incubation buffer containing (millimolar): NaCl, 117.5; KCl, 4; MgSO4, 
1.2; KH 2PO 4, 0.95; NaHCO3, 22.5; glucose, 11.1; and CaCl 2, 2.5. Rat kidney cortex 
mitochondria were isolated as described by Cain and Skilleter (7), with some 
modifications. All steps were carried out at 4 °C. Briefly, kidneys were isolated after 
perfusion with an ice-cold solution containing 140 mM NaCl and 10 mM KCl. The 
capsula was removed, medulla was dissected and cortex was collected in a Potter- 
Elvehjem homogenizer with Teflon pestle (clearance 0.5 mm) in three times the tissue 
weight of homogenization buffer (300 mM mannitol, 10 mM HEPES, 1 mM EGTA, 1 
mg/ml BSA at pH 7.4). Tissue was homogenized gently six times by hand, and 
suspension was centrifuged for 10 min at 500g. Supernatant was collected and 
centrifuged for 7 min at 11,000g. Pellet was washed with homogenization buffer and 
again centrifuged (7 min, 11,000g). Final pellet was diluted to a concentration of 5 
mg/ml mitochondrial protein in respiration medium (210 mM mannitol, 10 mM KCl, 10 
mM KH2PO4, 0.5 mM EGTA, 60 mM Tris-HCl, at pH 7.4).
Respiration measurements were done with a Clarke-type platinum electrode, using 1 
mg of cellular or mitochondrial protein in 2.0 ml of medium. Basal cellular O2 
consumption was measured at 37 °C in incubation buffer supplemented with 4 mM 
sodium lactate, 1 mM alanine, and 10 mM butyric acid (pH 7.4). Uncoupled cellular 
respiration was determined in the presence of 44 |iM DNP. Mitochondrial oxygen 
consumption was measured at 30 °C in respiration medium in the absence of ADP (state 
2), in the presence of ADP (state 3), after ADP consumption (state 4), and after the 
addition of dinitrophenol (DNP, final concentration 44 |iM). Succinate (10 mM) was 
used as the metabolic substrate, and rotenone (1 |iM) was added to block electron 
transport proximal to succinate entry into the respiratory chain. ADP-stimulated 
respiration (state 3) was measured in the presence of 0.3 mM ADP. Respiratory rates 
were calculated and expressed as nanogram atoms of oxygen per minute per milligram 
of protein (ng atom O/min-mg prot.).
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Analysis
Urine and perfusate samples were analyzed for electrolytes and glucose, as described in 
a previous report from our department (9). The concentration of iohexol in perfusate and 
urine samples were determined using reversed-phase high-performance liquid 
chromatography (HPLC), as described below. This HPLC method could not be used for 
the determination of iohexol concentrations in kidney tissue, because iohexol could not 
be separated from all tissue components. Concentrations in the kidneys were determined 
using a chemical method according to Bäck et al. (3). The kidneys were homogenized in 
5 ml distilled water using a Polytron homogenizer on setting 10 for 2 times 60 sec. A 
sample of 50 |il was used for further determination. Inulin concentration in kidney tissue 
and in perfusion samples were determined according to Heyrovski (14). Protein content 
in each proximal tubular cell and kidney cortex mitochondrial preparation was 
determined using the Bio-Rad Protein Assay from Bio-Rad (München, Germany) with 
BSA as protein standard.
HPLC assay
A 1084B Liquid Chromatograph of Hewlett Packard (Böblingen, Germany) was used, 
equipped with an auto-injector (HP 79841 A), terminal (HP 79850 B LC) and an UV 
absorbance detector (Spectroflow 773, Kratos analytical instruments, Ramsey, N.J., 
USA) at an operating wavelength of 254 nm. Chromatography was performed on a 
stainless steel column (125 x 4 mm) packed with LiChrospher 60 RP-Select B (Merck, 
Darmstadt, Germany), particle size 5 |im. The mobile phase consisted of 0.01 M 
potassium dihydrogen phosphate buffer (pH 2.6) and flow rate was 0.3 ml/min. 
Iodopyracet was used as internal standard (0.1 mg/ml). With a column temperature of 
40 °C, iohexol eluted as two peaks with retention times of 7.4 and 8.6 min with a ratio 
of 1:4. Within the same run, iodopyracet eluted with a retention time of 10.4 min. 
Sample preparation was performed using YM-10 ultrafiltration membranes (13 mm i.d.) 
with a molecular weight cut-off of 10,000 in the MPS-1 micropartition system (Amicon, 
Grace BV, Capelle a/d Ijssel, The Netherlands) to separate iohexol and pluronic F-108. 
Onto the membrane, 20-30 |il urine or 50-150 |il perfusate sample was pipetted, together 
with 50 |il of internal standard. Total volume was adjusted to 300 |il with mobile phase 
buffer (pH 2.6). The filter units were centrifuged for 20 min at 3,000g, and 180 |il of the 
filtrate was mixed with 320 |il mobile phase buffer. An aliquot of 20 |il of the resulting 
solution was injected onto the column. Concentrations in perfusate and urine were 
determined by comparing the peak area ratio of the second (and major) peak of iohexol 
and internal standard with a calibration curve of peak area ratio vs. iohexol 
concentration spiked to blank perfusate and urine. Linear calibration curves were
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obtained in all cases (r2 > 0.98). The interday precision of the HPLC assay was 
determined by measuring a spiked perfusate and urine sample with each run. The 
coefficient of variation was found to be 8.7% for the perfusate sample (10 |ig/ml, n=11) 
and 10.7% for urine (100 |ig/ml, n=12).
Renal excretion
The renal excretion of iohexol appeared to be composed of glomerular filtration and 
saturable absorption, which was assumed to take place at the luminal side. Since plasma 
proteins were not present in perfusate and iohexol did not bind to any of the perfusate 
constituents, drug concentrations can be considered as unbound. The renal excretion rate 
of iohexol can therefore be expressed as:
Rr = Qgf• CP - (6-1)
a P
Renal clearance is described by:
^  Rr
ClR = -TT (6-2)
CP
where QGF = glomerular filtration rate (ml/min); R R = renal excretion rate (^g/min);
ClR = renal clearance (ml/min); C P = drug concentration in perfusate (^g/ml); V amax= 
maximum rate of absorption (^g/min); Ka = Michaelis-Menten constant of absorption 
(Mg/ml).
Data analysis
All data are expressed as mean ± SD. Statistical differences between means were 
determined with Student's t-test, in which the level of significance was set to P<0.05. 
Renal excretion rate data were weighed reciprocally (1/Y2), and analyzed according to 
equation 1 by the nonlinear least square regression program PCNonlin (20). The 
goodness of fit was evaluated through the deviation between observed and model 
predicted values as R2=1-((D ev)2/((O bs)2, where ((O bs) 2 is the observed sum of 
squared observations and ((D ev)2 is the sum of squared deviations.
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Kidney function
The mean values for the functional parameters of baseline period (-30-0 min) of all IPK 
experiments are presented in Table 6-1 (N=32). After administration of iohexol, only 
small changes in renal function were observed. Compared to control IPK experiments, 
the renal perfusion pressure and fractional excretions of electrolytes and glucose were 
not altered. GFR, and urinary flow and pH were slightly changed in comparison to 
control experiments, and plotted against time after normalizing data to their control 
values (Fig. 6-1, left panel). At a perfusate concentration of 5 |ig/ml iohexol, 
pretreatment with diatrizoate, probenecid or polylysine abolished the functional 
alterations (Fig. 6-1, right panel).
Table 6-1 Experimental conditions ofthe isolated perfused rat kidney in baseline period 
of all IPK experiments.
Renal functional parameter Value
FEglucose (%) 3.1 ± 0.5
FENa (%) 1.8 ± 0.5
FEk (%) 25 ± 8
)%ÖEF 2.4 ± 0.7
)%
JEF 44 ± 12
GFR (^l/min) 414 ± 47
Urinary flow (^l/min) 21 ± 2
Urinary pH 5.5 ± 0.2
RPP (mm Hg) 88 ± 5
FRwater (%) 94.9 ± 0.4
Perfusate flow (ml/min) 12 ± 1
Mean ± SD, N=32. FE = fractional excretion, FR = fractional reabsorption, RPP = renal 
perfusion pressure.
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Figure 6-1. Glomerular filtration rate (GFR), urinary flow and urinary pH, as a function of 
time are shown. Renal functional values are normalized for the mean value of the baseline 
period (-30 to 0 min). Iohexol w^ as administered at time t=0 min. Asterisks indicate 
significantly different from control (P<0.05), tested over 30 to 120 min of experimental period. 
Curves on the left: the effects on kidney function for 4 different perfusate concentrations of 
iohexol and for control IPK experiments are presented (N=4). Concentrations used were: none 
(control, +); 5 ¡Jg/ml (*); 7.5 ¡Jg/ml (*); 10 ¡Jg/ml (l) and 20 ¡Jg/ml (*). Curves on the right: the 
effects on kidney function for control IPK experiments (+, N=4) and at a perfusate 
concentration of 5 Jg/ml iohexol together with 16 Jg/ml polylysine (D, N=5), 200 Jg/ml 
diatrizoate (o, N=3), or 86 Jg/ml probenecid (a, N=4).
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Renal excretion of iohexol
Iohexol was slowly eliminated from perfusion fluid. Fig. 6-2 shows the time course of 
the mean perfusate concentration and corresponding excretion rate data of the four 
iohexol doses studied, as a function of time. All doses gave linear concentration-time 
curves. The urinary excretion rate increased rapidly after addition of iohexol, followed 
by a gradual decrease. Renal handling data are presented in Table 6-2. At a low 
perfusate concentration (5 |ig/ml) the renal clearance was significantly lower than the 
clearance by glomerular filtration (ClR/GF<1), indicating reabsorption of iohexol. At 
higher iohexol concentrations the ratio ClR/GF increased until 1, indicating that a 
saturable mechanism is involved in the luminal disappearance of the drug.
Figure 6-2. Iohexol perfusate concentration (left panel) and urinary excretion rate (right 
panel), as a function of time. Doses added to the perfused kidneys were 1.25 (0); 1.88 (*); 2.5 
(n) and 5.0 mg (r). All data points are means of 4 experiments. For the sake of clarity standard 
deviations were omitted from this figure, but varied between 5 and 18% for perfusate 
concentration, and between 10 and 35% for renal excretion rate values.
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A plot of the renal excretion rate against perfusate concentration, a so called tubular 
titration curve, is presented in Fig. 6-3. The dotted line represents clearance by 
glomerular filtration only. The line through the data points was obtained after analyzing 
renal excretion data over the period 30 to 90 min, according to equation 6-1. The tubular 
titration curves for compounds that are actively reabsorbed, run below the glomerular 
filtration line and parallel it as this mechanism becomes saturated. Because the currently 
observed titration curve for iohexol diverges from the theoretical titration curve for 
active reabsorption, another approach had to be used to describe renal excretion data 
(equation 6-1). It is suggested that the drug binds to the luminal membrane of the kidney 
tubules and, subsequently, is internalized within the tubular cells. Saturation of this 
absorption mechanism appeared from the titration curve: at higher perfusate 
concentration the renal excretion rate line coincided with the glomerular filtration line.
Renal excretion rate (|jg/min)
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Figure 6-3. Tubular titration curve of iohexol. Renal excretion rate and rate of filtration as a 
function of perfusate concentration. Data obtained over the period 30-90 min are means of 4 
experiments. The solid line represents the fit according to equation 1, the dashed line 
corresponds to the clearance by glomerular filtration only. All data were corrected for the fall 
in GFR during the experiment. Insert: Renal excretion rate as a function of perfusate 
concentration with 3 additional doses, resulting in initial perfusate concentrations 50, 100 and 
250 ¡Jg/ml (N=1). Solid and dashed lines are positioned on top of each other.
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Table 6-2. Renal handling data o f iohexol in the isolated perfused rat kidney
dose perfusate conc. renal excretion ClR/GF amount in kidney/
(mg) (Mg/ml) rate (Mg/min) kidney perfusate
(Mg/g) ratio
1.25 5.6 ± 0.6 1.2 ± 0.3 0.63 ± 0.06 39 ± 25 7.5 ± 5.1
1.88 7.4 ± 0.4 2.0 ± 0.2 0.79 ± 0.05 35 ± 21 3.1 ± 1.7
2.5 10 ± 1.6 2.7 ± 0.5 0.85 ± 0.06 34 ± 7 2.2 ±
-H-.30.
5.0 16 ± 0.5 5.3 ± 0.1 1.02 ± 0.06 64 ± 16 2.7 ± 0.9
1.25b 5.3 ± 0.4 1.8 ± 0.2* 0.93 ± 0.03* 25 ± 5 5.2 ± 1.5
1.25c 5.9 ± 0.8 1.5 ± 0.2 0.77 ± 0.04* 31 ± 7 5.6 ± 1.9
1.25d 4.9 ± 0.5 1.2 ± 0.2 0.81 ± 0.03* 15 ± 8 3.4 ± 2.0
Mean ± SD (N=3-5) over the period of 30 to 90 min are given, except for the amount in kidney 
which was determined at the end of the experiment. ClR /GF means ratio of renal clearance 
over clearance by glomerular filtration. b In presence of 200 Jg/ml diatrizoate, c 86 Jg/ml 
probenecid, d 16 Jg/ml polylysine. * P<0.05 in comparison with same dose without treatment. * 
P<0.05 in comparison with same ratio after a dose of1.25mg.
The insert of Fig. 6-3 shows that this situation continues at perfusate concentrations up 
to 225 Mg/ml. Parameters obtained after fitting equation 6-1 to the data were a Vamiax of
1.4 ± 0.1 Mg/min and a Ka of 7.3 ± 1.3 Mg/ml. The coefficient of determination (R2) was 
0.968.
To investigate further iohexol binding, studies were performed in which the perfused 
kidneys were pretreated with diatrizoate, probenecid, or polylysine. Table 6-2 displays 
that all three agents were able to enhance iohexol clearance at the lowest perfusate 
concentration (5 Mg/ml). Fig. 6-4 shows the ratio of renal clearance over clearance by 
glomerular filtration during the experimental period (0-120 min) for all treatments. The 
ratio increased during the first 30 min of the experiment until a maximum, and remained 
stable for the rest of the time. The plateau value of the ClR/GF ratio showed a dose- 
dependency and reached 1 at a perfusate concentration of 20 Mg/ml. It is obvious that all 
three compounds enhanced iohexol clearance over the whole experimental period.
Renal accumulation of iohexol
The concentration of iohexol in the kidney was expressed as the amount of drug per 
weight of tissue, and is presented in Table 6-2. The concentration in kidney tissue 
divided by the concentration in perfusate at the end of the experiment, resulted in an 
accumulation ratio (kidney/perfusate ratio). Iohexol accumulated in kidney tissue 
(kidney/perfusate ratio>1), and a tendency could be observed from a high accumulation
131
Chapter 6
ratio at low perfusate concentration to a lower ratio at high perfusate concentration, 
suggesting that a saturable mechanism is involved in drug tissue uptake. As a control, in 
three separate perfusion experiments the concentration of the filtration marker inulin 
was determined in kidney tissue and perfusion fluid, and a kidney/perfusate ratio of
0.123 ± 0.007 was found. This indicates that accumulation of iohexol is a result of 
specific tubular cell binding and uptake, and that the contribution of concentration in 
extracellular fluid and tubular lumen to total tissue accumulation is negligible. 
Pretreatment with probenecid, diatrizoate and polylysine resulted in a diminished tissue 
accumulation of iohexol, although kidney/perfusate ratios were not significantly altered.
Figure 6-4. Renal clearance over glomerular filtration clearance (GFR) as a function of time. 
Curves on the left: 4 different perfusate concentrations were studied: 5 ¡Jg/ml (0), 7.5 ¡Jg/ml 
(*), 10 Jg/ml (m) and 20 Jg/ml (r). Curves on the right: a concentration of 5 Jg/ml iohexol was 
used, after preincubation with diatrizoate (o, 200 Jg/ml), probenecid (a, 86 Jg/ml) or 
polylysine (D, 16 Jg/ml). Data are means of 3 to 5 experiments. Standard deviations varied 
between 15 and 29%.
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Respiration measurements
Effect of iohexol on cellular and mitochondrial oxygen consumption is illustrated in 
Fig. 6-5. A concentration of 80 |ig/ml iohexol was used, which is comparable to the 
maximum concentration found in kidney tissue (Table 6-2). In proximal tubular cells, 
basal respiration was not affected but DNP-stimulated respiration was significantly 
inhibited by iohexol. In our mitochondrial preparation DNP-stimulated respiration was 
also significantly reduced, indicating a reduction in oxidative metabolism. Iohexol did 
not alter basal and ADP stimulated mitochondrial oxygen consumption. A respiratory 
control ratio (ratio of state 3 respiration over state 4 respiration) of 3.5 ± 0.1 could be 
determined for the control situation, indicating that our mitochondrial preparation is of 
good quality and tightly coupled. A ratio of 3.4 ± 0.3 was calculated in the presence of 
iohexol.
Figure 6-5. Respiratory rate of freshly isolated rat kidney proximal tubular cells (left panel) 
and mitochondria (right panel), in control situation (open bars) and in presence of 80 ¡Jg/ml 
iohexol (striped bars). State 2 respiration was measured before the addition of ADP, state 3 is 
the ADP-stimulated respiration, state 4 is the respiration measured after ADP consumption, 
and DNP is the dinitrophenol-stimulated respiration. Data are means ±  SD of 4-7 different 
preparations, asterisks indicate significantly different from control (P<0.05).
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Discussion
Clearance data of iohexol in the IPK showed that an absorptive mechanism is involved 
in its renal handling, which is assumed to be initiated by binding to the brush-border 
membrane. It has been speculated previously that contrast agent molecules might enter 
tubular cells from the lumen, because high iodine concentrations were found at the 
brush-border region shortly after administration (23). However, the presence of such an 
absorptive mechanism was never demonstrated. Our kinetic model, comprising of 
glomerular filtration and saturable absorption, is able to describe the renal clearance 
data adequately. At perfusate concentrations above 20 |ig/ml saturation of absorption 
occurs. It is most likely that because of the high doses used in human studies, an 
absorptive mechanism was never observed, and iohexol was supposed to be suitable as a 
filtration marker. Most studies in human subjects were performed with doses between 3 
and 7 g, resulting in initial plasma concentrations of approximately 1000 times higher 
than used in our IPK experiments (11,18). According to our results, at these 
concentrations renal clearance will indeed be determined only by glomerular filtration.
The renal clearance of iohexol was enhanced after pretreatment with diatrizoate, 
polylysine, or probenecid, probably due to inhibition of membrane binding. Polylysine 
has been shown to inhibit aminoglycoside binding to brush-border membranes of rat 
kidney cortex. Moreover, in vivo nephrotoxicity could be prevented when 
coadministered with gentamicin (28). It may be speculated that iohexol interacts with 
brush-border membrane components in a fashion similar to aminoglycosides. 
Subsequently, drug molecules are internalized in the tubular cells through an 
endocytotic mechanism, and sequestered within the lysosomal compartment. This 
sequestration may account for the observed vacuolization for iohexol in the proximal 
tubular cells (4,26). Although Heyman et al. (13) previously suggested that vacuoles are 
not a result of endocytosis, but formed after membrane injury induced by contrast 
agents from the paracellular zones. The clearance profile and tissue accumulation of 
iohexol in our IPK preparations, however, indicate that a reabsorptive process for the 
drug exist.
Although we can not differentiate between basolateral or luminal binding in the IPK, 
it seems likely that the luminal membrane is involved. Additional binding studies with 
isolated membrane vesicles of both membranes are needed to discriminate between 
basolateral and luminal binding. Supporting evidence for the luminal binding is 
provided by various reports on disruption of the brush-border membrane by contrast 
media. Tubular cells seem to be even more sensitive to membrane injury than to 
lysosomal disturbance after contrast medium administration (1,27). This is comparable
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to the membrane damage caused by aminoglycoside antibiotics, and supports our 
hypothesis that iohexol is handled by the kidney in a way comparable to 
aminoglycoside antibiotics. It is assumed that the cationic aminoglycosides bind to 
anionic phospholipids within the brush-border membranes (16). Whether membrane 
binding of nonionic iohexol molecules is based on a similar charge interaction between 
the amino groups of this contrast agent and membrane phospholipids, demands further 
research.
The inhibitor of organic anion transport, probenecid, also affected the renal clearance 
of iohexol. The effect of probenecid was investigated, because the tubular titration curve 
for iohexol in the IPK diverged from the theoretical curve, and a secretory component 
may be involved in the renal clearance of iohexol. In addition, other investigators 
suggested previously that the reduced renal accumulation of the contrast analog 
diatrizoate, determined after pretreatment with probenecid, was a result of inhibition of 
organic anion transport (22). Contrary to these findings, probenecid enhanced the 
clearance of iohexol in our IPK preparations. This effect, however, may be a result of 
inhibition of tissue metabolism rather than an interaction with the binding site for 
iohexol. Former reports showed that probenecid affected glucose uptake (17) and 
organic cation transport (8) also, by a reduction in oxidative metabolism. The effect of 
diatrizoate was investigated because this contrast analog is structurally related to 
iohexol, but negatively charged. Renal stop-flow experiments in the dog showed that the 
renal clearance of diatrizoate over inulin clearance was 0.9 (22), indicating a similar 
reabsorptive mechanism may be involved in diatrizioate clearance. The enhanced 
iohexol clearance after pretreatment with diatrizoate probably is a result of a decreased 
binding. Whether there is competition for the same binding site, remains to be 
elucidated.
At concentrations much lower than clinically used, iohexol accumulated in kidney 
tissue reaching tissue concentrations of 2 to 7.5 times the medium concentration. We 
investigated whether internalized iohexol affected oxidative metabolism, as was 
reported for high osmolar contrast agents (13,15). Although a direct effect of iohexol on 
basal and ADP stimulated respiration was not observed, the uncoupled respiratory rate 
was significantly reduced in both cell and mitochondrial preparations. The uncoupling 
agent dinitrophenol discharges the proton electrochemical gradient across the 
mitochondrial inner membrane, hereby stimulating oxygen consumption without ATP 
synthesis. Reduction in uncoupled respiration is an indication of loss of respiratory 
control and a reduction in mitochondrial oxidative metabolism (7), indicating that this 
low osmolar contrast agent may induce direct tubular cell injury. Similar results were 
obtained with the high osmolar agent diatrizoate, and it was suggested that
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mitochondrial Na-K-ATPase was affected (15,24). Heyman et al. (12,13) observed 
mitochondrial swelling and vacuolization after iothalamate administration, mainly in the 
medullary thick ascending limb. However, they concluded that renal injury through 
contrast media was indirect and induced by a limited oxygen supply in that part of the 
nephron. Humes et al. (15) showed that direct tubular cell injury may be additive to 
hypoxic cell injury in radiocontrast-induced renal dysfunction. Although our perfused 
kidney preparation exhibits signs of medullary thick ascending limb defects after 150 
min of perfusion, and also hypoxia in proximal tubules may occur (9), we do not expect 
a major influence on our results, because in most experiments data over the period of 
30-90 min were used. Furthermore, hypoxia limits all active transport processes by 
reduction of cellular energy, and therefore, reabsorption of iohexol may have even been 
underestimated as compared to the in vivo situation.
With regards to our results, the use of iohexol as a filtration marker may have clinical 
implications. Especially in patients with impaired renal function, the exposure time to 
contrast media is lengthened as a result of a prolonged half-life, and drug accumulation 
may be more extensive. Previous studies have shown that renal insufficiency is an 
important risk factor in the development of contrast-associated nephropathy (2,24).
In summary, renal handling of iohexol involves filtration and saturable absorption, 
resulting in tubular accumulation. The process of absorption is assumed to be initiated 
by binding of iohexol to the brush-border membrane, and could be inhibited by 
polylysine, diatrizoate and probenecid. Intracellularly accumulated contrast medium 
affects mitochondrial oxidative metabolism. As a consequence, iohexol is not a true 
marker of GFR.
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RENAL EXCRETION AND ACCUMULATION OF DIATRIZOATE
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Summ ary
The present study was designed to investigate the renal disposition of diatrizoate in the 
isolated perfused rat kidney (IPK). To the IPK, 5 different doses were added (between
1.13 and 44 mg), resulting in initial perfusate concentrations between 4.5 and 175 
Mg/ml. At all perfusate concentrations, the renal excretion rate of diatrizoate was 
significantly lower than the filtration rate, indicating that a reabsorptive mechanism is 
involved in renal diatrizoate handling. The ratio of diatrizoate clearance over GFR 
(ClR/GF) was 0.67 ± 0.04 at 4.5 Mg/ml, and increased slightly to 0.76 ± 0.03 at 175 
Mg/ml, suggesting that tubular reabsorption is mediated by a saturable mechanism. 
Accumulation of diatrizoate in kidney tissue was significantly reduced after 
preincubation of the perfused kidneys with the organic anion transport inhibitor 
probenecid, whereas renal clearance was not affected. At an initial perfusate 
concentration of 4.5 Mg/ml a kidney-to-perfusate ratio (K/P-ratio) of 2.5 ± 0.9 was 
found, which decreased to 1.3 ± 0.2 after preincubation with probenecid. At a perfusate 
concentration of 47 Mg/ml a K/P-ratio of 1.4 ± 0.3 was determined, which increased 
significantly to 2.5 ± 0.4 at a concentration of 175 Mg/ml. We suggest that this unusual 
profile in concentration-dependent accumulation may be explained by a renal clearance 
mechanism for diatrizoate that consists of saturable reabsorption in conjunction with 
active tubular secretion.
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Introduction
Diatrizoate is one of the most widely used radiocontrast agents. The compound is a 
derivative of benzoic acid, negatively charged at physiological pH, and excreted 
predominantly unchanged by the kidney (18,24). During its renal handling diatrizoate 
accumulates within proximal tubular cells (14,19), and many of the unwanted side 
effects reported for diatrizoate (i.e. direct tubular and cellular injury) might be a 
consequence of intracellular sequestration and interference with intracellular 
metabolism (1,10,20).
The various reports on the renal handling of diatrizoate do not agree on the different 
tubular transport processes that contribute to accumulation of the contrast agent. Mudge 
et al. (19) observed active, saturable and probenecid-sensitive uptake of diatrizoate in rat 
and rabbit renal cortex slices, which was absent in dog slices wherein the agent did not 
accumulate. Moreover, in dogs in vivo a diatrizoate over inulin clearance ratio of 0.9 
was determined, indicating that the compound is net reabsorbed (19,25). In contrast 
with these findings, Knoefel and Huang (14) were able to determine net secretion and 
significant accumulation of the compound in dog kidneys. Apparently, the variations in 
tubular diatrizoate accumulation observed in the different studies, seem to correlate with 
the presence of active secretion of the contrast analogue. In humans, the clearance of 
diatrizoate has been reported to be identical to that of inulin (7,17), but no data are 
available on a possible accumulation.
The probenecid-sensitivity of renal diatrizoate uptake and secretion (14,19), suggests 
that the organic anion carrier is involved. This transport system is responsible for the 
transepithelial secretion of a wide variety of organic acids, including benzoic acid (27). 
Organic anion secretion is characterized by active uptake at the basolateral membrane of 
the proximal tubular cells, transcellular distribution and facilitated diffusion across the 
brush-border membrane into the tubular lumen (21). The relative contribution of each of 
these steps determines the intracellular concentration of the anionic compound, although 
net tubular uptake of diatrizoate may also be influenced by intracellular binding (9).
The nature of the mechanism of reabsorption in renal diatrizoate handling is not 
known. In a previous study, we investigated the renal handling of another contrast 
analogue, iohexol, and observed that its clearance was determined by glomerular 
filtration and saturable absorption resulting in tubular accumulation (16). We suggested 
that absorption is initiated by binding of iohexol to the luminal membrane, followed by 
internalization of the membrane complex. Diatrizoate was able to inhibit iohexol 
absorption and, therefore, might be reabsorbed in a similar way.
The present study was designed to examine how accumulation of diatrizoate in the
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isolated perfused rat kidney (IPK) correlates with its renal handling. The purpose was to 
investigate as to whether secretory and reabsorptive mechanisms are involved in the 
overall renal clearance of diatrizoate.
M aterials and M ethods
Materials
Pluronic F-108 was from BASF (Arnhem, The Netherlands) and cyanocobalamin was 
obtained from Sigma (St.Louis, Mo.). Diatrizoate and probenecid were from Sigma, 
iohexol was purchased from Nycomed (Oslo, Norway), iodopyracet was obtained from 
Dagra (Diemen, The Netherlands). All other chemicals were of analytical grade and 
purchased from either Sigma or Merck (Darmstadt, Germany).
Experimental procedure
The isolation and perfusion of the rat kidney is described in detail elsewhere (6). 
Pluronic F-108 was used as oncotic agent in the albumin-free perfusion fluid. For the 
determination of glomerular filtration rate (GFR), cyanocobalamin was added to the 
perfusion fluid. GFR was monitored on line using a micro flow-through cuvette in 
which the cyanocobalamin concentration was measured colorimetrically. The 
experimental period was 120 min and started after a 30 min baseline period. During the 
baseline period the perfusate volume was 500 ml from which a sample of 5 ml was 
drawn. After the baseline period, the experimental perfusion fluid was connected to the 
kidney, with a total volume of 250 ml in which diatrizoate was already dissolved. Doses 
added to the perfused kidneys were 0 (time controls), 1.125, 11.8, 17.3, 25 and 44 mg of 
diatrizoate, resulting in initial perfusate concentrations of 0, 4.5, 47, 69, 100, and 175 
Mg/ml. Compounds used to affect diatrizoate clearance were the contrast analogue, 
iohexol, and the classic inhibitor of organic anion transport, probenecid. These agents 
were added to the IPK at the start of the baseline period, and remained in the perfusion 
fluid during the entire experimental period.
Urine samples were collected during control and experimental periods over 10 min 
intervals. Perfusate samples (300 m1) were drawn at the midpoint of each urine 
collection interval. Two additional perfusate samples were taken, one at the beginning 
of the experimental period (t=0), and one at the end of the experiment. At the end of the 
experiment the kidney was removed from the system, blotted, weighed, and frozen until 
analysis. Urine and perfusate samples were stored at -20 °C until analysis.
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Analysis
Urine and perfusate samples were analysed for electrolytes and glucose, according to a 
previous report from our department (6). The concentration of diatrizoate in perfusate 
and urine samples, and in kidney tissue were determined using reversed-phase high­
performance liquid chromatography (HPLC), as described below.
HPLC assay
For diatrizoate analysis, a 1084B Liquid Chromatograph (Hewlett Packard, Böblingen, 
Germany) was used, equipped with an auto-injector (HP 79841 A), terminal (HP 79850 
B LC) and an UV absorbance detector (Spectroflow 773, Kratos analytical instruments, 
Ramsey, N.J., USA) at an operating wavelength of 240 nm. Chromatography was 
performed on a stainless steel column (125 x 4 mm) packed with LiChrospher 60 RP- 
Select B (Merck, Darmstadt, Germany), particle size 5 Mm. The mobile phase consisted 
of 0.01 M potassium dihydrogen phosphate buffer (pH 2.6) and the flow rate was set at 
0.5 ml/min. Iodopyracet was used as internal standard (0.1 mg/ml). With a column 
temperature of 40 °C, diatrizoate and iodopyracet eluted with retention times of 6.1 and
9.5 min, respectively. Sample preparation was performed using YM-10 ultrafiltration 
membranes (13 mm i.d.) with a molecular weight cut-off of 10,000 in the MPS-1 
micropartition system (Amicon, Grace BV, Dronten, The Netherlands) to separate 
diatrizoate and pluronic F-108. Onto the membrane, 10-40 m1 urine or 25-150 m1 
perfusate sample was pipetted, together with 50 Ml of internal standard. Total volume 
was adjusted to 300 m1 with mobile phase buffer (pH 2.6). The filter units were 
centrifuged for 20 min at 3,000g, and 180 m1 of the filtrate was mixed with 320 m1 
mobile phase buffer. An aliquot of 10 m1 of the resulting solution was injected onto the 
column. Concentrations in perfusate and urine were determined by comparing the peak 
area ratio of diatrizoate and internal standard with the ratios of a calibration curve, 
prepared by adding various amounts of diatrizoate to blank perfusate and urine. Linear 
calibration curves were obtained in all cases (r2 > 0.995). The concentration in kidney 
tissue was determined in a similar way. The kidneys were homogenized in 2.5 ml 
distilled water using a Polytron homogenizer on setting 10 for 2 times 60 sec. A sample 
of 300 m1 was used for further determination as described for perfusate and urine 
samples. The interday precision of the HPLC assay was determined by measuring a 
spiked perfusate and urine sample with each run. The coefficient of variation was found 
to be 7.2% for perfusate samples (8.8 Mg/ml, n=8) and 3.6% for urine (120 Mg/ml, 
n=10).
Data analysis
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All data are expressed as mean ± SD. Statistical differences between means were 
determined with one-way analysis of variance followed by the least significant 
differences test for comparison of multiple means. Differences were considered 
significant if  P<0.05.
Results
Renal excretion ofdiatrizoate
Diatrizoate was eliminated slowly from perfusion fluid. Fig. 7-1 shows the time course 
of the mean perfusate concentration and corresponding excretion rate data of the five 
diatrizoate doses studied, as a function of time. All doses gave linear concentration-time 
curves. The urinary excretion rate increased rapidly after addition of diatrizoate, 
followed by a gradual decrease.
Figure 7-1. Diatrizoate perfusate concentration (left panel) and urinary excretion rate (right 
panel), as a function of time. Doses added to the perfused kidneys are indicated. All data points 
are means of 3-5 experiments. For the sake of clarity standard deviations were omitted from 
this figure, but varied between 2 and 13% for perfusate concentration, and between 7 and 40% 
for renal excretion rate values.
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Renal handling data are presented in Table 7-1. At all perfusate concentrations the renal 
clearance was significantly lower than the clearance by glomerular filtration 
(CLr /GF<1), indicating that diatrizoate is net reabsorbed. At a dose of 11.8 and 44 mg 
the ratio CLR/GF was significantly increased as compared to the lowest dose, 1.13 mg. 
This indicates that tubular reabsorption may be dose-dependent and, consequently, a 
saturable mechanism. In a previous study we showed that iohexol is reabsorbed in the 
perfused kidney via a saturable mechanism (16). Diatrizoate was able to inhibit iohexol 
reabsorption, and it was suggested that both contrast agents may share the same 
transport sites. The effect of 200 Mg/ml iohexol on the renal clearance of diatrizoate at a 
concentration of 4 Mg/ml was investigated. Table 7-1 shows the renal handling data of 
diatrizoate after iohexol pretreatment. CLR/GF was not significantly changed, indicating 
that iohexol had no effect on diatrizoate clearance. As a result of a slightly higher 
glomerular filtration rate the diatrizoate filtration rate and, consequently, total excretion 
rate were enhanced. Furthermore, the effect pretreatment with 86 Mg/ml probenecid on 
the clearance of diatrizoate at a concentration of 4 Mg/ml was investigated. Table 7-1 
shows that this inhibitor of organic anion transport did not affect renal diatrizoate 
excretion at the concentration studied.
Table 7-1. Renal handling data o f  diatrizoate in the isolated perfused ra t kidney
dose perfusate renal excretion filtration ClR/GF amount in
(mg) concentration rate (Mg/min) rate kidney
(Mg/ml) (Mg/min) (Mg/g)
44 164 ± 6 52 ± 2 68 ± 2 0 76 ± 0.03 396 ± 66
25 92 ± 12 25 ± 1 36 ± 2 0 70 ± 0.03 190 ± 43
17.3 63 ± 4 18 ± 2 25 ± 1 0 71 ± 0.03 97 ± 30
11.8 43 ± 5 13 ± 1 18 ± 1 0 73 ± 0.03 57 ± 9
1.13 4.0 ± 0.4 0.99 ± 0.04 1.5 ± 0.1 0 67 ± 0.04 9 ± 3
1.13b 4.3 ± 0.6 1.2 ± 0.1* 1.8 ± 0.1* 0 70 ± 0.03 10 ± 2
1.13c 3.7 ± 0.5 1.0 ± 0.1 1.6 ± 0.2 0 65 ± 0.04 4.8 ± 1.3*
Mean ±  SD (N=3-5) over the period of 30 to 90 min are given, except for the amount in kidney 
which was determined at the end of the experiment. ClR /GF means ratio of renal clearance 
over clearance by glomerular filtration. b In presence o f200 ¡Jg/ml iohexol, 
c 86 Jg/ml probenecid. * P<0.05 in comparison with the same dose without treatment. 
f  P<0.05in comparison with the lowest dose (1.25mg).
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Renal accumulation o f  diatrizoate
The concentration of diatrizoate in kidney tissue was expressed as the amount of drug 
per weight of tissue, and is presented in Table 7-1. The concentration in kidney tissue 
divided by the concentration in perfusate at the end of the experiment, resulted in an 
accumulation ratio. The accumulation ratio of diatrizoate (kidney/perfusate ratio) is 
shown in Fig. 7-1 for all doses and different experimental conditions studied. At the 
lowest dose studied (1.13 mg), a kidney/perfusate ratio of 2.5 ± 0.9 was determined 
which decreased to 1.4 ± 0.3 at the second dose (11.8 mg) and, subsequently, increased 
again dose-dependently. After preincubation with probenecid a significantly lower renal 
accumulation was observed (Table 7-1; Fig. 7-2, lower panel).
Table 7-2. Experimental conditions o f  the isolated perfused ra t kidney in baseline 
period  o f  all IPK  experiments, and in experimental period o f  control IPK  experiments 
and after administration ofthe highest dose (44 mg) diatrizoate3
Renal functional baseline period control IPK (N=4)b 44 mg diatrizoate
parameter (N=21) (N=4)b
FEglucose (%) 3.1 ± 0.2 4.4 ± 1.0 6.3 ± 2.0
FENa (%) 1.7 ± 0.2 1.6 ± 0.4 2.1 ± 1.1
FEk (%) 23 ± 6 30 ± 9 14 ± 4*
)%ÖEF 2.6 ± 0.3 1.9 ± 0.1 2.9 ± 0.9
FEMg (%) 43 ± 5 38 ± 8 30 ± 6
G FR (^l/min) 424 ± 26 320 ± 46 294 ± 24
Urinary flow (^l/min) 22 ± 1 17 ± 2 16 ± 2
Urinary pH 5.45 ± 0.07 5.53 ± 0.20 5.65 ± 0.10
RPP (mm Hg) 89 ± 5 87 ± 3 87 ± 4
FRwater (%) 94.8 ± 0.2 94.6 ± 0.3 94.2 ± 1.0
Perfusate flow (ml/min) 13 ± 1 13 ± 1 13 ± 1
a Mean ±  SD, FE = fractional excretion, FR = fractional reabsorption, RPP = renal perfusion 
pressure. b Experimental period of 30 to 90 min are averaged. *:P<0.05 as compared to 
control IPK experiments.
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figure 7-2. Accumulation of diatrizoate in kidney tissue. The kidney/perfusate ratio is presented 
for each dose, with and without pretreatment with 200 ¡Jg/ml iohexol or 86 ¡Jg/ml probenecid, 
as indicated in the figure. Bars are means ±  SD of 3-5 kidneys.
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Effects on kidney function
The mean values for the functional parameters of baseline period (-30 to 0 min) of all 
IPK experiments are presented in Table 7-2 (N=21). After administration of diatrizoate 
no significant changes in kidney functioning were observed, as compared to control IPK 
experiments, except for the fractional excretion of potassium which decreased 
significantly. Values of renal functional parameters in the experimental period (30 to 90 
min) are presented in Table 7-2 for control IPK experiments, as well as for the highest 
diatrizoate dose.
Discussion
The results of the present study show that over the concentration range studied the renal 
excretion of diatrizoate is dominated by reabsorption. With increasing concentrations a 
small increase in ClR/GF was observed, indicating that reabsorption is mediated by a 
saturable mechanism. The nature of this reabsorptive mechanism is unclear. In a 
previous study we showed that diatrizoate, polylysine and probenecid inhibited the 
reabsorption of iohexol, and we postulated that iohexol binds to the luminal membrane 
and is subsequently internalized (16). In the present study, no evidence was obtained for 
the involvement of such a mechanism in diatrizoate reabsorption. It cannot be fully 
excluded that diatrizoate is reabsorbed in a way similar to iohexol, however, the lack of 
an effect of iohexol on diatrizoate clearance suggests that another type of reabsorptive 
mechanism mediates its excretion.
Active reabsorption has been reported for other organic anions, viz. m- 
hydroxybenzoate, pyrazinoate, nicotinate, and urate (22,26). How reabsorption of these 
organic anions is regulated is not clear, but the urate transporter may be involved. In 
brush-border membrane vesicles of various species, the existence of an urate/anion 
exchanger has been demonstrated, which transports various other organic anions 
(11,12,23,28). Diatrizoate might be transported via this carrier system, thereby 
preventing urate from reabsorption which explains the uricosuric effect reported in 
humans (8).
The absence of complete saturation of reabsorption observed in the present study, 
seems not in agreement with the existence of an active reabsorptive mechanism. Passive 
reabsorption as described for benzoic acid and various of its iodinated derivatives has, 
however, never been demonstrated for diatrizoate (14,15,27). Moreover, Bollerup et al.
(3) observed that diatrizoate clearance was independent of urine flow, suggesting that 
passive reabsorption was not involved in its renal handling. Furthermore, the 
concentration-dependent accumulation observed in our perfused kidneys provides
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supporting evidence against a passive reabsorptive process. After 11.8 mg diatrizoate, a 
kidney/perfusate ratio of 1.4 ± 0.3 was determined which increased dose-dependently to 
2.5 ± 0.4 after the highest dose of 44 mg (P<0.05). If accumulation was determined by a 
passive process, no significant changes in accumulation ratio would have been 
observed.
The first diatrizoate dose (1.13 mg) resulted in a somewhat higher accumulation as 
compared to the other doses: the kidney/perfusate ratio was 2.5 ± 0.9. After treatment of 
the perfused kidneys with 86 |ig/ml probenecid, a kidney/perfusate ratio of 1.3 ± 0.2 
was obtained for the same dose. These results are somewhat confusing since probenecid 
did not affect the overall renal clearance of diatrizoate in the present investigation. 
There are two explanations for this phenomenon. Firstly, probenecid might inhibit the 
intracellular binding of diatrizoate. Twenty years ago, Goldstein and Arias (9) showed a 
noncompetitive inhibition of the rat liver ligandin catalyzed reaction of glutathione by 
diatrizoate. This anion binding protein was reported to be also present in kidney tissue 
(5), and probenecid was found to interact with renal ligandin (13). However, whether or 
not diatrizoate binds intracellularly to ligandin in kidney tissue, has never been 
investigated. Secondly, and more likely, probenecid may be able to inhibit a secretory as 
well as a reabsorptive mechanism involved in the renal handling of the contrast agent. 
Other investigators showed previously that the probenecid-sensitive organic anion 
carrier mediates renal diatrizoate secretion (2,14,19). Thus, it may be speculated that the 
unusual profile in concentration-dependent accumulation can be interpreted by the 
existence of a saturable active secretory mechanism in conjunction with mediated 
reabsorption. These findings are in close agreement with the excretion profile observed 
for urate in humans, rats and cebus monkeys (22). In these species, urate is net 
reabsorbed similarly to diatrizoate in the present investigation. Uricosuric drugs like 
probenecid and pyrazinoate produce a biphasic effect on urate excretion through an 
inhibitory effect on reabsorption as well as on secretion: at low inhibitor concentration 
the fractional excretion of urate is enhanced, but decreases again at increasing inhibitor 
concentration (12,22). Uptake studies in isolated membrane vesicles of kidney cortex 
are needed to reveal the mechanism of interaction of probenecid on diatrizoate 
accumulation.
In contrast with previous observations by Brown et al. (4) in the IPK, accumulation of 
diatrizoate did not affect the functional parameters. At a perfusate concentration of 444 
Mg/ml they observed a significant fall in glomerular filtration rate, renal perfusate flow, 
and fractional reabsorption of sodium. The difference between our study and that by 
Brown et al. (4) is most likely a result of the higher functionality and viability of our 
perfused kidney preparation. This is in agreement with the clinical risks associated with
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the use of diatrizoate in patients with impaired renal function, in which the effects may 
be more pronounced by insufficiently functioning kidneys (20).
In conclusion, the excretion data of diatrizoate in the isolated perfused rat kidney 
suggest that its renal handling involves filtration and mediated reabsorption. Because 
probenecid inhibited kidney tissue accumulation we suggest that a secretory mechanism 
also contributes to the overall renal clearance of diatrizoate. Both reabsorption and 
secretion are susceptible to probenecid inhibition and contribute to tubular diatrizoate 
accumulation.
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Summ ary
The uptake and accumulation of the organic anion fluorescein-sodium (Flu-Na) was 
investigated in freshly isolated proximal tubular cells (PTC) of the rat kidney. 
Furthermore, the influence of other organic anions on Flu-Na uptake was studied in 
order to characterize Flu-Na transport in PTC. Flu-Na showed concentration-dependent, 
saturable and probenecid-sensitive transport. Comparing the transport parameters with 
PAH, Flu-Na exhibited a higher affinity, but lower capacity to the organic anion 
transport system. The apparent Km for Flu-Na transport was 59 ± 15 |iM with a V maxof 
186 ± 26 pmol/mg protein-min, and for PAH 207 ± 11 |iM and 740 ± 46 pmol/mg 
protein-min, respectively. Dose-dependent inhibition of Flu-Na uptake with PAH 
resulted in an apparent inhibition constant K  of 249 |iM. This is in good agreement with 
the apparent Km of PAH, indicating that Flu-Na uptake is regulated by the PAH transport 
system. It is suggested that cellular uptake of both organic anions is mediated by a 
carrier at the basolateral membrane. However, after incubating cells with different 
concentrations of PSP the percentage of maximum inhibition was 84%, which was 
significantly different from the 32% with PAH, suggesting that another transport system 
may be involved in Flu-Na uptake. Experiments with confocal laser scanning 
microscopy showed cellular uptake of Flu-Na and accumulation in subcellular 
structures. After superfusion of PTC with rhodamine 123 these structures were 
identified as mitochondria.
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Introduction
Proximal tubular cells of the kidney are able to transport foreign organic anions from 
blood into urine via an active carrier mediated process. Substrates for the organic anion 
system are, among others para-aminohippurate (PAH), phenol red (PSP), urate, and 
many drugs. Different processes are involved in the tubular secretion of organic anions: 
uptake in the cell across the basolateral membrane, subsequent intracellular distribution 
and finally exit into the lumen across the apical membrane. Because secretion involves 
separate processes with different efficiencies, organic anions may accumulate within 
proximal tubules, sometimes leading to cellular toxicity (4,12,16,20). However, little is 
known about the intracellular disposition of drugs and their effects on cellular function.
Several methods have been developed to investigate transport kinetics in tubular 
secretion. A relatively simple technique to study drug transport across both membranes 
of proximal tubular cells is to use cells grown as monolayers on filters. However, Miller 
(15) recently reported that the PAH transport system was selectively lost in cell cultures, 
even in primary cultures of proximal tubular cells.
Another substrate frequently used to characterize organic anion transport, is the isolated 
perfused proximal tubule. A disadvantage of this method is the collapsed lumen of the 
tubules after isolation, leading to restricted outflow and extremely high accumulation 
values. Freshly isolated proximal tubular cells (PTC) of rat kidney have recently been 
shown useful in the study of organic anion and cation uptake and accumulation within 
these cells (5,7). Although cells were used in suspension, overall transport 
characteristics of organic cations seemed to resemble basolateral to apical flux as 
compared to cells cultured on filters (5).
Chemical or isotope assays are generally used to determine drug transport in 
substrates afterwards. With the development of sensitive fluorescence microscopic 
techniques, it is also possible to use fluorescence detection methods. However, excellent 
fluorescent properties are needed in the visualization of cells or compounds of interest 
(2,21). With a suitable probe for the organic anion system, it is possible to study drug 
transport, accumulation and intracellular disposition in proximal tubules of the kidney, 
in real time.
The fluorescent dye fluorescein is known to be transported by the organic anion 
system in frog kidney proximal tubules and it was shown that uptake into the tubules 
could be monitored by using a microfluorimeter (6). Sullivan et al. (22) have reported 
similar findings in isolated rabbit proximal tubules. Although they found an extremely 
high accumulation within the tubular cells, they could not detect any intracellular 
arrangement. Compartmentalisation of fluorescein within renal cells of crab bladder
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epithelium, teleost proximal tubules, and opossum kidney (OK) cells in culture, was 
recently reported by Miller et al. (14). However, nothing is yet known about the nature 
of this compartment and its role in overall transport.
The aim of this investigation was to characterize the transport kinetics and 
accumulation of fluorescein-sodium in freshly isolated PTC, and to visualize its 
intracellular disposition using confocal laser scanning microscopy.
M aterials and methods
Chemicals
Collagenase, BSA and HEPES were purchased from Boehringer Mannheim 
(Mannheim, Germany). Sodium pentobarbital was obtained from Apharmo (Arnhem, 
The Netherlands) and heparin from Organon (Oss, The Netherlands). Nycodenz was 
from Nycomed AS (Oslo, Norway). Fluorescein-sodium (Flu-Na) and uric acid were 
from Aldrich Chemie (Brussel, Belgium). [3H]-PAH (specific activity 185.0 
GBq/mmol) was purchased from Dupont (Boston, USA). Probenecid, sodium a- 
ketoglutarate, poly-l-lysine, d-(+)-6-methoxy-a-methyl-2 -naphtaleneacetic acid 
(naproxen) and l-(-)-6-methoxy-a-methyl-2-naphtaleneacetic acid (l-naproxen) were 
obtained from Sigma (St.Louis, Mo., USA). Sodium salicylate was obtained from
O.P.G. (Utrecht, The Netherlands). All other chemicals were of analytical grade and 
purchased from Merck (Darmstadt, Germany) or Sigma (St.Louis, Mo., USA).
Isolation o fra t PTC
A method previously described by Boom et al. (5) was used to isolate rat proximal 
tubular cells. Briefly, male Wistar rats weighing 180-220 g were anaesthetized with 
pentobarbital i.p. (60 mg/kg) and the femoral vein was cannulated for the administration 
of heparin (125 U/ 100 g). The aorta was cannulated above the renal arteries. The 
kidneys were perfused at a flow rate of 7.5 ml/min with 150 ml of HH-buffer containing 
(in mM): NaCl 137, KCl 5, MgSO4 0.8, Na2HPO4 0.33, KH2PO4 0.44, NaHCO3 26, and 
HEPES 25, supplemented with 0.5 mM EGTA. The perfusion fluid was set on pH 7.4, 
saturated with carbogen (95% O2/5% CO2) and kept at 37.5 °C. Subsequently, the 
kidneys were perfused with 15 ml HH-buffer in order to washout EGTA and perfused 
with 30 ml of HH-buffer containing 0.12% (w/v) collagenase and 4 mM CaCl2 in a 
recirculating system for 20 minutes. After perfusion, the capsule was removed and the 
cortex suspended in 60 ml ice-cold HH-buffer with 2.5% (w/v) BSA and 1.8 mM CaCl2 
(HH-BSA-buffer). The tissue suspension was filtered through two layers of nylon gauze 
(80 |im), the filtrate was centrifuged (3 min, 80g, 4 °C), and the resulting pellet was 
washed twice with HH-BSA-buffer.
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The PTC were purified by means of a nycodenz density gradient centrifugation: the 
cell pellet was resuspended in 4 ml HH-BSA-buffer, mixed with 2 ml 34% nycodenz 
solution (dissolved in 6.7 mM KCl, 1.22 mM CaCl2 and 10 mM HEPES, pH 7.4) and 
divided over two tubes. On the suspension, 1 ml of HH-BSA-buffer/34% nycodenz 
(4:1) and 0.5 ml HH-BSA-buffer were layered, and the tubes were centrifuged (3 min, 
2300 g, 4 °C). The band between the two nycodenz layers was removed and washed 
with ice-cold HH-BSA-buffer. The cells were washed twice in incubation buffer 
containing (in mM): NaCl 117.5, KCl 4, MgSO4 1.2, KH2PO4 0.95, NaHCO 3 22.5, 
glucose 11.1, and CaCl2 2.5 and suspended to a final concentration of 18 to 24-106 
cells/ml. Cell yield was 25 to 40-106 cells/rat and viability was higher than 90% as 
judged by trypan blue exclusion and LDH release.
Uptake experiments
Approximately 2-106 cells were incubated in a carbogen atmosphere with a total volume 
of 500 |il in incubation buffer (carbogen saturated) at 37 °C in a rotary shaker (200 
rotati ons/min). Cells were preincubated for 15 min. Incubations were stopped by 
addition of 5 ml ice-cold washing buffer, containing (in mM) NaCl 140, KCl 4, MgSO4 
1.2, KH2PO4 0.95, glucose 11.1, CaCl 2 2.5, adjusted to pH 7.4. After rapid 
centrifugation, the cells were washed twice with 5 ml of washing buffer. All washing 
and centrifugation procedures were carried out at 4 °C.
Concentration-dependent uptake of Flu-Na was determined by incubating PTC for 3 
min with different concentrations Flu-Na, in a range of 1 to 300 |iM. The cells in the 
pellet were lysed with 2.5 ml of distilled water and vortexed. Fluorescence in the 
suspension was measured using a spectrofluorophotometer Shimadzu RF-5000 
(Shimadzu Corporation, Kyoto, Japan). Concentrations were calculated by comparing 
fluorescence intensity (in photomultiplier units) with a calibration curve of spiked 
samples of blank cell suspensions with different concentrations Flu-Na, since relative 
fluorescence was dependent on the amount of protein used (21). Linear correlations 
were obtained in all cases (R2>0.997). The protein content in each sample was 
determined using the Bio-Rad Protein Assay from Bio-Rad (München, Germany), with 
BSA as the protein standard.
PAH uptake was determined by incubating PTC for 2 min with 5.4 |iCi [3H]-PAH and 
different concentrations of nonlabeled PAH. After incubation and washing, the cells 
were lysed with 1 ml of distilled water and radioactivity was determined by liquid 
scintillation counting after addition of 10 ml liquid scintillator (Aqualuma Plus, Lumac, 
Schaersberg, The Netherlands). Protein content was determined in blank samples.
For interaction experiments with Flu-Na, inhibitors were added either at the beginning
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of 15 min preincubation or together with Flu-Na. The uptake of 40 |iM Flu-Na was 
determined after 3 min incubation. Data are expressed as percentage of control uptake.
In order to determine accumulation in PTC, cells were incubated for 30 min with 
different concentrations Flu-Na or PAH. Cell to medium ratio was calculated by 
dividing the cellular uptake per cell volume (8 |il/mg protein) (7) by the concentration in 
medium.
For confocal fluorescent images, cells were attached to a cover slip coated with poly- 
l-lysine (0.1% w/v in deionized water), and kept in HH-buffer supplemented with 2.5 
mM CaCl2 and 11.1 mM glucose (pH 7.4) at room temperature until use. Cover slips 
were placed in a teflon culture dish, according to Ince et al. (9) with a final volume of 1 
ml, and superfused continuously with a flow-rate of 1 ml/min. Confocal fluorescent 
images were obtained with a MRC-600 (Bio-Rad Microscience Ltd., Hemel Hempstead, 
England) confocal laser scanning microscope. The system consisted of an argon-ion 
laser with a 488 nm line as excitation source, with a laser intensity of 10 mW and a 
neutral density filter at position 3, an inverted microscope (Nikon Diaphot, Tokyo, 
Japan), and a photomultiplier tube. The microscope was equipped with a 60x oil 
immersion objective exhibiting a numerical aperture of 1.4. Software used were Som 
4.82 and Time Course Ratiometric (Bio-Rad Microscience Ltd., Hemel Hempstead, 
England). Depth of the optical section was determined with a pinhole in the emission 
pathway (pinhole 30% open gave a z-resolution of approximately 1 |im). With a zoom 
factor of 5, images were accumulated to a maximum of 255 pixels.
Data analysis
All data are expressed as means ± S.D. Statistical differences between means were 
determined using Student's t-test. The significance level was set to p<0.05. A Michaelis­
Menten equation in combination with linear diffusion was fitted to the concentration- 
dependent uptake using PCNonlin (13). The maximum rate of carrier-mediated 
transport, Vmax (pmol/mg protein-min), the Michaelis constant, Km (^M), and the 
diffusion constant, k  (ml/mg protein-min), were determined. Data were weighted 
reciprocally (1/Y) and the goodness of fit was determined by R2. All curves were fitted 
individually and parameters were averaged, mean parameters were used to graph the 
mean fit.
The log-concentration inhibition curves were analyzed by means of nonlinear 
regression with the program LIGAND (17). The weighted residual sums of squares of 
one- and two-site models were compared, and significance was determined with the F- 
ratio test. Significance level was set on P<0.05.
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Results
Flu-Na uptake
The time-dependency of Flu-Na uptake was determined by incubating cells with 10 |iM 
Flu-Na for different time periods (Fig. 8-1). The uptake of Flu-Na increased during the 
first 10 min, whereafter equilibrium was reached. The time point of 3 min was chosen to 
study concentration-dependent uptake. Although the average 3 min time point in Fig. 8­
1 tends to deviate from the linear part of the uptake curve, this value did not differ 
significantly from the initial transport rates. Fig. 8-2 presents the uptake of different 
concentrations Flu-Na with and without coadministration of 5 mM probenecid. The 
uptake of Flu-Na was concentration-dependent and sensitive to probenecid. At high 
concentrations the nonlinear uptake paralleled the nonspecific uptake, indicating 
saturation of the transport carrier. Fitting the probenecid-sensitive data to the Michaelis­
Menten equation gave an apparent Km of 59 ± 15 |iM and a V max of 186 ± 26 pmol/mg 
protein-min (R2=0.986). The diffusion constant k, determined from the nonspecific 
uptake, was 1.65 ± 0.04 ml/mg protein-min.
Figure 8-1. Time-dependent uptake of 10 j M Flu-Na in PTC in the presence (open circles) and 
absence (closed circles) of 5 mM probenecid. Values are mean ±  SD of four different 
isolations.
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Figure 8-2. Concentration-dependent Flu-Na uptake in the presence (open circles) and 
absence (closed circles) of 5 mM probenecid. Cells were incubated for 3 min at 37 °C. Line 
through closed circles represents Michaelis-Menten fit in combination with linear diffusion. 
Line through open circles represents uptake by diffusion. Values are mean ±  SD of five 
different isolations.
PAH uptake
Fig. 8-3 shows the time-dependent uptake of 100 |iM PAH after incubating cells for 
different time periods. The uptake increased in time until equilibrium was reached after
5 min. Concentration-dependent PAH uptake (measured after 2 min of incubation) was 
nonlinear and saturable as was also seen for Flu-Na. Nonspecific uptake was determined 
by addition of 5 mM probenecid (Fig. 4) and gave a value of k  of 0.75 ± 0.03 ml/mg 
protein-min. Fitting of the Michaelis-Menten equation to the probenecid-corrected 
uptake resulted in an apparent Km of 207 ± 11 |iM and a V maxof  740 ± 46 pmol/mg 
protein-min (R2=0.984).
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Figure 8-3. Time-dependent uptake of 100 j M PAH in PTC. Values are mean ±  SD of four 
different isolations.
Figure 8-4. Concentration-dependent PAH uptake in the presence (open circles) or absence (closed circles) o f5  mM 
probenecid. Cells were incubated for 2 min at 37 °C. Line through closed circles represents Michaelis-Menten fit in
Uptake (pm ol/m g prot.*min)
C oncentra tion p-am inohippurate (æ M )
combination with linear diffusion. Line through open circles represents uptake by diffusion. Values are mean ± SD 
o f five different isolations.
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Accumulation in PTC
After incubating cells with different concentrations of Flu-Na or PAH, accumulation 
within the cells was determined (Fig. 8-5). For Flu-Na the cell-medium ratio reached a 
value of 3.5 at low concentrations, rapidly decreasing to 1 at higher concentrations. This 
indicates that Flu-Na accumulates in PTC only at concentrations below 50 |iM. At high 
concentrations accumulation is decreased due to saturation of the transport system. PAH 
accumulated more extensively in PTC, the cell/medium ratio achieved a value of 4.6.
Figure 8-5. Accumulation of Flu-Na (upper panel) and PAH (lower panel) in rat PTC. Data 
are expressed as the ratio of intracellular over medium concentration as a function of medium 
concentration. Incubation time was 30 min at 37 °C. Values are mean ±  SD of four different 
isolations.
Effect ofinhibitors on Flu-Na uptake
The effect of other organic anions on 40 |iM Flu-Na uptake was investigated by 
measuring the concentration-dependent inhibition. The organic anions tested were 
model compounds (probenecid, PAH and PSP), endogenous compounds (a- 
ketoglutarate and urate), and drugs (naproxen, its enantiomer without pharmacologic 
effect l-naproxen and sodium salicylate). Cells were preincubated with different 
concentrations of inhibitor during 15 min. Only a-ketoglutarate was added to the cells 
simultaneously with Flu-Na. Because a-ketoglutarate has been shown to stimulate PAH 
uptake in proximal tubules (20), cells were not preincubated with this compound. Fig. 8­
6 shows the log-concentration inhibition curves of the above mentioned organic anions. 
All curves were described best according to a one-site competition model, and IC50 
values, the concentrations of the inhibitor causing 50% inhibition of Flu-Na uptake, 
were determined. The log(IC50) values and the percentage of maximum inhibition, are 
given in Table 8-1.
Table8-1. Inhibitory potency o f  various anions on 40 p M  Flu-Na uptake
- log IC50 maximum inhibition 
(%)
N
Probenecid 3.74 ± 0.49 49 ± 9 5
p-Aminohippurate 3.38 ± 0.68 32 ± 5 5
Phenol red 3.44 ± 0.28 84 ± 7 5
a-Ketoglutarate 3.65 ± 0.64 33 ± 6 5
Urate 3.29 ± 0.40 38 ± 6 5
Sodium salicylate 2.78 ± 0.56 51 ± 12 8
Naproxen 4.15 ± 0.68 61 ± 6 5
l-Naproxen 3.95 ± 0.27 43 ± 9 5
Apparent inhibitory constant (-log IC50) and the percentage of maximum inhibition. Mean 
values ±  S.D. are given, N=number of different cell isolations used.
Figure 8-6. Inhibition of40 pM  Flu-Na uptake by various anionic compounds. Inhibitors 
were added at the start of the 15 min preincubation except for a-ketoglu.tarate which was 
added together with Flu-Na to PTC. Cells were incubated for 3 min at 37 °C and 
inhibition is expressed as percentage of control uptake. The line represents the fit 
according to a one-site competition model. Values are expressed as mean ±  SD.
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The most complete inhibition of Flu-Na uptake was obtained with PSP and naproxen. 
The difference in inhibitory potency and percentage of maximum inhibition between 
naproxen and its l(-)-enantiomer suggests a stereoselective interaction, but it failed to 
reach the level of significance.
CLSM experiments
Experiments with confocal laser scanning microscopy (CLSM) show active cellular 
uptake of Flu-Na in freshly isolated PTC. Figure 8-7 presents a typical cell under 
different experimental conditions. A remarkably high autofluorescence of the cells was 
observed, which was localized at one side of the cell. This is shown in figure 8-7B; to 
obtain this picture 147 frames were accumulated to reach the maximum pixel value of 
255 with a gain of 9.9. When cells were superfused with 0.5 |iM Flu-Na, the cell 
fluorescence increased very rapidly and accumulated within the autofluorescence 
regions (fig. 8-7C). For this picture 37 frames were accumulated under same 
experimental conditions. After superfusion of the cells with 0.2 |iM rhodamine 123 (a 
fluorescent mitochondrial marker) (10), these regions were detected as mitochondria 
(fig. 8-7D). Gain was set on 7.3 and the picture was obtained after accumulating 46 
frames. After detecting scattered light, the membrane surface was visualized (fig. 8-7A). 
The mitochondrial side of the cell has a more distinct membrane, this is assumed to be 
the basolateral membrane.
Discussion
Flu-Na accumulates in freshly isolated proximal tubular cells (PTC) of the rat kidney 
and uptake of Flu-Na was concentration-dependent, saturable and sensitive to 
probenecid, indicating that carrier mediated transport is involved. Fitting data to a 
Michaelis-Menten equation resulted in an apparent Km of 59 ± 15 |iM and a V maxof 186 
± 26 pmol/mg protein-min. Sullivan et al. (22) determined in isolated rabbit proximal 
tubules an apparent Km of 10 |iM, however, data were plotted after Lineweaver-Burke 
transformation without correction for the probenecid sensitive uptake. They found much 
higher accumulation within PTC (cell/medium ratio >100), because they used tubules 
with collapsed lumen in which efflux through the brush-border membrane was absent. 
Moreover, species differences in efflux mechanism of organic anions between rabbits 
and rats have been reported (20).
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Figure 8-7. Confocal laser scanning image o f  a typical cell, approximately 18 pm  
in diameter. In A, light scattering from  laser beam was detected showing cell 
surface. B presents the control image, indicating autofluorescence. After 
superfusion with 0.5 pM  Flu-Na fo r  15 min accumulation was observed in 
autofluorescent structures (C). After superfusion with 0.2 pM  rhodamine 123 fo r  
15 min, these autofluorescent structures were identified as mitochondria (D).
Figure 8-7. Confocal laser scanning image of a typical cell, approximately 18 pm in 
diameter. In A, light scattering from laser beam was detected showing cell surface. B 
presents the control image, indicating autofluorescence. After superfusion with 0.5 pM  
Flu-Na for 15 min accumulation was observed in autoñuorescent structures (C). After 
superfusion with 0.2 pM  rhodamine 123 for 15 min, these autofluorescent structures 
were identified as mitochondria (D).
To investigate whether Flu-Na transport is mediated by the PAH carrier system, PAH 
transport was characterized in rat PTC. The uptake was concentration-dependent 
(apparent Km of 207 ± 11 |iM), saturable, and PAH accumulated within the cells. 
Although it is difficult with isolated cells to determine at which membrane the transport 
system is localized, it is assumed that PAH is transported into the cell by a carrier at the 
basolateral membrane (BLM). Studies on basolateral transport of PAH in rat proximal 
tubules, using the stopped flow capillary perfusion method (24), resulted in an apparent 
Km of 0.080 mM. In isolated BLM vesicles a diversity in affinity constants (Km) for PAH 
were reported, varying between 0.054 mM (11) and 0.54 mM (3). Studies with PAH in
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isolated rat kidney brush-border membrane (BBM) vesicles showed a much lower 
affinity: Ohoka et al. (18) determined an apparent Km of 5.8 mM. After comparing our 
Km with these literature values, it is suggested that PAH transport resembles basolateral 
uptake. The cell/medium ratio for Flu-Na and PAH was highest at low concentrations 
and decreased with increasing medium concentration due to saturation of the transport 
carrier. This was also reported for PAH in cortical slices of rat kidneys (19).
Probenecid did not completely block fluorescein uptake. Inhibition experiments 
showed that approximately 50% of the uptake of 40 |iM Flu-Na was not susceptible to 
probenecid inhibition. A concentration up to 10 mM probenecid was without toxic 
effects (determined by using LDH-leakage test and trypan-blue exclusion, data not 
shown). It has been shown by others that this concentration does not affect cell 
permeability or membrane potential (8). Table 8-I shows the inhibitory potency for 
probenecid and other organic anions on the uptake of 40 |iM Flu-Na. Besides the 
differences in potency, there is also a variation in the percentage of maximum 
inhibition. The inhibitory constant K¡ of PAH on Flu-Na uptake appeared to be 249 |iM, 
which is in good agreement with the apparent Km of 207 |iM we found. This provides 
strong evidence that the same transport carrier is involved in both PAH and Flu-Na 
transport. Also a-ketoglutarate with a strong inhibitory effect on PAH influx (24) 
inhibited Flu-Na transport with a potency which is even higher than with PAH.
However, the inhibitory effectiveness of both urate and PSP suggest that the PAH 
transport mechanism is not the only carrier system involved in Flu-Na uptake in rat 
PTC. Both compounds, urate and PSP, hardly affected tubular secretion of PAH in rats 
and they are believed not to share the same transport system at the BLM of proximal 
tubular cells (20). Moreover, with a similar inhibitory potency PSP could inhibit 40 ^M 
Flu-Na uptake for almost 85%, which is much larger than the 32% of maximum 
inhibition with PAH. These findings suggest that another transport system is probably 
involved in Flu-Na uptake. Ammer et al. (1) reported in rabbit kidneys a moderate 
inhibitory potency for fluorescein against basolateral sulphate transport, with an 
apparent K¡ of 660 |iM. Although this value is 10 times larger than the K¡ of 60 |iM they 
found for fluorescein against PAH transport using the same model, it may contribute to 
absolute Flu-Na uptake in PTC.
Experiments with confocal laser scanning microscopy (CLSM) demonstrate active 
cellular and subcellular uptake of Flu-Na in freshly isolated PTC. Transport of Flu-Na 
into the cell is active, since it is against the electrochemical gradient. CLSM pictures 
clearly show that fluorescence accumulated in subcellular structures. The same 
structures showed autofluorescence, but fluorescence increased extensively in this 
region after perfusion with Flu-Na. Accumulation in a cellular compartment of Flu-Na
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in renal cells was also reported by Miller et al. (14) in teleost proximal tubules, crab 
urinary bladder and opossum kidney cells in culture. However, accumulation was 
limited to a perinuclear area. In crab urinary bladder, accumulation in the region of the 
nucleus was inhibitable by probenecid and PAH and was increased by the addition of 
glutarate to the incubation medium. In opossum kidney cells fluorescein accumulation 
was not limited to the region of the nucleus, because there was less cytoplasm in this 
area. This could be due to changes in subcellular structures after culturing. There was no 
clear evidence for the nature of this compartment, however, it was suggested that 
compartmentalisation plays an important role in the secretion of organic anions. It was 
concluded that self-protection of the cell against high cytoplasmic concentrations may 
be an underlying function.
After superfusion of PTC with rhodamine 123, it was obvious that the subcellular 
structures responsible for Flu-Na accumulation were mitochondria. CLSM images 
showed a large amount of mitochondria at one side of PTC, which is probably the 
basolateral side. Mitochondria contain several transport carriers, especially for anionic 
compounds. Tune et al. (23) proposed a mechanism by which nephrotoxic 
cephalosporins inhibited mitochondrial respiration, through competition with anion 
transport systems. They suggested that the sequestered and more reactive cephalosporin 
antibiotics may acylate these transporters, resulting in a reduced respiration.
In conclusion, Flu-Na is actively transported in freshly isolated rat PTC like an 
organic anion, however, more than one transport mechanism seems to be involved. It is 
suggested that the basolateral PAH transport system plays a major role in Flu-Na uptake 
in PTC. Experiments with CLSM showed accumulation of Flu-Na in mitochondria of 
these renal cells. Further experiments have to be done to investigate whether 
mitochondrial accumulation is specific for Flu-Na or common for other organic anions, 
and what the consequences are for cellular functioning.
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Summ ary
The interaction of the organic anion, fluorescein (Flu-Na), with mitochondria in renal 
proximal tubular cells (PTC) was investigated. Confocal microscopy was used to 
demonstrate Flu-Na accumulation in mitochondria of intact cells. Phenyl succinate 
inhibited the mitochondrial accumulation of the Flu-Na analog, carboxyfluorescein 
(CF), indicating that the dicarboxylate carrier may be involved in the intracellular 
compartmentation of organic anions. To characterize the interaction, radio-tracer uptake 
and respiration studies with renal mitochondria were carried out using succinate as a 
substrate. Respiration measurements in freshly isolated kidney cortex mitochondria 
revealed that Flu-Na inhibited ADP-stimulated and uncoupled respiratory rate, 
indicating that the organic anion inhibited the availability of succinate as a reducing 
agent. A similar effect on mitochondrial respiration was found for PAH and 
phenylsuccinate. Flu-Na inhibited 14C-succinate uptake concentration-dependently, and 
Dixon analysis revealed that the nature of interaction between Flu-Na and succinate was 
competitive. K¡ values of 0.5 ± 0.2 and 1.1 ± 0.8 mM were calculated for respiration 
experiments and tracer uptake studies, respectively. The data demonstrate that Flu-Na 
competitively interacts with a mitochondrial dicarboxylate transporter.
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Introduction
Organic anions that are actively secreted by the kidney, accumulate within cells of the 
proximal tubule. Various investigations showed that the fluorescent organic anion, 
fluorescein (Flu-Na), is handled by proximal tubules in a way similar to p- 
aminohippurate, the model substrate for the transport system. The advantage of using 
Flu-Na is that the compound can be visualized within cells and lumen using 
fluorescence microscopic techniques (8,10,22). Confocal microscopic images showed 
that Flu-Na is sequestered in rat proximal tubule cells within vesicular compartments, 
the major one being mitochondria (8).
The present study is concerned with the mechanism by which Flu-Na accumulates 
within mitochondria. So far, nine different anion carriers have been found in the 
mitochondrial inner membrane and all of these transporters play an important role in the 
regulation of cellular metabolism. The different carrier systems are closely related and 
have common substrates (6,15). Other xenobiotics have been shown to interact with 
mitochondrial anion transport systems. For example, valproic acid noncompetitively 
inhibits succinate transport (19). The immunosuppressive agent, cyclosporine A, 
showed two mechanisms of interaction: a noncompetitive interaction with succinate for 
binding to succinate-coenzyme Q dehydrogenase, and competitive inhibition with an 
oxidized form of one of the enzyme components (7). Beta-lactam antibiotics have been 
reported to interact with the mitochondrial phosphate carrier. The carrier is acylated by 
these antibacterial agents, primarily resulting in irreversible injury to this carrier and 
secondarily to mitochondrial oxidative metabolism (24). In each of these three 
examples, succinate-stimulated respiration is reduced either directly or indirectly. 
Measuring succinate stimulated oxygen consumption is a simple way to investigate drug 
effects on mitochondrial function. The rate of respiration is controlled by the uptake of 
the dicarboxylate into mitochondria. The principal transporter for uptake into 
mitochondria is the dicarboxylate carrier, although succinate may also be a substrate for 
the related tricarboxylate and oxoglutarate carriers (6). The dicarboxylate carrier 
catalyzes electroneutral exchange of dicarboxylates and phosphate through the 
mitochondrial inner membrane. Most of our present knowledge about mitochondrial 
succinate uptake comes from studies with isolated rat liver mitochondria. The kinetics 
of succinate uptake appeared to be saturable, concentration-, temperature- and pH- 
dependent, and sensitive to phenylsuccinate. Low concentrations of phenylsuccinate 
blocks dicarboxylate uptake in isolated mitochondria, but the drug is not transported 
into the matrix (14,18).
Here we use confocal microscopy of intact renal proximal tubular cells, and radio­
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tracer uptake and respiration studies with renal mitochondria to demonstrate that 
substrates for the renal organic anion transport system competitively interact with the 
mitochondrial dicarboxylate carrier.
M aterials and methods
Materials
Fluorescein (Flu-Na), succinic-acid, phenylsuccinic-acid and ethylene glycol-bis(ß- 
aminoethylether)-N, N, N', N'-tetraacetic acid (EGTA) were purchased from Aldrich 
Chemie (Steinheim, Germany) and [2,3-14C]succinic-acid (specific activity 2.2 
GBq/mmol) from Dupont (Boston, MA). Carboxyfluorescein-diacetate (CFDA), and 
tetramethylrosamine were from Molecular Probes (Eugene, OR). Bovine serum albumin 
(BSA) and 4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid (HEPES) were obtained 
from Boehringer Mannheim (Mannheim, Germany). Sodium pentobarbital was acquired 
from Apharmo (Arnhem, The Netherlands) and heparin from Organon (Oss, The 
Netherlands). All other chemicals were of analytical grade and purchased from Merck 
(Darmstadt, Germany) or Sigma (St.Louis, MO).
Confocal images o f  isolated proximal tubular cells
Proximal tubular cells were isolated as described in detail previously (8). For 
microscopy, cells were transferred to a Teflon chamber with a glass coverslip floor, 
containing 1.5 ml of incubation buffer (117.5 mM NaCl, 4 mM KCl, 1.2 mM MgSO4, 
0.95 mM KH2PO4, 22.5 mM NaHCO3, 11.1 mM glucose and 2.5 mM CaCl2). Cells 
were preincubated for 15 min in presence or absence (controls) of phenylsuccinate (25 
|iM or 1 mM) or nocodazole (20 |iM) at 37 °C under an atmosphere of 95% oxygen and 
5% carbon dioxide. Subsequently, CFDA was added to the cells reaching a final 
concentration of 2 |iM and incubation took place for 15 min at room temp. In double­
labelling experiments, cells were preincubated for 15 min at 37 °C under an atmosphere 
of 95% oxygen and 5% carbon dioxide, then CFDA (2 |iM) and tetramethylrosamine 
(0.5 |iM) were added simultaneously. Incubation with both dyes took place for 15 min at 
room temperature. Confocal fluorescent images were obtained with a Zeiss LSM 410 
confocal microscope (Carl Zeiss, Oberkochen, Germany). The system consisted of an 
inverted microscope, a mixed argon/krypton-ion laser with the 488 and 568 lines as 
excitation source (intensity 15 mW). The microscope was equipped with a 40x oil 
immersion objective, exhibiting a numerical aperture of 1.3. For measurement of 
tetramethylrosamine fluorescence, the 568 nm laser line, a 575 nm dichroic filter and a
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590 nm long pass emission filter were employed. For measurements of CF, the 488 nm 
laser line, a 510 nm dichroic filter and 515 nm long pass emission filter were employed. 
Neutral density filters passing 1 or 3% of the light and 20% laser power were used to 
minimize photobleaching. The photomultiplier gain was adjusted so that the average 
pixel intensity in the cells was between 40 and 60 on a scale of 0-255, and cellular 
autofluorescence was undetectable. For double-labelling studies, the photomultiplier 
gain in the CF channel was adjusted so that the tetramethylrosamine signal was not 
detectable. The software used to obtain the images was Zeiss LSM4 (Carl Zeiss, 
Oberkochen, Germany). Images were stored on an optical disk recorder and analyzed 
using a Macintosh computer equipped with image analysis software (Image 1.54, 
National Institutes of Health). The effect of phenylsuccinate on CF accumulation was 
measured. To this end, a field containing 20 cells was selected and a single 8 sec scan 
was collected in confocal fluorescence mode. O f this image the average pixel intensity 
for each cell was calculated of which the background was subtracted, and the value used 
was the mean of all measured cells. Of one preparation 4 fields were measured and 
averaged.
Isolation o f  kidney cortex mitochondria
Rat kidney cortex mitochondria were isolated as described by Cain and Skilleter (1), 
with some modifications. All steps were carried out at 4 °C. Briefly, male Wistar- 
Hannover rats (230-280 g) were anesthetized intraperitoneally with pentobarbital (60 
mg/kg). Heparin (125 U/100 g) was administered in the femoral vein. Mesenteric and 
coeliac arteries were ligated and the aorta was cannulated above the renal arteries. The 
kidneys were perfused with an ice-cold solution containing 140 mM NaCl and 10 mM 
KCl, the vena cava inferior was ligated and the left renal vein was cut open. After 
perfusion the kidneys were removed and kept in ice-cold isolation buffer (300 mM 
mannitol, 10 mM HEPES, 1 mM EGTA, 1 mg/ml BSA, adjusted to pH 7.4). The kidney 
capsule was removed, medulla was dissected and the cortex was collected in three times 
tissue weight of isolation buffer. Tissue was homogenized in six strokes by hand in a 
Potter-Elvehjem homogenizer with Teflon pestle (Braun, Melsungen, Germany). The 
clearance between pestle and Potter tube was 0.5 mm. The homogenate was filtered 
through two layers of woven gauzes, and centrifuged for 10 min at 500 g. Supernatant 
was collected and centrifuged for 7 min at 11,000 g. Mitochondrial pellet was washed 
with isolation buffer and again centrifuged (7 min, 11,000 g). Final pellet was diluted to 
a concentration of 5 mg/ml mitochondrial protein in respiration medium (210 mM 
mannitol, 10 mM KCl, 10 mM KH2PO4, 0.5 mM EGTA, 60 mM Tris-HCl, at pH 7.4) 
and kept on ice.
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Protein content was determined using the BioRad Protein Assay of BioRad (München, 
Germany) with BSA as the protein standard. The purity of the mitochondrial fraction 
was assessed by assaying the specific activity of the following marker enzymes, as 
described previously by Russel et al. (20): succinate dehydrogenase for mitochondria, 
Na,K-ATPase for basolateral membranes, alkaline phosphatase for brush-border 
membranes, acid phosphatase for lysosomes and NADPH-dependent cytochrome-c 
reductase according to Omura and Takesue (12) for smooth endoplasmic reticulum. The 
results of the enzymatic analysis (means ± SD of 6 different preparations, unless 
indicated otherwise) showed an enrichment in succinate dehydrogenase of 3.4 ± 0.5 fold 
(N=18), 1.3 ± 0.4 fold in Na,K-ATPase, 1.4 ± 0.5 fold in alkaline phosphatase, 1.4 ± 0.2 
fold in acid phosphatase and 0.9 ± 0.5 fold in NADPH-dependent cytochrome-c 
reductase. Respiration measurements or tracer uptake experiments were carried out 
immediately after isolation of the mitochondrial fraction.
Mitochondrial respiration
Oxygen consumption was measured using 1 mg of mitochondrial protein at 30 °C with 
a Clark-type platinum electrode in 2.0 ml of respiration medium, as previously 
described (1). Succinate (10 mM) was used as the metabolic substrate. The conversion 
of succinate is directly linked to the process of oxidative phosphorylation, and rotenone 
(5 |iM) was added to block electron transport proximal to succinate entry into the 
respiratory chain. ADP stimulated respiration (state 3) was measured in the presence of
0.3 mM ADP. Dinitrophenol (DNP, 44 |iM) was used as an uncoupling agent. DNP 
discharges the proton electrochemical gradient across the mitochondrial inner 
membrane, hereby stimulating oxygen consumption without ATP synthesis. The 
composition of the solutions used for respiration experiments is given in the figure 
legends. Respiratory rates are expressed as nanogram atoms of oxygen per minute per 
milligram of mitochondrial protein (ng atom O/ min-mg prot.).
MC-Succinate uptake
Uptake of 14C-succinate into mitochondria was measured in triplicate at 10 °C. 
Incubation was started by the addition of 25 |il of the mitochondrial suspension to 100 
|il respiration medium supplemented with antimycine (10 |iM), rotenone (5 |iM), the 
desired concentration of succinic acid and a tracer amount of 14C-succinic acid (50 nCi). 
Uptake was stopped at appropriate time intervals by the addition of 2.5 ml ice-cold stop 
buffer (190 mM mannitol, 10 mM KCl, 10 mM KH2PO4, 0.5 mM EGTA, 60 mM 
phenylsuccinic acid, at pH 7.4). Separation of mitochondria and extramitochondrial 
medium took place through Whatman GF/F filters, using a rapid vacuum filtration
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technique (20). Incubation tubes and filters were washed three times with 2.5 ml stop 
buffer. To the filters, 4 ml of scintillation fluid (Aqualuma Plus, Lumac, Schaersberg, 
The Netherlands) was added. The radioactivity remaining on the filters was counted in a 
Beckman LS 6000 LL liquid scintillation counter. Corrections were made for non­
specific filter binding in the absence of mitochondria. Uptake is expressed as pmol/mg 
mitochondrial protein.
Data analysis
All data are expressed as means ± SD and were performed on at least three different 
mitochondrial preparations. Statistical differences between means were determined 
using one-way analysis of variance followed by the least significant difference post test. 
Values were considered statistically different when P<0.05. The kinetic constants of the 
inhibitory potency of Flu-Na on succinate uptake in mitochondria were determined from 
the initial linear uptakes (10 sec) at various substrate concentrations. Inhibition of Flu- 
Na on succinate uptake was expressed relative to the maximum inhibition achieved with 
phenylsuccinate, and calculated by:
V= V° VpuNa -100% (9_1)
V0 -  Vp s  (  )
where V0 is the uptake of 100 |iM succinate without preincubation with fluorescein, 
Vpiu-Na is the uptake of 100 |iM succinate determined after preincubation with 
fluorescein and VPS is the uptake of succinate determined after preincubation with 12.5 
mM phenylsuccinate. The log-concentration inhibition curves were analyzed by means 
of the least squares nonlinear regression program GraphPad Inplot 4.0, assuming a one 
site competition model. Transformation of the data according to Dixon showed the 
nature of inhibition, and allowed calculation of an inhibitory constant (K) for Flu-Na 
(4). The K  i value was determined from the average of the intersection points and a 
standard deviation was derived from the sum of the estimated variance of each 
intersection point.
Results
Confocal microscopy
Carboxyfluorescein-diacetate (CFDA) is a nonfluorescent and uncharged analog of Flu- 
Na that enters proximal tubular cells mainly by diffusion. Once inside, the compound is
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hydrolyzed to carboxyfluorescein (CF), an anion, which is highly fluorescent (3). Fig. 9­
1 shows confocal images of rat kidney PTC incubated with 0.5 |iM tetramethylrosamine 
(upper panel) and 2 |iM CF (lower panel). Tetramethylrosamine stains mitochondria 
(25) and it is obvious that CF and tetramethylrosamine are localized in the same 
punctate compartment. This is similar to what was found previously for Flu-Na (8).
Figure 9-1. A representative confocal microscopic image o f  rat kidney PTC after 
double-labelling with 0.5 pM tetramethylrosamine (upper panel) and 2 pM CFDA 
(lower panel). Images were collected as described in Materials and Methods. 
Tetramethylrosamine stains mitochondria and the similar accumulation pattern 
obtained with CF (released from CFDA) indicates that this fluorescent anion is 
sequestered in the mitochondrial compartment. The polarity o f  the cells is based 
on the location o f the nucleus and mitochondria, which are basal in tubules. The 
experiment was replicated in four diff erent isolations. Bar is 10 pm.
After isolation of rat PTC, there is still a clear distinction between basolateral and 
brush-border region (Fig. 9-2, upper panel). The darker region in the image is the 
nucleus, which is located at the basolateral side. The nuclear envelop should be 
permeable to CF, and the relative fluorescence in this region could be considered as an 
indication of the level of free drug in cytoplasm. In addition to accumulation of CF in
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mitochondria, some punctate fluorescence was observed at the brush-border side of the 
cell compared to the darker nuclear region of the cells. When the cells were 
preincubated with an inhibitor of mitochondrial dicarboxylate transport, 
phenyl succinate, hardly any mitochondrial accumulation could be observed for CF 
whereas accumulation at the brush-border side increased profoundly (Fig. 9-2, lower 
panel). Phenyl succinate inhibited CF accumulation by 65 ± 4% (determined in 4 
different preparations).
Figure 9-2. Two representative confocal microscopic images o f  rat kidney PTC 
incubated with 2 pM CFDA, in controls (upper panel) or after preincubation with I mM 
phenylsuccinate (lower panel). Images were collected as described in Materials and 
Methods. Controls show the punctate compartment which is additive to mitochondrial 
Cf' accumulations. Phenylsuccinate blocks mitochondrial accumulation o f CF, resulting 
in an increase in accumulation in the punctate compartment. The difference in cellular 
fluorescence reflects changes in gain. The experiment was replicated in four different 
isolations.
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Mitochondrial respiration
To determine the nature of the interaction between Flu-Na and mitochondria, we 
measured respiration rates in isolated mitochondria. In Fig. 9-3, the control respiratory 
rate is shown as a function of succinate concentration. A clear concentration-dependent 
ADP-stimulated respiration (state 3) was observed, while the basal respiration (state 2) 
and recovery respiratory rate after ADP consumption (state 4) were only slightly 
dependent on the succinate concentration. The concentration of succinate used for most 
other experiments was 10 mM, which gives maximum state 3 respiration rates. Cain and 
Skilleter (1) demonstrated that respiratory control ratio values (RCR, ratio of state 3 
over state 4 respiration) above 3 for succinate-linked respiration are indicative of intact 
and well coupled mitochondria. With 50 mM succinate, the RCR was 4.1 ± 0.2 (N=4), 
indicating that our mitochondrial preparation was of good quality and tightly coupled.
Respiratory rate (ng a tom  O/m in * mg prot.)
C oncentra tion  succinate (mM)
Figure 9-3. Respiratory rate of rat kidney cortex mitochondria as a function of different 
succinate concentrations. Respiration was measured in 2 ml buffer at 30 °C, in basal state 
(state 2), in the ADP-stimulated state (state 3) and after ADP consumption (state 4). Data 
points are expressed as means ±  SD of four different isolations.
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Table 9-1. Effect o f  various anionic drugs on succinate respiration in ra t kidney cortex 
mitochondria.
Respiratory rate (ng atom O/min-mg 
prot.)a
Drugb N state 2a state 3a state 4a DNPc RCRd
Control 9 28 ± 7 97 ± 25 27 ± 6 77 ± 19 3 6 ± 0 2
Fluorescein 7 22 ± 6 67 ± 15* 25 ± 6 64 ± 31 2 8 ± 0 2 *
p-Aminohippurate 3 17 ± 4 66 ± 8* 24 ± 4 54 ± 18 2 8 ± 0 2 *
Probenecid 4 26 ± 10 104 ± 10 37 ± 8 93 ± 22 2 8 ± 0 4*
Phenylsuccinate 4 32 ± 6 86 ± 14 29 ± 4 63 ± 15 3 0 ± 0 3*
Valproate 4 24 ± 6 84 ± 26 31 ± 5 98 ± 6 2 7 ± 0 ,6*,t
Salicylate 4 27 ± 8 90 ± 24 29 ± 10 83 ± 31 3 2 ± 0 4
Indomethacin 4 32 ± 12 87 ± 27 32 ± 11 70 ± 13 2 7 ± 0 6*
Naproxen 4 34 ± 10 89 ± 23 35 ± 9 86 ± 22 2 6 ± 0 ,4*,t
a Oxygen consumption was measured prior to ADP addition (state 2), after addition of 0.3 mM ADP 
(state 3) and after ADP consumption (state 4). All data are expressed as means ± SD. b Mitochondria 
were preincubated for 3 min in respiration buffer in presence o f 100 flM  of the drug tested. c Uncoupled 
respiratory rate was measured in presence of 44 fM  dinitrophenol (DNP). d Respiratory control ratio 
(RCR) is the ratio of state 3 over state 4 respiration. A one-way analysis of variance followed by the least 
significant differences test has been used to assess statistical differences between means. * P<0.05 vs. 
control; fP<0.05 vs. salicylate.
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Table 9-1 presents the effects of Flu-Na and various other organic anions at 100 |iM 
on succinate stimulated respiration. No significant effects of these drugs could be 
observed on the basal respiration (state 2) of the mitochondrial fraction, although there 
was a tendency for reduced basal respiration with Flu-Na and PAH. After addition of 
ADP (state 3) Flu-Na and PAH significantly reduced respiratory rate, suggesting that the 
availability of succinate as a reducing agent was decreased. The other organic anions 
tested did not show any effect on state 3 respiration. Neither state 4 respiration nor the 
uncoupled rate were affected significantly by any of the agents tested. All drugs tested, 
except salicylate, significantly reduced RCR. This was a result of either a significant 
decrease in state 3 (Flu-Na, PAH), or a small but not significant increase in state 4 
respiratory rate (probenecid, valproate, indomethacin and naproxen). Respiratory rates 
measured after preincubation of mitochondria with various concentrations of Flu-Na are 
given in Fig. 9-4. Two succinate concentrations were used: 2.5 mM (upper panel) and 
10 mM succinate (lower panel). At some concentrations Flu-Na inhibited the succinate 
stimulated respiration significantly, however, a clear concentration-dependent inhibition 
could not be observed. A plot of the state 3 respiratory rate as a function of Flu-Na 
concentration according to Dixon (4), is presented in Fig. 9-5. The lines intersect above 
the x-axis and to the left of the y-axis, indicating that Flu-Na competitively inhibits 
succinate-dependent respiration. The K¡ value for Flu-Na determined from the 
intersection point was 0.5 ± 0.2 mM.
14C-Succinate uptake
To determine whether Flu-Na affected substrate uptake into mitochondria, we measured 
500 |iM 14C-succinate uptake. Uptake increased linearly with time during the first 2 min, 
afterwards steady-state was reached (Fig. 9-6). At all times, succinate uptake was 
significantly reduced by 12.5 mM phenylsuccinate. Initial uptake at 10 sec was inhibited 
by 71 ± 13 % (N=7; P<0.001). Succinate uptake values after preincubation with Flu-Na 
were calculated according to equation 9-1, and a plot of the log-concentration Flu-Na 
versus percentage of succinate uptake is presented in Fig. 9-7. The succinate 
concentration was 100 |iM, and the concentration at 50% inhibition (/C50) of Flu-Na 
derived from this plot was 0.92 ± 0.03 mM. Concentration-dependence of inhibition by 
Flu-Na was determined for two additional succinate concentrations, and transformation 
of the data according to Dixon (4) is shown in Fig. 9-8. In accordance with the results of 
inhibition of respiratory rate, Flu-Na inhibited 14C-succinate uptake into mitochondria 
competitively, and a K¡ value of 1.1 ± 0.8 mM could be calculated from the three 
intersection points.
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Figure 9-4. Upper panel: Respiration of rat kidney cortex mitochondria with 2.5 mM succinate 
as substrate, after preincubation of mitochondria for 3 min with different concentrations of 
Flu-Na. Respiration was measured in 2 ml buffer at 30 °C, in basal state (state 2), in the ADP- 
stimulated state (state 3) and after ADP consumption (state 4). Data points are expressed as 
means ±  SD of three different isolations. Lower panel: Similar conditions as above but 10 mM 
succinate was used as substrate. DNP: respiratory rate measured after the addition of 44 fM  
dinitrophenol. Data points are means ±  SD of four different isolations. * P<0.05 vs control 
respiration (0 f M  Flu-Na).
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Figure 9-5. Dixon-plot o f the reciprocal respiratory rate of rat kidney cortex mitochondria, 
measured after ADP addition (state 3), as a function of Flu-Na concentration. Two different 
substrate concentrations were used (2.5 and 10 mM succinate). Data points are expressed as 
means of three or four different isolations. The regression equations for both lines are 1.3-10 
5-x+1.4-102 (R2=0.85) and 5.5-106-x+1.0-102 (R2=0.57), for 2.5 mM and 10 mM succinate 
respectively.
Succinate uptake (pmol/mg prot.)
0 5 10 15 20 25 30
Time (min)
Figure 9-6. Time-dependent uptake of 14C-succinate into freshly isolated rat kidney cortex 
mitochondria at 10 °C, with and without preincubation with 12.5 mM phenylsuccinate for 
60 min. The extra-mitochondrial concentration was 500 ¡jM succinate. Phenylsuccinate is 
the ultimate inhibitor of dicarboxylate-mediated transport in mitochondria and therefore 
used to determine the contribution of diffusion in transmitochondrial transport of 
succinate. Values are expressed as means ±  SD of four different isolations.
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Figure 9-7. Inhibition of 14C-succinate uptake into freshly isolated rat kidney cortex 
mitochondria at 10 °C at various concentrations of Flu-Na. The extra-mitochondrial 
succinate concentration was 100 jM . Inhibition was expressed relative to the maximum 
inhibition achieved with phenylsuccinate (12.5 mM). Uptake w^ as measured at 10 sec, 
and values are expressed as means ±  SD of four different isolations.
Discussion
During secretion, drugs that are organic anions accumulate within PTC of the 
kidney. Although little is known about the intracellular disposition of drugs and 
their effects on cellular function, nephrotoxicity as a consequence of accumulation 
has been reported for example for cephalosporin antibiotics (5) and anti­
inflammatory agents (2). In the present study we used 1) fluorescent substrates and 
confocal microscopy to study organic anion distribution in intact, isolated PTC, and 
2) measurements of tracer uptake and respiration is isolated mitochondria to 
examine underlying mechanisms of uptake. Confocal images of isolated proximal 
tubular cells showed that the Flu-Na analog, CF, exhibited similar properties to the 
parent compound, and was sequestered mainly within mitochondria. The 
cytoplasmic fluorescence is low as compared to the mitochondrial fluorescence. 
Since CF (released from CFDA) and Flu-Na are distributed similarly, accumulation 
in mitochondria is a result of intracellular transport properties, rather than a result 
of concentration of enzymes within mitochondria.
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Figure 9-8. Dixon-plot of the reciprocal uptake of 14C-succinate into freshly isolated rat 
kidney cortex mitochondria, as a function of Flu-Na concentration. The extra­
mitochondrial concentrations were 100, 250 and 500 jM  of succinate. Uptake was 
measured at 10 sec, and values are expressed as means of four different isolations. The 
regression equations for the lines are 7.6-10~4-x+1.01 (R2=0.95), 4.7-10~4-x+0.60 
(R2=0.97) and 1.5-W4-x+0.36 (R2=0.93), for 100, 250 and 500 jM  succinate 
respectively.
The nature and function of a second, vesicular compartment is not yet known. 
Phenylsuccinate inhibited CF entry into mitochondria, but had no effect on cellular 
uptake of the CF precursor, CFDA, because CFDA enters cells by simple diffusion 
and is than hydrolyzed to the fluorescent anion CF.
Phenylsuccinate blocks mitochondrial dicarboxylate uptake irreversibly (14,18). 
It also blocks CF uptake by mitochondria in intact PTC, suggesting that CF 
probably enters mitochondria via the dicarboxylate transporter. However, 
phenylsuccinate seemed to prevent cellular exit of the fluorescent compound as 
well. As was reported previously, the passive permeability of the brush-border 
membrane for organic anions is considerably greater than the permeability of the 
basolateral membrane, and efflux across the brush-border membrane is therefore
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the principal route of exit (17). Although efflux is energetically downhill and need 
not be mediated, potential-driven efflux and anion exchange have been reported for 
organic anions at the brush-border membrane (17,20). In addition, Schmitt and 
Burckhardt (21) recently found an exchange mechanism for p-aminohippurate with 
dicarboxylates in bovine brush-border membranes. Although the existence of this 
exchange mechanism has, as yet, not been shown in rat brush-border membrane, 
phenylsuccinate might be able to block CF-anion exchange and, as a consequence, 
CF would be trapped within the proximal tubular cells.
To characterize the interaction between Flu-Na and mitochondria, studies were 
performed with freshly isolated kidney cortex mitochondria, using succinate as 
substrate. The oxygen uptake results demonstrate that our mitochondrial fraction 
was of good quality, with oxidation and phosphorylation tightly coupled. The effect 
of Flu-Na and various anionic drugs were tested on succinate stimulated 
respiration. Indomethacin, naproxen, valproic acid and probenecid tended to 
increase state 4 respiration. This can be explained as uncoupling of mitochondrial 
oxidation and phosphorylation, which is in good agreement with earlier findings for 
these drugs (9,13,16). Flu-Na, PAH and phenylsuccinate reduced the availability of 
succinate for oxidation. Dixon analysis revealed that the type of interaction 
between Flu-Na and succinate was competitive. This inhibitory effect may either be 
a result of competition for transport across the mitochondrial inner membrane, or 
competition for binding at the enzyme complex succinate-coenzyme Q 
dehydrogenase.
To distinguish between these effects, uptake of 14C-labelled succinate was 
measured in mitochondria with metabolism blocked by rotenone and antimycine. 
Flu-Na inhibited succinate uptake competitively. The inhibitory constant calculated 
from the tracer uptake experiments (1.1 mM) was two times higher than the 
constant obtained from the respiration studies (0.5 mM), although the difference 
was not significant. An explanation may be the difference in experimental 
condition. However, it should be noticd that the rather low correlation coefficient 
of the regression line from 10 mM succinate data points in Fig. 9-5 obviously 
weakens the reliability of the estimated inhibitory constant of Flu-Na with respect 
to mitochondrial respiration.
Inhibition of succinate uptake by Flu-Na together with the confocal observations 
for CF indicate that Flu-Na may be a substrate for the mitochondrial dicarboxylate 
carrier. Moreover, the comparable effect of PAH on mitochondrial respiration 
suggests that mitochondrial uptake may also be involved in the intracellular 
compartmentation of this organic anion. However, only direct measurement of
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(radio-labeled) Flu-Na and PAH uptake will give the decisive answers. It has been 
shown previously that metabolic substrates affected organic anion uptake in renal 
proximal tubules. Cis-inhibition with 1 mM glutarate, adipate or a-ketoglutarate 
reduced tubular uptake of 10 |iM Flu-Na, whereas preincubation with 100 |iM of 
these dicarboxylates stimulated cellular uptake (23). Nikiforov and Ostretsova (11) 
suggested that cellular Flu-Na uptake was linked to gluconeogenesis, however, the 
relationship between cellular uptake and oxidative metabolism remained 
unexplained. The metabolic substrate, pyruvate (5 mM), stimulated oxygen 
consumption and tissue accumulation of 50 ^M Flu-Na in kidney cortex slices. 
Regarding the results of our investigation, it may be speculated that this increase in 
tissue Flu-Na accumulation was due to an enhanced mitochondrial uptake of this 
organic anion. Exogenous administered pyruvate is rapidly taken up by the cells 
and sequestered within mitochondria, where it will be carboxylated to malate via 
the gluconeogenic pathway. Subsequently, malate is transported to cytoplasm via 
the dicarboxylate carrier, which may occur in exchange for Flu-Na. This could 
explain the enhanced gluconeogenic rate found in the cortex slices exposed to 
pyruvate and Flu-Na.
It seems unlikely that the interaction between Flu-Na and succinate will have 
clinically significant implications. When Flu-Na is used as a diagnostic agent, 
concentrations reached in plasma will be below 1 |iM. From a previous study we 
can estimate that the final concentration in renal PTC will never exceed 5 |iM, 
since at low extracellular concentrations the compound accumulates in renal cells 
reaching a three- to five-fold concentration intracellulary (8). The present results 
demonstrate that effective inhibition was not found for concentrations below 100 
|iM.
In conclusion, the interaction between the organic anion Flu-Na and mitochondria 
seems to be specific. Confocal images showed that the Flu-Na analog CF 
accumulates in mitochondria of rat PTC. Mitochondrial accumulation of CF was 
inhibited by the dicarboxylate uptake blocker, phenylsuccinate. Respiration and 
radio-tracer uptake studies showed that Flu-Na competitively interacts with the 
mitochondrial dicarboxylate carrier.
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Summ ary
The present study was designed to investigate the transport and accumulation 
characteristics of Lucifer Yellow in the isolated perfused rat kidney (IPK) and in freshly 
isolated rat kidney proximal tubular cells (PTC). After exposing perfused kidneys to a 
concentration of 10 |iM Lucifer Yellow, the ratio of renal clearance over glomerular 
filtration clearance (C L/G F) was 1.6 ± 0.2, indicating active secretion of the 
fluorescent dye. The renal clearance was significantly reduced by pretreatment with 0.5 
mM probenecid (CLR/GF = 0.77 ± 0.05) or 1.15 a-ketoglutarate (CLp/GF = 1.1 ± 0.1). 
Renal accumulation in the IPK was reduced to a similar extent by these inhibitors, 
suggesting that the basolateral organic anion system is involved in Lucifer Yellow 
secretion. Freshly isolated PTC were incubated in medium with 2 |iM Lucifer Yellow 
and cellular uptake was studied by means of confocal microscopy. Confocal images 
revealed that intracellular accumulated drug is compartmentalized in microtubule- 
dependent vesicular structures. Uptake of the dye was significantly reduced after 
preincubation with 1 mM p-aminohippurate, 0.5 mM probenecid and 1 mM a- 
ketoglutarate, confirming the contribution of the organic anion system in cellular 
Lucifer Yellow uptake. In conclusion, Lucifer Yellow may be a good model substrate to 
study intracellular accumulation of anionic drugs during secretory transport by the 
kidney.
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Introduction
Secretory transport of anionic drugs by the kidney takes predominantly place in the 
proximal tubules. The most extensively studied organic anion is p-aminohippurate 
(PAH); competition with this compound for secretion and inhibition of secretion by 
probenecid are usually accepted as good evidence for a drug to be a substrate for the 
organic anion system (23,24). In this regard, the fluorescent organic anion fluorescein 
(Flu-Na) has been shown useful as a model substrate for the carrier system. Flu-Na 
showed concentration-dependent, saturable and probenecid-sensitive transport, with a 
higher affinity for the organic anion transport system than PAH (12,29,30). Moreover, 
with the aid of sensitive fluorescence microscopic techniques the intracellular 
disposition of the fluorescent organic anion was visualized and intracellular 
accumulation within mitochondria (12) and vesicular structures of unidentified origin 
(13,16) were observed.
During secretory transport, organic anions may accumulate within proximal tubular 
cells, sometimes to a high extent (10). Although the membrane steps for secretion are 
well defined, little is known about the intracellular disposition (23,24,32). So far, Flu- 
Na has been a unique compound for which intracellular compartmentation was 
visualized. Twenty years ago it was shown that PAH and some other organic anions 
were able to bind intracellularly to proteins such as ligandin (8). Nevertheless, to date it 
is still unknown whether organic anions like PAH compartmentalize within proximal 
tubular cells (PTC) during transcellular transport. Confocal fluorescence microscopy 
can be applied to gain more insight in the intracellular disposition of organic anions, 
however, substrates with good fluorescent properties are needed.
In the present investigation the transport and accumulation characteristics of the 
fluorescent dye, Lucifer Yellow, were studied in the rat isolated perfused kidney (IPK) 
and in freshly isolated PTC of the rat kidney. This anionic dye is highly fluorescent and 
used as a marker in various biological systems (28). In renal kidney cells, Lucifer 
Yellow has been used as a marker for fluid-phase endocytosis (5,7,31), however, its 
secretory transport characteristics have never been investigated. In macrophages active 
and probenecid-sensitive transport was observed, and it was suggested that a transport 
system comparable to the organic anion secretory system in PTC of the kidney mediates 
Lucifer Yellow transport (26). Aim of this investigation was to study the renal handling 
of Lucifer Yellow and to examine the utility of this dye as a marker for studying renal 
secretory transport and intracellular accumulation of anionic drugs.
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M aterials and methods
Materials
Sodium pentobarbital was obtained from Apharmo (Arnhem, The Netherlands), 
pluronic F-108 was from BASF (Arnhem, The Netherlands), and inulin was from 
Organon (Oss, The Netherlands). Lucifer Yellow CH dilithium salt, luciferin and 
luciferase were purchased from Sigma (St. Louis, Mo.). All other chemicals were 
purchased from either Sigma or Merck (Darmstadt, Germany) and were of analytical 
grade.
Kidney isolation and perfusion
The isolation and perfusion of the rat kidney were done as described in detail previously
(4) with one modification: a-ketoglutarate was omitted from perfusion fluid and added 
only where indicated. Pluronic F-108 was used as oncotic agent in the albumin-free 
perfusion fluid. For the determination of glomerular filtration rate, inulin was added to 
the perfusion fluid (100 |ig/ml). The first 30 min after kidney isolation were used as 
baseline period, after which the experiment was started by the addition of 0.69 mg 
Lucifer Yellow, resulting in an initial perfusate concentration of 10 |iM. The influence 
of a high concentration a-ketoglutarate (1.15 mM) and probenecid (0.5 mM) on Lucifer 
Yellow clearance were studied. These inhibitory agents were added to the IPK at the 
start of the baseline period and remained in perfusion fluid during the experimental 
period. Urine samples were collected during control and experimental periods over 10 
min intervals. Perfusate samples (300 |il) were drawn at the midpoint of each urine 
collection interval. Two additional perfusate samples were taken: one at the beginning 
of the experimental period (t=0), and one at the end of the experiment. At the end of the 
experiment the kidney was removed from the system, blotted, weighed, and frozen until 
analysis. Urine and perfusate samples were stored at -20 °C until analysis. Perfusion 
fluid during experimental period, and perfusion and urine samples were protected from 
light.
Analytical methods
Inulin was determined according to a previously published method (6). The 
concentration of Lucifer Yellow in perfusate, urine and kidney samples was determined 
by means of fluorescence spectrophotometry. To this end, an aliquot of 50 |il of the 
perfusate sample was taken and adjusted to 600 |il with analysis buffer (Sörensen 
buffer, pH 7.36). Urine samples were diluted 10 times with buffer, from which an 
aliquot of 25 |il was taken and adjusted to 600 |il with 50 |il blank perfusion fluid and
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525 |il buffer. Fluorescence in these prepared samples was measured using a Perkin 
Elmer LS50 luminescence spectrophotometer (Perkin Elmer Ltd., Beaconsfield, 
Buckinghamshire, UK). The excitation wavelength was set to 425 nm, the emission 
wavelength to 525 nm and for both wavelengths a slit width of 5 nm was used. 
Concentrations were calculated by comparing fluorescence intensity (in photomultiplier 
units) with a calibration curve of spiked samples of blank perfusion fluid with different 
concentrations of Lucifer Yellow. The concentration of Lucifer Yellow in kidney tissue 
was determined similarly. The kidneys were homogenized in 2.5 ml distilled water with 
a Polytron homogenizer (Braun Melsungen, Germany) on setting 10 for 2 times 60 sec. 
Subsequently, to 500 |il of the kidney homogenate 100 |il 6N HCl was added, vortexed 
and centrifuged for 10 min at 2000g. Of the supernatant, an aliquot of 100 |il was taken 
and adjusted to 600 |il with buffer, and fluorescence intensities of quadruplicate samples 
was measured and averaged. Concentrations were calculated by comparing fluorescence 
intensity with a calibration curve of spiked samples of blank kidney homogenates with 
various concentrations of Lucifer Yellow.
Proximal tubular cell isolation and confocal microscopy
Proximal tubular cells were isolated as described in detail previously (12). For 
microscopy, cells were transferred to a Teflon chamber with a glass coverslip floor, 
containing 1.5 ml of incubation buffer (117.5 mM NaCl, 4 mM KCl, 1.2 mM MgSO4,
0.95 mM KH2PO4, 22.5 mM NaHCO3, 11.1 mM glucose and 2.5 mM CaCl2). Cells 
were preincubated for 15 min in absence (controls) and in presence of various inhibitors 
at 37 °C under an atmosphere of 95% oxygen and 5% carbon dioxide. Then Lucifer 
Yellow was added to the cells reaching a final concentration of 2 |iM and incubation 
took place for 30 min at room temperature.
Confocal fluorescent images were obtained with a Zeiss LSM 410 confocal 
microscope (Carl Zeiss, Oberkochen, Germany). The system consisted of an inverted 
microscope, a mixed argon/krypton-ion laser with the 488 and 568 lines as excitation 
source (intensity 15 mW). For measurement of Lucifer Yellow, the 488 nm laser line, a 
510 nm dichroic filter and 515 nm long pass emission filter were employed. The 
microscope was equipped with a 40x oil immersion objective, exhibiting a numerical 
aperture of 1.3. The software used to obtain the images was Zeiss LSM4 (Carl Zeiss, 
Oberkochen, Germany). Unless indicated otherwise, images were collected with a zoom 
setting of 2 (0.313 |im per pixel). Neutral density filters passing 10% of the light and 
20% of laser power were used to minimize photobleaching. The photomultiplier gain 
was adjusted so that the average pixel intensity in cells was 50 to 70 on a scale of 0-255.
To obtain an image, dye-loaded cells in the chamber were viewed under reduced,
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transmitted light illumination and a field containing 20 to 30 cells was selected. The 
plane of focus was adjusted to cut through the center of the cells. Then, in confocal 
fluorescence mode, a single 8 sec scan of the field was collected. The confocal image 
(512x512x8 bits) was viewed on a high resolution monitor, and stored on an optical 
disk. Fluorescence intensities were analyzed using a Macintosh computer equipped with 
image analysis software (Image 1.54, National Institutes of Health). Of each image, 20 
to 30 cells were selected and, after correction for autofluorescence and background, the 
average pixel intensity was calculated. The value used for that image was the mean of 
all measured cells, the value used for each isolation was the mean of 4 to 6 fields.
ATP measurement
ATP content in proximal tubular cells was determined by a modification of Miller and 
Horowitz (14) of the luciferin-luciferase procedure of Lust et al. (9). Briefly, an aliquot 
of 50 |il cell suspension (2-106 cells/ml incubation buffer) was incubated in 750 |il 
buffer alone (control) or supplemented with various inhibitors, and incubation took 
place for 30 min at 37 °C under an atmosphere of 95% oxygen and 5% carbon dioxide. 
Subsequently, the samples were centrifuged for 3 min at 100g and 100 |il 3N perchloric 
acid was added to the pellet, which was then vortex-mixed, let 5 min to rest, again 
vortexed and centrifuged for 3 min at 100g. The sample was neutralized with medium 
containing 2 N KOH, 0.4 M imidazole and 0.4 M KCl, vortex-mixed and centrifuged 
again. The supernatant was diluted 25 times and to 50 |il of this solution 500 |il assay 
medium was added, containing 50 mM glycylglycine, 7.5 mM dithiothreitol, 2 mM 
EGTA, 2 mM CaCl2, 0.04% BSA, 10 |ig/ml luciferin, and 20 mU/ml luciferase at pH 
8.0, and measured after 30 min by using a liquid scintillation counter. ATP 
concentrations were calculated by comparing scintillation counts with a calibration 
curve of various concentrations of ATP in perchloric acid:neutralization buffer 1:1.25.
Data analysis
All data are expressed as mean ± SD. Student's t-test was used to evaluate statistical 
significance in the renal clearance studies. Statistical differences between multiple 
means were determined with one-way analysis of variance followed by the least 
significant difference post test. Differences were considered significant if P<0.05.
Results
Renal handling o f  Lucifer Yellow in the IPK
After exposing the kidneys to a perfusate concentration of 10 |iM Lucifer Yellow, the
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renal clearance exceeded the clearance by glomerular filtration, indicating active 
secretion of the fluorescent dye. Fig. 10-1 shows the ratio of the renal clearance of 
Lucifer Yellow over the clearance by glomerular filtration (CLR/GF) during the 
experimental period (0-120 min) for control experiments, and after pretreatment with a- 
ketoglutarate or probenecid. The ratio increased during the first 30 min of the 
experiment until a maximum, whereafter a gradual decrease could be observed until a 
plateau at 60 min. It is obvious that pretreatment with both organic anions resulted in a 
significant inhibition of Lucifer Yellow clearance. In these experiments CLR/GF of 
Lucifer Yellow was stable after 30 min of perfusion. Over the experimental period of 30 
to 120 min, a reduction in Lucifer Yellow clearance of 32 ± 4% was induced by a- 
ketoglutarate, and of 52 ± 3% by probenecid. Furthermore, pretreatment with 
probenecid resulted in a CLR/GF<1 (P<0.05), indicating that Lucifer Yellow is net 
reabsorbed. The concentration of Lucifer Yellow determined in the kidney at the end of 
the experiments was expressed as the amount of drug per weight of tissue. This 
concentration divided by the concentration in perfusate at the end of the experiment, 
resulted in an accumulation ratio (kidney/perfusate ratio).
Renal c learance/G FR
Time (min)
Figure 10-1. Renal clearance over glomerular filtration clearance (GFR) as a function of time. 
A concentration of10 jM  Lucifer Yellow was used for control (O) and after pretreatment with
1.15 mM a-ketoglutarate f#) or 0.5 mM probenecid (A). Data are means of 4 experiments ±  
SD. *:P<0.05, **:P<0.01.
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This ratio determined after perfusing the kidneys with 10 |iM Lucifer Yellow is higher 
than 1, indicating accumulation of the dye (Fig. 10-2). Pretreatment of the perfused 
kidneys with a-ketoglutarate resulted in a reduction of the accumulation ratio by 37 ± 
7%, whereas probenecid inhibited this ratio by 62 ± 6%. Moreover, accumulation of 
Lucifer Yellow after pretreatment with probenecid is significantly lower than 1 
(P<0.05). This extent in reduction of accumulation is comparable with the decrease in 
Lucifer Yellow clearance by both organic anions. These findings suggest that the 
basolateral organic anion system is involved in Lucifer Yellow secretion and 
accumulation in the IPK.
Kidney/perfusate-ra tio
Figure 10-2. Accumulation of Lucifer Yellow in perfused kidneys. The kidney/perfusate ratio is 
obtained after dividing concentration in kidney tissue by the concentration in perfusate at the 
end of the experiment. Kidneys were perfused with 10 jM  Lucifer Yellow for 120 min without 
pretreatment (control) and after pretreatment with a-ketoglutarate (1.15 mM) or probenecid 
(0.5mM). Data are means of 4 experiments ±SD. *:P<0.05, **:P<0.01.
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Confocal microscopy and effect on cellular ATP
A confocal micrograph of PTC incubated for 30 min in medium containing 2 |iM 
Lucifer Yellow shows the intracellular accumulation pattern of the dye (Fig. 10-3). The 
darker region in the image is the nucleus, which is located facing the basolateral side of 
the cells. It is assumed that the nuclear envelop is permeable to small molecules like 
Lucifer Yellow, and the relative fluorescence in this region can be considered as free 
drug in cytoplasm. As has been demonstrated previously for another fluorescent anion, 
Flu-Na, cellular fluorescence was not uniformly distributed.
Figure 10-3. Confocal micrograph of freshly isolated PTC incubated to steady state with 2 jM  
Lucifer Yellow. Cells were viewed through a 63x oil immersion objective with a numerical 
aperture of1.25, and a zoom of 3 was used (0.132 jm  per pixel). All other settings as described 
in Materials and methods.
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Uptake of Lucifer Yellow was further investigated in freshly isolated PTC by means 
of confocal microscopy. The uptake of the fluorescent anion was susceptible to 
inhibition by other organic anions. Fig. 10-4 (upper panel) shows that preincubation of 
the cells with PAH, probenecid and phenylsuccinate reduced cellular fluorescence by 
approximately 40% (39 ± 5%, 41 ± 7% and 36 ± 3%, respectively). Preincubation with a 
high concentration of a-ketoglutarate (1 mM) resulted in a significant reduction of 
cellular fluorescence by 30 ± 6%, whereas preincubation with a low concentration a- 
ketoglutarate (1 |iM) increased cellular fluorescence slightly, but not significantly, by 13 
± 3%. This increase in cellular fluorescence was prevented by 5 mM lithium chloride. In 
agreement with the results of the IPK experiments, these findings suggest that Lucifer 
Yellow uptake is, at least in part, mediated by the organic anion carrier. The inhibitory 
effect of the organic anions tested was not a result of energy depletion. Fig. 10-4 (lower 
panel) displays the effect of preincubation of freshly isolated PTC with several organic 
anions on cellular ATP content. Only probenecid reduced the cellular ATP 
concentration significantly by 31 ± 18%. Sodium cyanide was used as control, which 
reduced the cellular ATP concentration by 70 ± 19%.
To investigate further the intracellular compartmentation of Lucifer Yellow, the effect 
of phenylsuccinate, an inhibitor of mitochondrial metabolite anion uptake (11,19), and 
nocodazole, an inhibitor of microtubule motors (1), on the cellular fluorescence were 
investigated. Fig. 10-5 shows that preincubation of PTC with 25 |iM phenylsuccinate 
reduced cellular fluorescence only by 34 ± 7%, whereas nocodazole (20 |iM) reduced it 
by 70 ± 5%. Combination of both agents did not result in an additive effect, but gave a 
reduction of 66 ± 6%. Nocodazole and phenylsuccinate showed no effect on cellular 
ATP content, which can be concluded from Fig. 10-4, lower panel. These findings 
suggest that Lucifer Yellow accumulation in rat kidney PTC involves mainly a 
microtubule-dependent vesicular structure.
Figure 10-4. Effect of various inhibitors on Lucifer Yellow uptake and ATP content in 
freshly isolated PTC. Upper panel: cells were incubated to steady state with 2 j M  
Lucifer Yellow without treatments (control) and after preincubation with probenecid (0.5 
mM), PAH or phenylsuccinate (1 mM), a-ketoglu.tarate (1 j M  or 1 mM), or a 
combination of a-ketoglutarate (1 j M) and lithium chloride (5 mM). Images were 
collected and analyzed as described in Materials and methods, and expressed as % of 
control uptake. Data are means of 4 to 6 different isolations. Lower panel: cells were 
incubated in buffer (control), supplemented with PAH (1 mM), probenecid (0.5 mM), 
lithium chloride (5 mM), phenylsuccinate (25 j M  and 1 mM), nocodazole (20 j M) or 
sodium cyanide (0.5 mM). Cellular ATP content was measured as described in 
Materials and methods. Data are means of 4 experiments of 2 different isolations ±  SD. 
*P<0.05.
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Figure 10-5. Effect of compartmentation inhibitors on cellular Lucifer Yellow 
accumulation. Freshly isolated PTC were incubated with 2 jM  Lucifer Yellow alone 
(control) and after preincubation with phenylsuccinate (25 jM ), nocodazole (20 jM ), or 
a combination of both inhibitors. Images were collected and analyzed as described in 
Materials and methods and expressed as % of control uptake. Data are means of 3 
different isolations. *:P<0.05, **:P<0.01.
Discussion
Active secretion, mediated by the organic anion system, has as yet never been reported 
for Lucifer Yellow in the kidney. In cultured renal cells the dye has been used as a 
marker for fluid-phase endocytosis, organized in the luminal to the basolateral direction 
(5,7,31). Although Goligorsky and Hruska (5) demonstrated in their primary culture of 
canine PTC a paracellular transfer of Lucifer Yellow from the basolateral to the luminal 
side, this flux was three times smaller than the flux in the luminal to the basolateral
201
Chapter 10
direction. In our perfused kidneys we clearly observed secretion of Lucifer Yellow, 
probably regulated by the organic anion system. An explanation why secretory transport 
was never observed in cultured renal cells may be that the organic anion system is lost 
in cultures of proximal tubular cells (17).
Studies on the secretion of the model substrate for the organic anion carrier, PAH, by 
the mammalian kidney showed indirect coupling to the sodium gradient through 
PAH/a-ketoglutarate (or glutarate) exchange and Na/a-ketoglutarate cotransport 
(3,21,22). Studies in isolated membrane vesicles convincingly showed that the 
cotransport system is located at the basolateral membrane of the proximal tubule 
(20,25). The sensitivity to pretreatment with the classical inhibitor of PAH transport, 
probenecid, and the inhibition of secretion and accumulation by a-ketoglutarate (1.15 
mM) in the present study, are in agreement with previous findings for PAH that the 
basolateral organic anion system mediates proximal tubular uptake of Lucifer Yellow. 
Furthermore, our results in rat PTC showed that a low concentration of a-ketoglutarate 
(1 |iM) stimulated Lucifer Yellow uptake, which was blocked completely by addition of 
5 mM lithium to the medium. Lithium is an inhibitor of Na/a-ketoglutarate cotransport 
(2) and, in accordance with the effect on Flu-Na uptake, at a concentration of 5 mM the 
compound not only abolished the a-ketoglutarate induced stimulation, but is also an 
inhibitor of dye uptake (15,16).
The studies with Lucifer Yellow in PTC were performed at steady-state uptake and the 
freshly isolated cells were used in suspension, which implies that the brush-border 
membrane had access to the medium containing the dye. In this system we observed a 
maximum reduction in cellular accumulation of only 40%, induced by 1 mM a- 
ketoglutarate, PAH, probenecid and phenylsuccinate. These findings suggest that uptake 
of Lucifer Yellow is only partly mediated by the organic anion system, and that it seems 
likely that an additional mechanism may also be involved. The inhibitory potencies of 
PAH and probenecid on Lucifer Yellow uptake are in good agreement with their effects 
on Flu-Na uptake using the same model (12). Only phenol red was able to inhibit Flu- 
Na uptake to a higher extent, and it was suggested that an additional transport system in 
Flu-Na uptake might have been the basolateral sulphate carrier. Whether this carrier 
system may be the second transporter involved in Lucifer Yellow uptake remains to be 
elucidated.
Fluid-phase endocytosis may also contribute to the overall cellular uptake of Lucifer 
Yellow. The confocal micrograph presented here clearly shows a vesicular accumulation 
of Lucifer Yellow. The staining pattern in our PTC preparation is very similar to the 
pattern found for Lucifer Yellow in cultured PTC (5) and in macrophages (27). The 
compartment that accumulates Lucifer Yellow in these studies was identified as an
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endosomal compartment. Endosomes play an important role in the intracellular transport 
and sorting of proteins and endocytosed materials, and microtubules are involved in this 
vesicular trafficking (1). The present results demonstrate that Lucifer Yellow 
compartmentation is highly sensitive to a microtubule disrupter, nocodazole, and 
confirm the previous suggestions that the dye is sequestered in endosomes. The 
mechanism of endosomal uptake is unclear. Consistent with fluid-phase endocytosis, 
these endosomes may be formed after invagination of the brush-border membrane (5). 
Another possibility may be that intracellular endosomal uptake is mediated by organic 
anion transporters present in the endosomal membranes, which was observed for the 
fluorescent anion in macrophages (27) and for other organic anions in cultured rat 
hepatocytes (18). Complex interaction and uptake experiments are needed to determine 
whether an organic anion transporter is involved in renal endosomal accumulation of 
Lucifer Yellow in PTC. Furthermore, whether endosomal compartmentation is specific 
for Lucifer Yellow or will also occur for other organic anions during renal secretion 
remains to be examined. Nevertheless, the findings that Lucifer Yellow is actively 
secreted by the kidney and that intracellular disposition could be visualized indicate that 
the dye may be a suitable marker for studying intracellular accumulation of anionic 
drugs.
There was a remarkable difference in staining pattern between Lucifer Yellow and 
Flu-Na as observed in a previous study in PTC, in which compartmentation within 
mitochondria was observed (12). In this study, pretreatment with 25 |iM 
phenylsuccinate, an inhibitor of mitochondrial metabolite anion uptake, inhibited Flu- 
Na accumulation in as much as 65%, and we suggested that this reduction in 
accumulation was a result of inhibition of mitochondrial compartmentation (11). The 
staining pattern presented here does not argue for mitochondrial accumulation of Lucifer 
Yellow. Moreover, pretreatment with 25 |iM phenylsuccinate resulted in only a small 
reduction in Lucifer Yellow accumulation, which was not further increased by 1 mM of 
the inhibitor of mitochondrial metabolite anion uptake (Fig. 10-5 vs. Fig. 10-4). These 
results suggest that most likely cellular uptake of Lucifer Yellow was affected only by 
phenylsuccinate and intracellular compartmentation remained undisturbed.
In conclusion, Lucifer Yellow is actively secreted in the IPK, and accumulates within 
the kidney cells. In rat isolated PTC, accumulated dye is compartmentalized 
predominantly in an endosomal compartment. In PTC, uptake of Lucifer Yellow was 
susceptible to inhibition by probenecid, PAH and 1 mM a-ketoglutarate, whereas a low 
concentration a-ketoglutarate (1 |iM) stimulated uptake. These results suggest that 
uptake of Lucifer Yellow in PTC is at least partly mediated by the organic anion carrier, 
although a second uptake system may also be involved. The present data reveal that
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Lucifer Yellow may be a good model substrate for studying intracellular accumulation 
of anionic drugs during secretory transport by the kidney.
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Summ ary
Previous studies with p-aminohippurate (PAH) and fluorescein (Flu-Na), have shown 
that cellular uptake and tubular secretion of organic anions is driven by indirect 
coupling to sodium. Here we used killifish proximal tubules and laser scanning confocal 
microscopy to study the transport of a larger organic anion, fluorescein-methotrexate 
(Flu-MTX, Mw 923 Da). When tubules were incubated in medium containing 2 )M  
Flu-MTX, dye accumulated in both cells and tubular lumens. At steady-state, luminal 
fluorescence was 4-5 times higher than cellular fluorescence. Ouabain (0.1 mM) did not 
affect cellular or luminal fluorescence, and replacement of medium sodium by N- 
methylglucamine had only a modest effect; preincubation with glutarate had no effect. 
KCN did not affect cellular uptake but abolished secretion into the lumen. Uptake and 
secretion of Flu-MTX was inhibited by micromolar concentrations of other organic 
anions (MTX, folate, probenecid, bromocresol green, BSP), but 1 mM PAH had a 
relatively small effect. Flu-MTX secretion into the lumen was inhibited by leukotriene 
C4, cyclosporine A and verapamil, none of which affected Flu-Na transport. Thus, a 
substantial component of Flu-MTX secretion is Na-independent and ouabain- 
insensitive. Both the basolateral and luminal steps in the Na-independent pathway differ 
from those usually associated with Flu-Na and PAH secretion.
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Introduction
The classical organic anion transport system in vertebrate renal proximal tubule is 
responsible for the excretion of a large number of metabolic wastes and xenobiotics 
(reviewed in ref. 25). Previous studies of organic anion transport in a number of 
preparations have demonstrated that secretion is sodium dependent and ouabain­
sensitive. Membrane vesicle studies, and experiments with intact renal tissue, have 
disclosed the mechanistic basis for these observations: indirect coupling of uptake at the 
basolateral membrane to Na through Na-divalent organic anion cotransport and organic 
anion exchange (25). These studies utilized small organic anions such as the model 
compounds p-aminohippurate (PAH) and fluorescein (Flu-Na) as substrates. However, 
the proximal tubule handles a wide range of anionic compounds, some quite large. It is 
generally assumed that these larger compounds are handled by the same mechanisms as 
smaller organic anions, since PAH and probenecid can reduce their transport and since 
many large organic anions are themselves potent inhibitors of Flu-Na and PAH transport 
(25).
In the present study, we used confocal fluorescence microscopy to examine the 
transport of three fluorescent organic anions by killifish renal proximal tubules (Fig. 1). 
One anion, Flu-Na (Mw 332 Da), has been studied previously using conventional 
fluorescence microscopy and has been shown to be secreted by the same Na-dependent 
mechanism as PAH (18, 19, 27, 28). Both of the others, Flu-MTX and sulforhodamine 
101 (Texas red free acid) are substantially larger, with molecular weights of 923 Da and 
606 Da, respectively. Although neither has been used as a substrate for renal transport 
studies, several reports indicate that the parent compound of one, MTX, undergoes net 
secretion in mammalian proximal tubule and that MTX uptake and secretion is sensitive 
to inhibition by probenecid and PAH (1,3,4,9,10).
As discussed previously, renal tissue from teleost fish offers several advantages for 
the study of secretory transport mechanisms (15,24). Teleost kidneys contain a high 
proportion of proximal tubules that are easily isolated and remain viable for long 
periods. When tubules are isolated, broken ends rapidly reseal to form a closed, fluid- 
filled luminal compartment that only communicates with the medium through the 
tubular epithelium. Thus, this tissue has the appropriate geometry for the study of 
transepithelial secretion in intact tubules. Moreover, secretory transport mechanisms 
found in teleost tubules appear to be identical to those found in mammalian proximal 
tubules (18,16,26). Finally, when teleost tubules are used along with fluorescent 
substrates and quantitative fluorescence microscopy, the mechanisms driving both 
uptake by the cells and secretion into the tubular lumen can be examined (17,18,26).
The present data show that killifish renal proximal tubules secrete Flu-MTX and
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sulforhodamine 101 by a two step process. However, unlike Flu-Na, a substantial 
fraction of the secretion of Flu-MTX and Sulforhodamine 101 is driven by Na- 
independent mechanisms.
C-NH(CH2)5NH-C-IMH
o s
Fluorescein Methotrexate
Figure 11-1. Structures o f the fluorescent organic anions used in the present study.
M aterials and methods
Chemicals
Flu-Na and Flu-MTX were purchased from Molecular Probes (Eugene, OR). 
Bromocresol green (BCG), bromosulfonphthalein (BSP), daunomycin, leukotriene C4, 
probenecid, tetraethylammonium (TEA) chloride, sulforhodamine 101 free acid and 
verapamil were purchased from Sigma Chemical Co (St. Louis, MO). Cyclosporin A 
(CSA) was obtained from Dr. G. Fricker, Sandoz Pharma AG (Basle, Switzerland). All 
other chemicals were obtained from commercial sources at the highest purity available.
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Animals and tubule Preparation
Killifish (Fundulus heteroclitus) were collected near Duke University Marine 
Laboratory (Beaufort, NC) and maintained in tanks with recirculating, artificial sea 
water (18° C) at the National Institute of Environmental Health Sciences.
Renal tubular masses were isolated in a marine teleost saline based on that of Forster 
and Taggart (8), containing (in mM) 140 NaCl, 2.5 KCl, 1.5 CaCl2, 1.0 MgCl2 and 20 
tris(hydroxymethyl)-amino methane (TRIS) at pH 8.0. In the Na depletion experiments, 
Na was replaced with N-methylglucamine. All experiments were carried out at 18-20°
C. Under a dissecting microscope each mass was teased with fine forceps to remove 
adherent hematopoietic tissue. For microscopy, individual killifish proximal tubules 
were dissected free of the masses and transferred to a foil-covered Teflon chamber 
(Bionique) containing 1 ml of marine teleost saline with 1-5 )M  fluorescent compound 
or precursor. The chamber floor was a 4x4 cm glass cover slip to which the tubules 
adhered lightly and through which the tissue could be viewed by means of an inverted 
microscope (below).
Confocal fluorescence microscopy
Tubules in the chamber were mounted on the stage of a Zeiss model 410 inverted laser 
scanning confocal microscope and viewed through a Zeiss 40x plan-neofluar water 
immersion objective (NA 1.3). The microscope was fitted with an Ar-Kr laser providing 
light at 488 and 568 nm. For measurements of Flu-Na and Flu-MTX fluorescence, the 
488 nm laser line, a 510 nm dichroic filter and a 515 nm long pass emission filter were 
employed. For measurements of sulforhodamine 101 fluorescence, the 568 nm laser 
line, a 575 nm dichroic filter and a 590 nm long pass emission filter were employed. 
Most images were collected with a zoom setting of 2 (0.313 )m  per pixel). Neutral 
density filters passing 1 or 3% of the light and 20% laser power were used to minimize 
photobleaching. Preliminary experiments showed that, under these conditions, 
fluorescence intensities in cells and tubular lumens were reduced by less than 5% in 
consecutive 8 sec scans. With these settings, and with photomultiplier gain adjusted so 
that the average pixel intensity in the lumens of control tubules was 150-200 (on a scale 
of 0-255), tissue autofluorescence was usually undetectable.
To obtain an image, dye-loaded tubules in the chamber were viewed under reduced, 
transmitted light illumination and a single proximal tubule with well defined lumen and 
undamaged epithelium was selected. The plane of focus was adjusted to cut through the 
center of the tubular lumen. Then, in confocal fluorescence mode, a single 8 sec scan of 
the tubule was collected. The confocal image (512x512x8 bits) was viewed on a high 
resolution monitor and saved to optical disk. Fluorescence intensities were measured
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from stored images using an Apple Power Macintosh 7100 computer and NIH Image 
version 1.58 software as described previously (16,17). Briefly, 3-5 adjacent cellular and 
luminal areas (at least 200-400 pixels each) were selected from each tubule. After 
background subtraction, the average pixel intensity for each area was calculated. Then 
the lumen-to-cell fluorescence ratio for each pair of adjacent areas was calculated. The 
values used for that tubule were the means of all measured areas.
Metabolism
Availabe data from mammalian studies suggest that we should expect minimal 
metabolism of Flu-MTX by fish tubules in the present short term incubation studies 
carried out at 18° C. In vivo, mammals only slowly metabolize methotrexate to its 7-OH 
derivative, which can be eliminated in urine and bile (see discussion in ref. 6). In 
addition, in perfused rabbit tubules that were bathed for 1 h in medium with 3H- 
methotrexate, metabolites accounted for only a small percentage of label in luminal 
fluid (1). We incubated killifish tubules (pooled tubules from 4 fish) in media with 2 
)M  3H-methotrexate (activity 1 )C i/m l) or 2 )M  Flu-MTX and analyzed water extracts 
using standard thin layer chromatography procedures. For analysis of 3H-methotrexate, 
cellulose-coated plates were developed in 0.1 M phosphate buffer (pH 7.0). Lanes were 
cut into 1 cm bands and each band was placed in a vial for extraction and liquid 
scintillation counting; greater than 95% of the radioactivity migrated with authentic 
methotrexate. For analysis of Flu-MTX, DEAE-cellulose coated plates were developed 
in 0.25 M ammonium bicarbonate/20% acetonitrile (pH 7.0). Plates were illuminated 
with violet-ultraviolet light and location of green fluorescence noted. Using this 
semiquantitative method, we estimate that greater than 90% of the fluorescence on the 
plate migrated with authentic Flu-MTX. No fluorescence could be detected in the region 
of the plate where FL would have run.
Statistics
Data are given as means ± SE. Means were considered to be statistically different, when 
the probability value (P) was less than 0.05 by use of the appropriate paired or unpaired 
t-test.
Results
In the present experiments, killifish renal proximal tubules were incubated in medium 
containing Flu-Na, Flu-MTX or sulforhodamine 101, confocal fluorescence images 
collected and fluorescence distribution patterns analyzed to obtain an indication of dye 
distribution in the tissue. Data are presented as steady state fluorescence intensity
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measurements made over the cellular and luminal regions of the tubules as well as 
paired lumen-to-cell fluorescence ratios. Two caveats must be kept in mind when 
interpreting such measurements. First, the signal from a fluorescent probe is sensitive to 
environment, e.g., pH or solvent polarity. As a result, absolute calibration of dye 
concentration in a single region of a tissue or a cell is difficult and the constant relating 
probe fluorescence to concentration could vary from region to region. Second, the 
steady state solute concentration in a tissue compartment is a function of all processes 
governing entry into and exit from that compartment. Changes in steady state solute 
concentration indicate that one or more of those processes has been altered. Often, 
additional knowledge about the nature of the treatment causing the change in 
concentration can be used to eliminate possibilities.
Figure 11-2. Effects o f Na-replacement, 0.1 mM ouabain, 1 mM p-aminohippurate 
(PAH) and 0.5 mM probenecid (PROB) on the transport o f FL in killifish renal proximal 
tubules. Tissue was incubated for 30 min in medium containing 1 juM FL and the 
indicated additions; images were collected and analyzed as described in METHODS. 
Data given as mean ± SE for 8-15 tubules from 1-2 fish. All treatments reduced luminal 
and cellular fluorescence significantly (P<0.01).
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Flu-Na transport
Previous studies from this laboratory and others have demonstrated that Flu-Na, like 
PAH, can be used as a model substrate for the organic anion transport system in 
vertebrate renal proximal tubule (18,19,27,28). The data in Fig. 11-2, obtained by 
analysis of confocal micrographs of killifish proximal tubules incubated to steady state 
in medium with 1 )M  Flu-Na, illustrate several hallmarks of this system. First, secretion 
is a two-step process. In control tubules, the average fluorescence intensity of the 
tubular lumen exceeded that of the cells which exceeded that of the medium (Fig. 11-2). 
This is the same pattern seen when teleost renal tubules are incubated with colored 
organic anions, such as, chlorophenol red, and dye concentration estimated by eye or 
measured by absorption microspectroscopy (12). Thus, it is unlikely that the 
fluorescence distribution pattern seen for Flu-Na reports primarily differences in probe 
environment. Rather, the pattern is due to concentrative transport steps at both the 
basolateral and luminal membranes. Second, Flu-Na transport is highly Na-dependent. 
Replacement of medium Na with N-methylglucamine abolished Flu-Na uptake and 
secretion and 100 )M  ouabain reduced cellular and luminal fluorescence by over 85% 
(Fig. 11-2). This concentration of ouabain has been previously shown to inhibit Na,K- 
ATPase in homogenates of teleost renal tubules and to greatly reduce 3H-PAH 
accumulation in intact tubules (14). Third, the uptake and secretion of Flu-Na is 
sensitive to inhibition by competitor organic anions. As shown in Fig. 11-2, 1 mM PAH 
or 0.5 mM probenecid abolished the uptake of 1 )M  Flu-Na, consistent with transport 
of the three compounds by a single system.
Flu-MTX transport
Confocal micrographs of killifish proximal tubules incubated for 30 min in medium 
with 2 )M  Flu-MTX showed fluorescence intensity in the lumen>cells>bath (Fig. 11- 
3A). This is the same general pattern of tissue fluorescence seen with other fluorescent 
and colored organic anions (above). It suggests two uphill steps during secretion: one at 
the basolateral membrane and the other at the luminal membrane. As has been 
demonstrated previously for FL and other fluorescent organic anions (17,19), cellular 
fluorescence was not uniformly distributed. Fluorescence intensity in the basal region of 
many cells was noticeably higher than in the apical region and nuclear fluorescence was 
below that seen in the rest of the cell (Fig. 11-3B). This is probably due to accumulation 
of Flu-MTX by mitochondria (14) and other vesicular compartments (19,20) embedded 
in cytoplasm and the absence of such compartments in the nucleus. With higher 
magnification and higher photomultiplier gain settings, punctate sites of Flu-MTX 
fluorescence could be seen throughout the cells (Fig. 11-3B). In addition, thin confocal
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sections at high magnification show some areas of relatively high fluorescence 
associated with the basolateral membrane, suggesting binding of the compound to the 
plasma membrane (Fig. 11-3C).
Figure 11-3. Confocal micrographs of tubules incubated to steady state in medium containing 
2 juM Flu-MTX. (A) A relatively low magnification view of a long section of a single tubule 
showing modest cellular fluorescence and strong luminal fluorescence. Portions of lateral 
intercellular spaces can be seen as long, dark areas between cells. (B) Higher magnification 
image collected at increased photomultiplier gain. At the left o f the image, the tubule bends 
back towards the cover slip. Areas o f bright, punctate fluorescence are seen within the 
epithelium. (C) Image of the basal region o f a tubule taken at still higher magnification and 
with reduced confocal pinhole diameter. Image contrast has been increased to emphasize 
labeling of the basal and lateral plasma membrane. The scale o f each image is indicated by a 
white 10 m bar.
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In preliminary experiments (data not shown), we followed the time course of Flu- 
MTX accumulation in individual tubules. Cellular fluorescence rose over the first 
several min and then reached a plateau. Luminal fluorescence increased linearly over the 
first 8 min and reached steady state within 10 min. At steady state, the lumen to cell 
fluorescence ratio averaged 4-5. All subsequent measurements of tubule fluorescence 
were made at steady state, i.e., after 15-30 min incubation with fluorescent substrate.
For tubules exposed to 2 )M  Flu-MTX, replacing medium Na with N- 
methylglucamine reduced cellular and luminal fluorescence, but only by 48 ± 22% and 
31 ± 13%, respectively (Fig. 11-4; significant inhibition, P<0.05). Even though Na- 
depletion had partially reduced both cellular and luminal fluorescence, the lumen/cell 
fluorescence ratio was still well over unity, indicating that secretion continued in the 
absence of sodium.
Figure 11-4. Effects o f Na-replacement, 0.1 mM ouabain, 10 /¿M glutarate and 1 mM KCN on 
the transport o f 2 //M  Flu-MTX. Tubules were incubated for 30 min in medium containing 2 
ß M  Flu-MTX and the indicated additions; images were collected and analyzed as described in 
METHODS. Data given as mean ± SE for 8-12 tubules from 2 fish. Na-free medium reduced 
cellular and luminal fluorescence significantly (P<0.05); KCN reduced luminal fluorescence 
significantly (P<0.01).
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In addition, 100 )M  ouabain had no effect on Flu-MTX transport (Fig. 11-4); 10 )M  
glutarate or 5 mM LiCl plus 10 )M  glutarate had no effects (Fig. 11-4). This 
concentration of glutarate has been shown to stimulate Na-dependent Flu-Na and PAH 
uptake in teleost proximal tubules (18,19) and in a variety of mammalian preparations 
(25); in those experiments, LiCl abolished the glutarate stimulation. Flu-MTX secretion 
was dependent on cellular metabolism, since 1 mM KCN greatly reduced luminal 
fluorescence (Fig. 11-4). However, KCN did not significantly reduce cellular 
fluorescence.
The transport of 2 )M  Flu-MTX into killifish proximal tubules was also sensitive to 
inhibition by other organic anions. Although PAH and probenecid reduced Flu-MTX 
uptake and secretion, these organic anions were not nearly as effective as when Flu was 
the substrate. Figure 11-5 shows that 1 mM PAH reduced both cellular and luminal 
fluorescence (from Flu-MTX) by 40 ± 14% and 27 ± 11%, respectively, and that 0.5 
mM probenecid reduced cellular and luminal fluorescence by 71 ± 18% and 35 ± 10% 
(P<0.01), respectively. Thus, after exposure to either PAH or probenecid, substantial 
Flu-MTX uptake and secretion were still observed.
The parent compound, MTX, caused a concentration dependent decrease in both 
cellular and luminal fluorescence (Fig. 11-5). The concentration of MTX causing 50% 
reduction of fluorescence in both compartments was about 100 )M . Folate was a less 
potent inhibitor of Flu-MTX transport, with 250 )M  inhibiting by slightly less than 
50%. The large organic anions, BSP and BCG were considerably more potent inhibitors 
of Flu-MTX secretion than MTX or folate (Fig. 11-5). At 10 )M , BSP and BCG 
reduced luminal fluorescence by over 90%; of the two, only BCG had a significant 
effect on cellular fluorescence.
In liver, secretion of large amphiphilic organic anions from hepatocyte to bile 
canaliculus is mediated by one or more multispecific organic anion transporting 
ATPases (22). These ATPases are distinct from the multidrug resistance transporter (p- 
glycoprotein) that is present at high levels in the canalicular membrane of hepatocytes 
and in the luminal membrane of renal proximal tubule cells (29). The organic anion 
transporting ATPases are sensitive to inhibition by a variety of anionic compounds. Of 
these, cysteinyl leukotrienes (LTC) have a particularly high affinity for the transporter, 
with LTC4 exhibiting a Km of 250 nM (11). Transport on these ATPases is also inhibited 
by cyclosporine A (CSA) with a K¡ of 3 )M  (3). To determine whether a transporter 
with similar specificity might be driving the transport of large organic anions from cell 
to lumen in proximal tubule, we measured the effects of LTC4 and CSA on Flu-MTX 
transport.
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figure 11-5. Inhibition of Flu-MTX transport by organic anions. Tubules were incubated 
for 30 min in medium containing 2 /jM  Flu-MTX and the indicated additions; images 
were collected and analyzed as described in METHODS. Data given as mean ± SE for 6­
15 tubules from 1-3 fish. All treatments reduced luminal fluorescence significantly 
(P<0.01); PAH, probenecid (PROB) and folate reduced cellular fluorescence 
significantly (P<0.01); bromocresol green (BCG) reduced cellular fluorescence 
significantly (P<0.05); bromosulphonphthalein (BSP) did not reduce cellular 
fluorescence.
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Fig. 11-6A shows that LTC4 at 100 and 300 nM reduced luminal fluorescence by 45 ± 
14% and 63 ± 21% (P<0.01), respectively, but did not significantly affect cellular 
fluorescence. Based on these results, LTC4 appears to be the most powerful inhibitor of 
Flu-MTX secretion tested. In addition, when tubules were incubated in Na-free medium 
and photomultiplier gain raised to increase sensitivity, 300 nM LTC4 abolished luminal 
fluorescence (luminal and cellular fluorescence in 10 tubules incubated in Na-free 
medium averaged 133 ± 10 and 20 ± 3 fluorescence units, respectively; luminal and 
cellular fluorescence in 12 tubules incubated in Na-free medium with 300 nM LTC4 
averaged 3 ± 1 and 19 ± 3 fluorescence units, respectively). These data argue that all of 
the Na-independent transport of Flu-MTX from cell to lumen was sensitive to inhibition 
by LTC4.
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Figure 11-6. Effects o f  cysteinyl leukotriene C4 (LTC4), cyclosporin A (CSA), verapamil 
(VERAP) and tetraethylammonium (TEA) on the transport o f  (A) 2 / ,M  Flu-MTX and  
(B) 1 ¿¿M Flu-Na. Tubules were incubated fo r  30 min in medium containing the 
fluorescen t substrate and the indicated additions; images were collected and analyzed  
as described  in METHODS. Data given as mean ±  SE. Flu-MTX data are fo r  12-24 
tubules from  3 fish (CSA, TEA verapamil) or 9-10 tubules from  a single fish  (LTC4); 
Flu-Na data are fo r  6-11 tubules from  a single fish. For Flu-MTX, LTC, CSA and 
verapamil significantly reduced luminal fluorescence (P<0.01); verapamil significantly 
reduced cellular fluorescence (P<0.05). None o f  the treatments significantly altered  
Flu-Na fluorescence.
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Fig. 11-6A also shows that CSA, at 5 )M , reduced luminal fluorescence by 49 ± 16%, 
but had no significant effects on cellular fluorescence. Surprisingly, Flu-MTX transport 
was also reduced by verapamil, an organic cation that inhibits transport through p- 
glycoprotein (7), but not through the canalicular organic anion ATPase (11). This 
inhibition was not related to the high affinity that verapamil exhibits for the renal 
organic cation transport system, since the model organic cation, TEA, at 1 mM, did not 
reduce Flu-MTX transport (Fig. 11-6A). In contrast, neither LTC4, CSA nor verapamil, 
at the concentrations used, had any effects on the transport of the small organic anion, 
Flu-Na (Fig. 11-6B). The CSA and verapamil results agree with previously published 
data for Flu-Na transport in killifish tubules (26).
We explored further the effects of verapamil on Flu-MTX transport. The data 
presented above demonstrate that, in contrast to Flu-Na, Flu-MTX transport was only 
partially inhibited by 500 )M  probenecid. Fig. 11-7 shows that increasing the 
probenecid concentration above 250 )M  caused no further reduction in cellular or 
luminal fluorescence from Flu-MTX. Clearly, at concentrations exceeding 250 )M , the 
probenecid-sensitive component of Flu-MTX transport was blocked. Fig. 11-7 also 
shows that when tubules incubated in medium with 2 )M  Flu-MTX were exposed to 
500 )M  probenecid plus 50 )M  verapamil luminal fluorescence was reduced by 66 ± 
24% when compared to 500 )M  probenecid alone (P<0.05). Cellular accumulation of 
Flu-MTX was not reduced further by verapamil plus probenecid when compared to 
probenecid alone. Thus, verapamil appeared to block a component of Flu-MTX 
transport from cell to lumen that was insensitive to 500 )M  probenecid.
Sulforhodamine 101 transport
To determine whether organic anions intermediate in size between Flu-Na and Flu- 
MTX are also transported by a Na-independent and ouabain-insensitive system, we 
followed the transport of sulforhodamine 101 free acid, a fluorescent organic anion with 
a Mw of 600 da. Fig. 11-8 shows that sulforhodamine 101, like Flu-Na and Flu-MTX 
was secreted into the lumens of killifish tubules. At steady state, the lumen to cell 
fluorescence ratio in control tubules averaged 5-8. Ouabain, at 0.1 mM, reduced cellular 
and luminal fluorescence by 31 ± 9% and 53 ± 12% (P<0.01), respectively, indicating a 
ouabain sensitivity part way between that of Flu-Na and Flu-MTX (Fig. 11-8). 
Sulforhodamine 101 transport was also inhibited by 1 mM PAH and 0.5 )M  
probenecid, with the latter compound being substantially more effective. LTC4, CSA 
and verapamil reduced luminal fluorescence, but had no significant effects on cellular 
fluorescence (Fig. 11-8).
Finally, in ouabain-treated tubules, LTC4 significantly reduced luminal but not cellular
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fluorescence (when photomultiplier gain was raised, luminal and cellular fluorescence 
in 8 tubules incubated in medium with 0.1 mM ouabain averaged 159 ± 19 and 27 ± 4 
fluorescence units, respectively; luminal and cellular fluorescence in 9 tubules incubated 
in medium with 0.1 mM ouabain plus 300 nM LTC4 averaged 69 ± 11 and 26 ± 3 
fluorescence units, respectively). Thus, based on these initial experiments, it appears 
that transport of sulforhodamine 101 occurs by both ouabain-sensitive and ouabain- 
insensitive pathways and that, like Flu-MTX, a component of sulforhodamine 101 
secretion is inhibited by LTC4, CSA and verapamil. A substantial portion of the 
ouabain-insensitive component of sulforhodamine 101 secretion is blocked by LTC4.
Figure 11-7. Verapamil (VERP) blocks the probenecid-insensitive component o f Flu-MTX 
transport. Tubules were incubated for 30 min in medium containing 2 //M  Flu-MTX and the 
indicated additions; images were collected and analyzed as described in METHODS. Data 
given as mean ± SE for 9-13 tubules from a single fish. All probenecid concentrations reduced 
luminal and cellular fluorescence significantly (P<0.01); verapamil plus probenecid 
significantly reduced luminal fluorescence when compared to probenecid alone (P<0.01).
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Figure 11-8. Effects o f ouabain (OUAB.), p-aminohippurate (PAH), probenecid (PROB, 
cyclosporin A (CsA), verapamil (VERAP) and cysteinyl leukotriene C4 (LTCJ on the 
transport o f sulforhodamine 101 in killifish renal proximal tubules. Tubules were 
incubated for 30 min in medium containing 5 /¿M sulforhodamine 101 and the indicated 
additions; images were collected and analyzed as described in METHODS. Differences 
in control values reilect primarily different photomultiplier gain settings. Data given as 
mean ±  SE for 6-14 tubules a single fish. Ouabain, PAH and probenecid reduced luminal 
and cellular fluorescence significantly (P<0.01); luminal fluorescence was reduced 
significantly by verapamil (P<0.01) and LTC4 (P<0.05).
Discussion
Organic anion secretion
The current model for organic anion secretion in renal proximal tubular cells involves 
uptake indirectly coupled to Na at the basolateral membrane followed by electrical 
potential-driven facilitated diffusion into the tubular lumen (the “classical” organic 
anion transport system, Fig. 11-9). Intracellular processes also affect organic anion 
transport, since there is evidence for compartmentation of organic anions and a 
dependence of secretion on an intact microtubular system (19,20). It follows from this 
series model of transepithelial transport that maneuvers affecting uptake into the cell 
would be expected to similarly alter secretion into the lumen. Examples of this 
phenomenon are the increases in cellular Flu-Na accumulation and transport into the 
lumen seen with 10-50 )M  glutarate and the decreases in both caused by Na-depletion
221
Chapter 11
or ouabain treatment (Fig. 11-2 and refs. 18 and 19). It also follows that, in the absence 
of other active transport mechanisms, organic anion uptake and secretion should be Na 
dependent and this is just what has been reported in studies of PAH and Flu-Na 
transport in intact renal tissue from a number of species (25).
Figure 11-9. Mechanisms of organic anion transport in renal proximal tubule. For 
convenience, mechanisms are shown in two cells; at present, there is no reason to believe that 
all steps will not be found in every renal proximal tubule cell. The top cell shows transport 
steps initially established by experiments with renal basolateral and brush border membrane 
vesicles (the “classical " Na-dependent, organic anion transport system with fluorescein (Flu- 
Na) as substrate; ref. 25). These include 1) Na-a-ketoglu.tarate (a-KG) cotransport and 2) o.- 
ketoglutarate-organic anion exchange at the basolateral membrane and 3) facilitated diffusion 
at the luminal (brush border) membrane. The bottom cell shows additional 4) basolateral and 
5) luminal steps proposed in the present imaging study of fluorescein-methotrexate (Flu-MTX) 
transport; the ATP-dependence o f step 5 has yet to be demonstrated. Accumulation of both 
substrates in intracellular compartments is also shown.
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The results of the present confocal imaging study with killifish renal proximal tubules 
argue for involvement of an additional pathway in the secretion of larger organic anions 
(Fig. 11-9). Most of the data were obtained with Flu-MTX as substrate, but initial 
experiments with a second large fluorescent organic anion, sulforhodamine 101, 
indicate that the transport system handles more than just methotrexate and derivatives. 
Tubules incubated in medium with either of these fluorescent solutes exhibited roughly 
the same pattern of tissue fluorescence as seen with the small organic anion, Flu-Na. 
That is, average luminal fluorescence exceeded average cellular fluorescence and 
cellular fluorescence exceeded medium fluorescence. Nevertheless, four telling 
differences were observed between the transport of the small organic anion, Flu-Na, and 
the large organic anions, Flu-MTX and sulforhodamine 101. First, at least half of the 
steady state accumulation of Flu-MTX in cells and tubular lumens remained after 
medium Na was replaced by N-methylglucamine. Ouabain had no effect on Flu-MTX 
transport and only partially reduced sulforhodamine 101 transport. In contrast, Na 
replacement and ouabain exposure nearly abolished the uptake and secretion of Flu-Na. 
Second, although Flu-MTX transport was sensitive to inhibition by the same variety of 
organic anions that affect Flu-Na and PAH transport, inhibition by 1 mM PAH and 0.5 
mM probenecid appeared to be only partial. Again, this is in contrast to data for Flu-Na, 
which show nearly complete inhibition of transport with those same concentrations of 
PAH and probenecid. Third, the transport of Flu-MTX and Sulforhodamine 101 was 
inhibited by CSA, an uncharged cyclic polypeptide derivative, and by verapamil, an 
organic cation, neither of which had any effects on Flu-Na transport. One thing CSA 
and verapamil do have in common is that they are inhibitors of some xenobiotic 
transport ATPases (see below). Finally, the most potent inhibitor of Flu-MTX secretion 
tested was LTC4, which was effective at submicromolar concentrations. LTC4 blocked 
luminal accumulation of Flu-MTX and Sulforhodamine 101, but had no effects on 
cellular accumulation. LTC4 inhibited the Na-independent component of Flu-MTX 
transport and the ouabain-insensitive component of sulforhodamine 101 transport. At 
the concentrations used, LTC4 had no effects on Flu-Na transport. Thus, based on Na- 
dependence and inhibitor specificity, a substantial portion of the secretion of Flu-MTX 
and sulforhodamine 101 is mediated by a transport system very different from that 
which drives Flu-Na secretion. In the next two sections, we consider the nature of the 
basolateral and luminal steps, focussing on the Flu-MTX data.
Basolateral uptake
Organic anions, such as, PAH, probenecid, MTX, folate, BSP and BCG significantly 
reduced steady state cellular accumulation of Flu-MTX, in some cases by as much as
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80-90%. By this criterion, a large fraction of the total cellular accumulation of Flu-MTX 
appears to be specific. From these data, we can construct a preliminary order of 
inhibitory effectiveness: BCG>MTX>folate=probenecid>PAH. Surprisingly, verapamil, 
an organic cation, also reduced cellular accumulation by about 40%. The portion of Flu- 
MTX uptake affected by verapamil was also inhibited by probenecid, since verapamil 
plus probenecid had no greater effect on cellular accumulation than probenecid alone. 
Further, the effects of verapamil do not appear to be related to Flu-MTX transport on the 
organic cation system or on a drug transporting ATPase, since neither TEA, CSA nor 
LTC4 had any effects on cellular accumulation of Flu-MTX. Note that verapamil did 
not inhibit the cellular accumulation or secretion of Flu-Na, which is highly dependent 
on cellular metabolism and ion gradients. This result argues that verapamil did not 
reduce Flu-MTX uptake by non-specific mechanisms, such as, cellular toxicity.
Cellular accumulation of Flu-MTX was not reduced when metabolism was abolished 
with KCN, even though luminal accumulation was inhibited completely. These 
observations along with the inhibitor studies discussed above suggest that cellular 
accumulation of Flu-MTX although specific is not energy dependent. Rather the high 
cellular accumulation seen in confocal micrographs could be a result of diffusive entry 
(simple diffusion and facilitated diffusion) combined with extensive binding to cellular 
elements. At steady state, the binding component appears to predominate. Two 
additional observations are consistent with this suggestion: first, confocal micrographs 
show accumulation of Flu-MTX associated with the basolateral membrane of killifish 
renal proximal tubule cells and intracellular structures (Fig. 11-3), and, second, 
preliminary experiments show high levels of specific Flu-MTX binding to a fraction of 
endosomes isolated from rat renal cortex (Masereeuw et al, unpublished findings). 
Together, these observations suggest that at a minimum Flu-MTX binds to multiple 
cellular structures.
Cellular accumulation of Flu-MTX was partially reduced when medium Na was 
replaced by N-methylglucamine, but was not affected by a concentration of ouabain that 
abolished PAH and Flu-Na accumulation and that inhibited teleost renal Na,K-ATPase 
(14). Although the effects of Na replacement could be explained by a small component 
of uptake being mediated by the Na-coupled system, the insensitivity of uptake to KCN 
argues against this. Rather, Flu-MTX binding might be sensitive to changes in the ionic 
composition of the cytoplasm and thus would be altered when tubules were incubated in 
Na-free medium; it is suggested that, under the conditions of the experiments, ouabain 
affected the composition of the cytoplasm in a somewhat different manner and this 
change did not significantly alter Flu-MTX binding. In contrast to Flu-MTX, cellular 
accumulation of sulforhodamine 101 was partially reduced by both Na replacement and
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ouabain. These results indicate that the cellular accumulation of sulforhodamine 101, an 
organic anion intermediate in size between Flu-Na and Flu-MTX, is mediated by both 
Na-dependent and Na-independent mechanisms. Clearly, additional experiments are 
needed to more completely characterize the transport and binding processes that lead to 
the Na independent accumulation of large organic anions in renal proximal tubule cells.
Secretion into the lumen
Killifish tubules incubated to steady state in medium containing 2 )M  Flu-MTX 
exhibited lumen to cell fluorescence ratios of 4-5, suggesting concentrative transport of 
that substrate across the luminal membrane. Consistent with metabolism-driven, 
concentrative transport, luminal fluorescence was reduced substantially when 
metabolism was inhibited by KCN. Na-replacement reduced luminal Flu-MTX by about 
40%, but cellular accumulation was similarly reduced. This could mean that Na 
replacement reduced luminal fluorescence in large part through decreased cellular 
accumulation. Indeed, many of the effects of the organic anions used as inhibitors of 
Flu-MTX transport could be explained on this basis. For example, Fig. 11-5 shows that 
although both cellular and luminal fluorescence fell with increasing MTX concentration, 
they fell together. Since we cannot differentiate effects on secretion into the lumen from 
those on uptake into the cell (above), most of the present data on organic anion effects 
on Flu-MTX transport provide little information about the specificity of the luminal 
step.
There were however three compounds, CSA, verapamil and LTC4, that decreased 
luminal fluorescence, but had no effects on cellular fluorescence or reduced it only 
slightly. These compounds had no effects on the cellular or luminal accumulation of 
Flu-Na, indicating that a large component of the cell to lumen transport of Flu-MTX is 
not shared with Flu-Na. LTC4, CSA and verapamil also reduced sulforhodamine 101 
accumulation in the lumen, suggesting that at least a portion of the cell to lumen 
transport of that dye is through the pathway shared with Flu-MTX but not with Flu-Na. 
LTC4 inhibited the Na-independent component of Flu-MTX transport and the ouabain- 
insensitive component of sulforhodamine 101 transport.
The lack of an effect of LTC4 and CSA on the steady state cellular accumulation of 
Flu-MTX and sulforhodamine 101 requires further comment. One might expect cellular 
fluorescence to increase when transport from cell to lumen was inhibited. However, 
many processes contribute to the measured steady state cellular levels of organic solutes. 
These include carrier-mediated and diffusional transport at both cellular membranes and 
intracellular compartmentation within vesicles or on macromolecules. As discussed 
previously for other solutes, our understanding of these mechanisms is still far from
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complete and without that understanding we are not yet able to explain the observation 
that many compounds that apparently block luminal drug transport have little effect on 
steady state cellular concentrations (16,17,26).
What is the nature of the luminal transporter for larger organic anions? The present 
data indicate that the transport of Flu-MTX from cell to lumen is specific, concentrative 
and dependent on cellular metabolism. At present we do not know whether CSA, 
verapamil or LTC4 inhibit Flu-MTX transport from cell to lumen by competition for a 
single carrier protein or a family of related proteins. Thus, it is not clear if  the luminal 
carrier(s) handles just anions or a mix of xenobiotics. It is unlikely however that the 
MDR transporter is involved, since this drug transporting ATPase handles organic 
cations, weak organic bases and some uncharged compounds, but not organic anions 
such as LTC4 (6), and since, in killifish tubules, LTC4 has no effects on the transport of 
daunomycin, a fluorescent substrate for the MDR transporter (Miller, unpublished data). 
A likely candidate would be a renal form of the hepatic canalicular (luminal) 
multispecific organic anion transporter (cMOAT), an ATPase which mediates the 
biliary excretion of large organic anions (21,22). Recent data indicate that hepatic 
cMOAT is closely related to human multidrug resistance-associated protein (MRP) with 
nearly 50% sequence identity (23). Experiments with isolated canalicular membrane 
vesicles have shown that cMOAT exhibits a high affinity for LTC4 (as a substrate for 
transport and a competitive inhibitor; ref. 11) and CSA (as a competitive inhibitor; ref. 
2). In that respect, the pattern of inhibition of cMOAT in hepatic membrane vesicles 
resembles that found in the present study for the cell to lumen transport of Flu-MTX. 
Although verapamil has no effects on ATP-driven LTC4 transport in hepatocyte 
canalicular membrane vesicles (11), there is suggestive evidence that it may inhibit 
MRP-mediated drug efflux in tumor cells (5). Verapamil sensitivity could represent one 
difference between the liver and kidney forms of related drug-transporting ATPases.
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SUMMARY, CONCLUSIONS AND FUTURE PERSPECTIVES
Summ ary
The kidney possesses various transport systems for the facilitated elimination of 
endogenous and exogenous compounds (like drugs) from the body. The mechanisms 
that mediate their secretion are located in the proximal tubules. The membrane passage 
steps of secretion are well defined, however, little is known about the intracellular 
disposition of drugs in the proximal tubules. Accumulation of drugs within tubular cells 
is an event that occurs frequently in the course of renal excretion. High intracellular 
concentrations can be achieved, which may be the basis for the development of 
nephrotoxicity. The purpose of the investigations described in this thesis was to gain 
more insight in the mechanisms by which organic anions and cations accumulate. The 
thesis is divided into three parts, of which part I (Chapter 1) is a general introduction 
reviewing the present knowledge on the renal handling of anionic and cationic drugs. 
The investigations were based on two different experimental approaches and account for 
the two other parts of this thesis. Part II (Chapter 2-7) describes studies performed in the 
isolated perfused rat kidney, in which the excretion profile of various drugs was 
investigated. In part III (Chapter 8-11) studies in isolated proximal tubular cells of the 
rat kidney and proximal tubules of killifish kidneys are presented. In these latter studies, 
fluorescence microscopy was applied to visualize intracellular compartmentation and 
luminal secretion of accumulated drugs.
I. General introduction
In Chapter 1 relevant literature on the mechanisms dealing with the renal handling of 
drugs and their accumulation in proximal tubular cells is summarized. Accumulation of 
drugs in tubular cells is primarily a consequence of active secretion. Active transport 
processes, such as organic anion transport, may raise the intracellular concentration of 
drugs by driving concentrative uptake into tubular cells against a negatively charged 
potential across the basolateral membrane. Uptake of cationic drugs is facilitated by this 
potential difference, and organic cations may accumulate above their electrochemical 
equilibrium through intracellular sequestration. Cationic drugs may accumulate in 
mitochondria, or become trapped in acidic subcellular structures such as endosomes or
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lysosomes. Facilitated diffusion into mitochondria or transporter-mediated uptake in 
acidic organelles have been characterized as possible driving forces for 
compartmentation within these organelles. Intracellular compartmentation of organic 
anions may involve the same subcellular structures, although the mechanisms of uptake 
remain to be elucidated but are likely to be different from cationic drugs.
Furthermore, in chapter 1 the accumulation of drugs in other transporting epithelia is 
discussed briefly, and some attention is paid to some of the clinical implications of renal 
drug disposition.
II. Studies in the isolated perfused rat kidney
With this model the overall renal handling of drugs was investigated. The various 
mechanisms involved in renal clearance could be interpreted from the drug excretion 
profiles, and the extent of tissue accumulation was determined. The influence of plasma 
protein binding on the tubular secretion and accumulation of organic anions was 
investigated with two methyl-substituted hippurates, 2- and 4-methylbenzoylglycine. 
The renal clearance of these compounds was studied in presence and in absence of 2% 
BSA in perfusion medium.
Chapter 2 describes the renal excretion and accumulation characteristics of 2- 
methylbenzoylglycine. Non-linear protein binding was found, which varied from 30 to 
70% over a concentration range of 1-250 ng/ml. Active renal secretion appeared to be a 
function of unbound drug, indicating that protein binding limits tubular secretion. As a 
consequence of the high perfusion flow rate (approximately 23 ml/min), a low renal 
extraction resulted, despite a high intrinsic clearance (i.e. CLint = TM /K  T of 10 ml/min). 
Active tubular secretion was described best by a model in which two Michaelis-Menten 
terms were used. The calculated kinetic parameters for the high affinity site for tubular 
secretion (mean ± SD) were a maximum transport capacity, TMH, of 3.0 ± 2.8 |ig/min 
and a Michaelis-Menten constant, KTH, of 0.5 ± 0.8 ng/ml. For the low affinity site these 
parameters were: TML = 250 ± 36 |ig/min and K  TL= 62 ± 17 |ig/ml. High accumulation 
in kidney tissue was determined for 2-methylbenzoylglycine: concentrations up to 175 
times the concentration in perfusion medium were reached. Renal accumulation data 
were described best by a model similar to that used to analyze renal secretion, indicating 
that the high accumulation in kidney tissue is a direct result of active tubular uptake.
In Chapter 3 the renal excretion and accumulation characteristics of 4- 
methylbenzoylglycine is described. Over a concentration range of 1-250 ng/ml, non­
linear protein binding was observed varying from 10 to 70%. In contrast with 2- 
methylbenzoylglycine, one Michaelis-Menten term was sufficient to describe active
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tubular secretion, and the average values of the kinetic parameters determined were: TM 
= 55 ± 2 |ig/min and KT = 4.2 ± 0.8 ng/ml. Although these parameters indicate a high 
intrinsic clearance (TM /KT) of 12 ml/min, renal clearance was limited by protein 
binding, in agreement with the results for 2-methylbenzoylglycine. Extensive 
accumulation of 4-methylbenzoylglycine in kidney tissue was found, concentrations of 
up to 600 times the perfusion medium concentration were reached. This is substantially 
higher than the ratio found with the 2-methyl substituted analog, indicating that 
compounds actively secreted by the kidney with a higher intrinsic clearance reach higher 
intracellular concentrations. These high concentrations were without harmful effects on 
kidney functioning. In isolated mitochondria of rat kidney cortex oxygen consumption 
was measured, which remained unaffected by the addition of 2- or 4- 
methylbenzoylglycine. Remarkably, a change in substitution from 4-methyl to 4- 
aminobenzoylglycine (PAH) resulted in a significant inhibition of mitochondrial oxygen 
consumption.
To determine the consequences of tubular accumulation for a drug with a mechanism 
of action dependent upon its transport, the renal handling and effects of 
hydrochlorothiazide were investigated (Chapter 4). The diuretic agent induced a dose- 
dependent increase in the fractional excretion of sodium, chloride and potassium, and in 
urinary flow and pH. Renal clearance was composed of glomerular filtration, active 
tubular secretion and passive reabsorption. The estimated kinetic parameters for 
secretion were a TM of 42 ± 6 |ig/min and a K  T of 38 ± 11 |ig/ml. The thiazide diuretic 
accumulated extensively in kidney tissue due to active cellular uptake and passive 
diffusion. The diuretic effect was analyzed according to the sigmoid Emax model, by 
plotting the sodium excretion rate against the hydrochlorothiazide perfusate 
concentration. Average parameters derived from this plot were an EC50 of 72 ± 5 
|ig/min, a slope factor, S, of 1.6 ± 0.8 and an apparant Emax of 6.3 ± 1.0 |ig/min. For the 
response curve of the sodium excretion rate vs the urinary excretion rate of 
hydrochlorothiazide, however, a simplification of the model had to be used because a 
maximum effect was not observed. Average parameters calculated from this latter curve 
were an Emax /  ERS^ 0 of 0.82 ± 0.09 and a slope factor, S, of 2.8 ± 0.2. The apparent 
maximum effect resulting from the perfusate concentration-response curve and the 
discrepancy with the renal excretion rate-response curve indicated that the diuretic effect 
of hydrochlorothiazide is restricted by saturable accumulation and secretion. As a 
consequence, an indirect relationship between the concentration of hydrochlorothiazide 
in perfusate and the induced diuretic effect resulted.
Chapter 5 deals with the transport kinetics of rhodamine 123. This organic cation and 
mitochondrial marker has shown to be a substrate for P-glycoprotein (Pgp) in multidrug
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resistant cells. Pgp is an ATP-binding transport protein, which is also present in normal 
tissues such as kidney, liver and intestine. In the kidney Pgp may play a role as a third 
transport mechanism involved in drug secretion (next to the organic anion and cation 
systems). Within the initial perfusate concentration range of 10-1000 ng/ml, the renal 
clearance of rhodamine 123 was 4-1 times higher than the clearance by glomerular 
filtration, respectively, indicating active, saturable secretion of rhodamine 123. The rate- 
limiting step in secretion was found to be membrane passage from cell to tubular lumen. 
Surprisingly, renal clearance was not inhibited by cyclosporin A, an inhibitor of Pgp- 
mediated transport, or digoxin, a substrate for Pgp. However, pretreatment of the 
kidneys with verapamil, quinidine (inhibitors of Pgp- and cation carrier-mediated 
transport) or cimetidine (inhibitor of cation transport) resulted in a significantly reduced 
rhodamine 123 clearance. These findings suggest that the renal organic cation carrier is 
involved in active secretion of rhodamine 123 and not Pgp. The organic cation 
accumulated extensively in the isolated perfused rat kidney; tissue concentrations of 
270-360 times the perfusate concentration were determined. Similar accumulation ratios 
at different perfusate concentrations were found, suggesting that the compound enters 
the tubular cells by (facilitated) diffusion. The high accumulation values could not be 
explained by the facilitated entry of the drug in proximal tubular cells, driven by the 
potential difference across the basolateral membrane. Most likely extensive 
accumulation occurs within mitochondria and acidic organelles.
In Chapter 6 the renal handling of the radiocontrast agent iohexol is described. Renal 
contrast agents provide a good visualization of the entire renal system as they are 
cleared predominantly by the kidney, and concentrated within tubular lumen. In clinical 
studies, iohexol has been used as a marker for the determination of glomerular filtration 
rate. The renal handling of iohexol was examined over a perfusate concentration range 
of 5-20 |ig/ml, concentrations that are 100 times lower than used clinically. At a 
perfusate concentration of 5 |ig/ml, a ratio of renal clearance over clearance by 
glomerular filtration (ClR/GF) of 0.63 ± 0.06 could be determined. This ratio increased 
till 1.02 ± 0.06 at 20 ng/ml, indicating that a saturable mechanism was involved in the 
luminal disappearance of the drug. Pretreatment of the kidneys with polylysine, 
probenecid or diatrizoate resulted in a significantly enhanced clearance of iohexol, 
probably due to inhibition of membrane binding. Renal clearance data were fitted to a 
kinetic model that consisted of filtration into the primary urine followed by saturable 
absorption at the luminal membrane. The average kinetic parameters determined were 
an absorption constant, Ka, of 7.3 ± 1.3 ng/ml, and a maximum rate of absorption, V 
amx, of 1.4 ± 0.1 |ig/min. Iohexol accumulated in kidney tissue, reaching a concentration 
of 2 to 7.5 times the perfusate concentration. In freshly isolated proximal tubular cells
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and kidney cortex mitochondria, iohexol reduced the uncoupled respiratory rate at a 
concentration comparable to the highest tissue concentration found in the isolated 
perfused rat kidney. From these findings we concluded that iohexol is not a true 
filtration marker.
The renal disposition of another contrast analog, diatrizoate, was investigated, which 
is described in Chapter 7. Of 5 different doses, with initial perfusate concentrations 
ranging between 4.5 and 175 |ig/ml, the renal clearance was studied. At all perfusate 
concentrations, the renal excretion rate of diatrizoate was significantly lower than the 
filtration rate, indicating that a reabsorptive mechanism is involved in renal diatrizoate 
handling. The ClR/GF was 0.67 ± 0.04 at 4.5 ^g/ml, and increased slightly to 0.76 ±
0.03 at 175 ng/ml, suggesting that tubular reabsorption is mediated by a saturable 
mechanism. Pretreatment of the kidneys with iohexol did not affect renal diatrizoate 
clearance, indicating that the mechanism of reabsorption might differ from that found 
for iohexol. Diatrizoate accumulated in kidney tissue, and accumulation was 
significantly reduced after preincubation of the perfused kidneys with the organic anion 
transport inhibitor probenecid, whereas renal clearance was not affected. At an initial 
perfusate concentration of 4.5 |ig/ml a kidney-to-perfusate ratio (K/P-ratio) of 2.5 ± 0.9 
was found, which decreased to 1.3 ± 0.2 after preincubation with probenecid. At a 
perfusate concentration of 47 |ig/ml a K/P-ratio of 1.4 ± 0.3 was determined, which 
increased significantly to 2.5 ± 0.4 at a concentration of 175 ng/ml. We suggested that 
this unusual profile in concentration-dependent accumulation could be explained by a 
renal clearance mechanism for diatrizoate that consisted of saturable reabsorption in 
conjunction with active tubular secretion.
III. Studies in isolated rat proximal tubular cells and killifish proximal tubules
Isolated proximal tubular cells of the rat kidney are suitable to study the mechanisms 
and kinetics of drug accumulation. A second preparation used were killifish proximal 
tubules, which contain a high proportion of proximal tubules that form closed, fluid- 
filled luminal compartments after isolation. Therefore, this preparation is suitable to 
study transepithelial secretion of drugs. With the aid of sensitive fluorescence 
microscopic techniques, the uptake, intracellular compartmentation and luminal 
secretion of fluorescent anionic model compounds were investigated.
The uptake and accumulation of the organic anion fluorescein-sodium (Flu-Na) in rat 
kidney proximal tubular cells are described in Chapter 8 . Flu-Na showed concentration- 
dependent, saturable and probenecid-sensitive transport. Comparing the transport 
parameters with PAH, Flu-Na exhibited a higher affinity, but lower capacity to the
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organic anion transport system. The average kinetic parameters determined for Flu-Na 
transport were an apparent Km of 59 ± 15 |iM and a V maxof 186 ± 26 pmol/mg 
protein-min. For PAH these parameters were 207 ± 11 |iM and 740 ± 46 pmol/mg 
protein-min, respectively. Subsequently, inhibition experiments with various 
endogenous (urate, a-ketoglutarate) and exogenous compounds (e.g. PAH, probenecid, 
phenol red) have been carried out. Dose-dependent inhibition of Flu-Na uptake with 
PAH resulted in an apparent inhibition constant K¡ of 249 |iM. This is in good 
agreement with the apparent Km of PAH, indicating that Flu-Na uptake is regulated by 
the PAH transport system. It is suggested that cellular uptake of both organic anions is 
mediated by a carrier at the basolateral membrane, although, additional systems may 
also be involved. This could be concluded from experiments in which cells were 
preincubated with different concentrations of phenol red, in which the percentage of 
maximum inhibition was 84%. This was significantly different from the 32% maximally 
obtained with PAH. A possible second transport system involved may be the basolateral 
sulphate carrier. Experiments with confocal laser scanning microscopy showed cellular 
uptake of Flu-Na and accumulation in subcellular structures. After superfusion of 
proximal tubular cells with rhodamine 123 these structures were identified as 
mitochondria.
In a follow-up study the interaction between Flu-Na and mitochondria was 
investigated further (Chapter 9). Confocal microscopy was used in a double labelling 
experiment with the Flu-Na analog, carboxyfluorescein (CF), to confirm accumulation 
in mitochondria of intact cells. Phenylsuccinate inhibited the mitochondrial 
accumulation of CF, indicating that the dicarboxylate carrier may be involved in the 
intracellular compartmentation of organic anions. To characterize the interaction, radio­
tracer uptake and respiration studies with renal mitochondria were carried out using 
succinate as a substrate. Respiration measurements in freshly isolated kidney cortex 
mitochondria revealed that Flu-Na inhibited ADP-stimulated and uncoupled respiratory 
rate, indicating that the organic anion inhibited the availability of succinate as a 
reducing agent. A similar effect on mitochondrial respiration was found for PAH and 
phenylsuccinate. Flu-Na inhibited 14C-succinate uptake concentration-dependently, and 
Dixon analysis revealed that the nature of interaction between Flu-Na and succinate was 
competitive. K¡ values of 0.5 ± 0.2 and 1.1 ± 0.8 mM were calculated for respiration 
experiments and tracer uptake studies, respectively. The data demonstrate that Flu-Na 
competitively interacts with a mitochondrial dicarboxylate transporter.
Chapter 10 is concerned with the disposition of another fluorescent organic anion 
Lucifer Yellow, in rat isolated perfused kidneys and proximal tubular cells. After 
exposing kidneys to a perfusate concentration of 10 |iM Lucifer Yellow, the C L/G F
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was 1.6 ± 0.2, indicating active secretion of the fluorescent dye. The renal clearance was 
significantly reduced by pretreatment with 0.5 mM probenecid (CLR/GF = 0.77 ± 0.05) 
or 1.15 a-ketoglutarate (CLR/GF = 1.1 ± 0.1). Renal accumulation in the perfused 
kidneys was reduced to a similar extent by these inhibitors, suggesting that the 
basolateral organic anion system is involved in Lucifer Yellow secretion. Freshly 
isolated proximal tubular cells were incubated in medium with 2 |iM Lucifer Yellow 
and cellular uptake was studied by means of confocal microscopy. Confocal images 
revealed that the fluorescent drug is compartmentalized intracellularly in microtubule- 
dependent vesicular structures, probably endosomes. Cellular uptake of the dye was 
significantly reduced after preincubation with 1 mM p-aminohippurate, 0.5 mM 
probenecid and 1 mM a-ketoglutarate. Pretreatment with a low concentration a- 
ketoglutarate (1 |iM) resulted in an enhanced cellular uptake, which was prevented by 
simultaneously administration of an inhibitor of the sodium-dicarboxylate carrier, 
lithium. Inhibition of all agents was not a result of a reduction in cellular ATP content, 
suggesting the contribution of the organic anion system in cellular Lucifer Yellow 
uptake. Our findings suggest that the fluorescent dye can be suitable as a marker for 
studying anionic drug accumulation in the kidney.
Finally, the last chapter of this thesis (Chapter 11) describes the renal handling of 
fluorescent organic anions in killifish proximal tubules. Previous investigations with 
PAH and Flu-Na showed that renal secretion of organic anions is driven by indirect 
coupling to sodium. In this study, we used a larger organic anion, fluorescein- 
methotrexate (Flu-MTX; Mw 923 Da). When tubules were incubated in medium 
containing 2 )M  Flu-MTX, dye accumulated in both cells and tubular lumens. At 
steady-state, luminal fluorescence was 4-5 times higher than cellular fluorescence. In 
contrast to Flu-Na, ouabain (0.1 mM) did not affect cellular or luminal fluorescence, 
and replacement of medium sodium by N-methylglucamine had only a modest effect; 
preincubation with glutarate had no effect. KCN did not affect cellular uptake but 
abolished secretion into the lumen. These findings indicate that proximal tubular 
secretion of Flu-Mtx is sodium-independent. Uptake and secretion of Flu-MTX were 
inhibited by micromolar concentrations of other organic anions (MTX, folate, 
probenecid, bromocresol green, BSP), but 1 mM PAH had a relatively small effect. Flu- 
MTX secretion into the lumen was inhibited by leukotriene C4, cyclosporine A and 
verapamil, none of which affected FL transport. These results reveal that Flu-MTX 
uptake and secretion in renal proximal tubules differ from the secretory steps found 
previously for Flu-Na and PAH.
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Conclusions
Experiments in the isolated perfused rat kidney showed that for anionic drugs which are 
actively secreted by the kidney, viz. the substituted hippurates and hydrochlorothiazide, 
the accumulation can be predicted simply from clearance experiments. When additional 
transport mechanisms are involved, the extent of accumulation can not be predicted 
from clearance experiments only, as is seen for diatrizoate. For such a compound, 
complex interaction studies are necessary to provide more insight into the mechanisms 
of accumulation. Furthermore, the perfused kidney is a suitable preparation to 
characterize the renal handling of cationic drugs too. Organic cations tend to accumulate 
to a lesser extent than anionic drugs, because the active step in secretion is located at the 
luminal side of proximal tubular cells. When accumulation occurs above the 
electrochemical gradient it is likely that the drug is compartmentalized intracellularly, 
which is seen for rhodamine 123. Confocal microscopy has been shown suitable to 
study intracellular compartmentation of fluorescent model compounds. A heterogenous 
compartmentation pattern was observed for organic anions, involving several 
subcellular structures like mitochondria and endosomes. The mechanisms of uptake 
into these organelles are still unknown. The high intracellular concentrations that can be 
reached are not necessarily detrimental for proximal tubular cells, although some drugs 
may interfere with mitochondrial metabolism. For iohexol, PAH and Flu-Na a reduced 
mitochondrial oxygen consumption was observed, which will result in a diminished 
ATP content of the cells.
Future perspectives
The membrane steps involved in the renal secretion of organic anions and cations have 
been characterized in detail in various species, however, much less attention has been 
paid to the intracellular events of secretion (3). For organic anions, it was generally 
believed that the high intracellular concentrations that can be reached were a driving 
force for luminal secretion (2,6). It appeared, however, that intracellularly organic 
anions may be compartmentalized, indicating that the free concentration in cytoplasm is 
much lower than expected (Chapter 8-11; (4)). To identify the subcellular structures 
involved in anionic drug sequestration, various sensitive microscopic techniques can be 
applied, like confocal fluorescence (1) or immuno-electron microscopy (7). The 
compartmentation of organic cations has been characterized in more detail, although the 
regulation of uptake remains to be elucidated (4,5). Moreover, the role of
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compartmentation in the overall transcellular secretion is still unclear. To characterize 
the mechanisms of compartmentation in detail, a great number of uptake and interaction 
experiments with the various subcellular organelles involved will be necessary. 
Furthermore, to get a better picture of the regulation of compartmentation and 
transcellular transport of drugs, studies in preparations of proximal tubules and their 
isolated cells are required. Detailed knowledge of the mechanisms that govern the 
intracellular disposition of anionic drugs in the course of tubular secretion may advance 
the understanding of the cellular and molecular basis for drug-induced nephropathy.
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SAMENVATTING EN CONCLUSIES
Samenvatting
De nier beschikt over verschillende transportsystemen om lichaamseigen en 
lichaamsvreemde stoffen (zoals farmaca) snel en effectief te kunnen verwijderen. De 
transportsystemen verantwoordelijk voor de actieve uitscheiding van farmaca zijn 
aanwezig in de cellen van de proximale tubulus. De mechanismen van transport in de 
transcellulaire secretie van farmaca zijn in detail onderzocht, maar tot nu toe is er nog 
weinig bekend over de intracellulaire verdeling in de proximale tubulus. Tijdens het 
uitscheidingsproces kunnen deze farmaca accumuleren in de tubuluscellen, waarbij 
soms zeer hoge concentraties worden bereikt. Deze hoge intracellulaire concentraties 
kunnen aanleiding geven tot het ontstaan van niertoxiciteit. Het doel van het onderzoek 
beschreven in dit proefschrift, was om meer inzicht te krijgen in de mechanismen die 
kunnen leiden tot accumulatie van anionische (negatief geladen) en kationische (positief 
geladen) verbindingen. Dit proefschrift is onderverdeeld in drie delen, waarvan het 
eerste deel (hoofdstuk 1) een algemene introductie is waarin een samenvatting van de 
huidige kennis omtrent de accumulatie van farmaca in tubuluscellen van de nier staat 
beschreven. De uitgevoerde experimenten staan beschreven in de overige twee delen, 
waarin een onderscheid is gemaakt op grond van de twee gekozen experimentele 
benaderingen. Deel II (hoofdstuk 2-7) beschrijft de studies uitgevoerd in de geïsoleerde 
geperfundeerde rattennier, waarin het excretiepatroon van verschillende farmaca en 
modelstoffen is bestudeerd. In deel III (hoofdstuk 8-11) staan de experimenten met vers 
geïsoleerde proximale tubuluscellen van de rattennier en proximale tubuli van de nier 
van de tandkarper (killifish) beschreven. In deze studies is gebruik gemaakt van 
confocale laserscanningmicroscopie om de intracellulaire ophoping en de luminale 
uitscheiding zichtbaar te kunnen maken.
I. Algemene introductie
In hoofdstuk 1 is de relevante literatuur over mechanismen van uitscheiding van 
farmaca in de nier en ophoping in proximale tubuluscellen samengevat. Ophoping van 
farmaca in tubuluscellen is primair een gevolg van het proces van actieve uitscheiding. 
Actieve transportprocessen, zoals het organisch-aniontransport, kunnen de concentratie
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van farmaca in de cel verhogen doordat de opname tegen de concentratiegradiënt in, en 
tegen een negatief geladen potentiaal over de basolaterale membraan plaatsvindt. De 
opname van kationische farmaca wordt juist vergemakkelijkt door dit potentiaalverschil, 
en accumulatie boven het elektrochemische evenwicht treedt pas op wanneer het 
farmacon in de cel wordt vastgehouden. Kationische farmaca kunnen ophopen in 
mitochondria of in zure organellen, zoals endosomen of lysosomen. Diffusie in 
mitochondria of opname via transporteiwitten in zure organellen zijn mogelijk de 
drijvende krachten die aan deze compartimentalisering ten grondslag liggen. De 
intracellulaire ophoping van organische anionen kan plaatsvinden in dezelfde 
subcellulaire organellen, maar de mechanismen die hieraan ten grondslag liggen moeten 
nog worden opgehelderd, hoewel deze waarschijnlijk af zullen wijken van die voor 
kationische farmaca.
In hoofdstuk 1 wordt verder nog kort de ophoping van farmaca in andere organen 
besproken en is er enige aandacht gewijd aan de klinische gevolgen die de ophoping van 
farmaca in de nier kan hebben.
II. Studies in de geïsoleerde geperfundeerde nier van de rat
In dit orgaanmodel is de verwerking van farmaca door de nier onderzocht. Aan de hand 
van het excretieprofiel werd inzicht verkregen in de verschillende mechanismen 
betrokken bij de renale klaring van een farmacon. Eveneens werd de mate van 
accumulatie bepaald in het nierweefsel. De invloed van plasma-eiwitbinding op de 
tubulaire secretie en accumulatie van organische anionen is bestudeerd met twee 
hippuurzuurderivaten (2- en 4-methylbenzoylglycine). De renale klaring van deze 
verbindingen is bestudeerd in af- en aanwezigheid van 2% runderserumalbumine in het 
perfusiemedium.
Hoofdstuk 2 beschrijft de uitscheidings- en stapelingskarakteristieken van 2- 
methylbenzoylglycine. Een niet-lineaire eiwitbinding werd gevonden, variërend van 30 
tot 70% over een concentratiegebied van 1 tot 250 |ig/ml. De actieve secretie door de 
nier was een functie van de vrije concentratie in het perfusiemedium, hetgeen betekent 
dat eiwitbinding de tubulaire secretie beperkt. Dit is primair een gevolg van de hoge 
perfusieflow (ca. 23 ml/min) waardoor, ondanks een hoge intrinsieke klaring (CLint = 
T^/Kj van 10 ml/min), de klaring toch laag is en daardoor afhankelijk van de 
eiwitbinding. Actieve secretie kon worden beschreven door een model met een lage en 
een hoge affiniteitsplaats. De berekende kinetische parameters voor de hoge 
affiniteitsplaats van tubulaire secretie waren (gemiddelde ± SD): een maximale 
transportcapaciteit, TMH, van 3.0 ± 2.8 |ig/min en een Michaelis-Menten-constante voor
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tubulaire secretie, KTH van 0.5 ± 0.8 |ig/ml, en voor de lage affiniteitsplaats: TML = 250 
± 36 |ig/min en KTL = 62 ± 17 |ig/ml. Voor 2-methylbenzoylglycine werden hoge 
accumulatiewaarden in het nierweefsel gevonden; concentraties tot 175-maal de 
mediumconcentratie werden bereikt. Ook de accumulati edata konden worden 
beschreven aan de hand van een vergelijkbaar twee-affiniteitsplaatsenmodel, hetgeen 
betekent dat de hoge accumulatie in het nierweefsel een direct gevolg is van actieve 
tubulaire opname.
In hoofdstuk 3 staan de uitscheidings- en accumulatiekarakteristieken voor 4- 
methylbenzoylglycine in de nier beschreven. Over een concentratiegebied van 1 tot 250 
|ig/ml werd een niet-lineaire eiwitbinding gevonden die varieërde van 10 tot 70%. In 
tegenstelling tot de resultaten verkregen met 2 -methylbenzoylglycine was één 
Michaelis-Menten-term voldoende om de tubulaire secretie te beschrijven. De 
gemiddelde waarden van de kinetische parameters voor tubulaire secretie waren: TM = 
55 ± 2 |ig/min en K  T = 4.2 ± 0.8 ng/ml. Hoewel een hoge intrinsieke klaring kon 
worden berekend aan de hand van de kinetische parameters (Clnnt = 12 ml/min) werd de 
secretie beperkt door eiwitbinding. In het nierweefsel werd een enorm hoge accumulatie 
van 4-methylbenzoylglycine gevonden, waarbij concentraties tot 600-maal de 
perfusaatconcentratie werden bereikt. Dit is substantieel hoger dan de ophoping van 2- 
methylbenzoylglycine, hetgeen betekent dat stoffen, die actief door de nier worden 
uitgescheiden en een hogere intrinsieke klaring hebben, hogere concentraties in de 
niercellen kunnen bereiken. De enorme accumulatie had overigens geen effect op de 
nierfunctie. In geïsoleerde mitochondria van de nierschorscellen werd de 
zuurstofconsumptie gemeten en deze bleek niet beïnvloed te worden door blootstelling 
aan 2-of 4-methylbenzoylglycine. Een interessante waarneming was dat een verandering 
in substitutie van 4-methyl- naar 4-aminobenzoylglycine (para-aminohippuurzuur, 
PAH) wel een remmend effect op de mitochondriële zuurstofconsumptie teweeg bracht.
Om te onderzoeken wat de gevolgen kunnen zijn van ophoping in niercellen voor een 
farmacon dat vanuit de luminale zijde zijn werking uitoefent, is de verwerking door de 
nier en het diuretische effect van hydrochloorthiazide onderzocht (hoofdstuk 4). Dit 
diureticum gaf een dosis-afhankelijke toename in de fractionele uitscheiding van 
natrium- chloor-, en kaliumionen, en in urine-flow en urine-pH. De renale klaring kon 
worden beschreven in termen van glomerulaire filtratie, actieve tubulaire secretie 
volgens Michaelis-Menten-kinetiek en aanzienlijke passieve reabsorptie. De kinetische 
parameters voor secretie waren een TM van 42 ± 6 |ig/min en een K  jvan 38 ± 11 
Hg/ml. Hydrochloorthiazide vertoonde een hoge accumulatie in het nierweefsel, welke 
een direct gevolg was van actieve tubulaire opname. Het diuretische effect werd 
geanalyseerd aan de hand van de uitscheidingssnelheid van natriumionen, en de relatie
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van deze effectparameter tot de concentratie van hydrochloorthiazide in het 
perfusiemedium kon worden beschreven met het klassieke sigmoïde Emax-model. De 
gemiddelde parameters afgeleid van deze concentratie-responscurve waren een EC50 van 
72 ± 5 |ig/min, een hellingsfactor van 1.6 ± 0.8 en een schijnbare Emax van 6.3 ± 1.0 
|ig/min. Echter, voor een beschrijving van de responscurve van de natrium- 
excretiesnelheid tegen de renale excretiesnelheid van hydrochloorthiazide was een 
vereenvoudiging van het model noodzakelijk, omdat er geen maximaal effect werd 
bereikt. De berekende parameters voor deze laatste curve waren een Emax /  ER50S van
0.82 ± 0.09 en een hellingsfactor, S, van 2.8 ± 0 .2 . Uit deze resultaten kan worden 
geconcludeerd dat het diuretisch effect van hydrochloorthiazide wordt beperkt door een 
verzadiging in tubulaire secretie en door accumulatie. Hierdoor ontstaat er een indirecte 
relatie tussen de concentratie van hydrochloorthiazide in het perfusiemedium en het 
diuretisch effect.
Hoofdstuk 5 beschrijft de transporteigenschappen van rhodamine 123. Dit 
fluorescerende organische kation staat bekend als mitochondriële merkstof, en in drug- 
resistente tumorcellijnen is gevonden dat het een substraat is voor P-glycoproteïne 
(Pgp). Pgp is een ATP-bindend transporteiwit, dat niet alleen in tumorcellen voorkomt, 
maar ook in normale weefsels zoals lever, darm en nieren. In de nier speelt Pgp 
mogelijk als derde transportsysteem (naast het organisch-anionsysteem en - 
kationsysteem) een rol in de verwerking van farmaca. Bij doseringen variërend van 1.5 
tot 150 |ig rhodamine 123 in 150 ml perfusiemedium werd, respectievelijk, een C L/G F 
van 4 tot 1 gevonden, wat erop duidt dat rhodamine 123 wordt uitgescheiden middels 
een actief, verzadigbaar mechanisme. De snelheidsbepalende stap in het secretieproces 
was het transport van de niercel naar het tubulaire lumen. Verrassend was dat de klaring 
niet kon worden geremd door voorbehandeling van de nieren met cyclosporine A, een 
Pgp-remmer, of digoxine, een Pgp-substraat. Preïncubatie met verapamil en quinidine 
(remmers van zowel Pgp- als organisch-kationtransport) of cimetidine (remmer van 
organisch-kationtransport) resulteerde wel in een significant gereduceerde rhodamine 
123-klaring. Deze bevindingen suggereren dat waarschijnlijk niet Pgp, maar het 
organisch-kationtransportsysteem betrokken is bij de uitscheiding van rhodamine 123 in 
de nier. Er werd een hoge accumulatie in het nierweefsel gevonden: 
weefselconcentraties die 270- tot 360-maal hoger waren dan de concentratie in het 
perfusiemedium konden worden bepaald. De vergelijkbare accumulatiewaarden bij 
verschillende perfusaatconcentraties suggereert dat opname van het kation in de niercel 
plaatsvindt middels (gefaciliteerde) diffusie. De hoge accumulatiewaarden kunnen niet 
alleen worden verklaard op grond van diffusie gedreven door de electrochemische 
gradiënt. Er vindt waarschijnlijk een sterke intracellulaire compartimentalisering plaats
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in mitochondria en eventueel in zure organellen (lysosomen, endosomen).
In hoofdstuk 6 staat de renale excretie en accumulatie van het radiocontrastmiddel 
iohexol beschreven. Deze contrastmiddelen worden uitsluitend via de nier geklaard en 
zijn zodoende geschikt om de nieren zichtbaar te maken. Iohexol wordt in klinische 
studies tevens gebruikt als merkstof voor de glomerulaire filtratiesnelheid. In de 
geperfundeerde nier is de renale klaring van iohexol in een laag concentratiegebied 
bestudeerd, tussen 5 en 20 |ig/ml, hetgeen een factor 100-maal lager is dan klinisch 
wordt toegepast. Bij de laagste perfusaatconcentratie werd een ratio van renale klaring 
over glomerulaire filtratieklaring (C L/G F) van 0.63 ± 0.06 gevonden, welke 
concentratie-afhankelijk toenam tot 1.02 ± 0.06 bij 20 |ig/ml. Hieruit kon worden 
opgemaakt dat er een verzadigbaar reabsorptieproces betrokken is bij de renale excretie 
van iohexol. Voorbehandeling van de geperfundeerde nieren met poly-l-lysine, 
probenecide en diatrizoaat resulteerde in een significante remming van de reabsorptie 
van iohexol. De excretiedata van iohexol konden worden beschreven met behulp van 
een farmacokinetisch model waarin de renale excretie wordt bepaald door glomerulaire 
filtratie en verzadigbare absorptie. De gemiddelde waarden van de parameters voor 
absorptie waren een absorptiesconstante, Ka van 7.3 ± 1.3 |ig/ml en een maximale 
snelheid van absorptie, Vamx van 1.4 ± 0.1 |ig/min. Iohexol accumuleerde in het 
nierweefsel tot concentraties die 2- tot 7.5-maal hoger lagen dan de concentratie in 
perfusiemedium. In geïsoleerde proximale tubuluscellen bleken deze intracellulaire 
concentraties in staat te zijn om de mitochondriële zuurstofconsumptie te remmen. Uit 
deze resultaten hebben we geconcludeerd dat iohexol geen zuivere marker is voor de 
bepaling van de glomerulaire filtratiesnelheid.
De renale klaring van nog een ander contrastmiddel, nl. het anion diatrizoaat, is 
bestudeerd, hetgeen beschreven staat in hoofdstuk 7. Het concentratiegebied dat is 
onderzocht lag tussen 4 en 180 ng/ml. Bij alle concentraties werd een significant lagere 
renale klaring van diatrizoaat t.o.v. de filtratieklaring gevonden en er was dus eveneens 
sprake van reabsorptie van het contrastmiddel. De C L/G F was 0.67 ± 0.04 bij 4.5 
Hg/ml, welke toenam tot 0.76 ± 0.03 bij 175 ng/ml, hetgeen betekent dat er mogelijk 
sprake is van een verzadigbaar reabsorptiemechanisme. Voorbehandeling van de 
geperfundeerde nieren met iohexol gaf echter geen verandering in de renale klaring van 
diatrizoaat te zien. Hieruit kunnen we concluderen dat het mechanisme van reabsorptie 
voor diatrizoaat afwijkt van dat voor iohexol. Ook voorbehandeling met probenecide 
gaf geen verandering in de renale klaring van diatrizoaat, maar verlaagde wel significant 
de accumulatie van het contrastmiddel in het nierweefsel. De accumulatieratio bij een 
perfusiemediumconcentratie van 4.5 |ig/ml werd verlaagd van 2.5 ± 0.9 tot 1.3 ± 0.2 
door probenecide. Bij een concentratie van 47 |ig/ml werd een ratio van 1.4 ± 0.3
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gevonden, welke significant toenam tot 2.5 ± 0.4 bij de hoogste mediumconcentratie. 
Dit bijzondere profiel van dosis-afhankelijke accumulatie kan worden verklaard door de 
bijdrage van zowel een actief secretiemechanisme, als een verzadigbaar 
reabsorptiemechanisme aan de totale renale klaring van diatrizoaat.
III. Studies ín geïsoleerde proximale tubuluscellen van de rat en proximale tubuli van de 
tandkarper
Vers geïsoleerde proximale tubuluscellen van de rattennier zijn een geschikt substraat 
gebleken om de mechanismen en kinetiek van accumulatie van farmaca te bestuderen. 
Een ander geschikt preparaat vormt de proximale tubulus van tandkarpernieren. Deze 
nieren bestaan uit een groot aantal proximale tubuli die na isolatie een met vloeistof 
gevulde luminaal compartiment omsluiten. Daarom is dit preparaat bij uitstek geschikt 
om transport en secretie van farmaca te bestuderen. Met behulp van confocale 
fluorescentiemicroscopie konden de opname, intracellulaire ophoping en uitscheiding in 
het lumen van fluorescerende verbindingen zichtbaar worden gemaakt.
De opname en accumulatie van het fluorescerende organische anion fluoresceïne- 
natrium (Flu-Na) staan beschreven in hoofdstuk 8 . De opname van Flu-Na in proximale 
tubuluscellen was concentratie-afhankelijk, verzadigbaar en rembaar met probenecide. 
In vergelijking met de kinetische parameters van transport voor PAH, vertoonde Flu-Na 
een hogere affiniteit maar lagere capaciteit voor het organisch-aniontransportsysteem. 
De gemiddelde kinetische parameters die zijn bepaald waren een schijnbare Michaelis- 
Mentenconstante, Km, van 59 ± 15 |iM en een maximale opnamesnelheid, V max, van 186 
± 26 pmol/mg eiwit-min. Voor PAH waren deze parameters 207 ± 11 |iM en 740 ± 46 
pmol/mg eiwit-min, respectievelijk. Vervolgens zijn inhibitie-experimenten uitgevoerd 
met endogene componenten (uraat, a-ketoglutaraat), modelstoffen (PAH, fenolrood) en 
farmaca (o.a. probenecide). Een dosis-afhankelijke remming van de opname van Flu-Na 
met PAH resulteerde in een schijnbare inhibitieconstante K  van 249 |iM, die goed 
overeenkomt met de bepaalde schijnbare Km voor PAH. Dit impliceert dat de opname 
van Flu-Na wordt gereguleerd door het PAH-transportsysteem, hoewel de bijdrage van 
een tweede transportsysteem niet kan worden uitgesloten. Dit kan worden 
geconcludeerd uit het feit dat inhibitie-experimenten met fenolrood een maximale 
remming van gemiddeld 84% te zien gaven, een waarde die significant afwijkt van de 
maximale remming van 32% bereikt met PAH. Een mogelijke tweede transportsysteem 
is het basolaterale sulfaattransportsysteem. Bij lage mediumconcentratie bereikte de 
cel/medium-ratio een waarde van 3,5; dit betekent dat accumulatie van Flu-Na in de 
proximale tubuluscel optreedt. Confocale laserscanningmicroscopie bevestigde actief
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transport en accumulatie en na perfusie met rhodamine 123 kon worden geconcludeerd 
dat het opgenomen Flu-Na ophoopt in mitochondria.
In een vervolgstudie werden de karakteristieken van Flu-Na-opname in mitochondria 
verder bestudeerd (hoofdstuk 9). Middels een dubbellabeling met een fluorescerende 
mitochondriële merkstof werd wederom met confocale microscopie de accumulatie van 
een aan Flu-Na sterk verwante verbinding, carboxyfluoresceïne (CF) in mitochondria 
bevestigd. Tevens bleek dat de mitochondriële ophoping rembaar was met 
phenyl succinaat, een remmer van de opname van anionische metabolieten (o.a. 
succinaat) in mitochondria. Teneinde de interactie van Flu-Na met het succinaat- 
transport verder te bestuderen, zijn zowel opnamestudies met radioactief gelabeld 
succinaat als respiratie-experimenten uitgevoerd. De respiratie-experimenten in vers 
geïsoleerde mitochondria van de cortex van de rattennier toonden aan dat Flu-Na de 
ADP-gestimuleerde en ontkoppelde respiratiesnelheid remde. Dit betekent dat Flu-Na 
de beschikbaarheid van succinaat als reducerend agens remt. Voor PAH werd eenzelfde 
effect op de mitochondriële ademhaling gevonden. Toediening van Flu-Na leidde tot 
een concentratie-afhankelijke, en competitieve, remming van de opname van 14C- 
succinaat in mitochondria. Inhibitieconstanten (K-waarden) van 0.5 ± 0.2 en 1.1 ± 0.8 
mM werden bepaald voor, respectievelijk, de respiratiemetingen en [14C-] 
succinaatopname. Deze resultaten laten zien dat Flu-Na een competitieve interactie 
aangaat met het mitochondriële dicarboxylzuurtransportsysteem.
Hoofdstuk 10 beschrijft de dispositie van het fluorescerende organische anion, 
Lucifer Yellow, in de geïsoleerde geperfundeerde nier en in proximale tubuluscellen van 
de rattennier. Na blootstelling van de nier aan een perfusieconcentratie van 10 |iM 
Lucifer Yellow, was de C L/G F 16 ± 0.2, wat betekent dat de fluorescerende stof actief 
wordt uitgescheiden. Na voorbehandeling van de nieren met 0.5 mM probenecide of 
1.15 mM a-ketoglutaraat was deze ratio significant lager (CLR/GF was 0.77 ± 0.05 en 
1.1 ± 0.1, respectievelijk). De accumulatie in de geperfundeerde nieren werd door deze 
twee remmers tot een vergelijkbaar niveau verlaagd, hetgeen suggereert dat Lucifer 
Yellow door het basolaterale organisch-aniontransportsysteem wordt opgenomen. In 
vers geïsoleerde proximale tubuluscellen werd de opname van Lucifer Yellow 
bestudeerd met behulp van confocale laser-scanningmicroscopie. De confocale beelden 
toonden aan dat de opgenomen stof in subcellulaire structuren accumuleerde. Deze 
blaasjesachtige structuren zijn gevoelig voor remmers van het microtubulaire systeem, 
en daarom vermoedelijk endosomen. In vers geïsoleerde proximale tubuluscellen bleek 
de opname van Lucifer Yellow eveneens rembaar met probenecide, maar ook met p- 
aminohippuurzuur, phenylsuccinaat en een hoge concentratie aan a-ketoglutaraat (1 
mM). Een lage concentratie a-ketoglutaraat (1 |iM) liet juist een toename van de
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cellulaire opname zien, welke door gelijktijdige toediening van lithium, een remmer van 
het Na-dicarboxylaattransportsysteem, teniet werd gedaan. Deze remming was niet het 
gevolg van een verlaging in de cellulaire ATP-concentratie. Al deze resultaten wijzen 
erop dat Lucifer-Yellow in de proximale tubulus van de nier actief wordt opgenomen 
door het organisch-aniontransportsysteem, welke indirect gekoppeld is aan de 
natriumgradiënt. Dit betekent dat de fluorescerende stof een goede marker zou kunnen 
zijn voor het bestuderen van de ophoping van anionische farmaca in de nier.
Het laatste hoofdstuk (hoofdstuk 11) beschrijft de opname en secretie van 
fluorescerende verbindingen in proximale tubuli van de tandkarper. Uit vooronderzoek 
is gebleken dat de renale secretie van PAH en Flu-Na indirect is gekoppeld aan het 
natriumion. In de huidige studie werd de opname en secretie van een groter organische 
anion bestudeerd, namelijk het fluoresceïne-methotrexaat (Flu-MTX; Mw=925). 
Wanneer tubuli werden geïncubeerd in medium met 2 |iM Flu-MTX kon ophoping van 
deze fluorescerende verbinding in de cellen en in het tubulaire lumen worden 
waargenomen. Bij evenwicht was de hoeveelheid fluorescentie in het lumen 4- tot 5- 
maal groter dan in de cellen. In tegenstelling tot voorgaande experimenten met Flu-Na, 
had preïncubatie met 0.1 mM ouabaïne geen effect op de cellulaire of luminale 
fluorescentie. Ook preïncubatie met glutaraat had geen effect, en wanneer al het natrium 
in het medium werd vervangen door N-methylglucamine kon er nauwelijks een 
verandering in de hoeveelheid fluorescentie worden waargenomen. Deze resultaten 
duiden erop dat het organische anion Flu-MTX op een natrium-onafhankelijke manier 
wordt uitgescheiden. De opname en secretie konden wel worden geremd door zeer lage 
concentraties van andere organische anionen, waaronder MTX, foliumzuur, 
probenecide, broomcresol-groen en broomfenol-rood, maar preïncubatie met 1 mM 
PAH had slechts een gering effect. De secretie van Flu-MTX kon worden geremd door 
leukotrieën-C4, cyclosporine A en verapamil. Van laatstgenoemde stoffen werd geen 
effect op de secretie van Flu-Na waargenomen. Uit deze resultaten kunnen we 
concluderen dat tijdens het secreti eproces zowel de passage over de basolaterale 
membraan als dat over de luminale membraan voor Flu-MTX anders is van die voor 
PAH en Flu-Na.
Conclusies
De experimenten in de geperfundeerde nier hebben aangetoond dat voor anionische 
farmaca zoals de hippuraten en hydrochloorthiazide, die actief door de nier worden 
uitgescheiden, vanuit eenvoudige klaringsstudies een goede voorspelling kan worden
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gedaan over de mate van accumulatie in het nierweefsel. Dit geldt echter niet meer 
indien meerdere transportprocessen een rol spelen in de renale uitscheiding van een 
organisch anion, zoals dat waarschijnlijk bij diatrizoaat het geval is. Hierbij kan men 
niet alléén vanuit klaringsstudies een voorspelling doen omtrent de accumulatie, maar 
zullen verdergaande interactiestudies nodig zijn om meer inzicht te krijgen in de 
processen die kunnen leiden tot accumulatie van dit farmacon. Organische kationen 
hebben minder aanleiding om te accumuleren boven hun electrochemische 
diffusiegradiënt, vanwege het feit dat de actieve transportstap in de luminale membraan 
is gelokaliseerd. Wanneer accumulatie wel optreedt is dit waarschijnlijk een direct 
gevolg van intracellulaire compartimentalisering. Confocale laser-scanningmicroscopie 
is een goede techniek gebleken om het proces van intracellulaire compartimentalisering 
verder te bestuderen. Hiermee kon worden aangetoond dat er voor anionische farmaca 
sprake is van heterogeniteit in compartimentalisering in proximale tubuluscellen. 
Meerdere subcellulaire organellen kunnen hierbij betrokken zijn, waaronder 
mitochondria en endosomen. Over de drijvende krachten voor ophoping in deze 
organellen is nog niets bekend. Accumulatie van farmaca, zelfs in hoge concentraties, 
hoeft niet direct toxisch te zijn voor de niercellen. Echter sommige farmaca, zoals 
iohexol, PAH en Flu-Na kunnen interfereren met het mitochondriële metabolisme, 
hetgeen tot een daling van het cellulaire ATP-gehalte kan leiden.
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ABBREVIATIONS
a: ratio of renal tissue concentration over unbound perfusate 
concentration transported passively
BLM: basolateral membrane
BBM: brush-border membrane
BCG: bromocresol green
BSA: bovine serum albumin
BSP: bromosulfonphthalein
CF: carboxyfluorescein
CFDA: carboxyfluorescein-diacetate
CLint: intrinsic secretion clearance (ml/min)
CLr: renal clearance (ml/min)
CLr/GF: renal fractional clearance
CLSM: confocal laser scanning microscopy
CM: cimetidine
cMOAT: canalicular multispecific organic anion transporter
C(p): concentration of drug (^g/ml) (in perfusion medium)
CSA: cyclosporin A
CT: concentration of drug in kidney tissue (^g/g)
Cu: unbound drug concentration in perfusion medium (^g/ml)
Cu,z: unbound drug concentration in perfusion medium at the end of the 
experiment (^g/ml)
DGX: digoxin
DNP: dinitrophenol
Eo: basal effect
EX50s: either perfusate concentration (EC 50, |ig/ml) or renal excretion rate 
(ER50, |ig/min) at half maximum effect
EGTA: ethylene glycol-bis-(ßaminoethyl ether)N,N'-tetraacetic acid
E :max* maximum effect
FE: fraction of a compound excreted in urine
Flu-Na: fluorescein-sodium
Flu-MTX: fluorescein-methotrexate
F(pr): fraction of excreted drug reabsorbed (passively)
fu: fraction of unbound drug
GF(R): glomerular filtration rate (ml/min)
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HEPES: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
HH: Hanks' HEPES
IPK: isolated perfused rat kidney
Ka: Michaelis-Menten constant of absorption (^g/ml)
Ka: Michaelis-Menten constant for renal accumulation (^g/rnl), and for the 
high affinity (Kah) or low affinity (Ka,L) site
Kd: dissociation constant for the binding of drug to protein (^g/ml)
Ki: inhibition constant of uptake into proximal tubular cells (^M)
Km: Michaelis-Menten constant (^M)
K/P: ratio of concentration in kidney tissue (^g/g) over concentration in 
perfusion medium at the end of the experiment (^g/ml)
Kt : Michaelis-Menten constant for tubular transport (^g/rnl), and for the 
high affinity (Kth ) or low affinity (Kt ,L) site
L: ligandin; intracellular anion binding protein in kideny and liver
LDH: lactate dehydrogenase
LTC4: leukotriene C4
MDCK: distal tubule derived kidney cell line of Madin-Darby canine
MDR: multidrug resistance
MRP: multidrug resistance-associated protein
OA: organic anion
OC: organic cation
OK: Opossum kidney derived epithelial cell line
P: total concentration of sites on protein available for drug binding 
(|ig/ml)
PAH: para-aminohippurate
Pgp: P-glycoprotein; product of multidrug resistance gene MDR-1
Prob: probenecid
PSP: phenolsulfonphthalein
PTC: proximal tubular cells
QD: quinidine
Qgf: glomerular filtration (ml/min)
RCR: respiratory control ratio
Rm: maximum capacity of renal accumulation (^g/g), and for the high 
affinity (Rmh) or low affinity (RhL) site (^g/g)
RPP: renal perfusion pressure
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Rr:
S:
TEA:
T :M*
Tris:
V :a,max
V :max
VP (VERA?): 
X-:
renal excretion rate (^g/rnin) 
slope factor of the effect curve 
tetraethylammonium
maximum capacity of tubular transport (^g/min), and for the high 
affinity (Tmh) or low affinity (ThL) site (^g/rnin) 
Tris(hydroxymethyl)aminomethane
maximum rate of absorption in the perfused rat kidney (^g/rnin) 
maximum rate of substrate uptake into isolated proximal tubular cells 
(pmol/mg protein) 
verapamil
inorganic or organic anion serving as counterion for organic anion 
transport across the brush-border membrane
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Stellingen
Op basis van klaringsstudies in de geïsoleerde geperfundeerde rattenier is 
het mogelijk om voor anionische farmaca, die uitsluitend actief door de nier 
worden uitgescheiden, een uitspraak te doen omtrent de mate van 
accumulatie in het nierweefsel.
D it proefschrift
De geïsoleerde rattenier, welke met onfysiologisch hoge flow wordt 
geperfundeerd, is geen geschikt model om de invloed van eiwitbinding op de 
renale klaring van een farmacon met een hoge in-vivo-extractieratio te 
bestuderen.
L.J. Lee, J.A. Cook an d  D.E. Sm ith. J. Pharmacol. Exp. Ther. 247:203-208, 1988 
D it proefschrift
In tegenstelling tot de bewering van Miller et al. blijkt dat het organische 
anion fluoresceïne in de proximale tubuluscel voornamelijk accumuleert in 
mitochondria.
D.S. Miller, D.M. Barnes and  J.B. Pritchard. Am. J. Physiol. 267:R16-R25, 1994 
D it proefschrift
Het gebruik van een lage concentratie iohexol als merkstof voor de bepaling 
van de glomerulaire filtratiesnelheid leidt tot een onderschatting van de 
werkelijke filtratiesnelheid.
D it proefschrift
Het remmende effect van probenecide op de tubulaire secretie van 
cimetidine kan alleen worden toegeschreven aan een interactie op carrier­
niveau wanneer een remmend effect van probenecide op het celmetabolisme 
is uitgesloten.
L.G. Gisclon et al. Clin. Pharmacol. Ther. 45:444-452, 1989
E. Brändle an d  J. Greven. Pharmacol. 45:231-240, 1992 
D it proefschrift
Van het schrijven van een proefschrift kan men leren dat elk nieuw 
hoofdstuk lastiger is op te schrijven dan het voorgaande.
D it proefschrift
Hoewel aan een nationale of internationale marathon in verhouding vele 
duizenden deelnemers meer meedoen dan aan welke andere sportwedstrijd 
ook, is dit voor de sportprogrammamakers van de Nederlandse televisie 
kennelijk niet voldoende om aandacht aan een dergelijk evenement te 
schenken.
De Nederlandse overheid zou op vierbaanswegen een inhaalverbod voor 
vrachtverkeer moeten invoeren om de doorstroom van al het overige verkeer 
te bevorderen.
Het begrip “accumulatie” kan mensen zo intrigeren dat ze er hun 
levenswerk van maken.
Arman, 1928 (“D rugs”, M useum  o f Modern Art, Brussel)
Het gegeven dat mensen met een kriebelhoest er de voorkeur aan geven een 
concert te bezoeken in plaats van de huisarts dient te worden onderworpen 
aan onderzoek, om vast te kunnen stellen of die methode geschikt is als 
alternatieve geneeswijze.
Om het aantal promoties binnen 4 jaar na aanvang van het onderzoek te 
bevorderen, zal de universiteit de promovendus de gelegenheid moeten 
geven om de promotiedatum als “deadline” eerder vast te stellen dan pas na 
goedkeuring van het manuscript.
Rosalinde Masereeuw, 
22 januari 1997
